{"DataElement":{"publicId":"6785267","version":"1","preferredName":"Individual Cancer History Malignant Neoplasm CPTAC Codelist Name","preferredDefinition":"The patient's medical background regarding the occurrence of cancer and cancer-related problems, using Clinical Proteomic Tumor Analysis Consortium (CPTAC) terminology.","longName":"6783941v1.0:6785216v1.0","context":"OCCPR","contextVersion":"1","DataElementConcept":{"publicId":"6783941","version":"1","preferredName":"Individual Cancer History Malignant Neoplasm","preferredDefinition":"A record of a patient's medical background regarding the occurrence of cancer and cancer-related problems._A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","longName":"6788187v1.0:2716428v1.0","context":"OCCPR","contextVersion":"1","ObjectClass":{"publicId":"6788187","version":"1","preferredName":"Individual Cancer History","preferredDefinition":"A record of a patient's medical background regarding the occurrence of cancer and cancer-related problems.","longName":"C18849","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Individual Cancer History","conceptCode":"C18849","definition":"A record of a patient's medical background regarding the occurrence of cancer and cancer-related problems.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BC44DFE-E85F-7048-E053-F662850AE054","latestVersionIndicator":"Yes","beginDate":"2019-06-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-20","modifiedBy":"ONEDATA","dateModified":"2019-06-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2716428","version":"1","preferredName":"Malignant Neoplasm","preferredDefinition":"A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues.  Malignant neoplasms usually metastasize to distant anatomic sites and may recur after excision.  The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin's and non-Hodgkin's lymphomas, leukemias, melanomas, and sarcomas. -- 2004","longName":"C9305","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"41B66B25-1221-583A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-12-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2007-12-20","modifiedBy":"ONEDATA","dateModified":"2007-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008555","version":"1","preferredName":"Medical Records and Forms","preferredDefinition":"the identification of patients' medical records and forms.","longName":"MED_RCD_AND_FORMS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CBFF50-BB95-6B3D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8B9BABD8-EB57-220B-E053-F662850AB9BC","latestVersionIndicator":"Yes","beginDate":"2019-06-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-18","modifiedBy":"KNABLEJ","dateModified":"2019-11-10","changeDescription":"11/10/19 jk Released per CPTAC SME (Linda) for Medical History CRF.  6-18-19 tt created for CPTAC Medical History CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6785216","version":"1","preferredName":"CPTAC Neoplasms Codelist Name","preferredDefinition":"Terminology used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) with the focus on neoplasms._The words or language units by which a thing is known.","longName":"6785216v1.0","context":"OCCPR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"130","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Benign Connective and Soft Tissue Neoplasm","valueDescription":"Benign Connective and Soft Tissue Neoplasm","ValueMeaning":{"publicId":"6797932","version":"1","preferredName":"Benign Connective and Soft Tissue Neoplasm","longName":"6797932","preferredDefinition":"A non-metastasizing neoplasm that arises from the connective and soft tissue.  Representative examples include lipoma, leiomyoma, fibroma, and osteoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benign Connective and Soft Tissue Neoplasm","conceptCode":"C53684","definition":"A neoplasm that arises from connective and soft tissue and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential. Representative examples include lipoma, leiomyoma, fibroma, and osteoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C6226E4-7F1B-5EC3-E053-F662850A91B2","latestVersionIndicator":"Yes","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C6226E4-7F34-5EC3-E053-F662850A91B2","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Benign Colon Neoplasm","valueDescription":"Benign Colon Neoplasm","ValueMeaning":{"publicId":"6797934","version":"1","preferredName":"Benign Colon Neoplasm","longName":"6797934","preferredDefinition":"A non-metastasizing neoplasm arising from the wall of the colon.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benign Colon Neoplasm","conceptCode":"C2894","definition":"A neoplasm that arises from the colon and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C6226E4-7F41-5EC3-E053-F662850A91B2","latestVersionIndicator":"Yes","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C6226E4-7F5A-5EC3-E053-F662850A91B2","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Acute Myelomonocytic Leukemia","valueDescription":"Acute Myelomonocytic Leukemia","ValueMeaning":{"publicId":"2836785","version":"1","preferredName":"Acute Myelomonocytic Leukemia","longName":"2836785","preferredDefinition":"An acute leukemia characterized by the proliferation of both neutrophil and monocyte precursors.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myelomonocytic Leukemia","conceptCode":"C7463","definition":"An acute leukemia characterized by the proliferation of both neutrophil and monocyte precursors.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62459E81-6815-8F6B-E040-BB89AD43368B","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"HARTLEYG","dateModified":"2016-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C2A11C0-C768-2737-E053-F662850A223E","beginDate":"2019-06-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-25","modifiedBy":"ONEDATA","dateModified":"2019-06-25","deletedIndicator":"No"},{"value":"Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A","valueDescription":"Acute Myeloid Leukemia with t(9;11)(p22.3;q23.3); MLLT3-KMT2A","ValueMeaning":{"publicId":"3926632","version":"1","preferredName":"Acute Myeloid Leukemia with t(9;11)(p22.3;q23.3); MLLT3-KMT2A","longName":"3926632","preferredDefinition":"An acute myeloid leukemia associated with t(9;11)(p22.3;q23.3) and MLLT3-KMT2A fusion protein expression. Morphologically it usually has monocytic features. It may present at any age but it is more commonly seen in children. Patients may present with disseminated intravascular coagulation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A","conceptCode":"C82403","definition":"An acute myeloid leukemia associated with t(9;11)(p21.3;q23.3) and MLLT3-KMT2A fusion protein expression. Morphologically it usually has monocytic features. It may present at any age but it is more commonly seen in children. Patients may present with disseminated intravascular coagulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E95A151A-B5AC-8777-E040-BB89AD433AA9","latestVersionIndicator":"Yes","beginDate":"2013-10-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Updated definition and VM Long Name_ghd_11.16.16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C2A11C0-C77C-2737-E053-F662850A223E","beginDate":"2019-06-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-25","modifiedBy":"ONEDATA","dateModified":"2019-06-25","deletedIndicator":"No"},{"value":"Acute Myeloid Leukemia","valueDescription":"Acute Myeloid Leukemia","ValueMeaning":{"publicId":"4263972","version":"1","preferredName":"Acute Myeloid Leukemia","longName":"4263972","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise categorized. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F63DCAA0-1110-5D4B-E040-BB89AD432C9C","latestVersionIndicator":"Yes","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"KUMMEROA","dateModified":"2022-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C2A11C0-C79C-2737-E053-F662850A223E","beginDate":"2019-06-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-25","modifiedBy":"ONEDATA","dateModified":"2019-06-25","deletedIndicator":"No"},{"value":"Acute Monocytic Leukemia","valueDescription":"Acute Monocytic Leukemia","ValueMeaning":{"publicId":"2590752","version":"1","preferredName":"Acute Monocytic Leukemia","longName":"2590752","preferredDefinition":"An acute myeloid leukemia in which the majority of monocytic cells are promonocytes.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Monocytic Leukemia","conceptCode":"C4861","definition":"An acute myeloid leukemia in which the majority of monocytic cells are promonocytes.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"27F3CBD2-0456-469E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C2A11C0-C7A6-2737-E053-F662850A223E","beginDate":"2019-06-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-25","modifiedBy":"ONEDATA","dateModified":"2019-06-25","deletedIndicator":"No"},{"value":"Acute Monoblastic and Monocytic Leukemia","valueDescription":"Acute Monoblastic and Monocytic Leukemia","ValueMeaning":{"publicId":"3926538","version":"1","preferredName":"Acute Monoblastic and Monocytic Leukemia","longName":"3926538","preferredDefinition":"Acute myeloid leukemia in which 80% or more of the leukemic cells are of monocytic lineage, including monoblasts, promonocytes, and monocytes. Bleeding disorders are common presenting features.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Monoblastic and Monocytic Leukemia","conceptCode":"C7318","definition":"Acute myeloid leukemia in which 80% or more of the leukemic cells are of monocytic lineage, including monoblasts, promonocytes, and monocytes. Bleeding disorders are common presenting features.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E958A876-023F-6C33-E040-BB89AD432D80","latestVersionIndicator":"Yes","beginDate":"2013-10-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C2A11C0-C7BB-2737-E053-F662850A223E","beginDate":"2019-06-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-25","modifiedBy":"ONEDATA","dateModified":"2019-06-25","deletedIndicator":"No"},{"value":"Acute Megakaryoblastic Leukemia","valueDescription":"Acute Megakaryoblastic Leukemia","ValueMeaning":{"publicId":"2558163","version":"1","preferredName":"Acute Megakaryoblastic Leukemia","longName":"2558163","preferredDefinition":"An acute myeloid leukemia in which at least 50% of the blasts are of megakaryocytic lineage. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Megakaryoblastic Leukemia","conceptCode":"C3170","definition":"An acute myeloid leukemia in which at least 50% of the blasts are of megakaryocytic lineage. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B040-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"HARTLEYG","dateModified":"2016-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C2A11C0-C7C6-2737-E053-F662850A223E","beginDate":"2019-06-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-25","modifiedBy":"ONEDATA","dateModified":"2019-06-25","deletedIndicator":"No"},{"value":"Acute Lymphoblastic Leukemia","valueDescription":"Acute Lymphoblastic Leukemia","ValueMeaning":{"publicId":"3322383","version":"1","preferredName":"Acute Lymphoblastic Leukemia","longName":"3322383","preferredDefinition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Lymphoblastic Leukemia","conceptCode":"C3167","definition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B36DFA8A-BB5D-6AE7-E040-BB89AD432073","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C2A11C0-C7DA-2737-E053-F662850A223E","beginDate":"2019-06-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-25","modifiedBy":"ONEDATA","dateModified":"2019-06-25","deletedIndicator":"No"},{"value":"Acute Erythroid Leukemia","valueDescription":"Acute Erythroid Leukemia","ValueMeaning":{"publicId":"2836778","version":"1","preferredName":"Acute Erythroid Leukemia","longName":"2836778","preferredDefinition":"An acute myeloid leukemia characterized by a predominant immature erythroid population.  There are two subtypes recognized: erythroleukemia and pure erythroid leukemia. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Erythroid Leukemia","conceptCode":"C8923","definition":"An acute myeloid leukemia characterized by a predominant immature erythroid population.  There are two subtypes recognized: erythroleukemia and pure erythroid leukemia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62459E81-675B-8F6B-E040-BB89AD43368B","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"HARTLEYG","dateModified":"2016-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C2A11C0-C7F9-2737-E053-F662850A223E","beginDate":"2019-06-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-25","modifiedBy":"ONEDATA","dateModified":"2019-06-25","deletedIndicator":"No"},{"value":"Bone Neoplasm","valueDescription":"Bone Neoplasm","ValueMeaning":{"publicId":"6797943","version":"1","preferredName":"Bone Neoplasm","longName":"6797943","preferredDefinition":"A benign, intermediate, or malignant neoplasm involving the bone or articular cartilage.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bone Neoplasm","conceptCode":"C9343","definition":"A benign, intermediate, or malignant neoplasm involving the bone or articular cartilage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C634886-F116-2A99-E053-F662850A8CA9","latestVersionIndicator":"Yes","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C634886-F12F-2A99-E053-F662850A8CA9","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Bladder Urachal Carcinoma","valueDescription":"Bladder Urachal Carcinoma","ValueMeaning":{"publicId":"6797945","version":"1","preferredName":"Bladder Urachal Carcinoma","longName":"6797945","preferredDefinition":"A rare variant of carcinoma of the urachal remnant of bladder.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Urachal Carcinoma","conceptCode":"C39842","definition":"A rare variant of carcinoma of the urachal remnant of bladder.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C634886-F13C-2A99-E053-F662850A8CA9","latestVersionIndicator":"Yes","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C634886-F155-2A99-E053-F662850A8CA9","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Bladder Carcinoma","valueDescription":"Bladder Carcinoma","ValueMeaning":{"publicId":"3210691","version":"1","preferredName":"Bladder Carcinoma","longName":"3210691","preferredDefinition":"A carcinoma arising from the bladder epithelium.  Approximately 90% of the bladder carcinomas are transitional cell carcinomas.  The remainder are squamous cell carcinomas, adenocarcinomas and small cell neuroendocrine carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bladder Carcinoma","conceptCode":"C4912","definition":"A carcinoma arising from the bladder epithelium.  Approximately 90% of the bladder carcinomas are transitional cell carcinomas.  The remainder are squamous cell carcinomas, adenocarcinomas and small cell neuroendocrine carcinomas.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-8ECC-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C634886-F15F-2A99-E053-F662850A8CA9","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Bile Duct Carcinoma","valueDescription":"Bile Duct Carcinoma","ValueMeaning":{"publicId":"6160858","version":"1","preferredName":"Bile Duct Carcinoma","longName":"6160858","preferredDefinition":"A malignant tumor arising from the epithelium of the intrahepatic or extrahepatic bile duct.  Carcinomas that arise from the intrahepatic bile ducts and the hepatic ducts are called cholangiocarcinomas and are almost always adenocarcinomas.  Carcinomas that arise from the extrahepatic bile ducts are adenocarcinomas, adenosquamous carcinomas, squamous cell carcinomas, small cell carcinomas, or mucoepidermoid carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bile Duct Carcinoma","conceptCode":"C27814","definition":"A carcinoma arising from the intrahepatic or extrahepatic bile ducts.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68F7AA8C-ED28-1FCD-E053-F662850A8E10","latestVersionIndicator":"Yes","beginDate":"2018-04-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-04-03","modifiedBy":"ONEDATA","dateModified":"2018-04-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C634886-F174-2A99-E053-F662850A8CA9","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Benign Tongue Neoplasm","valueDescription":"Benign Tongue Neoplasm","ValueMeaning":{"publicId":"6797947","version":"1","preferredName":"Benign Tongue Neoplasm","longName":"6797947","preferredDefinition":"A non-metastasizing neoplasm that arises from the tongue.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benign Tongue Neoplasm","conceptCode":"C3592","definition":"A neoplasm that arises from the tongue and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C634886-F182-2A99-E053-F662850A8CA9","latestVersionIndicator":"Yes","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C634886-F19B-2A99-E053-F662850A8CA9","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Benign Thyroid Gland Neoplasm","valueDescription":"Benign Thyroid Gland Neoplasm","ValueMeaning":{"publicId":"6797949","version":"1","preferredName":"Benign Thyroid Gland Neoplasm","longName":"6797949","preferredDefinition":"A benign neoplasm arising from the thyroid gland.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benign Thyroid Gland Neoplasm","conceptCode":"C3628","definition":"A neoplasm that arises from the thyroid gland and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C634886-F1A8-2A99-E053-F662850A8CA9","latestVersionIndicator":"Yes","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C634886-F1C1-2A99-E053-F662850A8CA9","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Benign Thymus Neoplasm","valueDescription":"Benign Thymus Neoplasm","ValueMeaning":{"publicId":"6797951","version":"1","preferredName":"Benign Thymus Neoplasm","longName":"6797951","preferredDefinition":"A non-metastasizing neoplasm that arises from the thymus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benign Thymus Neoplasm","conceptCode":"C4458","definition":"A non-metastasizing neoplasm that arises from the thymus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C634886-F1CE-2A99-E053-F662850A8CA9","latestVersionIndicator":"Yes","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C634886-F1E7-2A99-E053-F662850A8CA9","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Benign Supratentorial Neoplasm","valueDescription":"Benign Supratentorial Neoplasm","ValueMeaning":{"publicId":"6797953","version":"1","preferredName":"Benign Supratentorial Neoplasm","longName":"6797953","preferredDefinition":"A primary, noninvasive, slow growing neoplasm of the brain that occurs above the cerebellar tentorium.  Representative examples include craniopharyngioma, meningioma and pituitary adenoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benign Supratentorial Neoplasm","conceptCode":"C4963","definition":"A neoplasm that arises from above the cerebellar tentorium and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C634886-F1F4-2A99-E053-F662850A8CA9","latestVersionIndicator":"Yes","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C634886-F20D-2A99-E053-F662850A8CA9","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Benign Small Intestinal Neoplasm","valueDescription":"Benign Small Intestinal Neoplasm","ValueMeaning":{"publicId":"6797955","version":"1","preferredName":"Benign Small Intestinal Neoplasm","longName":"6797955","preferredDefinition":"A non-metastasizing neoplasm arising from the wall of the small intestine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benign Small Intestinal Neoplasm","conceptCode":"C3600","definition":"A neoplasm that arises from the small intestine and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C634886-F21A-2A99-E053-F662850A8CA9","latestVersionIndicator":"Yes","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C634886-F233-2A99-E053-F662850A8CA9","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Benign Skin Neoplasm","valueDescription":"Benign Skin Neoplasm","ValueMeaning":{"publicId":"6797957","version":"1","preferredName":"Benign Skin Neoplasm","longName":"6797957","preferredDefinition":"Abnormal growth of the cells that comprise the tissues of the skin, without any evidence of malignancy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benign Skin Neoplasm","conceptCode":"C2896","definition":"A neoplasm that arises from the skin and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C634886-F240-2A99-E053-F662850A8CA9","latestVersionIndicator":"Yes","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C634886-F259-2A99-E053-F662850A8CA9","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Benign Retroperitoneal Neoplasm","valueDescription":"Benign Retroperitoneal Neoplasm","ValueMeaning":{"publicId":"6797959","version":"1","preferredName":"Benign Retroperitoneal Neoplasm","longName":"6797959","preferredDefinition":"A non-metastasizing neoplasm that arises from the retroperitoneum.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benign Retroperitoneal Neoplasm","conceptCode":"C4447","definition":"A neoplasm that arises from the retroperitoneum and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C634886-F266-2A99-E053-F662850A8CA9","latestVersionIndicator":"Yes","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C634886-F27F-2A99-E053-F662850A8CA9","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Benign Respiratory Tract Neoplasm","valueDescription":"Benign Respiratory Tract Neoplasm","ValueMeaning":{"publicId":"6797961","version":"1","preferredName":"Benign Respiratory Tract Neoplasm","longName":"6797961","preferredDefinition":"A non-metastasizing neoplasm arising from the lung parenchyma, bronchial tree, or trachea.  Representative examples include lung hamartoma, lung papilloma, and tracheal leiomyoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benign Respiratory System Neoplasm","conceptCode":"C8531","definition":"A neoplasm that arises from the respiratory system and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C634886-F28C-2A99-E053-F662850A8CA9","latestVersionIndicator":"Yes","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C634886-F2A5-2A99-E053-F662850A8CA9","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Benign Pituitary Gland Neoplasm","valueDescription":"Benign Pituitary Gland Neoplasm","ValueMeaning":{"publicId":"6797963","version":"1","preferredName":"Benign Pituitary Gland Neoplasm","longName":"6797963","preferredDefinition":"A neoplasm without metastatic potential arising from the anterior or the posterior lobe of the pituitary gland.  The vast majority are adenomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benign Pituitary Gland Neoplasm","conceptCode":"C4782","definition":"A neoplasm that arises from the anterior or posterior lobe of pituitary gland and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C634886-F2B2-2A99-E053-F662850A8CA9","latestVersionIndicator":"Yes","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C634886-F2CB-2A99-E053-F662850A8CA9","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Benign Pharyngeal Neoplasm","valueDescription":"Benign Pharyngeal Neoplasm","ValueMeaning":{"publicId":"6797965","version":"1","preferredName":"Benign Pharyngeal Neoplasm","longName":"6797965","preferredDefinition":"A non-metastasizing neoplasm arising from the pharynx.  Representative examples include squamous papilloma and nasopharyngeal angiofibroma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benign Pharyngeal Neoplasm","conceptCode":"C3597","definition":"A neoplasm that arises from the pharynx and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C634886-F2D8-2A99-E053-F662850A8CA9","latestVersionIndicator":"Yes","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C634886-F2F1-2A99-E053-F662850A8CA9","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Benign Ovarian Neoplasm","valueDescription":"Benign Ovarian Neoplasm","ValueMeaning":{"publicId":"6797967","version":"1","preferredName":"Benign Ovarian Neoplasm","longName":"6797967","preferredDefinition":"A non-metastasizing neoplasm that arises from the ovary.  Representative examples include serous cystadenoma, mucinous cystadenoma, clear cell adenofibroma, benign Brenner tumor, thecoma, and fibroma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benign Ovarian Neoplasm","conceptCode":"C2895","definition":"A neoplasm that arises from the ovary and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential. Representative examples include serous cystadenoma, mucinous cystadenoma, clear cell adenofibroma, benign Brenner tumor, thecoma, and fibroma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C634886-F2FE-2A99-E053-F662850A8CA9","latestVersionIndicator":"Yes","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C634886-F317-2A99-E053-F662850A8CA9","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Benign Orbit Neoplasm","valueDescription":"Benign Orbit Neoplasm","ValueMeaning":{"publicId":"6797969","version":"1","preferredName":"Benign Orbit Neoplasm","longName":"6797969","preferredDefinition":"A non-metastasizing neoplasm that arises from the orbit.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benign Orbit Neoplasm","conceptCode":"C3620","definition":"A neoplasm that arises from the orbit and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C634886-F324-2A99-E053-F662850A8CA9","latestVersionIndicator":"Yes","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C634886-F33D-2A99-E053-F662850A8CA9","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Benign Neoplasm of the Meninges","valueDescription":"Benign Neoplasm of the Meninges","ValueMeaning":{"publicId":"6797971","version":"1","preferredName":"Benign Neoplasm of the Meninges","longName":"6797971","preferredDefinition":"A benign tumor occurring in the meninges, which surround the brain and spinal cord.  The most common are meningiomas. - 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benign Neoplasm of the Meninges","conceptCode":"C4957","definition":"A neoplasm that arises from the meninges and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C634886-F34A-2A99-E053-F662850A8CA9","latestVersionIndicator":"Yes","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C634886-F363-2A99-E053-F662850A8CA9","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Benign Neoplasm of Lower Jaw Bone","valueDescription":"Benign Neoplasm of Lower Jaw Bone","ValueMeaning":{"publicId":"6797973","version":"1","preferredName":"Benign Neoplasm of Lower Jaw Bone","longName":"6797973","preferredDefinition":"A non-metastasizing neoplasm that arises from the lower jaw bone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benign Neoplasm of Mandible","conceptCode":"C34417","definition":"A non-metastasizing neoplasm that arises from the mandible.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C634886-F370-2A99-E053-F662850A8CA9","latestVersionIndicator":"Yes","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C634886-F389-2A99-E053-F662850A8CA9","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Benign Neoplasm","valueDescription":"Benign Neoplasm","ValueMeaning":{"publicId":"2938141","version":"1","preferredName":"Benign Neoplasm","longName":"2938141v1.00","preferredDefinition":"A neoplasm characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benign Neoplasm","conceptCode":"C3677","definition":"A neoplasm characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7289D43E-7E19-ACC7-E040-BB89AD431D77","latestVersionIndicator":"Yes","beginDate":"2009-09-01","endDate":null,"createdBy":"UMLLOADER_TCGA","dateCreated":"2009-09-01","modifiedBy":"GDEEN","dateModified":"2023-04-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C634886-F393-2A99-E053-F662850A8CA9","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Benign Liver and Intrahepatic Bile Duct Epithelial Neoplasm","valueDescription":"Benign Liver and Intrahepatic Bile Duct Epithelial Neoplasm","ValueMeaning":{"publicId":"6797975","version":"1","preferredName":"Benign Liver and Intrahepatic Bile Duct Epithelial Neoplasm","longName":"6797975","preferredDefinition":"A non-metastasizing neoplasm that arises from the hepatocytes or intrahepatic bile ducts.  Representative examples include hepatocellular adenoma and bile duct adenoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benign Liver Epithelial Neoplasm","conceptCode":"C96756","definition":"A neoplasm that arises from the hepatocytes or intrahepatic bile duct epithelial cells and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential. Representative examples include hepatocellular adenoma and bile duct adenoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C634886-F3A1-2A99-E053-F662850A8CA9","latestVersionIndicator":"Yes","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C634886-F3BA-2A99-E053-F662850A8CA9","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Benign Lipomatous Neoplasm","valueDescription":"Benign Lipomatous Neoplasm","ValueMeaning":{"publicId":"6797977","version":"1","preferredName":"Benign Lipomatous Neoplasm","longName":"6797977","preferredDefinition":"A benign mesenchymal neoplasm composed of adipose (fatty) tissue.  The most common representative of this category is the lipoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benign Lipomatous Neoplasm","conceptCode":"C4502","definition":"A mesenchymal neoplasm composed of adipose (fatty) tissue. There is no evidence of atypical or malignant cytological and architectural features, invasive features, or metastases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C634886-F3C7-2A99-E053-F662850A8CA9","latestVersionIndicator":"Yes","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C634886-F3E0-2A99-E053-F662850A8CA9","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Benign Laryngeal Neoplasm","valueDescription":"Benign Laryngeal Neoplasm","ValueMeaning":{"publicId":"6797979","version":"1","preferredName":"Benign Laryngeal Neoplasm","longName":"6797979","preferredDefinition":"A non-metastasizing neoplasm that arises from the larynx.  Representative examples include squamous papilloma and hemangioma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benign Laryngeal Neoplasm","conceptCode":"C3601","definition":"A neoplasm that arises from the larynx and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C634886-F3ED-2A99-E053-F662850A8CA9","latestVersionIndicator":"Yes","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C634886-F406-2A99-E053-F662850A8CA9","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Benign Kidney Neoplasm","valueDescription":"Benign Kidney Neoplasm","ValueMeaning":{"publicId":"6797981","version":"1","preferredName":"Benign Kidney Neoplasm","longName":"6797981","preferredDefinition":"A non-metastasizing neoplasm that arises from the kidney.  Representative examples include cystic nephroma, metanephric adenoma, oncocytoma, and urothelial papilloma of the renal pelvis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benign Kidney Neoplasm","conceptCode":"C4778","definition":"A neoplasm that arises from the kidney and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C634886-F413-2A99-E053-F662850A8CA9","latestVersionIndicator":"Yes","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C634886-F42C-2A99-E053-F662850A8CA9","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Benign Bone Neoplasm","valueDescription":"Benign Bone Neoplasm","ValueMeaning":{"publicId":"6796715","version":"1","preferredName":"Benign Bone Neoplasm","longName":"6796715","preferredDefinition":"A neoplasm that arises from the bone or articular cartilage and does not invade adjacent tissues or metastasize to other anatomic sites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benign Bone Neoplasm","conceptCode":"C4880","definition":"A mesenchymal neoplasm that arises from bone or articular cartilage and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C510162-BE15-5254-E053-F662850ABD5A","latestVersionIndicator":"Yes","beginDate":"2019-06-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-27","modifiedBy":"ONEDATA","dateModified":"2019-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C510162-BE2E-5254-E053-F662850ABD5A","beginDate":"2019-06-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-27","modifiedBy":"ONEDATA","dateModified":"2019-06-27","deletedIndicator":"No"},{"value":"Benign Breast Neoplasm","valueDescription":"Benign Breast Neoplasm","ValueMeaning":{"publicId":"6796712","version":"1","preferredName":"Benign Breast Neoplasm","longName":"6796712","preferredDefinition":"A non-metastasizing neoplasm arising from the breast parenchyma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benign Breast Neoplasm","conceptCode":"C4505","definition":"A neoplasm that arises from the breast and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C510162-BDCC-5254-E053-F662850ABD5A","latestVersionIndicator":"Yes","beginDate":"2019-06-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-27","modifiedBy":"ONEDATA","dateModified":"2019-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C510162-BDE5-5254-E053-F662850ABD5A","beginDate":"2019-06-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-27","modifiedBy":"ONEDATA","dateModified":"2019-06-27","deletedIndicator":"No"},{"value":"Benign Brain Neoplasm","valueDescription":"Benign Brain Neoplasm","ValueMeaning":{"publicId":"6796713","version":"1","preferredName":"Benign Brain Neoplasm","longName":"6796713","preferredDefinition":"A primary, slow growing, noninvasive neoplasm of the brain. In children, astrocytomas of the cerebellum represent relatively common benign brain neoplasms. In adults meningiomas, neurilemomas and pituitary tumors comprise the majority of benign tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benign Brain Neoplasm","conceptCode":"C4781","definition":"A neoplasm that arises from the brain and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C510162-BDEF-5254-E053-F662850ABD5A","latestVersionIndicator":"Yes","beginDate":"2019-06-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-27","modifiedBy":"ONEDATA","dateModified":"2019-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C510162-BE08-5254-E053-F662850ABD5A","beginDate":"2019-06-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-27","modifiedBy":"ONEDATA","dateModified":"2019-06-27","deletedIndicator":"No"},{"value":"Benign Bladder Neoplasm","valueDescription":"Benign Bladder Neoplasm","ValueMeaning":{"publicId":"6796717","version":"1","preferredName":"Benign Bladder Neoplasm","longName":"6796717","preferredDefinition":"A non-metastasizing neoplasm that arises from the bladder.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benign Bladder Neoplasm","conceptCode":"C3618","definition":"A neoplasm that arises from the bladder and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C510162-BE3B-5254-E053-F662850ABD5A","latestVersionIndicator":"Yes","beginDate":"2019-06-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-27","modifiedBy":"ONEDATA","dateModified":"2019-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C510162-BE54-5254-E053-F662850ABD5A","beginDate":"2019-06-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-27","modifiedBy":"ONEDATA","dateModified":"2019-06-27","deletedIndicator":"No"},{"value":"Benign Adrenal Gland Neoplasm","valueDescription":"Benign Adrenal Gland Neoplasm","ValueMeaning":{"publicId":"6796719","version":"1","preferredName":"Benign Adrenal Gland Neoplasm","longName":"6796719","preferredDefinition":"A non-metastasizing neoplasm arising from the adrenal gland.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benign Adrenal Gland Neoplasm","conceptCode":"C3629","definition":"A neoplasm that arises from the adrenal gland and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C510162-BE61-5254-E053-F662850ABD5A","latestVersionIndicator":"Yes","beginDate":"2019-06-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-27","modifiedBy":"ONEDATA","dateModified":"2019-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C510162-BE7A-5254-E053-F662850ABD5A","beginDate":"2019-06-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-27","modifiedBy":"ONEDATA","dateModified":"2019-06-27","deletedIndicator":"No"},{"value":"B-Cell Non-Hodgkin Lymphoma","valueDescription":"B-Cell Non-Hodgkin Lymphoma","ValueMeaning":{"publicId":"4264847","version":"1","preferredName":"B-Cell Non-Hodgkin Lymphoma","longName":"4264847","preferredDefinition":"The most common type of non-Hodgkin lymphoma.  It includes the most frequently seen morphologic variants which are: diffuse large B-cell lymphoma, follicular lymphoma, small lymphocytic lymphoma and marginal zone B-cell lymphoma. -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"B-Cell Non-Hodgkin Lymphoma","conceptCode":"C3457","definition":"The most common type of non-Hodgkin lymphoma.  It includes the most frequently seen morphologic variants which are: diffuse large B-cell lymphoma, follicular lymphoma, small lymphocytic lymphoma and marginal zone B-cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67A42F0-016B-5F77-E040-BB89AD433177","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C510162-BE8E-5254-E053-F662850ABD5A","beginDate":"2019-06-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-27","modifiedBy":"ONEDATA","dateModified":"2019-06-27","deletedIndicator":"No"},{"value":"B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma","valueDescription":"B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma","ValueMeaning":{"publicId":"3928522","version":"1","preferredName":"B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma","longName":"3928522","preferredDefinition":"A group of lymphomas displaying molecular, morphologic, immunophenotypic, and clinical overlap between classical Hodgkin lymphoma and diffuse large B-cell lymphoma.  This term particularly applies to mediastinal lymphomas with overlapping features of mediastinal (thymic) large B-cell lymphoma and classical Hodgkin lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gray-Zone Lymphoma","conceptCode":"C37869","definition":"A group of lymphomas displaying molecular, morphologic, immunophenotypic, and clinical overlap between classic Hodgkin lymphoma and diffuse large B-cell lymphoma.  This term particularly applies to mediastinal lymphomas with overlapping features of mediastinal (thymic) large B-cell lymphoma and classic Hodgkin lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E96DEF43-3C53-7609-E040-BB89AD4366AC","latestVersionIndicator":"Yes","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C510162-BEA2-5254-E053-F662850ABD5A","beginDate":"2019-06-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-27","modifiedBy":"ONEDATA","dateModified":"2019-06-27","deletedIndicator":"No"},{"value":"Letterer-Siwe Disease","valueDescription":"Letterer-Siwe Disease","ValueMeaning":{"publicId":"3249983","version":"1","preferredName":"Letterer-Siwe Disease","longName":"3249983","preferredDefinition":"A multifocal, multisystem form of Langerhans-cell histiocytosis. There is involvement of multiple organ systems including the bones, skin, liver, spleen, and lymph nodes. Patients are usually infants presenting with fever, hepatosplenomegaly, lymphadenopathy, bone and skin lesions, and pancytopenia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Letterer-Siwe Disease","conceptCode":"C3160","definition":"A multifocal, multisystem form of Langerhans-cell histiocytosis. There is involvement of multiple organ systems including the bones, skin, liver, spleen, and lymph nodes. Patients are usually infants presenting with fever, hepatosplenomegaly, lymphadenopathy, bone and skin lesions, and pancytopenia.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6DD9D38-4544-E039-E040-BB89AD434D66","latestVersionIndicator":"Yes","beginDate":"2011-06-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B1944-8D72-3752-E053-F662850AB899","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Leiomyosarcoma","valueDescription":"Leiomyosarcoma","ValueMeaning":{"publicId":"4824388","version":"1","preferredName":"Leiomyosarcoma","longName":"4824388","preferredDefinition":"An uncommon, aggressive malignant smooth muscle neoplasm, usually occurring in post-menopausal women.  It is characterized by a proliferation of neoplastic spindle cells.  Morphologic variants include epithelioid, granular cell, inflammatory and myxoid leimyosarcomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leiomyosarcoma","conceptCode":"C3158","definition":"An uncommon, aggressive malignant smooth muscle neoplasm, usually occurring in post-menopausal women.  It is characterized by a proliferation of neoplastic spindle cells.  Morphologic variants include epithelioid, granular cell, inflammatory and myxoid leimyosarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"15EBDE73-B344-8DA9-E050-BB89AD4368FB","latestVersionIndicator":"Yes","beginDate":"2015-05-12","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-05-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B1944-8D87-3752-E053-F662850AB899","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Leukemia Cutis","valueDescription":"Leukemia Cutis","ValueMeaning":{"publicId":"3251348","version":"1","preferredName":"Leukemia Cutis","longName":"3251348","preferredDefinition":"Cutaneous involvement by an acute or chronic leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leukemia Cutis","conceptCode":"C88156","definition":"Cutaneous involvement by an acute or chronic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A758F49E-9E58-73F4-E040-BB89AD430DFE","latestVersionIndicator":"Yes","beginDate":"2011-07-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-05","modifiedBy":"COOPERM","dateModified":"2011-09-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B1944-8D92-3752-E053-F662850AB899","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Leukemia in Remission","valueDescription":"Leukemia in Remission","ValueMeaning":{"publicId":"6832682","version":"1","preferredName":"Leukemia in Remission","longName":"6832682","preferredDefinition":"History of leukemia after therapy with no evidence on the peripheral blood or bone marrow of leukemia (normalization of all hematologic parameters).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leukemia in Remission","conceptCode":"C4896","definition":"A finding of leukemia that is not growing and responds to treatment","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B1944-8DA0-3752-E053-F662850AB899","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B1944-8DB9-3752-E053-F662850AB899","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Lip and Oral Cavity Carcinoma","valueDescription":"Lip and Oral Cavity Carcinoma","ValueMeaning":{"publicId":"6832684","version":"1","preferredName":"Lip and Oral Cavity Carcinoma","longName":"6832684","preferredDefinition":"A carcinoma arising in the lip or oral cavity.  Most oral cavity carcinomas are squamous cell carcinomas of the tongue, buccal mucosa, or gums.  Less frequent morphologic variants include mucoepidermoid carcinoma and adenocarcinoma.  Lip carcinomas are usually basal cell or squamous cell carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lip and Oral Cavity Carcinoma","conceptCode":"C9315","definition":"A carcinoma arising in the lip or oral cavity.  Most oral cavity carcinomas are squamous cell carcinomas of the tongue, buccal mucosa, or gums.  Less frequent morphologic variants include mucoepidermoid carcinoma and adenocarcinoma.  Lip carcinomas are usually basal cell or squamous cell carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B1944-8DC6-3752-E053-F662850AB899","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B1944-8DDF-3752-E053-F662850AB899","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Lip Basal Cell Carcinoma","valueDescription":"Lip Basal Cell Carcinoma","ValueMeaning":{"publicId":"6832686","version":"1","preferredName":"Lip Basal Cell Carcinoma","longName":"6832686","preferredDefinition":"A basal cell carcinoma arising from the lip.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lip Basal Cell Carcinoma","conceptCode":"C8014","definition":"A basal cell carcinoma arising from the lip.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B1944-8DEC-3752-E053-F662850AB899","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B1944-8E05-3752-E053-F662850AB899","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Lip Carcinoma","valueDescription":"Lip Carcinoma","ValueMeaning":{"publicId":"6832688","version":"1","preferredName":"Lip Carcinoma","longName":"6832688","preferredDefinition":"A malignant epithelial neoplasm arising from the lips.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lip Carcinoma","conceptCode":"C3490","definition":"A malignant epithelial neoplasm arising from the lips.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B1944-8E12-3752-E053-F662850AB899","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B1944-8E2B-3752-E053-F662850AB899","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Lip Squamous Cell Carcinoma","valueDescription":"Lip Squamous Cell Carcinoma","ValueMeaning":{"publicId":"6832690","version":"1","preferredName":"Lip Squamous Cell Carcinoma","longName":"6832690","preferredDefinition":"A squamous cell carcinoma that arises from the lip.  It affects males more often than females and it usually involves the lower lip.  Risk factors include UV exposure, alcohol consumption, smoking, and immunosuppression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lip Squamous Cell Carcinoma","conceptCode":"C4042","definition":"A squamous cell carcinoma that arises from the lip.  It affects males more often than females and it usually involves the lower lip.  Risk factors include UV exposure, alcohol consumption, smoking, and immunosuppression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B1944-8E38-3752-E053-F662850AB899","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B1944-8E51-3752-E053-F662850AB899","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Lipid-Rich Carcinoma","valueDescription":"Lipid-Rich Carcinoma","ValueMeaning":{"publicId":"3669456","version":"1","preferredName":"Lipid-Rich Carcinoma","longName":"3669456","preferredDefinition":"A carcinoma characterized by the presence of malignant epithelial cells with clear cytoplasm which contains neutral lipids. A representative example is the lipid-rich breast carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lipid-Rich Carcinoma","conceptCode":"C4152","definition":"A carcinoma characterized by the presence of malignant epithelial cells with clear cytoplasm which contains neutral lipids. A representative example is the lipid-rich breast carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D4858C70-7788-328A-E040-BB89AD433B84","latestVersionIndicator":"Yes","beginDate":"2013-01-30","endDate":null,"createdBy":"MAESKEB","dateCreated":"2013-01-30","modifiedBy":"COOPERM","dateModified":"2020-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B1944-8E65-3752-E053-F662850AB899","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Hereditary Malignant Neoplasm","valueDescription":"Hereditary Malignant Neoplasm","ValueMeaning":{"publicId":"6832580","version":"1","preferredName":"Hereditary Malignant Neoplasm","longName":"6832580","preferredDefinition":"Cancer aggregating among blood relatives.  Does not necessarily imply a genetic inheritance.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hereditary Malignant Neoplasm","conceptCode":"C9479","definition":"Malignant neoplasms occurring in families at a rate greater than that expected by chance and caused by germline mutations in a specific gene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9ACEC6-3464-0695-E053-F662850A6026","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9ACEC6-347D-0695-E053-F662850A6026","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Rectal Carcinoma","valueDescription":"Rectal Carcinoma","ValueMeaning":{"publicId":"4839991","version":"1","preferredName":"Rectal Carcinoma","longName":"4839991","preferredDefinition":"A malignant epithelial neoplasm that arises from the rectum and invades through the muscularis mucosa into the submucosa.  The vast majority are adenocarcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rectal Carcinoma","conceptCode":"C9382","definition":"A malignant epithelial neoplasm that arises from the rectum. The vast majority are adenocarcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"17181BD7-C47D-F1F7-E050-BB89AD431A04","latestVersionIndicator":"Yes","beginDate":"2015-05-27","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-05-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E99360B-AADA-282F-E053-F662850A2209","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Radiation-Related Sarcoma","valueDescription":"Radiation-Related Sarcoma","ValueMeaning":{"publicId":"3179367","version":"1","preferredName":"Radiation-Related Sarcoma","longName":"3179367","preferredDefinition":"A malignant mesenchymal tumor that arises following exposure to ionizing or non-ionizing radiation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Radiation-Related Sarcoma","conceptCode":"C93125","definition":"A sarcoma that arises in the bones or soft tissues following exposure to ionizing or non-ionizing radiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9890B54F-86ED-2C65-E040-BB89AD4320B1","latestVersionIndicator":"Yes","beginDate":"2010-12-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E99360B-AAEE-282F-E053-F662850A2209","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Radiation-Related Malignant Neoplasm","valueDescription":"Radiation-Related Malignant Neoplasm","ValueMeaning":{"publicId":"6832406","version":"1","preferredName":"Radiation-Related Malignant Neoplasm","longName":"6832406","preferredDefinition":"A malignant neoplasm arising in a site exposed to radiation therapy. ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Radiation-Related Malignant Neoplasm","conceptCode":"C27209","definition":"A malignant neoplasm arising in a site exposed to radiation therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E99360B-AAFB-282F-E053-F662850A2209","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"SOKKERL","dateModified":"2019-08-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E99360B-AB14-282F-E053-F662850A2209","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Radiation-Related Leukemia","valueDescription":"Radiation-Related Leukemia","ValueMeaning":{"publicId":"6832408","version":"1","preferredName":"Radiation-Related Leukemia","longName":"6832408","preferredDefinition":"Leukemia that is caused by radiation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Radiation-Related Leukemia","conceptCode":"C26814","definition":"Leukemia that is caused by radiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E99360B-AB21-282F-E053-F662850A2209","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E99360B-AB3A-282F-E053-F662850A2209","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Prostate Neoplasm","valueDescription":"Prostate Neoplasm","ValueMeaning":{"publicId":"2593176","version":"1","preferredName":"Prostate Neoplasm","longName":"2593176","preferredDefinition":"A benign or malignant tumor involving the prostate gland. -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Neoplasm","conceptCode":"C3343","definition":"A benign, borderline, or malignant neoplasm that affects the prostate gland.  Representative examples include benign prostate phyllodes tumor, prostatic intraepithelial neoplasia, prostate carcinoma, and prostate sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28701A35-6618-579B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E99360B-AB44-282F-E053-F662850A2209","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"High Grade Astrocytic Tumor","valueDescription":"High Grade Astrocytic Tumor","ValueMeaning":{"publicId":"4722558","version":"1","preferredName":"High Grade Astrocytic Tumor","longName":"4722558","preferredDefinition":"An anaplastic astrocytoma (grade III astrocytic tumor) or glioblastoma (grade IV astrocytic tumor).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"High Grade Astrocytic Tumor","conceptCode":"C102897","definition":"An astrocytic tumor exhibiting high-grade morphological characteristics. This category includes anaplastic astrocytoma, glioblastoma, and astrocytoma, IDH-mutant, grade 4.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F886EE6-B73F-DB60-E050-BB89AD4356E3","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9ACEC6-3456-0695-E053-F662850A6026","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Hepatocellular Carcinoma","valueDescription":"Hepatocellular Carcinoma","ValueMeaning":{"publicId":"2573454","version":"1","preferredName":"Hepatocellular Carcinoma","longName":"2573454","preferredDefinition":"A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatocellular Carcinoma","conceptCode":"C3099","definition":"A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EBFB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-15","modifiedBy":"CHILLIJ","dateModified":"2007-03-27","changeDescription":"03/27/2007 - Updated with NCI Thesaurus definition (abbreviated version.)","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9ACEC6-3487-0695-E053-F662850A6026","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Hepatoblastoma","valueDescription":"Hepatoblastoma","ValueMeaning":{"publicId":"4264913","version":"1","preferredName":"Hepatoblastoma","longName":"4264913","preferredDefinition":"A malignant liver neoplasm that occurs almost exclusively in infants, although isolated cases in older children and adults have been reported. Grossly, hepatoblastoma is solid, well circumscribed, and more often solitary than multiple. Microscopically, most of the tumors are composed exclusively of immature hepatocytic elements. About a fourth of hepatoblastomas contain a stromal component that may be undifferentiated or develop into bone or cartilage. The treatment of choice for hepatoblastoma is surgical excision with adjuvant therapy. Liver transplantation is being increasingly used as well.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatoblastoma","conceptCode":"C3728","definition":"A malignant embryonal neoplasm that arises from the liver. It occurs almost exclusively in infants, although isolated cases in older children and adults have been reported. Microscopically,  it consists of either epithelial or epithelial and mesenchymal components.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67F3F28-FD89-6FE9-E040-BB89AD433764","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9ACEC6-3491-0695-E053-F662850A6026","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Hepatobiliary Neoplasm","valueDescription":"Hepato-Biliary Neoplasm","ValueMeaning":{"publicId":"3322766","version":"1","preferredName":"Hepato-Biliary Neoplasm","longName":"3322766","preferredDefinition":"A benign or malignant neoplasm involving the liver or the biliary tract.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatobiliary Neoplasm","conceptCode":"C8614","definition":"A benign or malignant neoplasm that affects the liver parenchyma, bile ducts, and gallbladder.  Representative examples of benign neoplasms include hepatocellular adenoma, bile duct adenoma, and gallbladder lipoma.  Representative examples of malignant neoplasms include hepatocellular carcinoma, intrahepatic and extrahepatic cholangiocarcinoma, and gallbladder carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3714D57-A8B9-7A8F-E040-BB89AD43536C","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9ACEC6-34A5-0695-E053-F662850A6026","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Hematopoietic and Lymphoid Cell Neoplasm","valueDescription":"Hematopoietic and Lymphoid Cell Neoplasm","ValueMeaning":{"publicId":"4265238","version":"1","preferredName":"Hematopoietic and Lymphoid Cell Neoplasm","longName":"4265238","preferredDefinition":"A cancer of the blood or bone marrow, such as leukemia or lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematopoietic and Lymphoid Cell Neoplasm","conceptCode":"C27134","definition":"A neoplasm that arises from hematopoietic and lymphoid cells. Representative examples include myeloproliferative neoplasms, myelodysplastic syndromes, leukemias, Hodgkin lymphomas, and non-Hodgkin lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F68C00B1-7851-6438-E040-BB89AD4373BF","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"TSESU","dateModified":"2023-01-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9ACEC6-34BA-0695-E053-F662850A6026","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Hemangioma","valueDescription":"Hemangioma","ValueMeaning":{"publicId":"4824378","version":"1","preferredName":"Hemangioma","longName":"4824378","preferredDefinition":"A benign vascular lesion characterized by the formation of capillary-sized or cavernous vascular channels.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hemangioma","conceptCode":"C3085","definition":"A benign vascular lesion characterized by the formation of capillary-sized or cavernous vascular channels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"15EBDE73-B1D7-8DA9-E050-BB89AD4368FB","latestVersionIndicator":"Yes","beginDate":"2015-05-12","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-05-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9ACEC6-34C4-0695-E053-F662850A6026","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Helicobacter Pylori-Related Carcinoma","valueDescription":"Helicobacter Pylori-Related Carcinoma","ValueMeaning":{"publicId":"6832582","version":"1","preferredName":"Helicobacter Pylori-Related Carcinoma","longName":"6832582","preferredDefinition":"A carcinoma that is caused by Helicobacter pylori.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Helicobacter Pylori-Related Carcinoma","conceptCode":"C27764","definition":"A carcinoma that is caused by Helicobacter pylori.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9ACEC6-34D2-0695-E053-F662850A6026","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9ACEC6-34EB-0695-E053-F662850A6026","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Head and Neck Neoplasm","valueDescription":"Head and Neck Neoplasm","ValueMeaning":{"publicId":"2593169","version":"1","preferredName":"Head and Neck Neoplasm","longName":"2593169","preferredDefinition":"A benign or malignant neoplasm affecting one of the following areas: base of skull and facial bones, sinuses, orbits, salivary glands, oral cavity, oropharynx, larynx, thyroid, facial and neck musculature and lymph nodes draining these areas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Head and Neck Neoplasm","conceptCode":"C3077","definition":"A benign or malignant neoplasm that affects the anatomic structures of the head and neck region.  Representative examples of benign neoplasms include salivary gland pleomorphic adenoma and nasal cavity papilloma.  Representative examples of malignant neoplasms include oral cavity squamous cell carcinoma, laryngeal squamous cell carcinoma, and salivary gland carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28701A35-6596-579B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9ACEC6-34F5-0695-E053-F662850A6026","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Head and Neck Carcinoma","valueDescription":"Head and Neck Carcinoma","ValueMeaning":{"publicId":"5581333","version":"1","preferredName":"Head and Neck Carcinoma","longName":"5581333","preferredDefinition":"A carcinoma that arises from the head and neck region.  Representative examples include oral cavity squamous cell carcinoma, laryngeal squamous cell carcinoma, and salivary gland carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Head and Neck Carcinoma","conceptCode":"C35850","definition":"A carcinoma that arises from the head and neck region.  Representative examples include oral cavity squamous cell carcinoma, laryngeal squamous cell carcinoma, and salivary gland carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42019733-B75C-634F-E053-F662850A5A61","latestVersionIndicator":"Yes","beginDate":"2016-11-23","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2016-11-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9ACEC6-350A-0695-E053-F662850A6026","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Hand-Schuller-Christian Disease","valueDescription":"Hand-Schuller-Christian Disease","ValueMeaning":{"publicId":"6832584","version":"1","preferredName":"Hand-Schuller-Christian Disease","longName":"6832584","preferredDefinition":"A multifocal, unisystem form of Langerhans-cell histiocytosis. There is involvement of multiple sites in one organ system, most frequently the bone. Patients are usually young children presenting with multiple destructive bone lesions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hand-Schuller-Christian Disease","conceptCode":"C6920","definition":"A multifocal, unisystem form of Langerhans-cell histiocytosis. There is involvement of multiple sites in one organ system, most frequently the bone. Patients are usually young children presenting with multiple destructive bone lesions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9ACEC6-3518-0695-E053-F662850A6026","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9ACEC6-3531-0695-E053-F662850A6026","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Lymphoma","valueDescription":"Lymphoma","ValueMeaning":{"publicId":"5581337","version":"1","preferredName":"Lymphoma","longName":"5581337","preferredDefinition":"A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphoma","conceptCode":"C3208","definition":"A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42019733-B7F3-634F-E053-F662850A5A61","latestVersionIndicator":"Yes","beginDate":"2016-11-23","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2016-11-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B9E27-5138-359A-E053-F662850ADB9D","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Male Malignant Nipple Neoplasm","valueDescription":"BR - 175.0; Breast-Male","ValueMeaning":{"publicId":"2572636","version":"1","preferredName":"BR - 175.0; Breast-Male","longName":"2572636","preferredDefinition":"A malignant neoplasm that affects the area of the nipple in males.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Male Malignant Nipple Neoplasm","conceptCode":"C120454","definition":"A malignant neoplasm that affects the area of the nipple in males.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8C9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"COOPERM","dateModified":"2015-03-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B9E27-514D-359A-E053-F662850ADB9D","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Abdominal Neoplasm","valueDescription":"Malignant Abdominal Neoplasm","ValueMeaning":{"publicId":"6832812","version":"1","preferredName":"Malignant Abdominal Neoplasm","longName":"6832812","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the organs and structures of the abdomen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Abdominal Neoplasm","conceptCode":"C156714","definition":"A primary or metastatic malignant neoplasm that affects the organs and structures of the abdomen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B9E27-515B-359A-E053-F662850ADB9D","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B9E27-5174-359A-E053-F662850ADB9D","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Adrenal Medulla Neoplasm","valueDescription":"Malignant Adrenal Medulla Neoplasm","ValueMeaning":{"publicId":"6832814","version":"1","preferredName":"Malignant Adrenal Medulla Neoplasm","longName":"6832814","preferredDefinition":"A primary or metastatic malignant neoplasm affecting the adrenal medulla.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Adrenal Medulla Neoplasm","conceptCode":"C4396","definition":"A primary or metastatic malignant neoplasm affecting the adrenal medulla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B9E27-5181-359A-E053-F662850ADB9D","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B9E27-519A-359A-E053-F662850ADB9D","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Ampulla of Vater Neoplasm","valueDescription":"Malignant Ampulla of Vater Neoplasm","ValueMeaning":{"publicId":"6832816","version":"1","preferredName":"Malignant Ampulla of Vater Neoplasm","longName":"6832816","preferredDefinition":"A primary or metastatic malignant neoplasm involving the ampulla of Vater.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Ampulla of Vater Neoplasm","conceptCode":"C3536","definition":"A primary or metastatic malignant neoplasm involving the ampulla of Vater.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B9E27-51A7-359A-E053-F662850ADB9D","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B9E27-51C0-359A-E053-F662850ADB9D","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Nodular Lymphocyte Predominant Hodgkin Lymphoma","valueDescription":"Nodular Lymphocyte Predominant Hodgkin Lymphoma","ValueMeaning":{"publicId":"2838645","version":"1","preferredName":"Nodular Lymphocyte Predominant Hodgkin Lymphoma","longName":"2838645","preferredDefinition":"A monoclonal B-cell neoplasm characterized by a nodular, or a nodular and diffuse, polymorphous proliferation of scattered large neoplastic cells known as popcorn or L&H cells; the L&H cells are CD15 negative, and rarely positive for CD30 antigen.  Patients are predominantly male, frequently in the 30-50 year age group.  Most patients present with limited stage disease (localized peripheral lymphadenopathy, stage I or II); the prognosis of patients with stage I and stage II disease is very good.  Advanced stages have an unfavorable prognosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nodular Lymphocyte Predominant B-Cell Lymphoma","conceptCode":"C7258","definition":"A B-cell lymphoma characterized by the presence of scattered clonal cells known as lymphocyte predominant cells (LP cells) in a background of reactive lymphocytes and histiocytes, and formation of a nodular or nodular and diffuse growth pattern.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A740CA-9584-2FE1-E040-BB89AD4311CA","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"DWARZEL","dateModified":"2012-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E972F13-4A66-03FE-E053-F662850AD6D9","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Hairy Cell Leukemia","valueDescription":"Hairy Cell Leukemia","ValueMeaning":{"publicId":"2838575","version":"1","preferredName":"Hairy Cell Leukemia","longName":"2838575","preferredDefinition":"A rare neoplasm of small B-lymphocytes with \"hairy\" projections in bone marrow, spleen and peripheral blood.  Most patients are middle-aged to elderly adults and present with splenomegaly and pancytopenia. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hairy Cell Leukemia","conceptCode":"C7402","definition":"A neoplasm of small B-lymphocytes with \"hairy\" projections in bone marrow, spleen, and peripheral blood.  Most patients present with splenomegaly and pancytopenia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A51A25-5837-CA49-E040-BB89AD435D3A","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"GDEEN","dateModified":"2023-06-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9ACEC6-353B-0695-E053-F662850A6026","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Grade III Prostatic Intraepithelial Neoplasia","valueDescription":"Grade III Prostatic Intraepithelial Neoplasia","ValueMeaning":{"publicId":"6832586","version":"1","preferredName":"Grade III Prostatic Intraepithelial Neoplasia","longName":"6832586","preferredDefinition":"High grade prostatic intraepithelial neoplasia characterized by the presence of severe architectural and cytologic abnormalities.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade III Prostatic Intraepithelial Neoplasia","conceptCode":"C3642","definition":"High grade prostatic intraepithelial neoplasia characterized by the presence of severe architectural and cytologic abnormalities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9ACEC6-3548-0695-E053-F662850A6026","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9ACEC6-3561-0695-E053-F662850A6026","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Grade III Meningioma","valueDescription":"Grade III Meningioma","ValueMeaning":{"publicId":"6832588","version":"1","preferredName":"Grade III Meningioma","longName":"6832588","preferredDefinition":"A malignant meningioma with aggressive clinical course.  It recurs in approximately 50-78% of the cases.  This category includes the anaplastic (malignant) meningioma, papillary meningioma, and rhabdoid meningioma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade 3 Meningioma","conceptCode":"C38938","definition":"A malignant meningioma with aggressive clinical course.  It recurs in approximately 50-78% of the cases.  This category includes the anaplastic (malignant) meningioma, papillary meningioma, and rhabdoid meningioma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9ACEC6-356E-0695-E053-F662850A6026","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9ACEC6-3587-0695-E053-F662850A6026","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Grade 3a Follicular Lymphoma","valueDescription":"Grade 3a Follicular Lymphoma","ValueMeaning":{"publicId":"3928530","version":"1","preferredName":"Grade 3a Follicular Lymphoma","longName":"3928530","preferredDefinition":"A grade 3 follicular lymphoma in which centrocytes are present.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade 3a Follicular Lymphoma","conceptCode":"C7191","definition":"A grade 3 follicular lymphoma in which centrocytes are present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E96DEF43-3D31-7609-E040-BB89AD4366AC","latestVersionIndicator":"Yes","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9ACEC6-359B-0695-E053-F662850A6026","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Grade 3 Follicular Lymphoma","valueDescription":"Grade 3 Follicular Lymphoma","ValueMeaning":{"publicId":"2593084","version":"1","preferredName":"Grade 3 Follicular Lymphoma","longName":"2593084","preferredDefinition":"A follicular lymphoma which contains more than 15 centroblasts per 40X high-power microscopic field.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade 3 Follicular Lymphoma","conceptCode":"C3460","definition":"A follicular lymphoma which contains more than 15 centroblasts per 40X high-power microscopic field.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286C5855-1A89-6248-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9ACEC6-35A6-0695-E053-F662850A6026","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Grade 2 Follicular Lymphoma","valueDescription":"Grade 2 Follicular Lymphoma","ValueMeaning":{"publicId":"3088717","version":"1","preferredName":"Grade 2 Follicular Lymphoma","longName":"3088717","preferredDefinition":"A follicular lymphoma which contains 6-15 centroblasts per 40X high-power microscopic field.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade 2 Follicular Lymphoma","conceptCode":"C8968","definition":"A follicular lymphoma which contains 6-15 centroblasts per 40X high-power microscopic field.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86E480BB-B6CD-7B51-E040-BB89AD433123","latestVersionIndicator":"Yes","beginDate":"2010-05-18","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-05-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9ACEC6-35BB-0695-E053-F662850A6026","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Grade 1 Follicular Lymphoma","valueDescription":"Grade 1 Follicular Lymphoma","ValueMeaning":{"publicId":"2593080","version":"1","preferredName":"Grade 1 Follicular Lymphoma","longName":"2593080","preferredDefinition":"A low-grade malignant lymphoma of predominantly follicular pattern. Follicles are of relatively uniform size and shape and the cells are usually somewhat larger than normal lymphocytes. Nuclei are irregular with prominent indentations and cytoplasm can rarely be identified. Cells exhibiting these characteristics are often called small cleaved cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade 1 Follicular Lymphoma","conceptCode":"C3465","definition":"A follicular lymphoma which contains up to 5 centroblasts per 40X high-power microscopic field.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286C5855-1A3B-6248-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9ACEC6-35C6-0695-E053-F662850A6026","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Glycogen-Rich Carcinoma","valueDescription":"Glycogen-Rich Carcinoma","ValueMeaning":{"publicId":"6832590","version":"1","preferredName":"Glycogen-Rich Carcinoma","longName":"6832590","preferredDefinition":"A carcinoma characterized by the presence of malignant epithelial cells with abundant clear cytoplasm which contains glycogen. A representative example is the glycogen-rich, clear cell breast carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glycogen-Rich Carcinoma","conceptCode":"C4153","definition":"A carcinoma characterized by the presence of malignant epithelial cells with abundant clear cytoplasm which contains glycogen. A representative example is the glycogen-rich, clear cell breast carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9ACEC6-35D4-0695-E053-F662850A6026","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9ACEC6-35ED-0695-E053-F662850A6026","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Glioma","valueDescription":"Glioma","ValueMeaning":{"publicId":"5043642","version":"1","preferredName":"Glioma","longName":"5043642","preferredDefinition":"A benign or malignant brain and spinal cord tumor that arises from glial cells (astrocytes, oligodendrocytes, ependymal cells). Tumors that arise from astrocytes are called astrocytic tumors or astrocytomas. Tumors that arise from oligodendrocytes are called oligodendroglial tumors. Tumors that arise from ependymal cells are called ependymomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glioma","conceptCode":"C3059","definition":"A benign or malignant brain and spinal cord tumor that arises from glial cells (astrocytes, oligodendrocytes, ependymal cells). Tumors that arise from astrocytes are called astrocytic tumors or astrocytomas. Tumors that arise from oligodendrocytes are called oligodendroglial tumors. Tumors that arise from ependymal cells are called ependymomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2434C622-BEA6-E3B1-E050-BB89AD43792A","latestVersionIndicator":"Yes","beginDate":"2015-11-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-11-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9ACEC6-3601-0695-E053-F662850A6026","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Glioblastoma","valueDescription":"Glioblastoma","ValueMeaning":{"publicId":"3686274","version":"1","preferredName":"Glioblastoma","longName":"3686274","preferredDefinition":"The most malignant astrocytic tumor (WHO grade IV). It is composed of poorly differentiated neoplastic astrocytes and it is characterized by the presence of cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation and necrosis. It typically affects adults and is preferentially located in the cerebral hemispheres. It may develop from diffuse astrocytoma WHO grade II or anaplastic astrocytoma (secondary glioblastoma), but more frequently, it manifests after a short clinical history de novo, without evidence of a less malignant precursor lesion (primary glioblastoma). Two histologic variants are recognized: giant cell glioblastoma and gliosarcoma. (WHO) ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glioblastoma","conceptCode":"C3058","definition":"The most malignant astrocytic tumor (WHO grade 4).  It is composed of poorly differentiated neoplastic astrocytes and is characterized by the presence of cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation, and necrosis. It typically affects adults and is preferentially located in the cerebral hemispheres. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D5C534CC-6FFB-BB02-E040-BB89AD4314F2","latestVersionIndicator":"Yes","beginDate":"2013-02-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9ACEC6-360C-0695-E053-F662850A6026","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Squamous Cell Carcinoma","valueDescription":"Squamous Cell Carcinoma","ValueMeaning":{"publicId":"4264988","version":"1","preferredName":"Squamous Cell Carcinoma","longName":"4264988","preferredDefinition":"A carcinoma arising from squamous epithelial cells.  Morphologically, it is characterized by the proliferation of atypical, often pleomorphic squamous cells.  Squamous cell carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated.  Well differentiated carcinomas are usually associated with keratin production and the presence of intercellular bridges between adjacent cells.  Representative examples are lung squamous cell carcinoma, skin squamous cell carcinoma, and cervical squamous cell carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Squamous Cell Carcinoma","conceptCode":"C2929","definition":"A carcinoma arising from squamous epithelial cells.  Morphologically, it is characterized by the proliferation of atypical, often pleomorphic squamous cells.  Squamous cell carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated.  Well differentiated carcinomas are usually associated with keratin production and the presence of intercellular bridges between adjacent cells.  Representative examples are lung squamous cell carcinoma, skin squamous cell carcinoma, and cervical squamous cell carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3EBF-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-82A4-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Splenic Manifestation of Leukemia","valueDescription":"Splenic Manifestation of Leukemia","ValueMeaning":{"publicId":"6832592","version":"1","preferredName":"Splenic Manifestation of Leukemia","longName":"6832592","preferredDefinition":"Infiltration and expansion of the white and/or red pulp and sinusoids of the spleen by leukemic cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Splenic Manifestation of Leukemia","conceptCode":"C7296","definition":"Infiltration and expansion of the white and/or red pulp and sinusoids of the spleen by leukemic cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AD117-82B1-781C-E053-F662850A5AA6","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-82CA-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Spindle Cell Sarcoma","valueDescription":"Spindle Cell Sarcoma","ValueMeaning":{"publicId":"4419560","version":"1","preferredName":"Spindle Cell Sarcoma","longName":"4419560","preferredDefinition":"A malignant mesenchymal neoplasm composed of spindle-shaped cells.  This is a morphologic term which can be applied to a wide range of sarcomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Spindle Cell Sarcoma","conceptCode":"C27005","definition":"A malignant mesenchymal neoplasm composed of spindle-shaped cells.  This is a morphologic term which can be applied to a wide range of sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF6CD43E-FBF3-E71D-E040-BB89AD437276","latestVersionIndicator":"Yes","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-82DE-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Spindle Cell Melanoma","valueDescription":"Spindle Cell Melanoma","ValueMeaning":{"publicId":"3729980","version":"1","preferredName":"Spindle Cell Melanoma","longName":"3729980","preferredDefinition":"A melanoma characterized by the presence of malignant spindle-shaped melanocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Spindle Cell Melanoma","conceptCode":"C4237","definition":"A melanoma characterized by the presence of malignant spindle-shaped melanocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB36A402-8E49-DCBB-E040-BB89AD436B1E","latestVersionIndicator":"Yes","beginDate":"2013-04-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-04-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-82E8-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Solid Neoplasm","valueDescription":"Solid Neoplasm","ValueMeaning":{"publicId":"5438011","version":"1","preferredName":"Solid Neoplasm","longName":"5438011","preferredDefinition":"A benign or malignant neoplasm arising from tissues that do not include fluid areas. Representative examples include epithelial neoplasms (e.g. lung carcinoma, prostate carcinoma, breast carcinoma, colon carcinoma), and neoplasms arising from the soft tissues and bones (e.g. leiomyosarcoma, liposarcoma, chondrosarcoma, osteosarcoma). Neoplasms originating from the blood or bone marrow (leukemias and myeloproliferative disorders) are not considered solid tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Solid Neoplasm","conceptCode":"C9292","definition":"A benign or malignant neoplasm arising from tissues that do not include fluid areas.  Representative examples include epithelial neoplasms (e.g. lung carcinoma, prostate carcinoma, breast carcinoma, colon carcinoma), and neoplasms arising from the soft tissues and bones (e.g. leiomyosarcoma, liposarcoma, chondrosarcoma, osteosarcoma).  Neoplasms originating from the blood or bone marrow (leukemias and myeloproliferative disorders) are not considered solid tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B3C588B-6791-0A60-E050-BB89AD432BC1","latestVersionIndicator":"Yes","beginDate":"2016-08-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-82FD-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Solid Carcinoma","valueDescription":"Solid Carcinoma","ValueMeaning":{"publicId":"3243459","version":"1","preferredName":"Solid Carcinoma","longName":"3243459","preferredDefinition":"A carcinoma morphologically characterized by the presence of solid sheets of malignant epithelial cells in tissues.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Solid Carcinoma","conceptCode":"C4137","definition":"A carcinoma morphologically characterized by the presence of solid sheets of malignant epithelial cells in tissues.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A55A32E7-33E7-D7C0-E040-BB89AD437508","latestVersionIndicator":"Yes","beginDate":"2011-06-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-06-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-8312-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Soft Tissue Sarcoma","valueDescription":"Soft Tissue Sarcoma","ValueMeaning":{"publicId":"3384698","version":"1","preferredName":"Soft Tissue Sarcoma","longName":"3384698","preferredDefinition":"A malignant mesenchymal neoplasm arising from muscle tissue, adipose tissue, blood vessels, fibrous tissue, or other supportive tissues excluding the bones.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Soft Tissue Sarcoma","conceptCode":"C9306","definition":"A malignant neoplasm arising from muscle tissue, adipose tissue, blood vessels, fibrous tissue, or other supportive tissues excluding the bones.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9A3DDB0-75C8-1600-E040-BB89AD432CFF","latestVersionIndicator":"Yes","beginDate":"2012-02-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-831D-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Soft Tissue Neoplasm","valueDescription":"Soft Tissue Neoplasm","ValueMeaning":{"publicId":"4722494","version":"1","preferredName":"Soft Tissue Neoplasm","longName":"4722494","preferredDefinition":"A benign or malignant neoplasm that arises from mesenchymal cells in extra skeletal sites.  The most common types are lipomatous (fatty), vascular, smooth muscle, fibrous, and fibrohistiocytic neoplasms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Soft Tissue Neoplasm","conceptCode":"C3377","definition":"A benign, intermediate, or malignant neoplasm that arises from the soft tissue.  The most common types are lipomatous (fatty), vascular, smooth muscle, fibrous, and fibrohistiocytic neoplasms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8748A7-4713-DF2B-E050-BB89AD4311E0","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-8331-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Small Lymphocytic Lymphoma","valueDescription":"Small Lymphocytic Lymphoma","ValueMeaning":{"publicId":"3251329","version":"1","preferredName":"Small Lymphocytic Lymphoma","longName":"3251329","preferredDefinition":"An indolent non-Hodgkin's lymphoma composed of monomorphic small, round B-lymphocytes in the lymph nodes.  When the lymphoid process involves predominantly the bone marrow and the peripheral blood it is called chronic lymphocytic leukemia. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Small Lymphocytic Lymphoma","conceptCode":"C7540","definition":"A non-Hodgkin lymphoma composed of monomorphic small, round B-lymphocytes in the lymph nodes.  When the lymphoid process predominantly involves the bone marrow and the peripheral blood it is called chronic lymphocytic leukemia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A758F49E-9BA2-73F4-E040-BB89AD430DFE","latestVersionIndicator":"Yes","beginDate":"2011-07-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-05","modifiedBy":"COOPERM","dateModified":"2011-09-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-8346-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Small Intestinal Neuroendocrine Tumor G1","valueDescription":"Small Intestinal Neuroendocrine Tumor G1","ValueMeaning":{"publicId":"6832594","version":"1","preferredName":"Small Intestinal Neuroendocrine Tumor G1","longName":"6832594","preferredDefinition":"A well differentiated, low grade neuroendocrine tumor (carcinoid tumor) that arises from the small intestine.  The mitotic count is less than 2 per 10 HPF and/or the Ki67 index is equal to or less than 2 percent.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Small Intestinal Neuroendocrine Tumor G1","conceptCode":"C4638","definition":"A well differentiated, low grade neuroendocrine neoplasm that arises from the small intestine. The mitotic count is less than 2 per 10 HPF and/or the Ki67 index is equal to or less than 2 percent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AD117-8353-781C-E053-F662850A5AA6","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-836C-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Small Intestinal Carcinoma","valueDescription":"Small Intestinal Carcinoma","ValueMeaning":{"publicId":"3210728","version":"1","preferredName":"Small Intestinal Carcinoma","longName":"3210728","preferredDefinition":"A carcinoma arising from the small intestine. The vast majority are adenocarcinomas. The remaining cases are adenosquamous, squamous, or undifferentiated carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Small Intestinal Carcinoma","conceptCode":"C7724","definition":"A carcinoma arising from the small intestine. The vast majority are adenocarcinomas. The remaining cases are adenosquamous, squamous, or undifferentiated carcinomas.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9552-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-8376-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Small Cell Sarcoma","valueDescription":"Small Cell Sarcoma","ValueMeaning":{"publicId":"6832596","version":"1","preferredName":"Small Cell Sarcoma","longName":"6832596","preferredDefinition":"A sarcoma characterized by the presence of small round or elongated malignant cells with a small amount of cytoplasm.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Small Cell Sarcoma","conceptCode":"C3746","definition":"A sarcoma characterized by the presence of small round or elongated malignant cells with a small amount of cytoplasm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AD117-8383-781C-E053-F662850A5AA6","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-839C-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Skin Squamous Cell Carcinoma","valueDescription":"Skin Squamous Cell Carcinoma","ValueMeaning":{"publicId":"4722553","version":"1","preferredName":"Skin Squamous Cell Carcinoma","longName":"4722553","preferredDefinition":"A carcinoma arising from the squamous cells of the epidermis.  Skin squamous cell carcinoma is most commonly found on sun-exposed areas.  The majority of the tumors are well-differentiated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Skin Squamous Cell Carcinoma","conceptCode":"C4819","definition":"A carcinoma arising from the squamous cells of the epidermis.  Skin squamous cell carcinoma is most commonly found on sun-exposed areas.  The majority of the tumors are well-differentiated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F886EE6-B5E9-DB60-E050-BB89AD4356E3","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-83B0-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Skin Neoplasm","valueDescription":"Skin Neoplasm","ValueMeaning":{"publicId":"6832597","version":"1","preferredName":"Skin Neoplasm","longName":"6832597","preferredDefinition":"A benign or malignant tumor involving the skin.  Representative examples of benign skin neoplasms include the benign melanocytic skin nevus, acanthoma, sebaceous adenoma, sweat gland adenoma, lipoma, hemangioma, fibroma, and benign fibrous histiocytoma.  Representative examples of malignant skin neoplasms include basal cell carcinoma, squamous cell carcinoma, melanoma, and Kaposi sarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Skin Neoplasm","conceptCode":"C3372","definition":"A benign, intermediate, or malignant neoplasm involving the skin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AD117-83BC-781C-E053-F662850A5AA6","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-83D5-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Skin Kaposi Sarcoma","valueDescription":"Skin Kaposi Sarcoma","ValueMeaning":{"publicId":"6832599","version":"1","preferredName":"Skin Kaposi Sarcoma","longName":"6832599","preferredDefinition":"A Kaposi sarcoma arising from the skin.  It presents with patches, plaques, or nodules.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Skin Kaposi Sarcoma","conceptCode":"C3550","definition":"A Kaposi sarcoma arising from the skin.  It presents with patches, plaques, or nodules.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AD117-83E2-781C-E053-F662850A5AA6","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-83FB-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Liver and Intrahepatic Bile Duct Carcinoma","valueDescription":"Liver and Intrahepatic Bile Duct Carcinoma","ValueMeaning":{"publicId":"5581335","version":"1","preferredName":"Liver and Intrahepatic Bile Duct Carcinoma","longName":"5581335","preferredDefinition":"Primary liver cancer is cancer that forms in the tissues of the liver. Secondary liver cancer is cancer that spreads to the liver from another part of the body.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Liver and Intrahepatic Bile Duct Carcinoma","conceptCode":"C7927","definition":"A carcinoma that arises from the hepatocytes or intrahepatic bile ducts.  The main subtypes are hepatocellular carcinoma (hepatoma) and cholangiocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42019733-B7A2-634F-E053-F662850A5A61","latestVersionIndicator":"Yes","beginDate":"2016-11-23","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2016-11-23","modifiedBy":"COOPERM","dateModified":"2019-02-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B1944-8E8F-3752-E053-F662850AB899","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Liver Angiosarcoma","valueDescription":"Liver Angiosarcoma","ValueMeaning":{"publicId":"6832692","version":"1","preferredName":"Liver Angiosarcoma","longName":"6832692","preferredDefinition":"A malignant vascular neoplasm arising from the liver.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Liver Angiosarcoma","conceptCode":"C4438","definition":"A malignant vascular neoplasm arising from the liver.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B1944-8E9D-3752-E053-F662850AB899","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B1944-8EB6-3752-E053-F662850AB899","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Liver Neuroendocrine Tumor","valueDescription":"Liver Neuroendocrine Tumor","ValueMeaning":{"publicId":"6832694","version":"1","preferredName":"Liver Neuroendocrine Tumor","longName":"6832694","preferredDefinition":"An extremely rare, usually solitary, well-differentiated neuroendocrine tumor (carcinoid tumor) arising from the liver.  There is mild nuclear atypia and low mitotic activity present. The neoplastic cells express immunohistochemical evidence of neuroendocrine differentiation.  The vast majority of carcinoid tumors found in the liver represent metastases from other anatomic sites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Liver Neuroendocrine Tumor","conceptCode":"C5783","definition":"An extremely rare, well differentiated neuroendocrine neoplasm arising from the liver. The neoplastic cells express immunohistochemical evidence of neuroendocrine differentiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B1944-8EC3-3752-E053-F662850AB899","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B1944-8EDC-3752-E053-F662850AB899","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Cecum Neoplasm","valueDescription":"Malignant Cecum Neoplasm","ValueMeaning":{"publicId":"6832836","version":"1","preferredName":"Malignant Cecum Neoplasm","longName":"6832836","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the cecum.  Representative examples include carcinoma, lymphoma, and sarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Cecum Neoplasm","conceptCode":"C9329","definition":"A primary or metastatic malignant neoplasm that affects the cecum.  Representative examples include carcinoma, lymphoma, and sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9BCBFF-EC9C-60FB-E053-F662850A38BC","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9BCBFF-ECB5-60FB-E053-F662850A38BC","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Central Nervous System Germ Cell Tumor","valueDescription":"Malignant Central Nervous System Germ Cell Tumor","ValueMeaning":{"publicId":"6832838","version":"1","preferredName":"Malignant Central Nervous System Germ Cell Tumor","longName":"6832838","preferredDefinition":"A germ cell tumor that affects the central nervous system, characterized by the presence of malignant morphologic characteristics.  Representative examples include choriocarcinoma, embryonal carcinoma, and germinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Central Nervous System Germ Cell Tumor","conceptCode":"C54099","definition":"A germ cell tumor that affects the central nervous system, characterized by the presence of malignant morphologic characteristics.  Representative examples include choriocarcinoma, embryonal carcinoma, and germinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9BCBFF-ECC2-60FB-E053-F662850A38BC","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9BCBFF-ECDB-60FB-E053-F662850A38BC","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Central Nervous System Mesenchymal, Non-Meningothelial Neoplasm","valueDescription":"Malignant Central Nervous System Mesenchymal, Non-Meningothelial Neoplasm","ValueMeaning":{"publicId":"6832840","version":"1","preferredName":"Malignant Central Nervous System Mesenchymal, Non-Meningothelial Neoplasm","longName":"6832840","preferredDefinition":"A metastasizing mesenchymal, non-meningothelial neoplasm that arises from the central nervous system.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Central Nervous System Mesenchymal, Non-Meningothelial Neoplasm","conceptCode":"C6758","definition":"A metastasizing mesenchymal, non-meningothelial neoplasm that arises from the central nervous system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9BCBFF-ECE8-60FB-E053-F662850A38BC","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9BCBFF-ED01-60FB-E053-F662850A38BC","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Central Nervous System Neoplasm","valueDescription":"Malignant Central Nervous System Neoplasm","ValueMeaning":{"publicId":"2581277","version":"1","preferredName":"Malignant Central Nervous System Neoplasm","longName":"2581277","preferredDefinition":"A primary or metastatic malignant neoplasm involving the brain or spinal cord.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Central Nervous System Neoplasm","conceptCode":"C4627","definition":"A primary or metastatic malignant neoplasm involving the brain or spinal cord.  Representative examples include anaplastic astrocytoma, glioblastoma, anaplastic (malignant) meningioma, lymphoma, and metastatic carcinoma from another anatomic site.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A8A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"ONEDATA","dateModified":"2006-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9BCBFF-ED0B-60FB-E053-F662850A38BC","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Cerebellar Neoplasm","valueDescription":"Malignant Cerebellar Neoplasm","ValueMeaning":{"publicId":"6832842","version":"1","preferredName":"Malignant Cerebellar Neoplasm","longName":"6832842","preferredDefinition":"Primary and secondary (metastatic) malignant tumors that occur in the cerebellum.  Histologic types include medulloblastomas, high grade (WHO Stage III or IV) cerebellar astrocytomas, lymphomas, gangliogliomas, gliosarcomas, and several other subtypes.  The most frequent malignant cerebellar neoplasm of childhood is medulloblastoma. In adults, metastases from other sites are relatively common. Clinical features include ataxia, headache, nausea, dizzyness, nystagmus, diplopia, papilledema, etc.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Cerebellar Neoplasm","conceptCode":"C3569","definition":"Primary and secondary (metastatic) malignant tumors that occur in the cerebellum.  Histologic types include medulloblastomas, high grade (WHO Stage III or IV) cerebellar astrocytomas, lymphomas, gangliogliomas, gliosarcomas, and several other subtypes.  The most frequent malignant cerebellar neoplasm of childhood is medulloblastoma. In adults, metastases from other sites are relatively common. Clinical features include ataxia, headache, nausea, dizziness, nystagmus, diplopia, papilledema, etc.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9BCBFF-ED19-60FB-E053-F662850A38BC","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9BCBFF-ED32-60FB-E053-F662850A38BC","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Cervical Neoplasm","valueDescription":"CX - 180.9; Cervix","ValueMeaning":{"publicId":"2572640","version":"1","preferredName":"CX - 180.9; Cervix","longName":"2572640","preferredDefinition":"Primary or metastatic malignant neoplasm involving the cervix. --2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Cervical Neoplasm","conceptCode":"C9311","definition":"A primary or metastatic malignant neoplasm involving the cervix.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8CD-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9BCBFF-ED46-60FB-E053-F662850A38BC","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Choroid Neoplasm","valueDescription":"Malignant Choroid Neoplasm","ValueMeaning":{"publicId":"6832844","version":"1","preferredName":"Malignant Choroid Neoplasm","longName":"6832844","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the choroid.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Choroid Neoplasm","conceptCode":"C3566","definition":"A primary or metastatic malignant neoplasm that affects the choroid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9BCBFF-ED54-60FB-E053-F662850A38BC","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9BCBFF-ED6D-60FB-E053-F662850A38BC","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Clitoral Neoplasm","valueDescription":"Malignant Clitoral Neoplasm","ValueMeaning":{"publicId":"6832846","version":"1","preferredName":"Malignant Clitoral Neoplasm","longName":"6832846","preferredDefinition":"A malignant neoplasm that affects the clitoris.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Clitoral Neoplasm","conceptCode":"C3557","definition":"A malignant neoplasm that affects the clitoris.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9BCBFF-ED7A-60FB-E053-F662850A38BC","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9BCBFF-ED93-60FB-E053-F662850A38BC","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Colon Neoplasm","valueDescription":"COL - 153.9; Colon","ValueMeaning":{"publicId":"2572643","version":"1","preferredName":"COL - 153.9; Colon","longName":"2572643","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the colon.  Representative examples include carcinoma, lymphoma, and sarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Colon Neoplasm","conceptCode":"C9242","definition":"A primary or metastatic malignant neoplasm that affects the colon.  Representative examples include carcinoma, lymphoma, and sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8D0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9BCBFF-EDA7-60FB-E053-F662850A38BC","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Colorectal Neoplasm","valueDescription":"Malignant Colorectal Neoplasm","ValueMeaning":{"publicId":"6832848","version":"1","preferredName":"Malignant Colorectal Neoplasm","longName":"6832848","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the colon or rectum.  Representative examples include carcinoma, lymphoma, and sarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Colorectal Neoplasm","conceptCode":"C4978","definition":"A primary or metastatic malignant neoplasm that affects the colon or rectum.  Representative examples include carcinoma, lymphoma, and sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9BCBFF-EDB5-60FB-E053-F662850A38BC","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9BCBFF-EDCE-60FB-E053-F662850A38BC","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Corneal Neoplasm","valueDescription":"Malignant Corneal Neoplasm","ValueMeaning":{"publicId":"6832850","version":"1","preferredName":"Malignant Corneal Neoplasm","longName":"6832850","preferredDefinition":"A malignant growth of cells within the cornea of the eye.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Corneal Neoplasm","conceptCode":"C3565","definition":"A primary or metastatic malignant neoplasm that affects the cornea.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9BCBFF-EDDB-60FB-E053-F662850A38BC","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9BCBFF-EDF4-60FB-E053-F662850A38BC","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Cranial Nerve Neoplasm","valueDescription":"Malignant Cranial Nerve Neoplasm","ValueMeaning":{"publicId":"6832852","version":"1","preferredName":"Malignant Cranial Nerve Neoplasm","longName":"6832852","preferredDefinition":"Abnormal malignant growth of the cells that comprise the cranial nerve.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Cranial Nerve Neoplasm","conceptCode":"C3571","definition":"A primary or metastatic malignant neoplasm that affects a cranial nerve.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9BCBFF-EE01-60FB-E053-F662850A38BC","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9BCBFF-EE1A-60FB-E053-F662850A38BC","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Basaloid Carcinoma","valueDescription":"Basaloid Carcinoma","ValueMeaning":{"publicId":"2861316","version":"1","preferredName":"Basaloid Carcinoma","longName":"2861316","preferredDefinition":"A malignant epithelial neoplasm characterized by the presence of neoplastic cells with hyperchromatic nuclei, small amount of cytoplasm, and peripheral nuclear palisading.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Basaloid Carcinoma","conceptCode":"C4121","definition":"A malignant epithelial neoplasm characterized by the presence of neoplastic cells with hyperchromatic nuclei, small amount of cytoplasm, and peripheral nuclear palisading.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67AD9A2F-13D1-E58B-E040-BB89AD437C2B","latestVersionIndicator":"Yes","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C5201B3-6FF0-5291-E053-F662850A82DE","beginDate":"2019-06-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-27","modifiedBy":"ONEDATA","dateModified":"2019-06-27","deletedIndicator":"No"},{"value":"Basal Cell Carcinoma","valueDescription":"Basal Cell Carcinoma","ValueMeaning":{"publicId":"6796707","version":"1","preferredName":"Basal Cell Carcinoma","longName":"6796707","preferredDefinition":"A carcinoma involving the basal cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Basal Cell Carcinoma","conceptCode":"C156767","definition":"A carcinoma involving the basal cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C5201B3-6FFD-5291-E053-F662850A82DE","latestVersionIndicator":"Yes","beginDate":"2019-06-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-27","modifiedBy":"ONEDATA","dateModified":"2019-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C5201B3-7015-5291-E053-F662850A82DE","beginDate":"2019-06-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-27","modifiedBy":"ONEDATA","dateModified":"2019-06-27","deletedIndicator":"No"},{"value":"Nodal Peripheral T-Cell Lymphoma of T Follicular Helper Cell Origin","valueDescription":"Nodal Peripheral T-Cell Lymphoma of T Follicular Helper Cell Origin","ValueMeaning":{"publicId":"6832285","version":"1","preferredName":"Nodal Peripheral T-Cell Lymphoma of T Follicular Helper Cell Origin","longName":"6832285","preferredDefinition":"A subset of node-based peripheral T-cell lymphomas with phenotypic features of T follicular helper (TFH) cells. This category includes angioimmunoblastic T-cell lymphomas, follicular T-cell lymphomas, and nodal peripheral T-cell lymphomas with T follicular helper phenotype.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Follicular Helper T-Cell Lymphoma","conceptCode":"C139005","definition":"A group of node-based peripheral T-cell lymphomas with phenotypic features of T follicular helper (TFH) cells. This category includes the following: follicular helper T-cell lymphoma, angioimmunoblastic-type; follicular helper T-cell lymphoma, follicular-type; and follicular helper T-cell lymphoma, not otherwise specified.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E972F13-4A74-03FE-E053-F662850AD6D9","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E972F13-4A8D-03FE-E053-F662850AD6D9","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Neurofibromatosis Type 2","valueDescription":"Neurofibromatosis Type 2","ValueMeaning":{"publicId":"2962078","version":"1","preferredName":"Neurofibromatosis Type 2","longName":"2962078","preferredDefinition":"An autosomal dominant disorder caused by mutations in the NF2 tumor suppressor gene.  It is characterized by the development of peripheral and central nervous system tumors including acoustic schwannomas, neurofibromas, gliomas, and meningiomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neurofibromatosis Type 2","conceptCode":"C3274","definition":"An autosomal dominant disorder caused by mutations in the NF2 tumor suppressor gene.  It is characterized by the development of peripheral and central nervous system tumors including acoustic schwannomas, neurofibromas, gliomas, and meningiomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"78BA0E7A-4A67-2225-E040-BB89AD436E34","latestVersionIndicator":"Yes","beginDate":"2009-11-19","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-11-19","modifiedBy":"GDEEN","dateModified":"2023-01-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E972F13-4A97-03FE-E053-F662850AD6D9","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Neurofibromatosis","valueDescription":"Neurofibromatosis","ValueMeaning":{"publicId":"2568792","version":"1","preferredName":"Neurofibromatosis","longName":"2568792","preferredDefinition":"A group of disorders characterized by an autosomal dominant pattern of inheritance with high rates of spontaneous mutation and multiple neurofibromas or neurilemmomas. NEUROFIBROMATOSIS 1 (generalized neurofibromatosis) accounts for approximately 95% of cases, although multiple additional subtypes (e.g., NEUROFIBROMATOSIS 2, neurofibromatosis 3, etc.) have been described. (From Neurochirurgie 1998 Nov;44(4):267-72)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neurofibromatosis","conceptCode":"C6727","definition":"An autosomal dominant hereditary neoplastic syndrome. Two distinct clinicopathological entities are recognized: neurofibromatosis type 1 and neurofibromatosis type 2. Neurofibromatosis type 1 is associated with the presence of cafe-au-lait cutaneous lesions, multiple neurofibromas, malignant peripheral nerve sheath tumors, optic nerve gliomas, and bone lesions. Neurofibromatosis type 2 is associated with the presence of schwannomas, meningiomas, and gliomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D9C5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-03-29","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-03-29","modifiedBy":"PWEST","dateModified":"2014-05-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E972F13-4AA2-03FE-E053-F662850AD6D9","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Neuroendocrine Neoplasm","valueDescription":"Neuroendocrine Neoplasm","ValueMeaning":{"publicId":"3211298","version":"1","preferredName":"Neuroendocrine Neoplasm","longName":"3211298","preferredDefinition":"A benign or malignant neoplasm composed of cells of neuroendocrine origin.  Representative examples include paraganglioma, carcinoid tumor, and neuroendocrine carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neuroendocrine Neoplasm","conceptCode":"C3809","definition":"An epithelial neoplasm with neuroendocrine differentiation. This category includes neuroendocrine tumors, neuroendocrine carcinomas, and paragangliomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-EA11-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E972F13-4AAC-03FE-E053-F662850AD6D9","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Lipoma","valueDescription":"Lipoma","ValueMeaning":{"publicId":"2974460","version":"1","preferredName":"Lipoma","longName":"2974460","preferredDefinition":"A benign, usually painless, well-circumscribed lipomatous tumor composed of adipose tissue.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lipoma","conceptCode":"C3192","definition":"A benign, usually painless, well-circumscribed lipomatous tumor composed of adipose tissue.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7BD8A964-F041-8A21-E040-BB89AD436C37","latestVersionIndicator":"Yes","beginDate":"2009-12-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B1944-8E6F-3752-E053-F662850AB899","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Liposarcoma","valueDescription":"Liposarcoma","ValueMeaning":{"publicId":"3179354","version":"1","preferredName":"Liposarcoma","longName":"3179354","preferredDefinition":"A usually painless malignant tumor that arises from adipose tissue.  Microscopically, it may contain a spectrum of neoplastic adipocytes ranging from lipoblasts to pleomorphic malignant adipocytes.  Representative morphologic variants include: well differentiated, dedifferentiated, pleomorphic, and myxoid/round cell liposarcoma.  The metastatic potential is higher in less differentiated tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Liposarcoma","conceptCode":"C3194","definition":"A usually painless malignant tumor that arises from adipose tissue.  Microscopically, it may contain a spectrum of neoplastic adipocytes ranging from lipoblasts to pleomorphic malignant adipocytes.  Morphologic variants include: well differentiated, dedifferentiated, pleomorphic, and myxoid liposarcoma.  The metastatic potential is higher in less differentiated tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9890B54F-84F7-2C65-E040-BB89AD4320B1","latestVersionIndicator":"Yes","beginDate":"2010-12-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-29","modifiedBy":"ONEDATA","dateModified":"2010-12-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B1944-8E7A-3752-E053-F662850AB899","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Digestive System Neoplasm","valueDescription":"Malignant Digestive System Neoplasm","ValueMeaning":{"publicId":"4722726","version":"1","preferredName":"Malignant Digestive System Neoplasm","longName":"4722726","preferredDefinition":"A primary or metastatic malignant neoplasm involving any part of the digestive system.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Digestive System Neoplasm","conceptCode":"C4890","definition":"A primary or metastatic malignant neoplasm involving any part of the digestive system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-1D9E-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9BCBFF-EE2E-60FB-E053-F662850A38BC","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Duodenal Neoplasm","valueDescription":"Malignant Duodenal Neoplasm","ValueMeaning":{"publicId":"6832854","version":"1","preferredName":"Malignant Duodenal Neoplasm","longName":"6832854","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the duodenum.  Representative examples include carcinoma, lymphoma, and sarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Duodenal Neoplasm","conceptCode":"C9328","definition":"A primary or metastatic malignant neoplasm that affects the duodenum.  Representative examples include carcinoma, lymphoma, and sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9BCBFF-EE3C-60FB-E053-F662850A38BC","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9BCBFF-EE55-60FB-E053-F662850A38BC","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Endocervical Neoplasm","valueDescription":"Malignant Endocervical Neoplasm","ValueMeaning":{"publicId":"6832856","version":"1","preferredName":"Malignant Endocervical Neoplasm","longName":"6832856","preferredDefinition":"A malignant neoplasm that affects the endocervix.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Endocervical Neoplasm","conceptCode":"C3553","definition":"A malignant neoplasm that affects the endocervix.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9BCBFF-EE62-60FB-E053-F662850A38BC","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9BCBFF-EE7B-60FB-E053-F662850A38BC","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Endocrine Neoplasm","valueDescription":"Malignant Endocrine Neoplasm","ValueMeaning":{"publicId":"4722740","version":"1","preferredName":"Malignant Endocrine Neoplasm","longName":"4722740","preferredDefinition":"A malignant neoplasm affecting the endocrine glands.  Representative examples include thyroid gland carcinoma, parathyroid gland carcinoma, pituitary gland carcinoma, and adrenal cortex carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Endocrine Neoplasm","conceptCode":"C3575","definition":"A malignant neoplasm affecting the endocrine glands.  Representative examples include thyroid gland carcinoma, parathyroid gland carcinoma, pituitary gland carcinoma, and adrenal cortex carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-202A-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9BCBFF-EE8F-60FB-E053-F662850A38BC","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Epiglottis Neoplasm","valueDescription":"Malignant Epiglottis Neoplasm","ValueMeaning":{"publicId":"6832873","version":"1","preferredName":"Malignant Epiglottis Neoplasm","longName":"6832873","preferredDefinition":"A malignant neoplasm that affects the epiglottis.  The vast majority of cases are squamous cell carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Epiglottis Neoplasm","conceptCode":"C4836","definition":"A malignant neoplasm that affects the epiglottis.  The vast majority of cases are squamous cell carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AD117-8409-781C-E053-F662850A5AA6","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-8422-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Esophageal Neoplasm","valueDescription":"ESOP - 150.9; Esophagus","ValueMeaning":{"publicId":"2572644","version":"1","preferredName":"ESOP - 150.9; Esophagus","longName":"2572644","preferredDefinition":"A primary or metastatic malignant neoplasm involving the esophagus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Esophageal Neoplasm","conceptCode":"C7478","definition":"A primary or metastatic malignant neoplasm involving the esophagus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8D1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-8436-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant External Ear Neoplasm","valueDescription":"Malignant External Ear Neoplasm","ValueMeaning":{"publicId":"6832875","version":"1","preferredName":"Malignant External Ear Neoplasm","longName":"6832875","preferredDefinition":"A malignant neoplasm that affects the external ear.  Representative examples include squamous cell carcinoma, basal cell carcinoma, and ceruminous adenocarcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant External Ear Neoplasm","conceptCode":"C4653","definition":"A malignant neoplasm that affects the external ear.  Representative examples include squamous cell carcinoma, basal cell carcinoma, and ceruminous adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AD117-8444-781C-E053-F662850A5AA6","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-845D-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Extrahepatic Bile Duct Neoplasm","valueDescription":"Malignant Extrahepatic Bile Duct Neoplasm","ValueMeaning":{"publicId":"6832877","version":"1","preferredName":"Malignant Extrahepatic Bile Duct Neoplasm","longName":"6832877","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the extrahepatic bile ducts.  Representative examples include carcinoma and sarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Extrahepatic Bile Duct Neoplasm","conceptCode":"C7483","definition":"A primary or metastatic malignant neoplasm that affects the extrahepatic bile ducts.  Representative examples include carcinoma and sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AD117-846A-781C-E053-F662850A5AA6","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-8483-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Fallopian Tube Neoplasm","valueDescription":"FT - 183.2; Fallopian Tube","ValueMeaning":{"publicId":"2572646","version":"1","preferredName":"FT - 183.2; Fallopian Tube","longName":"2572646","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the fallopian tube.  Representative examples include carcinoma, carcinosarcoma, and leiomyosarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Fallopian Tube Neoplasm","conceptCode":"C7480","definition":"A primary or metastatic malignant neoplasm that affects the fallopian tube.  Representative examples include carcinoma, carcinosarcoma, and leiomyosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8D3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-8497-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Eyelid Neoplasm","valueDescription":"Malignant Eyelid Neoplasm","ValueMeaning":{"publicId":"6832879","version":"1","preferredName":"Malignant Eyelid Neoplasm","longName":"6832879","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the eyelid.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Eyelid Neoplasm","conceptCode":"C6786","definition":"A primary or metastatic malignant neoplasm that affects the eyelid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AD117-84A5-781C-E053-F662850A5AA6","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-84BE-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Female Reproductive System Neoplasm","valueDescription":"Malignant Female Reproductive System Neoplasm","ValueMeaning":{"publicId":"4722593","version":"1","preferredName":"Malignant Female Reproductive System Neoplasm","longName":"4722593","preferredDefinition":"Cancer of the female reproductive tract, including the cervix, endometrium, fallopian tubes, ovaries, uterus, and vagina.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Female Reproductive System Neoplasm","conceptCode":"C4913","definition":"A primary or metastatic malignant neoplasm involving the female reproductive system.  Representative examples include endometrial carcinoma, cervical carcinoma, ovarian carcinoma, uterine corpus leiomyosarcoma, adenosarcoma, malignant mixed mesodermal (mullerian) tumor, and gestational choriocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F886EE6-BAD7-DB60-E050-BB89AD4356E3","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-84D2-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Fibrohistiocytic Neoplasm","valueDescription":"Malignant Fibrohistiocytic Neoplasm","ValueMeaning":{"publicId":"6832881","version":"1","preferredName":"Malignant Fibrohistiocytic Neoplasm","longName":"6832881","preferredDefinition":"A fibrohistiocytic neoplasm that metastasizes to other anatomic sites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Fibrohistiocytic Neoplasm","conceptCode":"C121500","definition":"A fibrohistiocytic neoplasm that metastasizes to other anatomic sites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AD117-84E0-781C-E053-F662850A5AA6","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-84F9-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Floor of the Mouth Neoplasm","valueDescription":"Malignant Floor of the Mouth Neoplasm","ValueMeaning":{"publicId":"6832883","version":"1","preferredName":"Malignant Floor of the Mouth Neoplasm","longName":"6832883","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the floor of the mouth.  The majority of cases are carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Floor of the Mouth Neoplasm","conceptCode":"C9318","definition":"A primary or metastatic malignant neoplasm that affects the floor of the mouth.  The majority of cases are carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AD117-8506-781C-E053-F662850A5AA6","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-851F-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Gallbladder Neoplasm","valueDescription":"GB - 156.0; Gallbladder","ValueMeaning":{"publicId":"2572647","version":"1","preferredName":"GB - 156.0; Gallbladder","longName":"2572647","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the gallbladder.  Representative examples include carcinoma, lymphoma, melanoma, and sarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gallbladder Malignant Neoplasm","conceptCode":"C7481","definition":"A primary or metastatic malignant neoplasm that affects the gallbladder.  Representative examples include carcinoma, lymphoma, melanoma, and sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8D4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-8533-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Gastric Neoplasm","valueDescription":"GAST - 151.9; Gastric","ValueMeaning":{"publicId":"2572649","version":"1","preferredName":"GAST - 151.9; Gastric","longName":"2572649","preferredDefinition":"A primary or metastatic malignant neoplasm involving the stomach.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Gastric Neoplasm","conceptCode":"C9331","definition":"A primary or metastatic malignant neoplasm involving the stomach.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8D6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-8548-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Genitourinary System Neoplasm","valueDescription":"Malignant Genitourinary System Neoplasm","ValueMeaning":{"publicId":"6832885","version":"1","preferredName":"Malignant Genitourinary System Neoplasm","longName":"6832885","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the genitourinary system.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Genitourinary System Neoplasm","conceptCode":"C156484","definition":"A primary or metastatic malignant neoplasm that affects the genitourinary system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AD117-8556-781C-E053-F662850A5AA6","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-856F-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Germ Cell Tumor","valueDescription":"Malignant Germ Cell Tumor","ValueMeaning":{"publicId":"4722797","version":"1","preferredName":"Malignant Germ Cell Tumor","longName":"4722797","preferredDefinition":"A gonadal or extragonadal malignant neoplasm that arises from germ cells. Representative examples include embryonal carcinoma, yolk sac tumor, and seminoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Germ Cell Tumor","conceptCode":"C4925","definition":"A gonadal or extragonadal malignant neoplasm that arises from germ cells. Representative examples include embryonal carcinoma, yolk sac tumor, and seminoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-24ED-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-8583-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Giant Cell Neoplasm","valueDescription":"Malignant Giant Cell Neoplasm","ValueMeaning":{"publicId":"6832887","version":"1","preferredName":"Malignant Giant Cell Neoplasm","longName":"6832887","preferredDefinition":"A malignant neoplasm characterized by then presence of atypical giant cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Giant Cell Neoplasm","conceptCode":"C4090","definition":"A malignant neoplasm characterized by then presence of atypical giant cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AD117-8591-781C-E053-F662850A5AA6","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-85AA-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Gingival Neoplasm","valueDescription":"Malignant Gingival Neoplasm","ValueMeaning":{"publicId":"6832889","version":"1","preferredName":"Malignant Gingival Neoplasm","longName":"6832889","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the gums.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Gingival Neoplasm","conceptCode":"C9317","definition":"A primary or metastatic malignant neoplasm that affects the gums.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AD117-85B7-781C-E053-F662850A5AA6","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-85D0-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Glottis Neoplasm","valueDescription":"Malignant Glottis Neoplasm","ValueMeaning":{"publicId":"6832891","version":"1","preferredName":"Malignant Glottis Neoplasm","longName":"6832891","preferredDefinition":"A malignant neoplasm that affects the glottic area of the larynx.  The vast majority of cases represent squamous cell carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Glottis Neoplasm","conceptCode":"C3544","definition":"A malignant neoplasm that affects the glottic area of the larynx.  The vast majority of cases represent squamous cell carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AD117-85DD-781C-E053-F662850A5AA6","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-85F6-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Hard Palate Neoplasm","valueDescription":"Malignant Hard Palate Neoplasm","ValueMeaning":{"publicId":"6832893","version":"1","preferredName":"Malignant Hard Palate Neoplasm","longName":"6832893","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the hard palate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Hard Palate Neoplasm","conceptCode":"C3528","definition":"A primary or metastatic malignant neoplasm that affects the hard palate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AD117-8603-781C-E053-F662850A5AA6","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-861C-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Head and Neck Neoplasm","valueDescription":"Malignant Head and Neck Neoplasm","ValueMeaning":{"publicId":"4722789","version":"1","preferredName":"Malignant Head and Neck Neoplasm","longName":"4722789","preferredDefinition":"A primary or metastatic malignant neoplasm affecting the head and neck.  Representative examples include oral cavity squamous cell carcinoma, laryngeal squamous cell carcinoma, and salivary gland carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Head and Neck Neoplasm","conceptCode":"C4013","definition":"A primary or metastatic malignant neoplasm affecting the head and neck.  Representative examples include oral cavity squamous cell carcinoma, laryngeal squamous cell carcinoma, and salivary gland carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-2441-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"COOPERM","dateModified":"2019-02-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-8630-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Hepatobiliary Neoplasm","valueDescription":"Malignant Hepatobiliary Neoplasm","ValueMeaning":{"publicId":"6832895","version":"1","preferredName":"Malignant Hepatobiliary Neoplasm","longName":"6832895","preferredDefinition":"A malignant neoplasm that affects the liver parenchyma, bile ducts, and gallbladder.  Representative examples include hepatocellular carcinoma, intrahepatic and extrahepatic cholangiocarcinoma, and gallbladder carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Hepatobiliary Neoplasm","conceptCode":"C8609","definition":"A malignant neoplasm that affects the liver parenchyma, bile ducts, and gallbladder.  Representative examples include hepatocellular carcinoma, intrahepatic and extrahepatic cholangiocarcinoma, and gallbladder carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AD117-863E-781C-E053-F662850A5AA6","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-8657-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Hypopharyngeal Neoplasm","valueDescription":"Malignant Hypopharyngeal Neoplasm","ValueMeaning":{"publicId":"6832897","version":"1","preferredName":"Malignant Hypopharyngeal Neoplasm","longName":"6832897","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the hypopharynx.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Hypopharyngeal Neoplasm","conceptCode":"C7190","definition":"A primary or metastatic malignant neoplasm that affects the hypopharynx.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AD117-8664-781C-E053-F662850A5AA6","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-867D-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Intestinal Neoplasm","valueDescription":"Malignant Intestinal Neoplasm","ValueMeaning":{"publicId":"6832899","version":"1","preferredName":"Malignant Intestinal Neoplasm","longName":"6832899","preferredDefinition":"A primary or metastatic malignant neoplasm involving the small intestine, large intestine, or both.  Representative examples are carcinomas, lymphomas, and sarcomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Intestinal Neoplasm","conceptCode":"C4572","definition":"A primary or metastatic malignant neoplasm involving the small intestine, large intestine, or both.  Representative examples are carcinomas, lymphomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AD117-868A-781C-E053-F662850A5AA6","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-86A3-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Kidney Neoplasm","valueDescription":"Malignant Kidney Neoplasm","ValueMeaning":{"publicId":"6832900","version":"1","preferredName":"Malignant Kidney Neoplasm","longName":"6832900","preferredDefinition":"Primary or metastatic malignant neoplasm involving the kidney.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Kidney Neoplasm","conceptCode":"C7548","definition":"Primary or metastatic malignant neoplasm involving the kidney.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AD117-86AF-781C-E053-F662850A5AA6","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-86C8-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Kidney Neoplasm Except Pelvis","valueDescription":"REN - 189.0; Kidney-except Pelvis","ValueMeaning":{"publicId":"2572659","version":"1","preferredName":"REN - 189.0; Kidney-except Pelvis","longName":"2572659","preferredDefinition":"A malignant neoplasm that affects the renal parenchyma but not the pelvis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Kidney Neoplasm Except Pelvis","conceptCode":"C120456","definition":"A malignant neoplasm that affects the renal parenchyma but not the pelvis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8E0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"COOPERM","dateModified":"2015-03-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-86DC-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Labia Majora Neoplasm","valueDescription":"Malignant Labia Majora Neoplasm","ValueMeaning":{"publicId":"6832902","version":"1","preferredName":"Malignant Labia Majora Neoplasm","longName":"6832902","preferredDefinition":"A malignant neoplasm that affects the labia majora.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Labia Majora Neoplasm","conceptCode":"C7638","definition":"A malignant neoplasm that affects the labia majora.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AD117-86EA-781C-E053-F662850A5AA6","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-8703-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Laryngeal Neoplasm","valueDescription":"Malignant Laryngeal Neoplasm","ValueMeaning":{"publicId":"6832904","version":"1","preferredName":"Malignant Laryngeal Neoplasm","longName":"6832904","preferredDefinition":"A primary or metastatic malignant neoplasm involving the larynx.  The majority are carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Laryngeal Neoplasm","conceptCode":"C7484","definition":"A primary or metastatic malignant neoplasm involving the larynx.  The majority are carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AD117-8710-781C-E053-F662850A5AA6","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-8729-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Lip Neoplasm","valueDescription":"Malignant Lip Neoplasm","ValueMeaning":{"publicId":"6832906","version":"1","preferredName":"Malignant Lip Neoplasm","longName":"6832906","preferredDefinition":"A primary or metastatic malignant neoplasm involving the lip.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Lip Neoplasm","conceptCode":"C7485","definition":"A primary or metastatic malignant neoplasm involving the lip.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AD117-8736-781C-E053-F662850A5AA6","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-874F-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Lipomatous Neoplasm","valueDescription":"Malignant Lipomatous Neoplasm","ValueMeaning":{"publicId":"6832908","version":"1","preferredName":"Malignant Lipomatous Neoplasm","longName":"6832908","preferredDefinition":"A malignant mesenchymal neoplasm arising from adipocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Lipomatous Neoplasm","conceptCode":"C4501","definition":"A malignant mesenchymal neoplasm arising from adipocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AD117-875C-781C-E053-F662850A5AA6","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-8775-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Lymph Node Neoplasm","valueDescription":"Malignant Lymph Node Neoplasm","ValueMeaning":{"publicId":"6160855","version":"1","preferredName":"Malignant Lymph Node Neoplasm","longName":"6160855","preferredDefinition":"A primary or metastatic malignant tumor involving the lymph node.  Lymphomas and metastatic carcinomas are representative examples. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Lymph Node Neoplasm","conceptCode":"C35812","definition":"A primary or metastatic malignant tumor involving the lymph node.  Lymphomas and metastatic carcinomas are representative examples.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68F7AA8C-EC3B-1FCD-E053-F662850A8E10","latestVersionIndicator":"Yes","beginDate":"2018-04-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-04-03","modifiedBy":"ONEDATA","dateModified":"2018-04-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-8789-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Major Salivary Gland Neoplasm","valueDescription":"Malignant Major Salivary Gland Neoplasm","ValueMeaning":{"publicId":"6832910","version":"1","preferredName":"Malignant Major Salivary Gland Neoplasm","longName":"6832910","preferredDefinition":"A primary or metastatic malignant neoplasm affecting the major salivary glands.  Representative examples include carcinoma, lymphoma, and sarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Major Salivary Gland Neoplasm","conceptCode":"C4762","definition":"A primary or metastatic malignant neoplasm affecting the major salivary glands.  Representative examples include carcinoma, lymphoma, and sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AD117-8797-781C-E053-F662850A5AA6","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-87B0-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Male Reproductive System Neoplasm","valueDescription":"Malignant Male Reproductive System Neoplasm","ValueMeaning":{"publicId":"4722578","version":"1","preferredName":"Malignant Male Reproductive System Neoplasm","longName":"4722578","preferredDefinition":"A primary or metastatic malignant neoplasm involving the male reproductive system.  Representative examples include prostate carcinoma, penile carcinoma, testicular seminoma, and testicular embryonal carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Male Reproductive System Neoplasm","conceptCode":"C8561","definition":"A primary or metastatic malignant neoplasm involving the male reproductive system.  Representative examples include prostate carcinoma, penile carcinoma, testicular seminoma, and testicular embryonal carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F886EE6-B8CA-DB60-E050-BB89AD4356E3","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-87C4-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Mastocytosis","valueDescription":"Malignant Mastocytosis","ValueMeaning":{"publicId":"6832912","version":"1","preferredName":"Malignant Mastocytosis","longName":"6832912","preferredDefinition":"Malignant neoplasm originating from mast cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Mastocytosis","conceptCode":"C8991","definition":"A group of malignant mast cell disorders including aggressive systemic mastocytosis, mast cell leukemia, mast cell sarcoma, and systemic mastocytosis with an associated myeloid neoplasm. Individuals with advanced systemic mastocytosis have a reduced life expectancy, with median survival measured in months to years.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AD117-87D2-781C-E053-F662850A5AA6","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-87EB-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Maxillary Sinus Neoplasm","valueDescription":"Malignant Maxillary Sinus Neoplasm","ValueMeaning":{"publicId":"6832914","version":"1","preferredName":"Malignant Maxillary Sinus Neoplasm","longName":"6832914","preferredDefinition":"A primary or metastatic malignant neoplasm involving the maxillary sinus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Maxillary Sinus Neoplasm","conceptCode":"C3540","definition":"A primary or metastatic malignant neoplasm involving the maxillary sinus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AD117-87F8-781C-E053-F662850A5AA6","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-8811-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Mediastinal Neoplasm","valueDescription":"Malignant Mediastinal Neoplasm","ValueMeaning":{"publicId":"5098092","version":"1","preferredName":"Malignant Mediastinal Neoplasm","longName":"5098092","preferredDefinition":"A primary or metastatic malignant neoplasm affecting the mediastinum.  Representative examples of primary malignant mediastinal neoplasms include malignant germ cell tumors, malignant mesenchymal tumors, lymphomas, and malignant peripheral nerve sheath tumors.  A representative example of metastatic malignant neoplasm to the mediastinum is the metastatic carcinoma to the mediastinum from another anatomic site.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Mediastinal Neoplasm","conceptCode":"C3549","definition":"A primary or metastatic malignant neoplasm affecting the mediastinum.  Representative examples of primary malignant mediastinal neoplasms include malignant germ cell tumors, malignant mesenchymal tumors, lymphomas, and malignant peripheral nerve sheath tumors.  A representative example of metastatic malignant neoplasm to the mediastinum is the metastatic carcinoma to the mediastinum from another anatomic site.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28CB2A73-E7AE-BA84-E050-BB89AD435ED5","latestVersionIndicator":"Yes","beginDate":"2016-01-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-8825-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Mesothelioma","valueDescription":"Malignant Mesothelioma","ValueMeaning":{"publicId":"5581350","version":"1","preferredName":"Malignant Mesothelioma","longName":"5581350","preferredDefinition":"A malignant neoplasm of the pleura or peritoneum, arising from mesothelial cells.  It is associated with exposure to asbestos.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Mesothelioma","conceptCode":"C4456","definition":"A malignant neoplasm that arises from mesothelial cells, usually in the pleura or peritoneum. It is associated with exposure to asbestos.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42019733-B9BA-634F-E053-F662850A5A61","latestVersionIndicator":"Yes","beginDate":"2016-11-23","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2016-11-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-8839-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Middle Ear Neoplasm","valueDescription":"Malignant Middle Ear Neoplasm","ValueMeaning":{"publicId":"6832916","version":"1","preferredName":"Malignant Middle Ear Neoplasm","longName":"6832916","preferredDefinition":"A malignant neoplasm that affects the middle ear.  Representative examples include adenocarcinoma and squamous cell carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Middle Ear Neoplasm","conceptCode":"C4765","definition":"A malignant neoplasm that affects the middle ear.  Representative examples include adenocarcinoma and squamous cell carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AD117-8847-781C-E053-F662850A5AA6","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-8860-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Mixed Neoplasm","valueDescription":"Malignant Mixed Neoplasm","ValueMeaning":{"publicId":"4824499","version":"1","preferredName":"Malignant Mixed Neoplasm","longName":"4824499","preferredDefinition":"A malignant neoplasm composed of a carcinomatous epithelial component and a sarcomatous mesenchymal component. Representative examples include malignant mixed mesodermal (Mullerian) tumor of the female reproductive system and carcinosarcoma of the salivary gland and the lung.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Mixed Neoplasm","conceptCode":"C3729","definition":"A malignant neoplasm composed of a carcinomatous epithelial component and a sarcomatous mesenchymal component. Representative examples include malignant mixed mesodermal (Mullerian) tumor of the female reproductive system and carcinosarcoma of the salivary gland and the lung.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"15EE070C-4B1D-0882-E050-BB89AD43797F","latestVersionIndicator":"Yes","beginDate":"2015-05-12","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-05-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AD117-8874-781C-E053-F662850A5AA6","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Prostate Carcinoma","valueDescription":"Prostate Carcinoma","ValueMeaning":{"publicId":"5581340","version":"1","preferredName":"Prostate Carcinoma","longName":"5581340","preferredDefinition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42019733-B85C-634F-E053-F662850A5A61","latestVersionIndicator":"Yes","beginDate":"2016-11-23","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2016-11-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9923E9-85A8-2DCE-E053-F662850AB844","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Primitive Neuroectodermal Tumor","valueDescription":"Primitive Neuroectodermal Tumor","ValueMeaning":{"publicId":"2838710","version":"1","preferredName":"Primitive Neuroectodermal Tumor","longName":"2838710","preferredDefinition":"A malignant neoplasm that originates in the neuroectoderm. The neuroectoderm constitutes the portion of the ectoderm of the early embryo that gives rise to the central and peripheral nervous systems and includes some glial cell precursors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primitive Neuroectodermal Tumor","conceptCode":"C3716","definition":"A malignant neoplasm that originates in the neuroectoderm. The neuroectoderm constitutes the portion of the ectoderm of the early embryo that gives rise to the central and peripheral nervous systems and includes some glial cell precursors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A7EC44-0A4C-AA83-E040-BB89AD437747","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9923E9-85BD-2DCE-E053-F662850AB844","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Primary Peritoneal Carcinoma","valueDescription":"Primary Peritoneal Carcinoma","ValueMeaning":{"publicId":"4722587","version":"1","preferredName":"Primary Peritoneal Carcinoma","longName":"4722587","preferredDefinition":"A rare carcinoma that arises from the peritoneum and resembles the malignant surface epithelial-stromal tumors that arise from the ovary.  Serous adenocarcinoma is the most common histologic variant. It affects women almost exclusively.  The diagnosis of primary peritoneal carcinoma can be made only if both ovaries are not involved by tumor, or, if the ovaries are involved, the tumor is confined to the ovarian surface without invasion of the ovarian stroma and the peritoneal involvement is greater than the ovarian surface involvement.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Peritoneal Carcinoma","conceptCode":"C40022","definition":"A rare carcinoma that arises from the peritoneum and resembles the malignant surface epithelial-stromal tumors that arise from the ovary.  Serous adenocarcinoma is the most common histologic variant. It affects women almost exclusively.  The diagnosis of primary peritoneal carcinoma can be made only if both ovaries are not involved by tumor, or, if the ovaries are involved, the tumor is confined to the ovarian surface without invasion of the ovarian stroma and the peritoneal involvement is greater than the ovarian surface involvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F886EE6-B9DC-DB60-E050-BB89AD4356E3","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9923E9-85D2-2DCE-E053-F662850AB844","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Primary Myelofibrosis","valueDescription":"Primary Myelofibrosis","ValueMeaning":{"publicId":"5589180","version":"1","preferredName":"Primary Myelofibrosis","longName":"5589180","preferredDefinition":"A chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, proliferation of atypical megakaryocytes and granulocytes in the bone marrow, anemia, splenomegaly, and extramedullary hematopoiesis. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Myelofibrosis","conceptCode":"C2862","definition":"A chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, proliferation of atypical megakaryocytes and granulocytes in the bone marrow, anemia, splenomegaly, and extramedullary hematopoiesis. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42EB656D-407F-53A3-E053-F662850A238D","latestVersionIndicator":"Yes","beginDate":"2016-12-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-12-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9923E9-85E7-2DCE-E053-F662850AB844","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Primary Mediastinal (Thymic) Large B-Cell Lymphoma","valueDescription":"Mediastinal (Thymic) Large B-Cell Lymphoma","ValueMeaning":{"publicId":"2838609","version":"1","preferredName":"Mediastinal (Thymic) Large B-Cell Lymphoma","longName":"2838609","preferredDefinition":"A large B-cell non-Hodgkin lymphoma arising in the mediastinum.  Morphologically it is characterized by a massive diffuse lymphocytic proliferation associated with compartmentalizing fibrosis.  Response to intensive chemotherapy, with or without radiotherapy, is usually good. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Mediastinal Large B-Cell Lymphoma","conceptCode":"C9280","definition":"A large B-cell non-Hodgkin lymphoma arising in the mediastinum.  Morphologically it is characterized by a massive diffuse lymphocytic proliferation associated with compartmentalizing fibrosis.  Response to intensive chemotherapy, with or without radiotherapy, is usually good. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6485A-AEF5-B656-E040-BB89AD437D5F","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"SOKKERL","dateModified":"2018-10-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9923E9-85FC-2DCE-E053-F662850AB844","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Primary Malignant Neoplasm","valueDescription":"Primary Malignant Neoplasm","ValueMeaning":{"publicId":"3211557","version":"1","preferredName":"Primary Malignant Neoplasm","longName":"3211557v1.00","preferredDefinition":"A malignant tumor at the original site of growth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Malignant Neoplasm","conceptCode":"C84509","definition":"A malignant tumor at the original site of growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F5324E1-CB2A-4BBA-E040-BB89AD4346F8","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"GDEEN","dateModified":"2023-04-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9923E9-8607-2DCE-E053-F662850AB844","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Primary Malignant Liver Neoplasm","valueDescription":"LIV - 155; Liver-Primary-NOS","ValueMeaning":{"publicId":"2572667","version":"1","preferredName":"LIV - 155; Liver-Primary-NOS","longName":"2572667","preferredDefinition":"An epithelial or non-epithelial malignant neoplasm that arises from the liver. Representative examples include hepatocellular carcinoma, intrahepatic cholangiocarcinoma, lymphoma, and sarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Malignant Liver Neoplasm","conceptCode":"C34803","definition":"An epithelial or non-epithelial malignant neoplasm that arises from the liver. Representative examples include hepatocellular carcinoma, intrahepatic cholangiocarcinoma, lymphoma, and sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8E8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9923E9-861C-2DCE-E053-F662850AB844","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Primary Cutaneous T-Cell Non-Hodgkin Lymphoma","valueDescription":"Cutaneous T-Cell Non-Hodgkin Lymphoma","ValueMeaning":{"publicId":"3210998","version":"1","preferredName":"Cutaneous T-Cell Non-Hodgkin Lymphoma","longName":"3210998","preferredDefinition":"A T-cell non-Hodgkin lymphoma arising from the skin. Representative examples include mycosis fungoides and primary cutaneous anaplastic large cell lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Cutaneous T-Cell Non-Hodgkin Lymphoma","conceptCode":"C3467","definition":"A T-cell non-Hodgkin lymphoma arising from the skin. Representative examples include mycosis fungoides and primary cutaneous anaplastic large cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BF80-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9923E9-8631-2DCE-E053-F662850AB844","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Precursor Lymphoid Neoplasm","valueDescription":"Precursor Lymphoid Neoplasm","ValueMeaning":{"publicId":"6832389","version":"1","preferredName":"Precursor Lymphoid Neoplasm","longName":"6832389","preferredDefinition":"A neoplasm of immature malignant lymphocytes (lymphoblasts) committed to the B-cell or T-cell lineage.  Neoplasms involving the bone marrow and the peripheral blood are called precursor lymphoblastic leukemias or acute lymphoblastic leukemias.  Neoplasms involving primarily lymph nodes or extranodal sites are called lymphoblastic lymphomas. -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Precursor Lymphoid Neoplasm","conceptCode":"C7055","definition":"A neoplasm of immature malignant lymphocytes (lymphoblasts) committed to the B-cell or T-cell lineage.  Neoplasms involving the bone marrow and the peripheral blood are called precursor lymphoblastic leukemias or acute lymphoblastic leukemias.  Neoplasms involving primarily lymph nodes or extranodal sites are called lymphoblastic lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9923E9-863F-2DCE-E053-F662850AB844","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9923E9-8658-2DCE-E053-F662850AB844","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Polycythemia Vera","valueDescription":"Polycythemia Vera","ValueMeaning":{"publicId":"2838666","version":"1","preferredName":"Polycythemia Vera","longName":"2838666","preferredDefinition":"A chronic myeloproliferative disorder characterized by an increased red blood cell production.  Excessive proliferation of the myeloid lineage is observed as well.  The major symptoms are related to hypertension or to vascular abnormalities caused by the increased red cell mass.  The cause is unknown.  With currently available treatment, the median survival exceeds 10 years.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polycythemia Vera","conceptCode":"C3336","definition":"A chronic myeloproliferative neoplasm characterized by an increased red blood cell production. The bone marrow is hypercellular due to a panmyelotic proliferation typically characterized by pleomorphic megakaryocytes. The major symptoms are related to hypertension, splenomegaly or to episodes of thrombosis and/or hemorrhage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A740CA-960E-2FE1-E040-BB89AD4311CA","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9923E9-8662-2DCE-E053-F662850AB844","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Pleuropulmonary Blastoma","valueDescription":"Pleuropulmonary Blastoma","ValueMeaning":{"publicId":"4975900","version":"1","preferredName":"Pleuropulmonary Blastoma","longName":"4975900","preferredDefinition":"A malignant neoplasm affecting the lungs and/or the pleura.  Pleuropulmonary blastoma is seen in children.  Microscopically, the tumor may show features of chondrosarcoma, leiomyosarcoma, rhabdomyosarcoma, liposarcoma, or undifferentiated sarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pleuropulmonary Blastoma","conceptCode":"C5669","definition":"A malignant neoplasm affecting the lungs and/or the pleura. Pleuropulmonary blastoma is seen in children. Microscopically, the tumor may show features of chondrosarcoma, leiomyosarcoma, rhabdomyosarcoma, liposarcoma, or undifferentiated sarcoma. In approximately 25% of patients with pleuropulmonary blastoma, there are other lesions or neoplasms that may affect patients or their families, including lung or kidney cysts, and ovarian or testicular neoplasms. Heterozygous germline mutations in DICER1 gene have been identified in families harboring pleuropulmonary blastomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1DC25021-A1AE-9879-E050-BB89AD437398","latestVersionIndicator":"Yes","beginDate":"2015-08-20","endDate":null,"createdBy":"DAVISJ","dateCreated":"2015-08-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9923E9-866D-2DCE-E053-F662850AB844","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Pleural Neoplasm","valueDescription":"Pleural Neoplasm","ValueMeaning":{"publicId":"6832391","version":"1","preferredName":"Pleural Neoplasm","longName":"6832391","preferredDefinition":"A benign or malignant neoplasm that involves the serous membrane that lines the lungs and thoracic cavity. Most pleural neoplasms are metastatic. Diffuse malignant mesothelioma is the most common primary malignant neoplasm of the pleura.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pleural Neoplasm","conceptCode":"C3332","definition":"A benign or malignant neoplasm that involves the serous membrane that lines the lungs and thoracic cavity. Most pleural neoplasms are metastatic. Diffuse malignant mesothelioma is the most common primary malignant neoplasm of the pleura.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9923E9-867B-2DCE-E053-F662850AB844","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9923E9-8694-2DCE-E053-F662850AB844","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Pleural Mesothelioma","valueDescription":"Pleural Mesothelioma","ValueMeaning":{"publicId":"6832393","version":"1","preferredName":"Pleural Mesothelioma","longName":"6832393","preferredDefinition":"A neoplasm that arises from the mesothelial cells of the pleura.  The primary cause is exposure to asbestos. The major histologic variants are the epithelioid malignant mesothelioma, desmoplastic malignant mesothelioma, and sarcomatoid malignant mesothelioma.  Patients present with persistent cough and shortness of breath.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pleural Mesothelial Neoplasm","conceptCode":"C9351","definition":"A mesothelial neoplasm that arises from the pleura. It includes adenomatoid tumor, well differentiated papillary mesothelial tumor, and malignant mesothelioma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9923E9-86A1-2DCE-E053-F662850AB844","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9923E9-86BA-2DCE-E053-F662850AB844","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Plasmacytoma","valueDescription":"Plasmacytoma","ValueMeaning":{"publicId":"3210724","version":"1","preferredName":"Plasmacytoma","longName":"3210724","preferredDefinition":"A malignant (clonal) proliferation of plasma cells that are cytologically and immunophenotypically identical to those of plasma cell myeloma, but manifest a localized osseous or extraosseous growth pattern. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plasmacytoma","conceptCode":"C9349","definition":"A malignant neoplasm characterized by the presence of a monoclonal population of plasma cells forming a tumor mass.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-94B6-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9923E9-86C4-2DCE-E053-F662850AB844","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Plasma Cell Neoplasm","valueDescription":"Plasma Cell Neoplasm","ValueMeaning":{"publicId":"2593071","version":"1","preferredName":"Plasma Cell Neoplasm","longName":"2593071","preferredDefinition":"An unusual leukemia characterized by the presence of clonal (malignant) plasma cells in the peripheral blood.  The plasma cells infiltrate the spleen, liver, bone marrow, and lymph nodes. The total number of leukocytes in the peripheral blood may range from normal levels to 80,000 or 90,000 per cu mm, and 5% to 90% may be plasma cells.  Although there are clinicopathologic differences between plasma cell leukemia and plasma cell myeloma, they may be phases of the same malignant process. -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plasma Cell Neoplasm","conceptCode":"C4665","definition":"A clonal proliferation of immunoglobulin-secreting plasma cells. This category includes multiple myeloma, plasma cell leukemia, plasmacytoma, and plasma cell post-transplant lymphoproliferative disorder.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286C5855-1934-6248-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9923E9-86CE-2DCE-E053-F662850AB844","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Stage 0 Oral Cavity Cancer AJCC v6 and v7","valueDescription":"Stage 0 Oral Cavity Cancer AJCC v6 and v7","ValueMeaning":{"publicId":"6832604","version":"1","preferredName":"Stage 0 Oral Cavity Cancer AJCC v6 and v7","longName":"6832604","preferredDefinition":"Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage 0 Oral Cavity Cancer AJCC v6 and v7","conceptCode":"C4587","definition":"Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AFD88-FAE1-779A-E053-F662850ABDFF","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AFD88-FAFA-779A-E053-F662850ABDFF","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Stage 0 Lung Cancer AJCC v6 and v7","valueDescription":"Stage 0 Lung Cancer","ValueMeaning":{"publicId":"3744982","version":"1","preferredName":"Stage 0 Lung Cancer","longName":"3744982","preferredDefinition":"Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage 0 Lung Cancer AJCC v6 and v7","conceptCode":"C27467","definition":"Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DC233BF1-5C88-FE53-E040-BB89AD437B2F","latestVersionIndicator":"Yes","beginDate":"2013-05-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-05-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AFD88-FB0E-779A-E053-F662850ABDFF","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Cutaneous Squamous Cell Carcinoma of the Head and Neck","valueDescription":"Cutaneous Squamous Cell Carcinoma of the Head and Neck","ValueMeaning":{"publicId":"6798870","version":"1","preferredName":"Cutaneous Squamous Cell Carcinoma of the Head and Neck","longName":"6798870","preferredDefinition":"A squamous cell carcinoma that arises from the skin of the head and neck.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cutaneous Squamous Cell Carcinoma of the Head and Neck","conceptCode":"C133252","definition":"A squamous cell carcinoma that arises from the skin of the head and neck.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C643043-FA92-5653-E053-F662850AE3D4","latestVersionIndicator":"Yes","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C643043-FAAB-5653-E053-F662850AE3D4","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Cutaneous Melanoma","valueDescription":"Cutaneous Melanoma","ValueMeaning":{"publicId":"2798718","version":"1","preferredName":"Cutaneous Melanoma","longName":"2798718","preferredDefinition":"A primary melanoma arising from atypical melanocytes in the skin.  Precursor lesions include acquired and congenital melanocytic nevi, and dysplastic nevi.  Several histologic variants have been recognized, including superficial spreading melanoma, acral lentiginous melanoma, nodular melanoma, and lentigo maligna melanoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cutaneous Melanoma","conceptCode":"C3510","definition":"A primary melanoma arising from atypical melanocytes in the skin.  Precursor lesions include acquired and congenital melanocytic nevi, and dysplastic nevi.  Several histologic variants have been recognized, including superficial spreading melanoma, acral lentiginous melanoma, nodular melanoma, and lentigo maligna melanoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B4B7C4C-6A82-156F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-09","endDate":null,"createdBy":"UMLLOADER_SEERHG","dateCreated":"2008-11-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C643043-FABF-5653-E053-F662850AE3D4","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Cribriform Carcinoma","valueDescription":"Cribriform Carcinoma","ValueMeaning":{"publicId":"6608073","version":"1","preferredName":"Cribriform Carcinoma","longName":"6608073","preferredDefinition":"A carcinoma characterized by the presence of a cribriform architectural pattern. Representative examples include the intraductal cribriform breast carcinoma and invasive cribriform breast carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cribriform Carcinoma","conceptCode":"C3680","definition":"A carcinoma characterized by the presence of a cribriform architectural pattern. Representative examples include the intraductal cribriform breast carcinoma and invasive cribriform breast carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F2324E2-475C-684E-E053-F662850A6EA6","latestVersionIndicator":"Yes","beginDate":"2019-01-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-01-10","modifiedBy":"ONEDATA","dateModified":"2019-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C643043-FACA-5653-E053-F662850AE3D4","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Craniopharyngioma","valueDescription":"Craniopharyngioma","ValueMeaning":{"publicId":"4265243","version":"1","preferredName":"Craniopharyngioma","longName":"4265243","preferredDefinition":"A benign, partly cystic, epithelial tumor of the sellar region, presumably derived from Rathke pouch epithelium. It affects mainly children and young adults. There are two clinicopathological forms: adamantinomatous craniopharyngioma and papillary craniopharyngioma. The most significant factor associated with recurrence is the extent of surgical resection, with lesions greater than 5 cm in diameter carrying a markedly worse prognosis. (Adapted from WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Craniopharyngioma","conceptCode":"C2964","definition":"A benign, partly cystic, epithelial tumor of the sellar region, presumably derived from Rathke pouch epithelium. It affects mainly children and young adults. There are two clinicopathological forms: adamantinomatous craniopharyngioma and papillary craniopharyngioma. The most significant factor associated with recurrence is the extent of surgical resection, with lesions greater than 5 cm in diameter carrying a markedly worse prognosis. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F68C00B1-794B-6438-E040-BB89AD4373BF","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C643043-FAD5-5653-E053-F662850AE3D4","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Cranial Nerve Neoplasm","valueDescription":"Cranial Nerve Neoplasm","ValueMeaning":{"publicId":"6798872","version":"1","preferredName":"Cranial Nerve Neoplasm","longName":"6798872","preferredDefinition":"Abnormal growth of the cells that comprise the cranial nerves.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cranial Nerve Neoplasm","conceptCode":"C2963","definition":"Abnormal growth of the cells that comprise the cranial nerves.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C643043-FAE2-5653-E053-F662850AE3D4","latestVersionIndicator":"Yes","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C643043-FAFB-5653-E053-F662850AE3D4","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Corneal Melanoma","valueDescription":"Corneal Melanoma","ValueMeaning":{"publicId":"6798874","version":"1","preferredName":"Corneal Melanoma","longName":"6798874","preferredDefinition":"A melanoma within the cornea of the eye.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Corneal Melanoma","conceptCode":"C4553","definition":"A melanoma that arises from the cornea.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C643043-FB08-5653-E053-F662850AE3D4","latestVersionIndicator":"Yes","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C643043-FB21-5653-E053-F662850AE3D4","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Conjunctival Melanoma","valueDescription":"Conjunctival Melanoma","ValueMeaning":{"publicId":"6798876","version":"1","preferredName":"Conjunctival Melanoma","longName":"6798876","preferredDefinition":"A malignant melanoma within the conjunctiva of the eye.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Conjunctival Melanoma","conceptCode":"C4550","definition":"A melanoma that arises from the conjunctiva.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C643043-FB2E-5653-E053-F662850AE3D4","latestVersionIndicator":"Yes","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C643043-FB47-5653-E053-F662850AE3D4","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Conjunctival Kaposi Sarcoma","valueDescription":"Conjunctival Kaposi Sarcoma","ValueMeaning":{"publicId":"6798878","version":"1","preferredName":"Conjunctival Kaposi Sarcoma","longName":"6798878","preferredDefinition":"A Kaposi sarcoma arising from the conjunctiva.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Conjunctival Kaposi Sarcoma","conceptCode":"C4578","definition":"A Kaposi sarcoma arising from the conjunctiva.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C643043-FB54-5653-E053-F662850AE3D4","latestVersionIndicator":"Yes","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C643043-FB6D-5653-E053-F662850AE3D4","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Composite Lymphoma","valueDescription":"Composite Lymphoma","ValueMeaning":{"publicId":"3905955","version":"1","preferredName":"Composite Lymphoma","longName":"3905955","preferredDefinition":"Coexistence of Hodgkin and non-Hodgkin lymphoma in the same anatomic site.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Composite Lymphoma","conceptCode":"C38661","definition":"Coexistence of Hodgkin and non-Hodgkin lymphoma in the same anatomic site.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E6D73054-E924-04B1-E040-BB89AD437E4C","latestVersionIndicator":"Yes","beginDate":"2013-09-20","endDate":null,"createdBy":"WONGW","dateCreated":"2013-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C643043-FB81-5653-E053-F662850AE3D4","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Comedocarcinoma","valueDescription":"Comedocarcinoma","ValueMeaning":{"publicId":"2678767","version":"1","preferredName":"Comedocarcinoma","longName":"2678767","preferredDefinition":"A high grade carcinoma characterized by the presence of comedo-type of tumor cell necrosis in which the necrotic areas are surrounded by a solid proliferation of malignant pleomorphic cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Comedo-Type Adenocarcinoma","conceptCode":"C4188","definition":"A high grade carcinoma characterized by the presence of comedo-type tumor cell necrosis in which the necrotic areas are surrounded by a solid proliferation of malignant pleomorphic cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"398E4724-32F5-1D49-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C643043-FB8C-5653-E053-F662850AE3D4","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Combined Carcinoid and Adenocarcinoma","valueDescription":"Combined Carcinoid and Adenocarcinoma","ValueMeaning":{"publicId":"6043409","version":"1","preferredName":"Combined Carcinoid and Adenocarcinoma","longName":"6043409","preferredDefinition":"A malignant epithelial neoplasm composed of a mixture of neuroendocrine cells with morphologic and immunohistochemical characteristics of carcinoid tumor and malignant glandular cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Combined Carcinoid and Adenocarcinoma","conceptCode":"C4139","definition":"A malignant epithelial neoplasm composed of a mixture of neuroendocrine cells with morphologic and immunohistochemical characteristics of carcinoid tumor and malignant glandular cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"60A2E2DC-902E-0D00-E053-F662850A3E8D","latestVersionIndicator":"Yes","beginDate":"2017-12-18","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2017-12-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C643043-FBA1-5653-E053-F662850AE3D4","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Colorectal Carcinoma","valueDescription":"Colorectal Carcinoma","ValueMeaning":{"publicId":"4722734","version":"1","preferredName":"Colorectal Carcinoma","longName":"4722734","preferredDefinition":"A malignant epithelial neoplasm that arises from the colon or rectum and invades through the muscularis mucosa into the submucosa.  The vast majority are adenocarcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Colorectal Carcinoma","conceptCode":"C2955","definition":"A malignant epithelial neoplasm that arises from the colon or rectum and invades through the muscularis mucosa into the submucosa.  The vast majority are adenocarcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-1E70-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C643043-FBAC-5653-E053-F662850AE3D4","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Colon Neuroendocrine Tumor G1","valueDescription":"Colon Neuroendocrine Tumor G1","ValueMeaning":{"publicId":"6798879","version":"1","preferredName":"Colon Neuroendocrine Tumor G1","longName":"6798879","preferredDefinition":"A well differentiated, low grade neuroendocrine tumor (carcinoid tumor) that arises from the colon.  The mitotic count is less than 2 per 10 HPF and/or the Ki67 index is equal to or less than 2 percent.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Colon Neuroendocrine Tumor G1","conceptCode":"C5497","definition":"A well differentiated, low grade neuroendocrine neoplasm that arises from the colon. The mitotic count is less than 2 per 10 HPF and/or the Ki67 index is equal to or less than 2 percent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C643043-FBB6-5653-E053-F662850AE3D4","latestVersionIndicator":"Yes","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C643043-FBCF-5653-E053-F662850AE3D4","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Colon Carcinoma","valueDescription":"Colon Carcinoma","ValueMeaning":{"publicId":"5581331","version":"1","preferredName":"Colon Carcinoma","longName":"5581331","preferredDefinition":"A malignant epithelial neoplasm that arises from the colon and invades through the muscularis mucosa into the submucosa.  The vast majority are adenocarcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Colon Carcinoma","conceptCode":"C4910","definition":"A malignant epithelial neoplasm that arises from the colon and invades through the muscularis mucosa into the submucosa.  The vast majority are adenocarcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42019733-B716-634F-E053-F662850A5A61","latestVersionIndicator":"Yes","beginDate":"2016-11-23","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2016-11-23","modifiedBy":"COOPERM","dateModified":"2019-02-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C643043-FBE3-5653-E053-F662850AE3D4","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Classic Hodgkin Lymphoma","valueDescription":"Classical Hodgkin Lymphoma","ValueMeaning":{"publicId":"2838033","version":"1","preferredName":"Classical Hodgkin Lymphoma","longName":"2838033","preferredDefinition":"In more than 95% of cases, a monoclonal B-cell lymphoproliferation characterized by a bimodal age distribution (15-30 years of life and late life), often associated with EBV infection.  In less than 5% of cases, this is a monoclonal proliferation of T-lymphocytes. Morphologically, it is characterized by the presense of Reed-Sternberg cells and mononuclear Hodgkin cells.  The Reed-Sternberg and mononuclear Hodgkin cells are CD30 positive in nearly all cases and CD15 positive in the majority of cases.  -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Classic Hodgkin Lymphoma","conceptCode":"C7164","definition":"A category of Hodgkin lymphomas that includes the following four histologic subtypes: lymphocyte-rich, nodular sclerosis, mixed cellularity, and lymphocyte-depleted classic Hodgkin lymphoma. The vast majority of Hodgkin lymphomas belong to this category.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62837FF7-842C-6F46-E040-BB89AD433964","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C643043-FBF8-5653-E053-F662850AE3D4","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Chronic Myelomonocytic Leukemia","valueDescription":"Chronic Myelomonocytic Leukemia","ValueMeaning":{"publicId":"2771865","version":"1","preferredName":"Chronic Myelomonocytic Leukemia","longName":"2771865","preferredDefinition":"A myelodysplastic/myeloproliferative disease which is characterized by persistent monocytosis, absence of a Philadelphia chromosome and BCR/ABL fusion gene, fewer than 20% blasts in the bone marrow or blood, and myelodysplasia.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Myelomonocytic Leukemia","conceptCode":"C3178","definition":"A myelodysplastic/myeloproliferative neoplasm which is characterized by persistent monocytosis, absence of a Philadelphia chromosome and BCR/ABL fusion gene, fewer than 20 percent blasts in the bone marrow and blood, myelodysplasia, and absence of PDGFRA or PDGFRB rearrangement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54342348-5E2F-4602-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-11","modifiedBy":"SOKKERL","dateModified":"2022-11-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C643043-FC03-5653-E053-F662850AE3D4","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Chronic Myelogenous Leukemia, BCR-ABL1 Positive","valueDescription":"CML","ValueMeaning":{"publicId":"2837953","version":"1","preferredName":"CML","longName":"2837953","preferredDefinition":"The most common chronic myeloproliferative disorder characterized by neutrophilic leukocytosis.  It is associated with the Philadelphia (Ph) chromosome and/or the BCR/ABL fusion gene.  Most patients are middle-aged or elderly.  Common findings at presentation include fatigue, weight loss, anemia, night sweats, and splenomegaly.  The disease is bi- or triphasic: an initial indolent chronic phase is followed by accelerated or blast phase.  Allogeneic bone marrow transplantation is currently the only curative therapy (adapted from WHO 2001).  -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Myeloid Leukemia, BCR-ABL1 Positive","conceptCode":"C3174","definition":"A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6282862D-CE51-EC8D-E040-BB89AD434A77","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C643043-FC17-5653-E053-F662850AE3D4","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Chronic Lymphocytic Leukemia","valueDescription":"Chronic Lymphocytic Leukemia","ValueMeaning":{"publicId":"4264837","version":"1","preferredName":"Chronic Lymphocytic Leukemia","longName":"4264837","preferredDefinition":"The most common type of chronic lymphoid leukemia.  It comprises 90% of chronic lymphoid leukemias in the United States.  Morphologically, the neoplastic cells are small, round B-lymphocytes.  This type of leukemia is not considered to be curable with available therapy. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Lymphocytic Leukemia","conceptCode":"C3163","definition":"The most common type of chronic lymphoid leukemia.  It comprises 90% of chronic lymphoid leukemias in the United States.  Morphologically, the neoplastic cells are small, round B-lymphocytes.  This type of leukemia is not considered to be curable with available therapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67A42EF-FFD5-5F77-E040-BB89AD433177","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C643043-FC2C-5653-E053-F662850AE3D4","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Chronic Leukemia","valueDescription":"Chronic Leukemia","ValueMeaning":{"publicId":"6798881","version":"1","preferredName":"Chronic Leukemia","longName":"6798881","preferredDefinition":"A slowly progressing leukemia characterized by a clonal (malignant) proliferation of maturing and mature myeloid cells or mature lymphocytes.  When the clonal cellular population is composed of myeloid cells, the process is called chronic myelogenous leukemia.  When the clonal cellular population is composed of lymphocytes, it is classified as chronic lymphocytic leukemia, hairy cell leukemia, or T-cell large granular lymphocyte leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Leukemia","conceptCode":"C3483","definition":"A slowly progressing leukemia characterized by a clonal (malignant) proliferation of maturing and mature myeloid cells or mature lymphocytes.  When the clonal cellular population is composed of myeloid cells, the process is called chronic myelogenous leukemia.  When the clonal cellular population is composed of lymphocytes, it is classified as chronic lymphocytic leukemia, hairy cell leukemia, or T-cell large granular lymphocyte leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C643043-FC39-5653-E053-F662850AE3D4","latestVersionIndicator":"Yes","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C643043-FC52-5653-E053-F662850AE3D4","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Choroid Plexus Carcinoma","valueDescription":"Choroid plexus carcinoma","ValueMeaning":{"publicId":"2578711","version":"1","preferredName":"Choroid plexus carcinoma","longName":"2578711","preferredDefinition":"Choroid Plexus Carcinoma (WHO grade III) is a malignant Choroid Plexus Tumor which shows anaplastic features and usually invades neighboring brain structures. CSF metastases are frequent. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Choroid Plexus Carcinoma","conceptCode":"C4715","definition":"A malignant neoplasm arising from the choroid plexus.  It shows anaplastic features and usually invades neighboring brain structures. Cerebrospinal fluid metastases are frequent. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0084-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C643043-FC5C-5653-E053-F662850AE3D4","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Stage 0 Lip and Oral Cavity Cancer AJCC v6 and v7","valueDescription":"Stage 0 Lip and Oral Cavity Cancer AJCC v6 and v7","ValueMeaning":{"publicId":"6832606","version":"1","preferredName":"Stage 0 Lip and Oral Cavity Cancer AJCC v6 and v7","longName":"6832606","preferredDefinition":"Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage 0 Lip and Oral Cavity Cancer AJCC v6 and v7","conceptCode":"C7939","definition":"Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AFD88-FB1C-779A-E053-F662850ABDFF","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AFD88-FB35-779A-E053-F662850ABDFF","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Stage 0 Intrahepatic Bile Duct Cancer AJCC v8","valueDescription":"Stage 0 Intrahepatic Bile Duct Cancer AJCC v8","ValueMeaning":{"publicId":"6587569","version":"1","preferredName":"Stage 0 Intrahepatic Bile Duct Cancer AJCC v8","longName":"6587569","preferredDefinition":"Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ (intraductal tumor). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage 0 Intrahepatic Bile Duct Cancer AJCC v8","conceptCode":"C134609","definition":"Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ (intraductal tumor). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CD4D5B3-9E92-7238-E053-F662850A34EF","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AFD88-FB49-779A-E053-F662850ABDFF","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Stage 0 Gastric Cancer AJCC v6 and v7","valueDescription":"Stage 0 Gastric Cancer","ValueMeaning":{"publicId":"3444120","version":"1","preferredName":"Stage 0 Gastric Cancer","longName":"3444120","preferredDefinition":"Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ: intraepithelial tumor without invasion of the lamina propria.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage 0 Gastric Cancer AJCC v6 and v7","conceptCode":"C7788","definition":"Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ: intraepithelial tumor without invasion of the lamina propria.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEAB03DB-ACA9-C6D9-E040-BB89AD4356B3","latestVersionIndicator":"Yes","beginDate":"2012-04-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AFD88-FB5E-779A-E053-F662850ABDFF","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Stage 0 Cutaneous Melanoma AJCC v6 and v7","valueDescription":"Stage 0 Skin Melanoma","ValueMeaning":{"publicId":"3357762","version":"1","preferredName":"Stage 0 Skin Melanoma","longName":"3357762","preferredDefinition":"Stage 0 includes: Tis, N0, M0. Tis: Melanoma in situ. N0: No regional lymph node metastases. M0: No detectable evidence of distant metastases. (from AJCC 6th and 7th Eds.) ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage 0 Cutaneous Melanoma AJCC v6 and v7","conceptCode":"C8423","definition":"Stage 0 includes: Tis, N0, M0.  Tis: Melanoma in situ.  N0: No regional lymph node metastases.  M0: No detectable evidence of distant metastases. (from AJCC 6th and 7th Eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6E3F2CD-0721-CF89-E040-BB89AD432510","latestVersionIndicator":"Yes","beginDate":"2012-01-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-19","modifiedBy":"ONEDATA","dateModified":"2012-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AFD88-FB73-779A-E053-F662850ABDFF","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Stage 0 Colon Cancer AJCC v6 and v7","valueDescription":"Stage 0 Colon Cancer AJCC v6 and v7","ValueMeaning":{"publicId":"6832608","version":"1","preferredName":"Stage 0 Colon Cancer AJCC v6 and v7","longName":"6832608","preferredDefinition":"Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ: intraepithelial or invasion of lamina propria.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage 0 Colon Cancer AJCC v6 and v7","conceptCode":"C3638","definition":"Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ: intraepithelial or invasion of lamina propria.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AFD88-FB81-779A-E053-F662850ABDFF","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AFD88-FB9A-779A-E053-F662850ABDFF","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Stage 0 Cervical Cancer AJCC v7","valueDescription":"Stage 0 Cervical Cancer","ValueMeaning":{"publicId":"2838727","version":"1","preferredName":"Stage 0 Cervical Cancer","longName":"2838727","preferredDefinition":"Stage 0 includes: (Tis, N0, M0). Tis: Carcinoma in situ. N0: No regional lymph node metastasis. M0: No distant metastasis. FIGO no longer includes stage 0. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage 0 Cervical Cancer AJCC v7","conceptCode":"C89550","definition":"Stage 0 includes: (Tis, N0, M0). Tis: Carcinoma in situ. N0: No regional lymph node metastasis.  M0: No distant metastasis. FIGO no longer includes stage 0. (AJCC 7th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A85C92-100F-B23A-E040-BB89AD431D54","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AFD88-FBAE-779A-E053-F662850ABDFF","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Stage 0 Breast Cancer AJCC v6 and v7","valueDescription":"Stage 0 Breast Cancer","ValueMeaning":{"publicId":"3419373","version":"1","preferredName":"Stage 0 Breast Cancer","longName":"3419373","preferredDefinition":"Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th Eds.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage 0 Breast Cancer AJCC v6 and v7","conceptCode":"C3641","definition":"Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BB9ECD53-19AB-8642-E040-BB89AD43080C","latestVersionIndicator":"Yes","beginDate":"2012-03-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Updated VMD with latest version of NCIt concept defintion. mc 3/20/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AFD88-FBC3-779A-E053-F662850ABDFF","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Anal Neoplasm","valueDescription":"Malignant Anal Neoplasm","ValueMeaning":{"publicId":"6832817","version":"1","preferredName":"Malignant Anal Neoplasm","longName":"6832817","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the anal canal or perianal skin.  Representative examples include carcinomas, lymphomas, and melanomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Anal Neoplasm","conceptCode":"C7379","definition":"A primary or metastatic malignant neoplasm that affects the anal canal or perianal skin.  Representative examples include carcinomas, lymphomas, and melanomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B9E27-51CA-359A-E053-F662850ADB9D","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B9E27-51E3-359A-E053-F662850ADB9D","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Anterior Tongue Neoplasm","valueDescription":"Malignant Anterior Tongue Neoplasm","ValueMeaning":{"publicId":"6832819","version":"1","preferredName":"Malignant Anterior Tongue Neoplasm","longName":"6832819","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the anterior portion of the tongue.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Anterior Tongue Neoplasm","conceptCode":"C6061","definition":"A primary or metastatic malignant neoplasm that affects the anterior portion of the tongue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B9E27-51F0-359A-E053-F662850ADB9D","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B9E27-5209-359A-E053-F662850ADB9D","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Appendix Neoplasm","valueDescription":"Malignant Appendix Neoplasm","ValueMeaning":{"publicId":"6832821","version":"1","preferredName":"Malignant Appendix Neoplasm","longName":"6832821","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the appendix.  Representative examples include carcinoma and lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Appendix Neoplasm","conceptCode":"C9333","definition":"A primary or metastatic malignant neoplasm that affects the appendix.  Representative examples include carcinoma and lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B9E27-5216-359A-E053-F662850ADB9D","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B9E27-522F-359A-E053-F662850ADB9D","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Basal Cell Neoplasm","valueDescription":"Malignant Basal Cell Neoplasm","ValueMeaning":{"publicId":"6832823","version":"1","preferredName":"Malignant Basal Cell Neoplasm","longName":"6832823","preferredDefinition":"A neoplasm composed of basal cells that metastasizes to other anatomic sites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Basal Cell Neoplasm","conceptCode":"C7586","definition":"A neoplasm composed of basal cells that metastasizes to other anatomic sites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B9E27-523C-359A-E053-F662850ADB9D","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B9E27-5255-359A-E053-F662850ADB9D","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Bladder Neoplasm","valueDescription":"VES - 188.9; Bladder","ValueMeaning":{"publicId":"2572631","version":"1","preferredName":"VES - 188.9; Bladder","longName":"2572631","preferredDefinition":"A primary or metastatic malignant neoplasm involving the bladder.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Bladder Neoplasm","conceptCode":"C9334","definition":"A primary or metastatic malignant neoplasm involving the bladder.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8C4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B9E27-5269-359A-E053-F662850ADB9D","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Bone Marrow Neoplasm","valueDescription":"Malignant Bone Marrow Neoplasm","ValueMeaning":{"publicId":"6832825","version":"1","preferredName":"Malignant Bone Marrow Neoplasm","longName":"6832825","preferredDefinition":"Malignant neoplasms that either originate from the bone marrow (e.g. myeloid leukemias) or involve the bone marrow as secondary-metastatic tumors (e.g. metastatic carcinomas to the bone marrow).  --2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Bone Marrow Neoplasm","conceptCode":"C35501","definition":"Malignant neoplasms that either originate from the bone marrow (e.g. myeloid leukemias) or involve the bone marrow as secondary-metastatic tumors (e.g. metastatic carcinomas to the bone marrow).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B9E27-5277-359A-E053-F662850ADB9D","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B9E27-5290-359A-E053-F662850ADB9D","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Bone Neoplasm","valueDescription":"Malignant Bone Neoplasm","ValueMeaning":{"publicId":"5581327","version":"1","preferredName":"Malignant Bone Neoplasm","longName":"5581327","preferredDefinition":"A primary or metastatic malignant neoplasm affecting the bone or articular cartilage.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Bone Neoplasm","conceptCode":"C4016","definition":"A primary or metastatic malignant neoplasm affecting the bone or articular cartilage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42019733-B68A-634F-E053-F662850A5A61","latestVersionIndicator":"Yes","beginDate":"2016-11-23","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2016-11-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B9E27-52A4-359A-E053-F662850ADB9D","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Brain Neoplasm","valueDescription":"Malignant Brain Neoplasm","ValueMeaning":{"publicId":"5581328","version":"1","preferredName":"Malignant Brain Neoplasm","longName":"5581328","preferredDefinition":"A primary or metastatic malignant neoplasm affecting the brain.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Brain Neoplasm","conceptCode":"C3568","definition":"A primary or metastatic malignant neoplasm affecting the brain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42019733-B6AD-634F-E053-F662850A5A61","latestVersionIndicator":"Yes","beginDate":"2016-11-23","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2016-11-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B9E27-52B9-359A-E053-F662850ADB9D","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Brain Stem Neoplasm","valueDescription":"Malignant Brain Stem Neoplasm","ValueMeaning":{"publicId":"6832827","version":"1","preferredName":"Malignant Brain Stem Neoplasm","longName":"6832827","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the brain stem.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Brain Stem Neoplasm","conceptCode":"C3570","definition":"A primary or metastatic malignant neoplasm that affects the brain stem.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B9E27-52C7-359A-E053-F662850ADB9D","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B9E27-52E0-359A-E053-F662850ADB9D","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Breast Neoplasm","valueDescription":"Malignant Breast Neoplasm","ValueMeaning":{"publicId":"6832828","version":"1","preferredName":"Malignant Breast Neoplasm","longName":"6832828","preferredDefinition":"A primary or metastatic malignant neoplasm involving the breast.  The vast majority of cases are carcinomas arising from the breast parenchyma or the nipple.  Malignant breast neoplasms occur more frequently in females than in males.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Breast Neoplasm","conceptCode":"C9335","definition":"A primary or metastatic malignant neoplasm involving the breast.  The vast majority of cases are carcinomas arising from the breast parenchyma or the nipple.  Malignant breast neoplasms occur more frequently in females than in males.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B9E27-52EA-359A-E053-F662850ADB9D","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B9E27-5303-359A-E053-F662850ADB9D","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Buccal Mucosa Neoplasm","valueDescription":"Malignant Buccal Mucosa Neoplasm","ValueMeaning":{"publicId":"6832830","version":"1","preferredName":"Malignant Buccal Mucosa Neoplasm","longName":"6832830","preferredDefinition":"A primary or metastatic malignant neoplasm involving the buccal mucosa.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Buccal Mucosa Neoplasm","conceptCode":"C9320","definition":"A primary or metastatic malignant neoplasm involving the buccal mucosa.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B9E27-5310-359A-E053-F662850ADB9D","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B9E27-5329-359A-E053-F662850ADB9D","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Cardiac Neoplasm","valueDescription":"Malignant Cardiac Neoplasm","ValueMeaning":{"publicId":"6832832","version":"1","preferredName":"Malignant Cardiac Neoplasm","longName":"6832832","preferredDefinition":"A primary or metastatic malignant neoplasm involving the heart.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Cardiac Neoplasm","conceptCode":"C3548","definition":"A primary or metastatic malignant neoplasm involving the heart.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B9E27-5336-359A-E053-F662850ADB9D","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B9E27-534F-359A-E053-F662850ADB9D","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Cardiovascular Neoplasm","valueDescription":"Malignant Cardiovascular Neoplasm","ValueMeaning":{"publicId":"6832834","version":"1","preferredName":"Malignant Cardiovascular Neoplasm","longName":"6832834","preferredDefinition":"A primary or metastatic malignant neoplasm involving the cardiovascular system.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Cardiovascular Neoplasm","conceptCode":"C114940","definition":"A primary or metastatic malignant neoplasm involving the cardiovascular system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B9E27-535C-359A-E053-F662850ADB9D","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B9E27-5375-359A-E053-F662850ADB9D","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Thymus Neoplasm","valueDescription":"Malignant Thymus Neoplasm","ValueMeaning":{"publicId":"6835296","version":"1","preferredName":"Malignant Thymus Neoplasm","longName":"6835296","preferredDefinition":"A primary or metastatic malignant neoplasm involving the thymus. This category includes malignant thymomas, thymic lymphomas, primary thymic carcinomas, and metastatic carcinomas from other anatomic sites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Thymus Neoplasm","conceptCode":"C4962","definition":"A primary or metastatic malignant neoplasm involving the thymus. This category includes malignant thymomas, thymic lymphomas, primary thymic carcinomas, and metastatic carcinomas from other anatomic sites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED61D98-17DE-2CE5-E053-F662850A8D49","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED61D98-17F7-2CE5-E053-F662850A8D49","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Thoracic Neoplasm","valueDescription":"Malignant Thoracic Neoplasm","ValueMeaning":{"publicId":"6835294","version":"1","preferredName":"Malignant Thoracic Neoplasm","longName":"6835294","preferredDefinition":"A primary or metastatic malignant neoplasm affecting the tissues of the thorax.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Thoracic Neoplasm","conceptCode":"C3576","definition":"A primary or metastatic malignant neoplasm affecting the tissues of the thorax.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED61D98-17B8-2CE5-E053-F662850A8D49","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED61D98-17D1-2CE5-E053-F662850A8D49","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Thyroid Gland Neoplasm","valueDescription":"Malignant Thyroid Gland Neoplasm","ValueMeaning":{"publicId":"6835298","version":"1","preferredName":"Malignant Thyroid Gland Neoplasm","longName":"6835298","preferredDefinition":"A primary or metastatic malignant neoplasm affecting the thyroid gland.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Thyroid Gland Neoplasm","conceptCode":"C7510","definition":"A primary or metastatic malignant neoplasm affecting the thyroid gland.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED61D98-1804-2CE5-E053-F662850A8D49","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED61D98-181D-2CE5-E053-F662850A8D49","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Tongue Neoplasm","valueDescription":"Malignant Tongue Neoplasm","ValueMeaning":{"publicId":"6835300","version":"1","preferredName":"Malignant Tongue Neoplasm","longName":"6835300","preferredDefinition":"A malignant neoplasm affecting the tongue.  The vast majority of cases are carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Tongue Neoplasm","conceptCode":"C9345","definition":"A malignant neoplasm affecting the tongue.  The vast majority of cases are carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED61D98-182A-2CE5-E053-F662850A8D49","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED61D98-1843-2CE5-E053-F662850A8D49","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Tonsillar Neoplasm","valueDescription":"Malignant Tonsillar Neoplasm","ValueMeaning":{"publicId":"6835302","version":"1","preferredName":"Malignant Tonsillar Neoplasm","longName":"6835302","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the tonsil.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Tonsillar Neoplasm","conceptCode":"C7404","definition":"A primary or metastatic malignant neoplasm that affects the tonsil.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED61D98-1850-2CE5-E053-F662850A8D49","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED61D98-1869-2CE5-E053-F662850A8D49","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Tracheal Neoplasm","valueDescription":"Malignant Tracheal Neoplasm","ValueMeaning":{"publicId":"6835304","version":"1","preferredName":"Malignant Tracheal Neoplasm","longName":"6835304","preferredDefinition":"A primary or metastatic malignant neoplasm involving the trachea.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Tracheal Neoplasm","conceptCode":"C9346","definition":"A primary or metastatic malignant neoplasm involving the trachea.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED61D98-1876-2CE5-E053-F662850A8D49","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED61D98-188F-2CE5-E053-F662850A8D49","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Ureter Neoplasm","valueDescription":"Malignant Ureter Neoplasm","ValueMeaning":{"publicId":"6835306","version":"1","preferredName":"Malignant Ureter Neoplasm","longName":"6835306","preferredDefinition":"A primary or metastatic malignant tumor involving the ureter.  The majority are carcinomas. -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Ureter Neoplasm","conceptCode":"C7543","definition":"A primary or metastatic malignant tumor involving the ureter.  The majority are carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED61D98-189C-2CE5-E053-F662850A8D49","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED61D98-18B5-2CE5-E053-F662850A8D49","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Urethral Neoplasm","valueDescription":"Malignant Urethral Neoplasm","ValueMeaning":{"publicId":"6835308","version":"1","preferredName":"Malignant Urethral Neoplasm","longName":"6835308","preferredDefinition":"A primary or metastatic malignant neoplasm involving the urethra.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Urethral Neoplasm","conceptCode":"C7507","definition":"A primary or metastatic malignant neoplasm involving the urethra.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED61D98-18C2-2CE5-E053-F662850A8D49","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED61D98-18DB-2CE5-E053-F662850A8D49","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Urinary System Neoplasm","valueDescription":"Malignant Urinary System Neoplasm","ValueMeaning":{"publicId":"4722496","version":"1","preferredName":"Malignant Urinary System Neoplasm","longName":"4722496","preferredDefinition":"A primary or metastatic malignant tumor involving the urinary system.  Common tumor types include carcinomas, lymphomas, and sarcomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Urinary System Neoplasm","conceptCode":"C9297","definition":"A primary or metastatic malignant neoplasm involving the urinary system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8748A7-474D-DF2B-E050-BB89AD4311E0","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED61D98-18F0-2CE5-E053-F662850A8D49","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Metastatic Malignant Neoplasm in the Liver","valueDescription":"Metastatic Malignant Neoplasm in the Liver","ValueMeaning":{"publicId":"4722601","version":"1","preferredName":"Metastatic Malignant Neoplasm in the Liver","longName":"4722601","preferredDefinition":"A malignant neoplasm that has spread to the liver from another (primary) anatomic site.  Such malignant neoplasms may be carcinomas, lymphomas, melanomas, or sarcomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metastatic Malignant Neoplasm in the Liver","conceptCode":"C4758","definition":"A malignant neoplasm that has spread to the liver from another (primary) anatomic site. Representative examples include carcinomas, lymphomas, melanomas, or sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A2532-F923-F227-E050-BB89AD433E96","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED67F1D-8A1C-5ED9-E053-F662850AF7E1","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Metastatic Malignant Neoplasm in the Lung","valueDescription":"Metastatic Malignant Neoplasm in the Lung","ValueMeaning":{"publicId":"4722602","version":"1","preferredName":"Metastatic Malignant Neoplasm in the Lung","longName":"4722602","preferredDefinition":"The spread of a malignant neoplasm to the lung. This may be from a primary lung malignant neoplasm, or from a malignant neoplasm at a distant site.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metastatic Malignant Neoplasm in the Lung","conceptCode":"C3577","definition":"The spread of a malignant neoplasm to the lung. This may be from a primary lung malignant neoplasm, or from a malignant neoplasm at a distant site.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A2532-F946-F227-E050-BB89AD433E96","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED67F1D-8A31-5ED9-E053-F662850AF7E1","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Metastatic Malignant Neoplasm in the Mediastinum","valueDescription":"Metastatic Malignant Neoplasm in the Mediastinum","ValueMeaning":{"publicId":"6835455","version":"1","preferredName":"Metastatic Malignant Neoplasm in the Mediastinum","longName":"6835455","preferredDefinition":"The spread of a malignant neoplasm to the mediastinum from an adjacent or distant anatomic site.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metastatic Malignant Neoplasm in the Mediastinum","conceptCode":"C3578","definition":"The spread of a malignant neoplasm to the mediastinum from an adjacent or distant anatomic site.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED67F1D-8A3F-5ED9-E053-F662850AF7E1","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED67F1D-8A58-5ED9-E053-F662850AF7E1","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Metastatic Malignant Neoplasm in the Nervous System","valueDescription":"Metastatic Malignant Neoplasm in the Nervous System","ValueMeaning":{"publicId":"6835457","version":"1","preferredName":"Metastatic Malignant Neoplasm in the Nervous System","longName":"6835457","preferredDefinition":"The spread of a malignant neoplasm to the nervous system.  This may be from a primary nervous system malignant neoplasm, or from a malignant neoplasm at a distant site.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metastatic Malignant Neoplasm in the Nervous System","conceptCode":"C8547","definition":"The spread of a malignant neoplasm to the nervous system.  This may be from a primary nervous system malignant neoplasm, or from a malignant neoplasm at a distant site.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED67F1D-8A65-5ED9-E053-F662850AF7E1","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED67F1D-8A7E-5ED9-E053-F662850AF7E1","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Metastatic Malignant Neoplasm in the Ovary","valueDescription":"Metastatic Malignant Neoplasm in the Ovary","ValueMeaning":{"publicId":"6835459","version":"1","preferredName":"Metastatic Malignant Neoplasm in the Ovary","longName":"6835459","preferredDefinition":"The spread of a malignant neoplasm to the ovary.  This may be from a primary ovarian malignant neoplasm involving the opposite ovary, or from a malignant neoplasm at a distant site.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metastatic Malignant Neoplasm in the Ovary","conceptCode":"C7456","definition":"The spread of a malignant neoplasm to the ovary.  This may be from a primary ovarian malignant neoplasm involving the opposite ovary, or from a malignant neoplasm at a distant site.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED67F1D-8A8B-5ED9-E053-F662850AF7E1","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED67F1D-8AA4-5ED9-E053-F662850AF7E1","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Metastatic Malignant Neoplasm in the Skin","valueDescription":"Metastatic Malignant Neoplasm in the Skin","ValueMeaning":{"publicId":"4722605","version":"1","preferredName":"Metastatic Malignant Neoplasm in the Skin","longName":"4722605","preferredDefinition":"The spread of a malignant neoplasm to the skin.  This may be from a primary skin malignant neoplasm, or from a malignant neoplasm at a distant site.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metastatic Malignant Neoplasm in the Skin","conceptCode":"C5629","definition":"The spread of a malignant neoplasm to the skin.  This may be from a primary skin malignant neoplasm, or from a malignant neoplasm at a distant site.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A2532-F98F-F227-E050-BB89AD433E96","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED67F1D-8AB8-5ED9-E053-F662850AF7E1","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Metastatic Melanoma","valueDescription":"Metastatic Melanoma","ValueMeaning":{"publicId":"3775984","version":"1","preferredName":"Metastatic Melanoma","longName":"3775984","preferredDefinition":"A melanoma that has spread from its primary site to another anatomic site.  Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metastatic Melanoma","conceptCode":"C8925","definition":"A melanoma that has spread from its primary site to another anatomic site.  Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DE8224EE-CCDA-B892-E040-BB89AD4353A2","latestVersionIndicator":"Yes","beginDate":"2013-06-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-06-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED67F1D-8ACD-5ED9-E053-F662850AF7E1","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Metastatic Sarcoma","valueDescription":"Metastatic Sarcoma","ValueMeaning":{"publicId":"6835461","version":"1","preferredName":"Metastatic Sarcoma","longName":"6835461","preferredDefinition":"A sarcoma that has spread from its original site of growth to another anatomic site.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metastatic Sarcoma","conceptCode":"C152076","definition":"A sarcoma that has spread from its original site of growth to another anatomic site.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED67F1D-8ADB-5ED9-E053-F662850AF7E1","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED67F1D-8AF4-5ED9-E053-F662850AF7E1","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Metastatic Well Differentiated Neuroendocrine Neoplasm","valueDescription":"Metastatic Well Differentiated Neuroendocrine Neoplasm","ValueMeaning":{"publicId":"6835465","version":"1","preferredName":"Metastatic Well Differentiated Neuroendocrine Neoplasm","longName":"6835465","preferredDefinition":"A well differentiated neuroendocrine neoplasm that has spread from the original site of growth to another anatomic site.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metastatic Neuroendocrine Tumor","conceptCode":"C147065","definition":"A neuroendocrine tumor that has spread from its original site of growth to another anatomic site.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED67F1D-8B01-5ED9-E053-F662850AF7E1","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED67F1D-8B1A-5ED9-E053-F662850AF7E1","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Methotrexate-Associated Lymphoma","valueDescription":"Methotrexate-Associated Lymphoma","ValueMeaning":{"publicId":"6835467","version":"1","preferredName":"Methotrexate-Associated Lymphoma","longName":"6835467","preferredDefinition":"A non-Hodgkin or Hodgkin lymphoma that develops in patients who are immunosuppressed with methotrexate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methotrexate-Associated Lymphoma","conceptCode":"C150678","definition":"A non-Hodgkin or Hodgkin lymphoma that develops in patients who are immunosuppressed with methotrexate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED67F1D-8B27-5ED9-E053-F662850AF7E1","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED67F1D-8B40-5ED9-E053-F662850AF7E1","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Mixed Cellularity Classic Hodgkin Lymphoma","valueDescription":"Mixed Cellularity Classical Hodgkin Lymphoma","ValueMeaning":{"publicId":"4973638","version":"1","preferredName":"Mixed Cellularity Classical Hodgkin Lymphoma","longName":"4973638","preferredDefinition":"A subtype of classical Hodgkin lymphoma with scattered Reed-Sternberg and Hodgkin cells in a diffuse or vaguely nodular mixed inflammatory background without nodular sclerosing fibrosis. (WHO, 2008)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mixed Cellularity Classic Hodgkin Lymphoma","conceptCode":"C3517","definition":"A subtype of classic Hodgkin lymphoma with scattered Reed-Sternberg and Hodgkin cells in a diffuse or vaguely nodular mixed inflammatory background without nodular sclerosing fibrosis. (WHO, 2008)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1D88C8D5-A82F-472E-E050-BB89AD434958","latestVersionIndicator":"Yes","beginDate":"2015-08-17","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED67F1D-8B54-5ED9-E053-F662850AF7E1","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Mixed Epithelioid and Spindle Cell Melanoma","valueDescription":"Mixed Epithelioid and Spindle Cell Melanoma","ValueMeaning":{"publicId":"6835469","version":"1","preferredName":"Mixed Epithelioid and Spindle Cell Melanoma","longName":"6835469","preferredDefinition":"A melanoma characterized by the presence of malignant large epithelioid melanocytes and malignant spindle-shaped melanocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mixed Epithelioid and Spindle Cell Melanoma","conceptCode":"C66756","definition":"A melanoma characterized by the presence of malignant large epithelioid melanocytes and malignant spindle-shaped melanocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED67F1D-8B62-5ED9-E053-F662850AF7E1","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED67F1D-8B7B-5ED9-E053-F662850AF7E1","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Benign Female Reproductive System Neoplasm","valueDescription":"Benign Female Reproductive System Neoplasm","ValueMeaning":{"publicId":"6797936","version":"1","preferredName":"Benign Female Reproductive System Neoplasm","longName":"6797936","preferredDefinition":"A non-metastasizing neoplasm that arises from the female reproductive system. Representative examples include uterine corpus leiomyoma, endocervical polyp, and benign ovarian germ cell tumor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benign Female Reproductive System Neoplasm","conceptCode":"C4934","definition":"A neoplasm that arises from the female reproductive system and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C62F83B-6A58-170D-E053-F662850AD8EA","latestVersionIndicator":"Yes","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C62F83B-6A71-170D-E053-F662850AD8EA","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Ependymoma","valueDescription":"Ependymoma, NOS","ValueMeaning":{"publicId":"2573054","version":"1","preferredName":"Ependymoma, NOS","longName":"2573054","preferredDefinition":"A WHO grade II, slow growing tumor of children and young adults, usually located intraventricularly. It is the most common ependymal neoplasm. It often causes clinical symptoms by blocking cerebrospinal fluid pathways. Key histological features include perivascular pseudorosettes and ependymal rosettes. (WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ependymoma","conceptCode":"C3017","definition":"A WHO grade 2, slow growing tumor of children and young adults, usually located intraventricularly. It is the most common ependymal neoplasm. It often causes clinical symptoms by blocking cerebrospinal fluid pathways. Key histological features include perivascular pseudorosettes and ependymal rosettes. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EA6B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-04","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-04","modifiedBy":"PWEST","dateModified":"2014-05-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-97B5-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Endometrial Carcinoma","valueDescription":"Endometrial Carcinoma","ValueMeaning":{"publicId":"5581346","version":"1","preferredName":"Endometrial Carcinoma","longName":"5581346","preferredDefinition":"A malignant tumor arising from the epithelium that lines the cavity of the uterine body.  The vast majority of endometrial carcinomas are adenocarcinomas; squamous cell and adenosquamous carcinomas represent a minority of the cases.  Endometrioid adenocarcinoma is the most frequently seen variant of endometrial adenocarcinoma.  Uterine bleeding is an initial clinical sign.  The prognosis depends on the stage of the tumor, the depth of myometrial wall invasion, and the degree of differentiation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Endometrial Carcinoma","conceptCode":"C7558","definition":"A malignant tumor arising from the epithelium that lines the cavity of the uterine body.  The vast majority of endometrial carcinomas are adenocarcinomas; squamous cell and adenosquamous carcinomas represent a minority of the cases.  Endometrioid adenocarcinoma is the most frequently seen variant of endometrial adenocarcinoma.  Uterine bleeding is an initial clinical sign.  The prognosis depends on the stage of the tumor, the depth of myometrial wall invasion, and the degree of differentiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42019733-B92E-634F-E053-F662850A5A61","latestVersionIndicator":"Yes","beginDate":"2016-11-23","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2016-11-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-97C9-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Endocrine Neoplasm","valueDescription":"Endocrine Neoplasm","ValueMeaning":{"publicId":"3249071","version":"1","preferredName":"Endocrine Neoplasm","longName":"3249071","preferredDefinition":"A benign or malignant neoplasm arising from the epithelial cells of an endocrine organ. --2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Endocrine Neoplasm","conceptCode":"C3010","definition":"A benign or malignant neoplasm arising from the epithelial cells of an endocrine organ. Representative examples include pituitary gland adenoma, pituitary gland carcinoma, thyroid gland carcinoma, carcinoid tumor, and neuroendocrine carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6CA5E9E-1A39-D7DA-E040-BB89AD432E47","latestVersionIndicator":"Yes","beginDate":"2011-06-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-28","modifiedBy":"COOPERM","dateModified":"2011-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-97DE-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Embryonal Neoplasm","valueDescription":"Embryonal Neoplasm","ValueMeaning":{"publicId":"6832469","version":"1","preferredName":"Embryonal Neoplasm","longName":"6832469","preferredDefinition":"A usually malignant neoplasm composed of primitive (immature) tissues that resemble fetal tissues.  Medulloblastoma, ependymoblastoma, pineoblastoma, and Wilms tumor are representative embryonal neoplasms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Embryonal Neoplasm","conceptCode":"C3264","definition":"A usually malignant neoplasm composed of primitive (immature) tissues that resemble fetal tissues.  Medulloblastoma, ependymoblastoma, pineoblastoma, and Wilms tumor are representative embryonal neoplasms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9A76BA-97EC-69B5-E053-F662850AA843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9805-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Embryonal Carcinoma","valueDescription":"Embryonal Carcinoma","ValueMeaning":{"publicId":"2838044","version":"1","preferredName":"Embryonal Carcinoma","longName":"2838044","preferredDefinition":"A highly malignant, primitive form of carcinoma, probably of germinal cell or teratomatous derivation, usually arising in a gonad and rarely in other sites. It is rare in the female ovary, but in the male it accounts for 20% of all testicular tumors. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, p1595)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Embryonal Carcinoma","conceptCode":"C3752","definition":"A non-seminomatous malignant germ cell tumor characterized by the presence of large germ cells with abundant cytoplasm resembling epithelial cells, geographic necrosis, high mitotic activity, and pseudoglandular and pseudopapillary structures formation. It can arise from the testis, ovary, and extragonadal sites (central nervous system and mediastinum).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62837FF7-8551-6F46-E040-BB89AD433964","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-980F-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Dysgerminoma","valueDescription":"Dysgerminoma","ValueMeaning":{"publicId":"3249006","version":"1","preferredName":"Dysgerminoma","longName":"3249006","preferredDefinition":"Dysgerminoma arises primarily in the ovaries, but can occur both primarily and secondarily at other sites, particularly CNS.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dysgerminoma","conceptCode":"C2996","definition":"A malignant germ cell tumor characterized by the presence of a monotonous primitive germ cell population.  The neoplastic cells form aggregates and have an abundant pale cytoplasm and uniform nuclei.  The aggregates of the germ cells are separated by fibrous septa which contain inflammatory cells, mostly T-lymphocytes.  It arises primarily in the ovaries, but can occur both primarily and secondarily at other sites, particularly the central nervous system.  It responds to chemotherapy and radiotherapy. Its prognosis is related to the tumor stage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6CA5E9E-150A-D7DA-E040-BB89AD432E47","latestVersionIndicator":"Yes","beginDate":"2011-06-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-981A-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Duodenal Neuroendocrine Tumor G1","valueDescription":"Duodenal Neuroendocrine Tumor G1","ValueMeaning":{"publicId":"6832471","version":"1","preferredName":"Duodenal Neuroendocrine Tumor G1","longName":"6832471","preferredDefinition":"A well differentiated, low grade neuroendocrine tumor (carcinoid tumor) that arises from the duodenum.  The mitotic count is less than 2 per 10 HPF and/or the Ki67 index is equal to or less than 2 percent.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Duodenal Neuroendocrine Tumor G1","conceptCode":"C6425","definition":"A well differentiated, low grade neuroendocrine neoplasm that arises from the duodenum. The mitotic count is less than 2 per 10 HPF and/or the Ki67 index is equal to or less than 2 percent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9A76BA-9828-69B5-E053-F662850AA843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9841-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Ductal Breast Carcinoma In Situ","valueDescription":"Ductal Carcinoma In Situ","ValueMeaning":{"publicId":"3262799","version":"1","preferredName":"Ductal Carcinoma In Situ","longName":"3262799","preferredDefinition":"A carcinoma entirely confined to the mammary ducts.  It is also known as DCIS.  There is no evidence of invasion of the basement membrane.  Currently, it is classified into three categories: High-grade DCIS, intermediate-grade DCIS and low-grade DCIS. In this classification the DCIS grade is defined by a combination of nuclear grade, architectural growth pattern and presence of necrosis.  The size of the lesion as well as the grade and the clearance margins play a major role in dictating the most appropriate therapy for DCIS.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Ductal Carcinoma In Situ","conceptCode":"C2924","definition":"A breast carcinoma entirely confined to the mammary ducts. It is also known as DCIS. There is no evidence of invasion of the basement membrane. Currently, it is classified into three categories: High-grade DCIS, intermediate-grade DCIS and low-grade DCIS. In this classification the DCIS grade is defined by a combination of nuclear grade, architectural growth pattern and presence of necrosis. The size of the lesion as well as the grade and the clearance margins play a major role in dictating the most appropriate therapy for DCIS.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AAB50210-A094-7298-E040-BB89AD4308A3","latestVersionIndicator":"Yes","beginDate":"2011-08-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-08-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9855-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Distal Bile Duct Carcinoma","valueDescription":"Distal Bile Duct Carcinoma","ValueMeaning":{"publicId":"4039072","version":"1","preferredName":"Distal Bile Duct Carcinoma","longName":"4039072","preferredDefinition":"A carcinoma that arises from the distal part of the extrahepatic bile duct.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Distal Bile Duct Carcinoma","conceptCode":"C7109","definition":"A carcinoma that arises from the common bile duct distal to the insertion of the cystic duct.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EEFFA5EA-6831-E8CD-E040-BB89AD4345DA","latestVersionIndicator":"Yes","beginDate":"2014-01-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-01-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9869-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Digestive System Neoplasm","valueDescription":"Digestive System Neoplasm","ValueMeaning":{"publicId":"6832472","version":"1","preferredName":"Digestive System Neoplasm","longName":"6832472","preferredDefinition":"A benign or malignant neoplasm involving any part of the digestive system.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Digestive System Neoplasm","conceptCode":"C3052","definition":"A benign or malignant neoplasm involving any part of the digestive system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9A76BA-9876-69B5-E053-F662850AA843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"JKNABLE","dateModified":"2024-01-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-988F-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Digestive System Carcinoma In Situ","valueDescription":"Digestive System Carcinoma In Situ","ValueMeaning":{"publicId":"6832474","version":"1","preferredName":"Digestive System Carcinoma In Situ","longName":"6832474","preferredDefinition":"An intraepithelial carcinoma arising from any part of the digestive system without evidence of invasion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Digestive System Carcinoma In Situ","conceptCode":"C35180","definition":"An intraepithelial carcinoma arising from any part of the digestive system without evidence of invasion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9A76BA-989C-69B5-E053-F662850AA843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-98B5-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Digestive System Carcinoma","valueDescription":"Digestive System Carcinoma","ValueMeaning":{"publicId":"6832476","version":"1","preferredName":"Digestive System Carcinoma","longName":"6832476","preferredDefinition":"A malignant neoplasm that arises from the epithelium of any part of the digestive system.  Representative examples include colorectal carcinoma, esophageal carcinoma, and pancreatic carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Digestive System Carcinoma","conceptCode":"C96963","definition":"A malignant neoplasm that arises from the epithelium of any part of the digestive system.  Representative examples include colorectal carcinoma, esophageal carcinoma, and pancreatic carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9A76BA-98C2-69B5-E053-F662850AA843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-98DB-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Diffuse Large B-Cell Lymphoma","valueDescription":"Diffuse Large B-Cell Lymphoma","ValueMeaning":{"publicId":"2838040","version":"1","preferredName":"Diffuse Large B-Cell Lymphoma","longName":"2838040","preferredDefinition":"A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes.  It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases.  Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma.  Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diffuse Large B-Cell Lymphoma","conceptCode":"C8851","definition":"A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes.  It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases.  Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma.  Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62837FF7-850A-6F46-E040-BB89AD433964","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"SOKKERL","dateModified":"2018-10-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-98E5-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Descending Colon Neuroendocrine Tumor G1","valueDescription":"Descending Colon Neuroendocrine Tumor G1","ValueMeaning":{"publicId":"6832478","version":"1","preferredName":"Descending Colon Neuroendocrine Tumor G1","longName":"6832478","preferredDefinition":"A well differentiated, low grade neuroendocrine tumor (carcinoid tumor) that arises from the descending colon.  The mitotic count is less than 2 per 10 HPF and/or the Ki67 index is equal to or less than 2 percent.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Descending Colon Neuroendocrine Tumor G1","conceptCode":"C6428","definition":"A well differentiated, low grade neuroendocrine neoplasm that arises from the descending colon. The mitotic count is less than 2 per 10 HPF and/or the Ki67 index is equal to or less than 2 percent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9A76BA-98F2-69B5-E053-F662850AA843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-990B-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Disseminated Malignant Neoplasm","valueDescription":"Disseminated Malignant Neoplasm","ValueMeaning":{"publicId":"6832480","version":"1","preferredName":"Disseminated Malignant Neoplasm","longName":"6832480","preferredDefinition":"Cancer that is spread throughout the body, a metastatic phenomenon.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disseminated Malignant Neoplasm","conceptCode":"C27470","definition":"Cancer that is spread throughout the body, a metastatic phenomenon.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9A76BA-9918-69B5-E053-F662850AA843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9931-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Skin Carcinoma","valueDescription":"Skin Carcinoma","ValueMeaning":{"publicId":"3935812","version":"1","preferredName":"Skin Carcinoma","longName":"3935812","preferredDefinition":"Skin cancer that arises in basal cells or squamous cells but not in melanocytes (pigment-producing cells of the skin).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Skin Carcinoma","conceptCode":"C4914","definition":"A carcinoma that arises from the skin.  Representative examples are basal cell carcinoma and squamous cell carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9D24C44-E3A5-94AD-E040-BB89AD43540A","latestVersionIndicator":"Yes","beginDate":"2013-10-28","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2013-10-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9949-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Skin Basal Cell Carcinoma","valueDescription":"Skin Basal Cell Carcinoma","ValueMeaning":{"publicId":"2961462","version":"1","preferredName":"Skin Basal Cell Carcinoma","longName":"2961462","preferredDefinition":"The most frequently seen skin cancer. It arises from basal cells of the epidermis and pilosebaceous units. Clinically it is divided into the following types: nodular, ulcerative, superficial, multicentric, erythematous, and sclerosing or morphea-like.. More than 95% of these carcinomas occur in patients over 40. They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck and the remaining 15% on the trunk and extremities. Basal cell carcinoma usually grows in a slow and indolent fashion. However, if untreated, the tumor may invade the subcutaneous fat, skeletal muscle and bone. Distant metastases are rare. Excision, curettage and irradiation cure most basal cell carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Skin Basal Cell Carcinoma","conceptCode":"C2921","definition":"The most frequently seen skin cancer. It arises from basal cells of the epidermis and pilosebaceous units. Clinically it is divided into the following types: nodular, ulcerative, superficial, multicentric, erythematous, and sclerosing or morphea-like. More than 95% of these carcinomas occur in patients over 40. They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck and the remaining 15% on the trunk and extremities. Basal cell carcinoma usually grows in a slow and indolent fashion. However, if untreated, the tumor may invade the subcutaneous fat, skeletal muscle and bone. Distant metastases are rare. Excision, curettage and irradiation cure most basal cell carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"78AB07DC-B5C7-F05E-E040-BB89AD43180B","latestVersionIndicator":"Yes","beginDate":"2009-11-18","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-11-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9954-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Sezary Syndrome","valueDescription":"Sezary Syndrome","ValueMeaning":{"publicId":"2560040","version":"1","preferredName":"Sezary Syndrome","longName":"2560040","preferredDefinition":"A generalized peripheral (mature) T-cell neoplasm characterized by the presence of erythroderma, lymphadenopathy, and neoplastic, cerebriform T-lymphocytes in the blood.  Sezary syndrome is an aggressive disease. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sezary Syndrome","conceptCode":"C3366","definition":"A generalized peripheral (mature) T-cell neoplasm characterized by the presence of erythroderma, lymphadenopathy, and neoplastic, cerebriform T-lymphocytes in the blood.  Sezary syndrome is an aggressive disease. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B795-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-995E-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Seminoma","valueDescription":"Seminoma","ValueMeaning":{"publicId":"2575033","version":"1","preferredName":"Seminoma","longName":"2575033","preferredDefinition":"A radiosensitive malignant germ cell tumor found in the testis (especially undescended), and extragonadal sites (anterior mediastinum and pineal gland).  It is characterized by the presence of uniform cells with clear or dense cytoplasm which contains glycogen, and by a large nucleus which contains one or more nucleoli.  The neoplastic germ cells form aggregates separated by fibrous septa.  The fibrous septa contain chronic inflammatory cells, mainly lymphocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Seminoma","conceptCode":"C9309","definition":"A radiosensitive malignant germ cell tumor found in the testis (especially undescended), and extragonadal sites (anterior mediastinum and pineal gland).  It is characterized by the presence of uniform cells with clear or dense cytoplasm which contains glycogen, and by a large nucleus which contains one or more nucleoli.  The neoplastic germ cells form aggregates separated by fibrous septa.  The fibrous septa contain chronic inflammatory cells, mainly lymphocytes.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F226-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-05-23","modifiedBy":"COOPERM","dateModified":"2016-10-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9968-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Secondary Malignant Neoplasm","valueDescription":"Secondary Malignant Neoplasm","ValueMeaning":{"publicId":"2578090","version":"1","preferredName":"Secondary Malignant Neoplasm","longName":"2578090","preferredDefinition":"A malignant neoplasm that arises from a pre-existing lower grade lesion, or as a result of a primary lesion that has spread to secondary sites, or due to a complication of a cancer treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Secondary Malignant Neoplasm","conceptCode":"C4968","definition":"A malignant neoplasm that arises from a pre-existing lower grade lesion, or as a result of a primary lesion that has spread to secondary sites, or due to a complication of a cancer treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE17-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-02","modifiedBy":"COOPERM","dateModified":"2015-10-22","changeDescription":"Changed definition to match current NCIt definition, replacing NCI-GLOSS definition. mc 10/22/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-997C-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Secondary Carcinoma","valueDescription":"Secondary Carcinoma","ValueMeaning":{"publicId":"6832484","version":"1","preferredName":"Secondary Carcinoma","longName":"6832484","preferredDefinition":"A carcinoma that arises from a pre-existing lower grade epithelial lesion, or as a result of a primary carcinoma that has spread to secondary sites, or due to a complication of a cancer treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Secondary Carcinoma","conceptCode":"C36310","definition":"A carcinoma that arises from a pre-existing lower grade epithelial lesion, or as a result of a primary carcinoma that has spread to secondary sites, or due to a complication of a cancer treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9A76BA-998A-69B5-E053-F662850AA843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-99A3-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Schwannomatosis","valueDescription":"Schwannomatosis","ValueMeaning":{"publicId":"6832486","version":"1","preferredName":"Schwannomatosis","longName":"6832486","preferredDefinition":"A rare genetic disorder characterized by the presence of multiple schwannomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Schwannomatosis","conceptCode":"C6557","definition":"Rare genetic disorder caused by mutations in the SMARCB1 and LZTR1 genes. It is characterized by the presence of multiple Schwannomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9A76BA-99B0-69B5-E053-F662850AA843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-99C9-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Sarcomatoid Carcinoma","valueDescription":"Sarcomatoid Carcinoma","ValueMeaning":{"publicId":"2838764","version":"1","preferredName":"Sarcomatoid Carcinoma","longName":"2838764","preferredDefinition":"Cancer that arises in cells that appear spindle-shaped when viewed under a microscope. These cancers can occur in various places in the body, including the skin, lungs, kidney, breast, gastrointestinal tract, bone, and muscle.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sarcomatoid Carcinoma","conceptCode":"C27004","definition":"A malignant epithelial neoplasm characterized by the presence of spindle cells and anaplastic morphologic features.  Giant cells and a sarcomatous component may also be present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A85C92-12DF-B23A-E040-BB89AD431D54","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-99D3-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Sarcoma of the Extremity","valueDescription":"Sarcoma of the Extremity","ValueMeaning":{"publicId":"6832488","version":"1","preferredName":"Sarcoma of the Extremity","longName":"6832488","preferredDefinition":"A sarcoma that arises from the soft tissues or bones of the upper or lower extremity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sarcoma of the Extremity","conceptCode":"C155647","definition":"A sarcoma that arises from the soft tissues or bones of the upper or lower extremity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9A76BA-99E0-69B5-E053-F662850AA843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-99F9-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Sarcoma","valueDescription":"Sarcoma","ValueMeaning":{"publicId":"4265252","version":"1","preferredName":"Sarcoma","longName":"4265252","preferredDefinition":"A malignant mesenchymal tumor for which a distinct line of differentiation cannot be determined. This term may be used for small biopsy specimens for which adequate tissue is not present for definitive classification.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sarcoma","conceptCode":"C9118","definition":"A usually aggressive malignant neoplasm of the soft tissue or bone. It arises from muscle, fat, fibrous tissue, bone, cartilage, and blood vessels. Sarcomas occur in both children and adults. The prognosis depends largely on the degree of differentiation (grade) of the neoplasm. Representative subtypes are liposarcoma, leiomyosarcoma, osteosarcoma, and chondrosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F68D1573-4B91-FC76-E040-BB89AD43431A","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9A03-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Salivary Gland Carcinoma","valueDescription":"Salivary Gland Carcinoma","ValueMeaning":{"publicId":"6832489","version":"1","preferredName":"Salivary Gland Carcinoma","longName":"6832489","preferredDefinition":"A carcinoma that arises from the major or minor salivary glands.  Representative examples include carcinoma ex pleomorphic adenoma, adenocarcinoma, adenoid cystic carcinoma, and mucoepidermoid carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Salivary Gland Carcinoma","conceptCode":"C9272","definition":"A carcinoma that arises from the major or minor salivary glands.  Representative examples include carcinoma ex pleomorphic adenoma, adenocarcinoma, adenoid cystic carcinoma, and mucoepidermoid carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9A76BA-9A0F-69B5-E053-F662850AA843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9A28-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Rhabdomyosarcoma","valueDescription":"Rhabdomyosarcoma","ValueMeaning":{"publicId":"4265253","version":"1","preferredName":"Rhabdomyosarcoma","longName":"4265253","preferredDefinition":"A rare aggressive malignant mesenchymal neoplasm arising from skeletal muscle. It usually occurs in children and young adults. Only a small percentage of tumors arise in the skeletal muscle of the extremities. The majority arise in other anatomical sites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rhabdomyosarcoma","conceptCode":"C3359","definition":"A rare aggressive malignant mesenchymal neoplasm arising from skeletal muscle. It usually occurs in children and young adults. Only a small percentage of tumors arise in the skeletal muscle of the extremities. The majority arise in other anatomic sites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F68D1573-4BB4-FC76-E040-BB89AD43431A","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9A32-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Retroperitoneal Carcinoma","valueDescription":"Retroperitoneal Carcinoma","ValueMeaning":{"publicId":"6832491","version":"1","preferredName":"Retroperitoneal Carcinoma","longName":"6832491","preferredDefinition":"A rare carcinoma that arises from the retroperitoneal space.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Retroperitoneal Carcinoma","conceptCode":"C7352","definition":"A rare carcinoma that arises from the retroperitoneal space.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9A76BA-9A3F-69B5-E053-F662850AA843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9A58-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Retinoblastoma","valueDescription":"Retinoblastoma","ValueMeaning":{"publicId":"4265254","version":"1","preferredName":"Retinoblastoma","longName":"4265254","preferredDefinition":"A malignant tumor that originates in the nuclear layer of the retina. As the most common primary tumor of the eye in children, retinoblastoma is still relatively uncommon, accounting for only 1% of all malignant tumors in pediatric patients. These tumors may be multifocal, bilateral, congenital, inherited, or acquired. Seventy-five percent of retinoblastomas are unilateral; 60% occur sporadically. A predisposition to retinoblastoma has been associated with 13q14 cytogenetic abnormalities. Patients with the inherited form also appear to be at increased risk for secondary nonocular malignancies such as osteosarcoma, malignant fibrous histiocytoma, and fibrosarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Retinoblastoma","conceptCode":"C7541","definition":"A malignant tumor that originates in the nuclear layer of the retina. As the most common primary tumor of the eye in children, retinoblastoma is still relatively uncommon, accounting for only 1% of all malignant tumors in pediatric patients. Approximately 95% of cases are diagnosed before age 5. These tumors may be multifocal, bilateral, congenital, inherited, or acquired. Seventy-five percent of retinoblastomas are unilateral; 60% occur sporadically. A predisposition to retinoblastoma has been associated with 13q14 cytogenetic abnormalities. Patients with the inherited form also appear to be at increased risk for secondary nonocular malignancies such as osteosarcoma, malignant fibrous histiocytoma, and fibrosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F68D1573-4BEC-FC76-E040-BB89AD43431A","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9A62-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Retinal Melanoma","valueDescription":"Retinal Melanoma","ValueMeaning":{"publicId":"6832493","version":"1","preferredName":"Retinal Melanoma","longName":"6832493","preferredDefinition":"A melanoma affecting the retinal portion of the eye. --2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Retinal Melanoma","conceptCode":"C8601","definition":"A melanoma affecting the retinal portion of the eye.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9A76BA-9A6F-69B5-E053-F662850AA843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9A88-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Respiratory Tract Neoplasm","valueDescription":"Respiratory Tract Neoplasm","ValueMeaning":{"publicId":"6832495","version":"1","preferredName":"Respiratory Tract Neoplasm","longName":"6832495","preferredDefinition":"A benign or malignant, primary or metastatic neoplasm involving the respiratory tract.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Respiratory System Neoplasm","conceptCode":"C3355","definition":"A benign or malignant, primary or metastatic neoplasm involving the respiratory system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9A76BA-9A95-69B5-E053-F662850AA843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9AAE-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Resectable Malignant Neoplasm","valueDescription":"Resectable Malignant Neoplasm","ValueMeaning":{"publicId":"6832497","version":"1","preferredName":"Resectable Malignant Neoplasm","longName":"6832497","preferredDefinition":"Malignant neoplasm that is amenable to surgical resection.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Resectable Malignant Neoplasm","conceptCode":"C150602","definition":"Malignant neoplasm that is amenable to surgical resection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9A76BA-9ABB-69B5-E053-F662850AA843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9AD4-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Resectable Carcinoma","valueDescription":"Resectable Carcinoma","ValueMeaning":{"publicId":"6832499","version":"1","preferredName":"Resectable Carcinoma","longName":"6832499","preferredDefinition":"Carcinoma that is amenable to surgical resection.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Resectable Carcinoma","conceptCode":"C150604","definition":"Carcinoma that is amenable to surgical resection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9A76BA-9AE1-69B5-E053-F662850AA843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9AFA-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Reproductive System Neoplasm","valueDescription":"Reproductive System Neoplasm","ValueMeaning":{"publicId":"6832501","version":"1","preferredName":"Reproductive System Neoplasm","longName":"6832501","preferredDefinition":"A benign or malignant, primary or metastatic neoplasm affecting the male and female reproductive system.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Reproductive System Neoplasm","conceptCode":"C3674","definition":"A benign or malignant, primary or metastatic neoplasm affecting the male and female reproductive system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9A76BA-9B07-69B5-E053-F662850AA843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9B20-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Renal Pelvis Carcinoma","valueDescription":"Renal Pelvis Carcinoma","ValueMeaning":{"publicId":"6832503","version":"1","preferredName":"Renal Pelvis Carcinoma","longName":"6832503","preferredDefinition":"A carcinoma arising in the renal pelvis.  The majority of renal pelvis carcinomas are transitional cell and less frequently squamous cell carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Renal Pelvis Carcinoma","conceptCode":"C6142","definition":"A carcinoma arising in the renal pelvis.  The majority of renal pelvis carcinomas are transitional cell and less frequently squamous cell carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9A76BA-9B2D-69B5-E053-F662850AA843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9B46-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Regressing Melanoma","valueDescription":"Regressing Melanoma","ValueMeaning":{"publicId":"6832505","version":"1","preferredName":"Regressing Melanoma","longName":"6832505","preferredDefinition":"A skin lesion characterized by the disappearance of the melanoma cells from the primary melanoma site. The disappearance of the malignant cells is associated with fibroplasia of the papillary dermis. According to some authors, complete regression of the primary melanoma may occur in 4-8% of patients.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Regressing Melanoma","conceptCode":"C4228","definition":"A skin lesion characterized by the disappearance of the melanoma cells from the primary melanoma site. The disappearance of the malignant cells is associated with fibroplasia of the papillary dermis. According to some authors, complete regression of the primary melanoma may occur in 4-8% of patients.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9A76BA-9B53-69B5-E053-F662850AA843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9B6C-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Refractory Sarcoma","valueDescription":"Refractory Sarcoma","ValueMeaning":{"publicId":"6832507","version":"1","preferredName":"Refractory Sarcoma","longName":"6832507","preferredDefinition":"A sarcoma that does not respond to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Refractory Sarcoma","conceptCode":"C148301","definition":"A sarcoma that does not respond to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9A76BA-9B79-69B5-E053-F662850AA843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9B92-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Refractory Melanoma","valueDescription":"Refractory Melanoma","ValueMeaning":{"publicId":"6832509","version":"1","preferredName":"Refractory Melanoma","longName":"6832509","preferredDefinition":"Melanoma that does not respond to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Refractory Melanoma","conceptCode":"C147983","definition":"Melanoma that does not respond to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9A76BA-9B9F-69B5-E053-F662850AA843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9BB8-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Refractory Malignant Neoplasm","valueDescription":"Refractory Malignant Neoplasm","ValueMeaning":{"publicId":"6832510","version":"1","preferredName":"Refractory Malignant Neoplasm","longName":"6832510","preferredDefinition":"A malignant neoplasm that does not respond to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Refractory Malignant Neoplasm","conceptCode":"C120186","definition":"A malignant neoplasm that does not respond to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9A76BA-9BC4-69B5-E053-F662850AA843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9BDD-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Refractory Malignant Central Nervous System Neoplasm","valueDescription":"Refractory Malignant Central Nervous System Neoplasm","ValueMeaning":{"publicId":"6832512","version":"1","preferredName":"Refractory Malignant Central Nervous System Neoplasm","longName":"6832512","preferredDefinition":"A malignant central nervous system neoplasm that is resistant to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Refractory Primary Malignant Central Nervous System Neoplasm","conceptCode":"C153842","definition":"A primary malignant central nervous system neoplasm that is resistant to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9A76BA-9BEA-69B5-E053-F662850AA843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9C03-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Refractory Lymphoma","valueDescription":"Refractory Lymphoma","ValueMeaning":{"publicId":"6832514","version":"1","preferredName":"Refractory Lymphoma","longName":"6832514","preferredDefinition":"A lymphoma that does not respond to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Refractory Lymphoma","conceptCode":"C134154","definition":"A lymphoma that does not respond to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9A76BA-9C10-69B5-E053-F662850AA843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9C29-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Refractory Leukemia","valueDescription":"Refractory Leukemia","ValueMeaning":{"publicId":"6832516","version":"1","preferredName":"Refractory Leukemia","longName":"6832516","preferredDefinition":"Leukemia that is resistant to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Refractory Leukemia","conceptCode":"C148426","definition":"Leukemia that is resistant to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9A76BA-9C36-69B5-E053-F662850AA843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9C4F-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Refractory Carcinoma","valueDescription":"Refractory Carcinoma","ValueMeaning":{"publicId":"3855326","version":"1","preferredName":"Refractory Carcinoma","longName":"3855326","preferredDefinition":"Cancer that does not respond to treatment. The cancer may be resistant at the beginning of treatment, or it may become resistant during treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Refractory Carcinoma","conceptCode":"C8511","definition":"A carcinoma that does not respond to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3EC2004-E72D-D6FB-E040-BB89AD432FAD","latestVersionIndicator":"Yes","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9C63-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Refractory Anemia","valueDescription":"Refractory Anemia","ValueMeaning":{"publicId":"2771856","version":"1","preferredName":"Refractory Anemia","longName":"2771856","preferredDefinition":"A myelodysplastic syndrome characterized mainly by dysplasia of the erythroid series.  Refractory anemia is uncommon.  It is primarily a disease of older adults.  The median survival exceeds 5 years.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Refractory Anemia","conceptCode":"C2872","definition":"A myelodysplastic syndrome characterized mainly by dysplasia of the erythroid series.  Refractory anemia is uncommon.  It is primarily a disease of older adults.  The median survival exceeds 5 years.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54340434-AF1D-4116-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9C6E-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Recurrent Sarcoma","valueDescription":"Recurrent Sarcoma","ValueMeaning":{"publicId":"6832518","version":"1","preferredName":"Recurrent Sarcoma","longName":"6832518","preferredDefinition":"The reemergence of sarcoma after a period of remission.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recurrent Sarcoma","conceptCode":"C148302","definition":"The reemergence of sarcoma after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9A76BA-9C7C-69B5-E053-F662850AA843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9C95-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Recurrent Malignant Neoplasm","valueDescription":"Recurrent Malignant Neoplasm","ValueMeaning":{"publicId":"3652738","version":"1","preferredName":"Recurrent Malignant Neoplasm","longName":"3652738","preferredDefinition":"The reemergence of a malignant neoplasm after a period of remission.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recurrent Malignant Neoplasm","conceptCode":"C4813","definition":"The reemergence of a malignant neoplasm after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D36A1FED-D937-F005-E040-BB89AD43139E","latestVersionIndicator":"Yes","beginDate":"2013-01-16","endDate":null,"createdBy":"RODGERSC","dateCreated":"2013-01-16","modifiedBy":"COOPERM","dateModified":"2020-07-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9CA9-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Recurrent Malignant Central Nervous System Neoplasm","valueDescription":"Recurrent Malignant Central Nervous System Neoplasm","ValueMeaning":{"publicId":"6832520","version":"1","preferredName":"Recurrent Malignant Central Nervous System Neoplasm","longName":"6832520","preferredDefinition":"The reemergence of a malignant central nervous system neoplasm after a period of remission.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recurrent Primary Malignant Central Nervous System Neoplasm","conceptCode":"C153823","definition":"The reemergence of a primary malignant central nervous system neoplasm after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9A76BA-9CB6-69B5-E053-F662850AA843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9CCF-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Recurrent Lymphoma","valueDescription":"Recurrent Lymphoma Recurrent Lymphoma","ValueMeaning":{"publicId":"6832522","version":"1","preferredName":"Recurrent Lymphoma Recurrent Lymphoma","longName":"6832522","preferredDefinition":"The reemergence of a lymphoma after a period of remission.: The reemergence of a lymphoma after a period of remission.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recurrent Lymphoma","conceptCode":"C134157","definition":"The reemergence of a lymphoma after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Recurrent Lymphoma","conceptCode":"C134157","definition":"The reemergence of a lymphoma after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9A76BA-9CDD-69B5-E053-F662850AA843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9CF6-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Recurrent Leukemia","valueDescription":"Recurrent Leukemia","ValueMeaning":{"publicId":"6832524","version":"1","preferredName":"Recurrent Leukemia","longName":"6832524","preferredDefinition":"The reemergence of leukemia after a period of remission.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recurrent Leukemia","conceptCode":"C148425","definition":"The reemergence of leukemia after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9A76BA-9D03-69B5-E053-F662850AA843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9D1C-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive","valueDescription":"Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive","ValueMeaning":{"publicId":"6832526","version":"1","preferredName":"Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive","longName":"6832526","preferredDefinition":"The reemergence of chronic myelogenous leukemia after a period of remission.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recurrent Chronic Myeloid Leukemia, BCR-ABL1 Positive","conceptCode":"C9070","definition":"The reemergence of chronic myeloid leukemia, BCR-ABL1 positive after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9A76BA-9D29-69B5-E053-F662850AA843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9D42-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Recurrent Chronic Lymphocytic Leukemia","valueDescription":"Recurrent Chronic Lymphocytic Leukemia","ValueMeaning":{"publicId":"6832528","version":"1","preferredName":"Recurrent Chronic Lymphocytic Leukemia","longName":"6832528","preferredDefinition":"The reemergence of chronic lymphocytic leukemia after a period of remission.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recurrent Chronic Lymphocytic Leukemia","conceptCode":"C8645","definition":"The reemergence of chronic lymphocytic leukemia after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9A76BA-9D4F-69B5-E053-F662850AA843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9D68-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Recurrent Carcinoma","valueDescription":"Recurrent Carcinoma","ValueMeaning":{"publicId":"6832529","version":"1","preferredName":"Recurrent Carcinoma","longName":"6832529","preferredDefinition":"The reemergence a carcinoma after a period of remission.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recurrent Carcinoma","conceptCode":"C7619","definition":"The reemergence of a carcinoma after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9A76BA-9D74-69B5-E053-F662850AA843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9D8D-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Recurrent Acute Myelomonocytic Leukemia","valueDescription":"Recurrent Acute Myelomonocytic Leukemia","ValueMeaning":{"publicId":"6832531","version":"1","preferredName":"Recurrent Acute Myelomonocytic Leukemia","longName":"6832531","preferredDefinition":"The reemergence of acute myelomonocytic leukemia after a period of remission.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recurrent Acute Myelomonocytic Leukemia","conceptCode":"C156717","definition":"The reemergence of acute myelomonocytic leukemia after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9A76BA-9D9A-69B5-E053-F662850AA843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9DB3-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Recurrent Acute Myeloid Leukemia with t (9;11) (p21.3; q23.3); MLLT3-KMT2A","valueDescription":"Recurrent Acute Myeloid Leukemia with t (9;11) (p21.3; q23.3); MLLT3-KMT2A","ValueMeaning":{"publicId":"6832533","version":"1","preferredName":"Recurrent Acute Myeloid Leukemia with t (9;11) (p21.3; q23.3); MLLT3-KMT2A","longName":"6832533","preferredDefinition":"The reemergence of acute myeloid leukemia with t (9;11) (p21.3; q23.3); MLLT3-KMT2A after a period of remission.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recurrent Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A","conceptCode":"C156719","definition":"The reemergence of acute myeloid leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9A76BA-9DC0-69B5-E053-F662850AA843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9DD9-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Recurrent Acute Myeloid Leukemia with Multilineage Dysplasia","valueDescription":"Recurrent Acute Myeloid Leukemia with Multilineage Dysplasia","ValueMeaning":{"publicId":"6832535","version":"1","preferredName":"Recurrent Acute Myeloid Leukemia with Multilineage Dysplasia","longName":"6832535","preferredDefinition":"The reemergence of acute myeloid leukemia with multilineage dysplasia after a period of remission.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recurrent Acute Myeloid Leukemia with Multilineage Dysplasia","conceptCode":"C156720","definition":"The reemergence of acute myeloid leukemia with multilineage dysplasia after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9A76BA-9DE6-69B5-E053-F662850AA843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9DFF-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Recurrent Acute Myeloid Leukemia","valueDescription":"Recurrent Acute Myeloid Leukemia","ValueMeaning":{"publicId":"6832537","version":"1","preferredName":"Recurrent Acute Myeloid Leukemia","longName":"6832537","preferredDefinition":"The reemergence of acute myeloid leukemia after a period of remission.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recurrent Acute Myeloid Leukemia","conceptCode":"C148427","definition":"The reemergence of acute myeloid leukemia after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9A76BA-9E0C-69B5-E053-F662850AA843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9E25-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Recurrent Acute Monoblastic and Monocytic Leukemia","valueDescription":"Recurrent Acute Monoblastic and Monocytic Leukemia","ValueMeaning":{"publicId":"6832539","version":"1","preferredName":"Recurrent Acute Monoblastic and Monocytic Leukemia","longName":"6832539","preferredDefinition":"The reemergence of acute monoblastic and monocytic leukemia after a period of remission.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recurrent Acute Monoblastic and Monocytic Leukemia","conceptCode":"C156722","definition":"The reemergence of acute monoblastic and monocytic leukemia after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9A76BA-9E32-69B5-E053-F662850AA843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9E4B-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Recurrent Acute Megakaryoblastic Leukemia","valueDescription":"Recurrent Acute Megakaryoblastic Leukemia","ValueMeaning":{"publicId":"6832541","version":"1","preferredName":"Recurrent Acute Megakaryoblastic Leukemia","longName":"6832541","preferredDefinition":"The reemergence of acute megakaryoblastic leukemia after a period of remission.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recurrent Acute Megakaryoblastic Leukemia","conceptCode":"C156731","definition":"The reemergence of acute megakaryoblastic leukemia after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9A76BA-9E58-69B5-E053-F662850AA843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9E71-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Recurrent Acute Lymphoblastic Leukemia","valueDescription":"Recurrent Acute Lymphoblastic Leukemia","ValueMeaning":{"publicId":"6832543","version":"1","preferredName":"Recurrent Acute Lymphoblastic Leukemia","longName":"6832543","preferredDefinition":"The reemergence of acute lymphoblastic leukemia after a period of remission.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recurrent Acute Lymphoblastic Leukemia","conceptCode":"C142810","definition":"The reemergence of acute lymphoblastic leukemia after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9A76BA-9E7E-69B5-E053-F662850AA843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9E97-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Recurrent Acute Leukemia","valueDescription":"Recurrent Acute Leukemia","ValueMeaning":{"publicId":"6832545","version":"1","preferredName":"Recurrent Acute Leukemia","longName":"6832545","preferredDefinition":"The reemergence of acute leukemia after a period of remission.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recurrent Acute Leukemia","conceptCode":"C148429","definition":"The reemergence of acute leukemia after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9A76BA-9EA4-69B5-E053-F662850AA843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9EBD-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Recurrent Acute Erythroid Leukemia","valueDescription":"Recurrent Acute Erythroid Leukemia","ValueMeaning":{"publicId":"6832547","version":"1","preferredName":"Recurrent Acute Erythroid Leukemia","longName":"6832547","preferredDefinition":"The reemergence of acute erythroid leukemia after a period of remission.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recurrent Acute Erythroid Leukemia","conceptCode":"C156723","definition":"The reemergence of acute erythroid leukemia after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9A76BA-9ECA-69B5-E053-F662850AA843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9EE3-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Rectal Neuroendocrine Tumor G1","valueDescription":"Rectal Neuroendocrine Tumor G1","ValueMeaning":{"publicId":"6832549","version":"1","preferredName":"Rectal Neuroendocrine Tumor G1","longName":"6832549","preferredDefinition":"A well differentiated, low grade neuroendocrine tumor (carcinoid tumor) that arises from the rectum. The mitotic count is less than 2 per 10 HPF and/or the Ki67 index is equal to or less than 2 percent.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rectal Neuroendocrine Tumor G1","conceptCode":"C5547","definition":"A well differentiated, low grade neuroendocrine neoplasm that arises from the rectum. The mitotic count is less than 2 per 10 HPF and/or the Ki67 index is equal to or less than 2 percent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9A76BA-9EF0-69B5-E053-F662850AA843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A76BA-9F09-69B5-E053-F662850AA843","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Gestational Trophoblastic Tumor","valueDescription":"Gestational Trophoblastic Tumor","ValueMeaning":{"publicId":"4722594","version":"1","preferredName":"Gestational Trophoblastic Tumor","longName":"4722594","preferredDefinition":"A group of interrelated trophoblastic diseases arising from pregnancy. They are commonly associated with hyperplasia of trophoblasts (TROPHOBLAST) and markedly elevated human CHORIONIC GONADOTROPIN. They include HYDATIDIFORM MOLE, invasive mole (HYDATIDIFORM MOLE, INVASIVE), placental-site trophoblastic tumor (TROPHOBLASTIC TUMOR, PLACENTAL SITE), and CHORIOCARCINOMA. These neoplasms have varying propensities for invasion and spread.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gestational Trophoblastic Tumor","conceptCode":"C4699","definition":"A diverse group of pregnancy-related tumors characterized by excessive proliferation of trophoblasts. It includes gestational choriocarcinoma, epithelioid trophoblastic tumor, placental site trophoblastic tumor, and mixed trophoblastic tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F886EE6-BAFA-DB60-E050-BB89AD4356E3","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AACCC-11EA-7C53-E053-F662850A78BF","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Germinoma","valueDescription":"Germinoma","ValueMeaning":{"publicId":"2578733","version":"1","preferredName":"Germinoma","longName":"2578733","preferredDefinition":"The most common type of germ cell tumor affecting the central nervous system.  It is composed of uniform cells with large vesicular nuclei, prominent nucleoli and clear cytoplasm.  Lymphocytic or lymphoplasmacytic infiltrates are usually seen admixed with the tumor cells.  Less frequently giant syncytiotrophoblastic cells are also present.  Germinomas are usually radiosensitive and they have a favorable prognosis.  - 2002","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Germinoma","conceptCode":"C3753","definition":"A malignant germ cell tumor arising in the central nervous system. It is characterized by the presence of primitive, large malignant germ cells and lymphocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-009A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"REEVESD","dateModified":"2006-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AACCC-11F4-7C53-E053-F662850A78BF","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Germ Cell Tumor","valueDescription":"Germ Cell Tumor","ValueMeaning":{"publicId":"4265239","version":"1","preferredName":"Germ Cell Tumor","longName":"4265239","preferredDefinition":"A benign or malignant, gonadal or extragonadal neoplasm that originates from germ cells. Representative examples include teratoma, seminoma, embryonal carcinoma, and yolk sac tumor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Germ Cell Tumor","conceptCode":"C3708","definition":"A benign or malignant, gonadal or extragonadal neoplasm that originates from germ cells. Representative examples include teratoma, seminoma, embryonal carcinoma, and yolk sac tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F68C00B1-7893-6438-E040-BB89AD4373BF","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"TAYLORT","dateModified":"2019-10-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AACCC-11FE-7C53-E053-F662850A78BF","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Gastrointestinal Stromal Tumor","valueDescription":"Gastrointestinal Stromal Tumor","ValueMeaning":{"publicId":"4265240","version":"1","preferredName":"Gastrointestinal Stromal Tumor","longName":"4265240","preferredDefinition":"A mesenchymal neoplasm most commonly seen in the gastrointestinal tract.  Cases involving tissues outside the gastrointestinal tract have also been reported (extragastrointestinal gastrointestinal stromal tumor).  It is a specific KIT-expressing and KIT-signaling-driven mesenchymal tumor.  Until recently, surgery has been the only effective therapy for this tumor.  However, many patients still experience recurrence.  Conventional chemotherapy and radiation therapy have been of limited value.  A KIT tyrosine kinase inhibitor, imatinib mesylate (also known as STI-571 or Gleevec), is now effective in the treatment of relapsed and unresectable cases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gastrointestinal Stromal Tumor","conceptCode":"C3868","definition":"A stromal tumor most commonly seen in the gastrointestinal tract. Rare cases of solitary masses in the omentum or the mesentery have also been reported (extragastrointestinal gastrointestinal stromal tumor).  It is a tumor that differentiates along the lines of interstitial cells of Cajal.  Most cases contain KIT- or PDGFRA-activating mutations. Until recently, surgery has been the only effective therapy for this tumor.  However, many patients still experience recurrence.  Conventional chemotherapy and radiation therapy have been of limited value.  A KIT tyrosine kinase inhibitor, imatinib mesylate (also known as STI-571 or Gleevec), is now effective in the treatment of relapsed and unresectable cases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F68C00B1-78B6-6438-E040-BB89AD4373BF","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AACCC-1212-7C53-E053-F662850A78BF","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Gastric Neuroendocrine Tumor G1","valueDescription":"Gastric Neuroendocrine Tumor G1","ValueMeaning":{"publicId":"6832566","version":"1","preferredName":"Gastric Neuroendocrine Tumor G1","longName":"6832566","preferredDefinition":"A well differentiated, low grade neuroendocrine tumor (carcinoid tumor) that arises from the stomach.  The vast majority of cases arise from the corpus-fundus region.  The mitotic count is less than 2 per 10 HPF and/or the Ki67 index is equal to or less than 2 percent.  It may be associated with autoimmune chronic atrophic gastritis, multiple endocrine neoplasia type 1, or it may be sporadic.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gastric Neuroendocrine Tumor G1","conceptCode":"C4635","definition":"A well differentiated, low grade neuroendocrine neoplasm that arises from the stomach. The vast majority of cases arise from the corpus-fundus region. The mitotic count is less than 2 per 10 HPF and/or the Ki67 index is equal to or less than 2 percent.  It may be associated with autoimmune chronic atrophic gastritis, multiple endocrine neoplasia type 1, or it may be sporadic.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AACCC-121F-7C53-E053-F662850A78BF","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AACCC-1238-7C53-E053-F662850A78BF","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Gastric Carcinoma","valueDescription":"Gastric Carcinoma","ValueMeaning":{"publicId":"5581343","version":"1","preferredName":"Gastric Carcinoma","longName":"5581343","preferredDefinition":"A malignant epithelial tumor of the stomach mucosa. The vast majority of gastric carcinomas are adenocarcinomas, arising from the gastric glandular epithelium.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gastric Carcinoma","conceptCode":"C4911","definition":"A malignant epithelial tumor of the stomach mucosa. The vast majority of gastric carcinomas are adenocarcinomas, arising from the gastric glandular epithelium.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42019733-B8C5-634F-E053-F662850A5A61","latestVersionIndicator":"Yes","beginDate":"2016-11-23","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2016-11-23","modifiedBy":"COOPERM","dateModified":"2019-02-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AACCC-124D-7C53-E053-F662850A78BF","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Ampulla of Vater Carcinoma","valueDescription":"Ampulla of Vater Carcinoma","ValueMeaning":{"publicId":"6790710","version":"1","preferredName":"Ampulla of Vater Carcinoma","longName":"6790710","preferredDefinition":"A carcinoma arising from the ampulla of Vater.  The vast majority of cases are adenocarcinomas.  Signs and symptoms include jaundice, abdominal pain, anorexia, nausea, vomiting, and weight loss.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ampulla of Vater Carcinoma","conceptCode":"C3908","definition":"A carcinoma arising from the ampulla of Vater.  The vast majority of cases are adenocarcinomas.  Signs and symptoms include jaundice, abdominal pain, anorexia, nausea, vomiting, and weight loss.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C2A54A1-B20B-23E2-E053-F662850A517A","latestVersionIndicator":"Yes","beginDate":"2019-06-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-25","modifiedBy":"ONEDATA","dateModified":"2019-06-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C2A54A1-B224-23E2-E053-F662850A517A","beginDate":"2019-06-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-25","modifiedBy":"ONEDATA","dateModified":"2019-06-25","deletedIndicator":"No"},{"value":"Amelanotic Melanoma","valueDescription":"Amelanotic Melanoma","ValueMeaning":{"publicId":"3251354","version":"1","preferredName":"Amelanotic Melanoma","longName":"3251354","preferredDefinition":"A melanoma characterized by the complete absence of melanin pigment in the melanoma cells. It occurs more frequently on the face and it is often associated with desmoplastic reaction.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amelanotic Melanoma","conceptCode":"C3802","definition":"A melanoma characterized by the complete absence of melanin pigment in the melanoma cells. It occurs more frequently on the face and it is often associated with desmoplastic reaction.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A758F49E-9EF5-73F4-E040-BB89AD430DFE","latestVersionIndicator":"Yes","beginDate":"2011-07-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C2A54A1-B238-23E2-E053-F662850A517A","beginDate":"2019-06-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-25","modifiedBy":"ONEDATA","dateModified":"2019-06-25","deletedIndicator":"No"},{"value":"Aleukemic Leukemia","valueDescription":"Aleukemic Leukemia","ValueMeaning":{"publicId":"6790712","version":"1","preferredName":"Aleukemic Leukemia","longName":"6790712","preferredDefinition":"A leukemia characterized by the absence of leukemic cells in the peripheral blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aleukemic Leukemia","conceptCode":"C4982","definition":"A leukemia characterized by the absence of leukemic cells in the peripheral blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C2A54A1-B245-23E2-E053-F662850A517A","latestVersionIndicator":"Yes","beginDate":"2019-06-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-25","modifiedBy":"ONEDATA","dateModified":"2019-06-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C2A54A1-B25E-23E2-E053-F662850A517A","beginDate":"2019-06-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-25","modifiedBy":"ONEDATA","dateModified":"2019-06-25","deletedIndicator":"No"},{"value":"Alcohol-Related Carcinoma","valueDescription":"Alcohol-Related Carcinoma","ValueMeaning":{"publicId":"6790714","version":"1","preferredName":"Alcohol-Related Carcinoma","longName":"6790714","preferredDefinition":"A carcinoma that is caused by alcohol abuse.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alcohol-Related Carcinoma","conceptCode":"C27927","definition":"A carcinoma that is caused by alcohol abuse.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C2A54A1-B26B-23E2-E053-F662850A517A","latestVersionIndicator":"Yes","beginDate":"2019-06-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-25","modifiedBy":"ONEDATA","dateModified":"2019-06-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C2A54A1-B284-23E2-E053-F662850A517A","beginDate":"2019-06-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-25","modifiedBy":"ONEDATA","dateModified":"2019-06-25","deletedIndicator":"No"},{"value":"Aggravated Malignant Neoplasm","valueDescription":"Aggravated Malignant Neoplasm","ValueMeaning":{"publicId":"6790716","version":"1","preferredName":"Aggravated Malignant Neoplasm","longName":"6790716","preferredDefinition":"A malignant neoplasm that shows clinical and/or pathologic progression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aggravated Malignant Neoplasm","conceptCode":"C3851","definition":"A malignant neoplasm that shows clinical and/or pathologic progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C2A54A1-B291-23E2-E053-F662850A517A","latestVersionIndicator":"Yes","beginDate":"2019-06-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-25","modifiedBy":"ONEDATA","dateModified":"2019-06-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C2A54A1-B2AA-23E2-E053-F662850A517A","beginDate":"2019-06-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-25","modifiedBy":"ONEDATA","dateModified":"2019-06-25","deletedIndicator":"No"},{"value":"Advanced Lymphoma","valueDescription":"Advanced Lymphoma","ValueMeaning":{"publicId":"6790718","version":"1","preferredName":"Advanced Lymphoma","longName":"6790718","preferredDefinition":"Lymphoma that has spread extensively to other anatomic sites or is no longer responding to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Advanced Lymphoma","conceptCode":"C153172","definition":"Lymphoma that has spread extensively to other anatomic sites or is no longer responding to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C2A54A1-B2B7-23E2-E053-F662850A517A","latestVersionIndicator":"Yes","beginDate":"2019-06-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-25","modifiedBy":"ONEDATA","dateModified":"2019-06-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C2A54A1-B2D0-23E2-E053-F662850A517A","beginDate":"2019-06-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-25","modifiedBy":"ONEDATA","dateModified":"2019-06-25","deletedIndicator":"No"},{"value":"Adult Lymphoma","valueDescription":"Adult Lymphoma","ValueMeaning":{"publicId":"6790720","version":"1","preferredName":"Adult Lymphoma","longName":"6790720","preferredDefinition":"A lymphoma that occurs in adults.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adult Lymphoma","conceptCode":"C7587","definition":"A lymphoma that occurs in adults.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C2A54A1-B2DD-23E2-E053-F662850A517A","latestVersionIndicator":"Yes","beginDate":"2019-06-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-25","modifiedBy":"ONEDATA","dateModified":"2019-06-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C2A54A1-B2F6-23E2-E053-F662850A517A","beginDate":"2019-06-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-25","modifiedBy":"ONEDATA","dateModified":"2019-06-25","deletedIndicator":"No"},{"value":"Adrenal Cortex Carcinoma","valueDescription":"Adrenal Cortex Carcinoma","ValueMeaning":{"publicId":"3248212","version":"1","preferredName":"Adrenal Cortex Carcinoma","longName":"3248212","preferredDefinition":"A rare, usually large (greater than 5cm), malignant epithelial tumor arising from the adrenal cortical cells.  Symptoms are usually related to the excessive production of hormones, and include Cushing's syndrome and virilism in women.  Common sites of metastasis include liver, lung, bone, and retroperitoneal lymph nodes.  Advanced radiologic procedures have enabled the detection of small tumors, resulting in the improvement of the 5-year survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adrenal Cortical Carcinoma","conceptCode":"C9325","definition":"A rare, usually large (greater than 5cm), malignant epithelial tumor arising from the adrenal cortical cells.  Symptoms are usually related to the excessive production of hormones, and include Cushing's syndrome and virilism in women.  Common sites of metastasis include liver, lung, bone, and retroperitoneal lymph nodes.  Advanced radiologic procedures have enabled the detection of small tumors, resulting in the improvement of the 5-year survival.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6B537E2-7FB8-5E57-E040-BB89AD4339B4","latestVersionIndicator":"Yes","beginDate":"2011-06-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C2A54A1-B30A-23E2-E053-F662850A517A","beginDate":"2019-06-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-25","modifiedBy":"ONEDATA","dateModified":"2019-06-25","deletedIndicator":"No"},{"value":"Adenosquamous Carcinoma","valueDescription":"Adenosquamous Carcinoma","ValueMeaning":{"publicId":"4264016","version":"1","preferredName":"Adenosquamous Carcinoma","longName":"4264016","preferredDefinition":"A carcinoma composed of malignant glandular cells and malignant squamous cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adenosquamous Carcinoma","conceptCode":"C3727","definition":"An invasive carcinoma composed of malignant glandular cells and malignant squamous cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F63DCAA0-11A0-5D4B-E040-BB89AD432C9C","latestVersionIndicator":"Yes","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C2A54A1-B314-23E2-E053-F662850A517A","beginDate":"2019-06-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-25","modifiedBy":"ONEDATA","dateModified":"2019-06-25","deletedIndicator":"No"},{"value":"Adenoid Cystic Carcinoma","valueDescription":"Adenoid Cystic Carcinoma","ValueMeaning":{"publicId":"4264017","version":"1","preferredName":"Adenoid Cystic Carcinoma","longName":"4264017","preferredDefinition":"A malignant tumor arising from the epithelial cells.  Microscopically, the neoplastic epithelial cells form cylindrical spatial configurations (cribriform or classic type of adenoid cystic carcinoma), cordlike structures (tubular type of adenoid cystic carcinoma), or solid structures (basaloid variant of adenoid cystic carcinoma).  Adenoid cystic carcinomas mostly occur in the salivary glands.  Other primary sites of involvement include the lacrimal gland, the larynx, and the lungs.  Adenoid cystic carcinomas spread along nerve sheaths, resulting in severe pain, and they tend to recur.  Lymph node metastases are unusual; hematogenous tumor spread is characteristic.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adenoid Cystic Carcinoma","conceptCode":"C2970","definition":"A malignant tumor arising from the epithelial cells.  Microscopically, the neoplastic epithelial cells form cylindrical spatial configurations (cribriform or classic type of adenoid cystic carcinoma), cordlike structures (tubular type of adenoid cystic carcinoma), or solid structures (basaloid variant of adenoid cystic carcinoma).  Adenoid cystic carcinomas mostly occur in the salivary glands.  Other primary sites of involvement include the lacrimal gland, the larynx, and the lungs.  Adenoid cystic carcinomas spread along nerve sheaths, resulting in severe pain, and they tend to recur.  Lymph node metastases are unusual; hematogenous tumor spread is characteristic.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F63DCAA0-11C3-5D4B-E040-BB89AD432C9C","latestVersionIndicator":"Yes","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C2A54A1-B31E-23E2-E053-F662850A517A","beginDate":"2019-06-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-25","modifiedBy":"ONEDATA","dateModified":"2019-06-25","deletedIndicator":"No"},{"value":"Ganglioneuroblastoma","valueDescription":"Ganglioneuroblastoma","ValueMeaning":{"publicId":"2578727","version":"1","preferredName":"Ganglioneuroblastoma","longName":"2578727","preferredDefinition":"A moderately malignant neoplasm composed of primitive neuroectodermal cells dispersed in myxomatous or fibrous stroma intermixed with mature ganglion cells. It may undergo transformation into a neuroblastoma. It arises from the sympathetic trunk or less frequently from the adrenal medulla, cerebral cortex, and other locations. Cervical ganglioneuroblastomas may be associated with HORNER SYNDROME and the tumor may occasionally secrete vasoactive intestinal peptide, resulting in chronic diarrhea.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ganglioneuroblastoma","conceptCode":"C3790","definition":"A malignant neuroblastic tumor characterized by the presence of neuroblastic cells, ganglion cells, and a stroma with Schwannian differentiation constituting more than fifty-percent of the tumor volume.  There are two histologic subtypes identified: ganglioneuroblastoma, intermixed and ganglioneuroblastoma, nodular.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0094-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-23","modifiedBy":"ONEDATA","dateModified":"2006-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AACCC-1258-7C53-E053-F662850A78BF","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Gallbladder Carcinoma","valueDescription":"Gallbladder Carcinoma","ValueMeaning":{"publicId":"5581349","version":"1","preferredName":"Gallbladder Carcinoma","longName":"5581349","preferredDefinition":"A malignant tumor arising from the epithelium of the gallbladder. It is usually associated with the presence of gallstones. Clinical symptoms are not specific and usually present late in the course. Morphologically, most gallbladder carcinomas are adenocarcinomas; squamous cell carcinomas, adenosquamous carcinomas, signet ring carcinomas, and undifferentiated carcinomas can also occur.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gallbladder Carcinoma","conceptCode":"C3844","definition":"A malignant tumor arising from the epithelium of the gallbladder. It is usually associated with the presence of gallstones. Clinical symptoms are not specific and usually present late in the course. Morphologically, most gallbladder carcinomas are adenocarcinomas; squamous cell carcinomas, adenosquamous carcinomas, signet ring carcinomas, and undifferentiated carcinomas can also occur.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42019733-B997-634F-E053-F662850A5A61","latestVersionIndicator":"Yes","beginDate":"2016-11-23","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2016-11-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AACCC-126F-7C53-E053-F662850A78BF","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Follicular Lymphoma","valueDescription":"Follicular Lymphoma","ValueMeaning":{"publicId":"3088584","version":"1","preferredName":"Follicular Lymphoma","longName":"3088584","preferredDefinition":"A neoplasm of follicle centre B cells which has at least a partial follicular pattern.  Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide.  Most patients have widespread disease at diagnosis.  Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present.  The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)].  Histological grade correlates with prognosis.  Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Follicular Lymphoma","conceptCode":"C3209","definition":"A neoplasm of follicle centre B cells which has at least a partial follicular pattern.  Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide.  Most patients have widespread disease at diagnosis.  Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present.  The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)].  Histological grade correlates with prognosis.  Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86E3DD57-D19B-A26A-E040-BB89AD437117","latestVersionIndicator":"Yes","beginDate":"2010-05-18","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-05-18","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AACCC-127A-7C53-E053-F662850A78BF","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Follicular Dendritic Cell Sarcoma","valueDescription":"Follicular Dendritic Cell Sarcoma/Tumor","ValueMeaning":{"publicId":"2839726","version":"1","preferredName":"Follicular Dendritic Cell Sarcoma/Tumor","longName":"2839726","preferredDefinition":"A neoplasm composed of spindle to ovoid cells which have morphologic and immunophenotypic characteristics of follicular dendritic cells. It affects lymph nodes and other sites including the tonsils, gastrointestinal tract, spleen, liver, soft tissues, skin, and oral cavity. It usually behaves as a low grade sarcoma. Treatment options include complete surgical removal of the tumor with or without adjuvant chemotherapy or radiotherapy. Recurrences have been reported in up to half of the cases. Cases which present with abdominal involvement and a high morphologic grade usually have a poorer prognosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Follicular Dendritic Cell Sarcoma","conceptCode":"C9281","definition":"A neoplasm composed of spindle to ovoid cells which have morphologic and immunophenotypic characteristics of follicular dendritic cells. It affects lymph nodes and other sites including the tonsils, gastrointestinal tract, spleen, liver, soft tissues, skin, and oral cavity. It usually behaves as a low grade sarcoma. Treatment options include complete surgical removal of the tumor with or without adjuvant chemotherapy or radiotherapy. Recurrences have been reported in up to half of the cases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6332FCA8-8A75-1FC8-E040-BB89AD432A49","latestVersionIndicator":"Yes","beginDate":"2009-02-18","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-18","modifiedBy":"ONEDATA","dateModified":"2009-02-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AACCC-128E-7C53-E053-F662850A78BF","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Fibrosarcoma","valueDescription":"Fibrosarcoma","ValueMeaning":{"publicId":"2568825","version":"1","preferredName":"Fibrosarcoma","longName":"2568825","preferredDefinition":"A malignant mesenchymal tumor affecting soft tissues and bone. It is classified as adult or infantile.  Infantile fibrosarcomas generally have a much more favorable prognosis than adult fibrosarcomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fibrosarcoma","conceptCode":"C3043","definition":"A malignant mesenchymal fibroblastic neoplasm affecting the soft tissue and bone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D9E6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-03-29","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-03-29","modifiedBy":"CAMPBELB","dateModified":"2007-02-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AACCC-1299-7C53-E053-F662850A78BF","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Fibroblastic Reticular Cell Tumor","valueDescription":"Fibroblastic Reticular Cell Tumor","ValueMeaning":{"publicId":"6832568","version":"1","preferredName":"Fibroblastic Reticular Cell Tumor","longName":"6832568","preferredDefinition":"A very rare dendritic cell tumor affecting the lymph nodes, spleen, and soft tissues. Morphologically it is similar to the interdigitating dendritic cell sarcoma or follicular dendritic cell sarcoma. The tumor cells are positive for cytokeratin and CD68. Clinical outcome is variable.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fibroblastic Reticular Cell Sarcoma","conceptCode":"C81758","definition":"A very rare dendritic cell sarcoma affecting the lymph nodes, spleen, and soft tissues. Morphologically it is similar to the interdigitating dendritic cell sarcoma or follicular dendritic cell sarcoma. The tumor cells are positive for cytokeratin and CD68.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AACCC-12A6-7C53-E053-F662850A78BF","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AACCC-12BF-7C53-E053-F662850A78BF","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Female Malignant Nipple Neoplasm","valueDescription":"BR - 174.0; Breast-Fem","ValueMeaning":{"publicId":"2572635","version":"1","preferredName":"BR - 174.0; Breast-Fem","longName":"2572635","preferredDefinition":"A malignant neoplasm that affects the area of the nipple in females.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Female Malignant Nipple Neoplasm","conceptCode":"C120455","definition":"A malignant neoplasm that affects the area of the nipple in females.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8C8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"COOPERM","dateModified":"2015-03-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AACCC-12D3-7C53-E053-F662850A78BF","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Fallopian Tube Carcinoma","valueDescription":"Fallopian Tube Carcinoma","ValueMeaning":{"publicId":"3210700","version":"1","preferredName":"Fallopian Tube Carcinoma","longName":"3210700","preferredDefinition":"A carcinoma arising from the fallopian tube which is attached to the uterine corpus (uterine body). Most patients are postmenopausal, and postmenopausal bleeding is the most frequently seen symptom. Morphologically, the majority of fallopian tube carcinomas are serous or endometrioid adenocarcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fallopian Tube Carcinoma","conceptCode":"C3867","definition":"A carcinoma arising from the fallopian tube. Most patients are postmenopausal, and postmenopausal bleeding is the most frequently seen symptom. Morphologically, the majority of fallopian tube carcinomas are serous or endometrioid adenocarcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9080-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AACCC-12DE-7C53-E053-F662850A78BF","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Eyelid Melanoma","valueDescription":"Eyelid Melanoma","ValueMeaning":{"publicId":"6832570","version":"1","preferredName":"Eyelid Melanoma","longName":"6832570","preferredDefinition":"A melanoma that arises from the upper or lower eyelid.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Eyelid Melanoma","conceptCode":"C4358","definition":"A melanoma that arises from the upper or lower eyelid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AACCC-12EC-7C53-E053-F662850A78BF","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AACCC-1305-7C53-E053-F662850A78BF","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Eye Carcinoma","valueDescription":"Eye Carcinoma","ValueMeaning":{"publicId":"6832572","version":"1","preferredName":"Eye Carcinoma","longName":"6832572","preferredDefinition":"A carcinoma that arises from any of the structures of the eye.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Eye Carcinoma","conceptCode":"C6079","definition":"A carcinoma that arises from any of the structures of the eye.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AACCC-1312-7C53-E053-F662850A78BF","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AACCC-132B-7C53-E053-F662850A78BF","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","valueDescription":"Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","ValueMeaning":{"publicId":"4722745","version":"1","preferredName":"Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","longName":"4722745","preferredDefinition":"An indolent, extranodal type of non-Hodgkin lymphoma composed of small B-lymphocytes (centrocyte-like cells).  The gastrointestinal tract is the most common site of involvement.  Other common sites of involvement include lung, head and neck, ocular adnexae, skin, thyroid, and breast.  Gastric involvement is associated with the presence of H. pylori infection. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","conceptCode":"C3898","definition":"An indolent, extranodal type of non-Hodgkin lymphoma composed of small B-lymphocytes (centrocyte-like cells).  The gastrointestinal tract is the most common site of involvement.  Other common sites of involvement include lung, head and neck, ocular adnexae, skin, thyroid, and breast.  Gastric involvement is associated with the presence of H. pylori infection. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8AB028-C4AE-4E21-E050-BB89AD43094A","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AACCC-133F-7C53-E053-F662850A78BF","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"External Ear Squamous Cell Carcinoma","valueDescription":"External Ear Squamous Cell Carcinoma","ValueMeaning":{"publicId":"6832574","version":"1","preferredName":"External Ear Squamous Cell Carcinoma","longName":"6832574","preferredDefinition":"A squamous cell carcinoma that arises from the skin of the external ear.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"External Ear Squamous Cell Carcinoma","conceptCode":"C6083","definition":"A squamous cell carcinoma that arises from the external ear.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AACCC-134D-7C53-E053-F662850A78BF","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AACCC-1366-7C53-E053-F662850A78BF","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"External Ear Basal Cell Carcinoma","valueDescription":"External Ear Basal Cell Carcinoma","ValueMeaning":{"publicId":"6832576","version":"1","preferredName":"External Ear Basal Cell Carcinoma","longName":"6832576","preferredDefinition":"A basal cell carcinoma that arises from the skin of the external ear.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"External Ear Basal Cell Carcinoma","conceptCode":"C6082","definition":"A basal cell carcinoma that arises from the skin of the external ear.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AACCC-1373-7C53-E053-F662850A78BF","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AACCC-138C-7C53-E053-F662850A78BF","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Ewing Sarcoma","valueDescription":"Ewing Sarcoma","ValueMeaning":{"publicId":"2593150","version":"1","preferredName":"Ewing Sarcoma","longName":"2593150","preferredDefinition":"A small round cell tumor that lacks morphologic, immunohistochemical, and electron microscopic evidence of neuroectodermal differentiation. It represents one of the two ends of the spectrum called Ewing sarcoma/peripheral neuroectodermal tumor. It affects mostly males under age 20, and it can occur in soft tissue or bone. Pain and the presence of a mass are the most common clinical symptoms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ewing Sarcoma","conceptCode":"C4817","definition":"A small round cell tumor that lacks morphologic, immunohistochemical, and electron microscopic evidence of neuroectodermal differentiation. It represents one of the two ends of the spectrum called Ewing sarcoma/peripheral neuroectodermal tumor. It affects mostly males under age 20, and it can occur in soft tissue or bone. Pain and the presence of a mass are the most common clinical symptoms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286E976F-6E8E-3730-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AACCC-1396-7C53-E053-F662850A78BF","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Essential Thrombocythemia","valueDescription":"Essential Thrombocythemia","ValueMeaning":{"publicId":"2838061","version":"1","preferredName":"Essential Thrombocythemia","longName":"2838061","preferredDefinition":"A chronic myeloproliferative disorder that involves primarily the megakaryocytic lineage and it is characterized by sustained thrombocytosis in the blood, increased numbers of large, mature megakaryocytes in the bone marrow, and episodes of thrombosis and/or hemorrhage.  The cause is unknown.  Median survival times of 10-15 years are commonly reported.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Essential Thrombocythemia","conceptCode":"C3407","definition":"A chronic myeloproliferative neoplasm that involves primarily the megakaryocytic lineage. It is characterized by sustained thrombocytosis in the blood, increased numbers of large, mature megakaryocytes in the bone marrow, and episodes of thrombosis and/or hemorrhage. (WHO, 2008)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62843923-FF56-E9AE-E040-BB89AD435A7B","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AACCC-13A0-7C53-E053-F662850A78BF","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Esophageal Carcinoma","valueDescription":"Esophageal Carcinoma","ValueMeaning":{"publicId":"3210699","version":"1","preferredName":"Esophageal Carcinoma","longName":"3210699","preferredDefinition":"A malignant epithelial tumor arising from the esophageal mucosa. Two major histologic types of esophageal carcinoma have been described: squamous cell carcinoma and adenocarcinoma. This type of cancer is associated with excessive ethanol and cigarette usage.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Esophageal Carcinoma","conceptCode":"C3513","definition":"A malignant epithelial tumor arising from the esophageal mucosa. Two major histologic types of esophageal carcinoma have been described: squamous cell carcinoma and adenocarcinoma. This type of cancer is associated with excessive ethanol and cigarette usage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9054-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AACCC-13AB-7C53-E053-F662850A78BF","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Epithelioid Cell Melanoma","valueDescription":"Epithelioid Cell Melanoma","ValueMeaning":{"publicId":"3729982","version":"1","preferredName":"Epithelioid Cell Melanoma","longName":"3729982","preferredDefinition":"A melanoma characterized by the presence of malignant large epithelioid melanocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Epithelioid Cell Melanoma","conceptCode":"C4236","definition":"A melanoma characterized by the presence of malignant large epithelioid melanocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB36A402-8E6F-DCBB-E040-BB89AD436B1E","latestVersionIndicator":"Yes","beginDate":"2013-04-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-04-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AACCC-13B6-7C53-E053-F662850A78BF","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Epithelial-Myoepithelial Carcinoma","valueDescription":"Epithelial-Myoepithelial Carcinoma","ValueMeaning":{"publicId":"3248470","version":"1","preferredName":"Epithelial-Myoepithelial Carcinoma","longName":"3248470","preferredDefinition":"A malignant neoplasm which occurs mostly in the major salivary glands (most frequently in the parotid gland), but also in the minor salivary glands of the oral mucosa and the tracheobronchial tree. It is characterized by the presence of ductal structures which are lined by an inner layer of cuboidal epithelial-type cells and an outer layer of myoepithelial cells with clear or eosinophilic cytoplasm.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Epithelial-Myoepithelial Carcinoma","conceptCode":"C4199","definition":"A malignant neoplasm which occurs mostly in the major salivary glands (most frequently in the parotid gland), but also in the minor salivary glands of the oral mucosa and the tracheobronchial tree. It is characterized by the presence of ductal structures which are lined by an inner layer of cuboidal epithelial-type cells and an outer layer of myoepithelial cells with clear or eosinophilic cytoplasm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6B722DF-A86F-76E3-E040-BB89AD43333E","latestVersionIndicator":"Yes","beginDate":"2011-06-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-27","modifiedBy":"COOPERM","dateModified":"2011-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AACCC-13CB-7C53-E053-F662850A78BF","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Thyroid Gland Carcinoma","valueDescription":"Thyroid Gland Carcinoma","ValueMeaning":{"publicId":"5581344","version":"1","preferredName":"Thyroid Gland Carcinoma","longName":"5581344","preferredDefinition":"A carcinoma arising from the thyroid gland. It is usually an adenocarcinoma and includes the following main subtypes: follicular, papillary, medullary, poorly differentiated, and anaplastic.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thyroid Gland Carcinoma","conceptCode":"C4815","definition":"A carcinoma arising from the thyroid gland. It includes the following main subtypes: follicular, papillary, medullary, poorly differentiated, and anaplastic carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42019733-B8E8-634F-E053-F662850A5A61","latestVersionIndicator":"Yes","beginDate":"2016-11-23","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2016-11-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AACCC-13E4-7C53-E053-F662850A78BF","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Thymoma","valueDescription":"thymoma","ValueMeaning":{"publicId":"2579823","version":"1","preferredName":"thymoma","longName":"2579823","preferredDefinition":"A neoplasm originating from thymic tissue, usually benign, and frequently encapsulated. Although it is occasionally invasive, metastases are extremely rare. It consists of any type of thymic epithelial cell as well as lymphocytes that are usually abundant and probably not neoplastic. Malignant lymphomas that involve the thymus, e.g., lymphosarcoma, Hodgkin's disease (previously termed granulomatous thymoma), should not be regarded as thymoma. (Stedman, 25th ed)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thymoma","conceptCode":"C3411","definition":"A neoplasm arising from the epithelial cells of the thymus.  Although thymomas are usually encapsulated tumors, they may invade the capsule and infiltrate the surrounding tissues or even metastasize to distant anatomic sites.  The following morphologic subtypes are currently recognized: type A, type B, type AB, metaplastic, micronodular, microscopic, and sclerosing thymoma.  Thymomas type B are further subdivided into types B1, B2, and B3. Thymoma type B3 usually has the most aggressive clinical course.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-04DC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-16","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AACCC-13EF-7C53-E053-F662850A78BF","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Thymic Carcinoma","valueDescription":"Thymic Carcinoma","ValueMeaning":{"publicId":"3248551","version":"1","preferredName":"Thymic Carcinoma","longName":"3248551","preferredDefinition":"A diverse group of carcinomas of the thymus gland, previously known as thymoma type C (WHO-1999).  It includes morphologic variants derived from purely epithelial cells, as well as from cells with neuroendocrine differentiation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thymic Carcinoma","conceptCode":"C7569","definition":"A diverse group of carcinomas of the thymus gland, previously known as thymoma type C.  It includes morphologic variants derived from purely epithelial cells, as well as from cells with neuroendocrine differentiation.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6BBE041-BBF6-9503-E040-BB89AD435A00","latestVersionIndicator":"Yes","beginDate":"2011-06-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AACCC-1403-7C53-E053-F662850A78BF","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Thoracic Neoplasm","valueDescription":"Thoracic Neoplasm","ValueMeaning":{"publicId":"6832696","version":"1","preferredName":"Thoracic Neoplasm","longName":"6832696","preferredDefinition":"A benign or malignant, primary or metastatic neoplasm involving the tissues of the thorax.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thoracic Neoplasm","conceptCode":"C3406","definition":"A benign or malignant, primary or metastatic neoplasm involving the tissues of the thorax.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AACCC-1410-7C53-E053-F662850A78BF","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AACCC-1429-7C53-E053-F662850A78BF","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Therapy-Related Malignant Neoplasm","valueDescription":"Therapy-Related Malignant Neoplasm","ValueMeaning":{"publicId":"2943994","version":"1","preferredName":"Therapy-Related Malignant Neoplasm","longName":"2943994","preferredDefinition":"The development of a malignant neoplasm in response to medical or surgical treatment, induced by the treatment itself.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapy-Related Malignant Neoplasm","conceptCode":"C4969","definition":"The development of a malignant neoplasm in response to medical or surgical treatment, induced by the treatment itself.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"742DD56B-1072-A7E6-E040-BB89AD43063D","latestVersionIndicator":"Yes","beginDate":"2009-09-22","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-09-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AACCC-143D-7C53-E053-F662850A78BF","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Therapy-Related Leukemia","valueDescription":"Therapy-Related Leukemia","ValueMeaning":{"publicId":"6832698","version":"1","preferredName":"Therapy-Related Leukemia","longName":"6832698","preferredDefinition":"A leukemia arising as a result of the mutagenic effect of chemotherapy agents that are used for the treatment of a malignant tumor or exposure to ionizing radiation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapy-Related Leukemia","conceptCode":"C80683","definition":"A leukemia arising as a result of the mutagenic effect of chemotherapy agents that are used for the treatment of a malignant tumor or exposure to ionizing radiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AACCC-144B-7C53-E053-F662850A78BF","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AACCC-1464-7C53-E053-F662850A78BF","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Testicular Leukemia","valueDescription":"Testicular Leukemia","ValueMeaning":{"publicId":"6832699","version":"1","preferredName":"Testicular Leukemia","longName":"6832699","preferredDefinition":"A myeloid or more commonly lymphoid leukemia (acute or chronic) affecting the testis.  Microscopically, there is interstitial infiltration of the testis by leukemic cells.  Acute lymphoblastic leukemia with testicular involvement is not uncommon in boys.  Sometimes (up to 10% of the cases), testicular involvement may be the initial manifestation of relapsed acute lymphoblastic leukemia.  --03","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Testicular Leukemia","conceptCode":"C9277","definition":"A myeloid or more commonly lymphoid leukemia (acute or chronic) affecting the testis.  Microscopically, there is interstitial infiltration of the testis by leukemic cells.  Acute lymphoblastic leukemia with testicular involvement is not uncommon in boys.  Sometimes (up to 10% of the cases), testicular involvement may be the initial manifestation of relapsed acute lymphoblastic leukemia.  --03","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AACCC-146E-7C53-E053-F662850A78BF","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AACCC-1487-7C53-E053-F662850A78BF","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Teratoma","valueDescription":"Teratoma","ValueMeaning":{"publicId":"3116442","version":"1","preferredName":"Teratoma","longName":"3116442","preferredDefinition":"(ter-a-TOW-ma) A type of germ cell tumor that may contain several different types of tissue, such as hair, muscle, and bone.  Teratomas occur most often in the ovaries in women, the testicles in men, and the tailbone in children.  Not all teratomas are malignant.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Teratoma","conceptCode":"C3403","definition":"A non-seminomatous germ cell tumor characterized by the presence of various tissues which correspond to the different germinal layers (endoderm, mesoderm, and ectoderm). It occurs in the testis, ovary, and extragonadal sites including central nervous system, mediastinum, lung, and stomach. According to the level of differentiation of the tissues which comprise the tumor, teratomas are classified as benign (grade 0 or 1), immature (grade 2), and malignant (grade 3). Grade 0 teratomas contain only mature elements; grade 1 teratomas have a limited degree of immaturity; grade 2 teratomas have a more extensive degree of immaturity; grade 3 teratomas are composed exclusively of immature tissues. The prognosis depends on patient age, tumor size and grade, and stage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8A5774F7-9AEE-402E-E040-BB89AD43676B","latestVersionIndicator":"Yes","beginDate":"2010-07-01","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-07-01","modifiedBy":"ONEDATA","dateModified":"2010-07-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AACCC-1491-7C53-E053-F662850A78BF","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Supratentorial Neoplasm","valueDescription":"Supratentorial Neoplasm","ValueMeaning":{"publicId":"6832701","version":"1","preferredName":"Supratentorial Neoplasm","longName":"6832701","preferredDefinition":"A benign or malignant neoplasm that occurs within the intracranial cavity above the tentorium cerebelli.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Supratentorial Neoplasm","conceptCode":"C3397","definition":"A benign or malignant neoplasm that occurs within the intracranial cavity above the tentorium cerebelli.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AACCC-149F-7C53-E053-F662850A78BF","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AACCC-14B8-7C53-E053-F662850A78BF","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Stage 0 Skin Cancer","valueDescription":"Stage 0 Skin Cancer","ValueMeaning":{"publicId":"6832703","version":"1","preferredName":"Stage 0 Skin Cancer","longName":"6832703","preferredDefinition":"Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ.  N0: No regional lymph node metastasis.  M0: No clinical or radiographic evidence of distant metastasis.  (AJCC 6th and 7th eds.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage 0 Skin Cancer","conceptCode":"C3640","definition":"Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ.  N0: No regional lymph node metastasis.  M0: No clinical or radiographic evidence of distant metastasis.  (AJCC 6th and 7th eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AACCC-14C5-7C53-E053-F662850A78BF","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AACCC-14DE-7C53-E053-F662850A78BF","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Stage 0 Rectal Cancer AJCC v6 and v7","valueDescription":"Stage 0 Rectal Cancer AJCC v6 and v7","ValueMeaning":{"publicId":"6832705","version":"1","preferredName":"Stage 0 Rectal Cancer AJCC v6 and v7","longName":"6832705","preferredDefinition":"Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ: intraepithelial or invasion of the lamina propria.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 6th and 7th eds.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage 0 Rectal Cancer AJCC v6 and v7","conceptCode":"C4853","definition":"Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ: intraepithelial or invasion of the lamina propria.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 6th and 7th eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AACCC-14EB-7C53-E053-F662850A78BF","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AACCC-1504-7C53-E053-F662850A78BF","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Stage 0 Pharyngeal Cancer","valueDescription":"Stage 0 Pharyngeal Cancer","ValueMeaning":{"publicId":"6832707","version":"1","preferredName":"Stage 0 Pharyngeal Cancer","longName":"6832707","preferredDefinition":"Stage 0 carcinoma of the pharynx according to the American Joint Committee on Cancer, 6th, 7th, and 8th editions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage 0 Pharyngeal Cancer","conceptCode":"C4942","definition":"Stage 0 carcinoma of the pharynx according to the American Joint Committee on Cancer, 6th, 7th, and 8th editions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AACCC-1511-7C53-E053-F662850A78BF","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AACCC-152A-7C53-E053-F662850A78BF","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Wilms Tumor","valueDescription":"Wilms Tumor","ValueMeaning":{"publicId":"2593188","version":"1","preferredName":"Wilms Tumor","longName":"2593188","preferredDefinition":"An embryonal neoplasm characterized by the presence of epithelial, mesenchymal, and blastema components. The vast majority of cases arise from the kidney. A small number of cases with morphologic features resembling Wilms tumor of the kidney have been reported arising from the ovary and the cervix.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Wilms Tumor","conceptCode":"C3267","definition":"An embryonal neoplasm characterized by the presence of epithelial, mesenchymal, and blastema components. The vast majority of cases arise from the kidney. A small number of cases with morphologic features resembling Wilms tumor of the kidney have been reported arising from the ovary and the cervix.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28701A35-66BA-579B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B6DDA-0749-7758-E053-F662850A2630","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Vulvar Carcinoma","valueDescription":"Vulvar Carcinoma","ValueMeaning":{"publicId":"3210732","version":"1","preferredName":"Vulvar Carcinoma","longName":"3210732","preferredDefinition":"A carcinoma arising from the vulva.  It usually affects elderly women but has been observed in premenopausal women as well.  The most frequently seen histologic type is squamous cell carcinoma. The most common site of involvement is the labia majora.  In many cases, the development of vulvar cancer is preceded by condyloma or squamous dysplasia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vulvar Carcinoma","conceptCode":"C4866","definition":"A carcinoma arising from the vulva.  It usually affects elderly women but has been observed in premenopausal women as well.  The most frequently seen histologic type is squamous cell carcinoma. The most common site of involvement is the labia majora.  In many cases, the development of vulvar cancer is preceded by condyloma or squamous dysplasia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9600-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B6DDA-0753-7758-E053-F662850A2630","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Virus-Related Lymphoma","valueDescription":"Virus-Related Lymphoma","ValueMeaning":{"publicId":"6832784","version":"1","preferredName":"Virus-Related Lymphoma","longName":"6832784","preferredDefinition":"Lymphoma that is caused by a virus infection.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Virus-Related Lymphoma","conceptCode":"C27699","definition":"Lymphoma that is caused by a virus infection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B6DDA-0760-7758-E053-F662850A2630","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B6DDA-0779-7758-E053-F662850A2630","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Vaginal Carcinoma","valueDescription":"Vaginal Carcinoma","ValueMeaning":{"publicId":"3125025","version":"1","preferredName":"Vaginal Carcinoma","longName":"3125025","preferredDefinition":"A carcinoma arising from the vaginal epithelium. The majority of vaginal carcinomas are squamous cell carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vaginal Carcinoma","conceptCode":"C3917","definition":"A carcinoma arising from the vaginal epithelium. The majority of vaginal carcinomas are squamous cell carcinomas.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C8C84BA-753B-B840-E040-BB89AD4308AA","latestVersionIndicator":"Yes","beginDate":"2010-07-29","endDate":null,"createdBy":"WHITES","dateCreated":"2010-07-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B6DDA-0783-7758-E053-F662850A2630","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Uveal Melanoma","valueDescription":"Uveal Melanoma","ValueMeaning":{"publicId":"3251352","version":"1","preferredName":"Uveal Melanoma","longName":"3251352","preferredDefinition":"A melanoma derived from melanocytes of the uveal tract.  It is the most common primary intraocular tumor in the United States and Western Europe.  Similar to melanoma of the skin, it is rare in Africa and Asia.  Diagnostic procedures include ophthalmoscopic exam, fluorescein angiography and ultrasound.  Treatment includes: surgical excision of the eye, iridocyclectomy and tumor resection.  Recent treatments also include radiotherapy or photo coagulation.  Classification of uveal melanomas recognizes four cell types within these tumors: epithelioid, intermediate, mixed cell, and spindle cell types.  The spindle cell type uveal melanomas are further sub-classified as spindle cell type A and spindle cell type B.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Uveal Melanoma","conceptCode":"C7712","definition":"A melanoma derived from melanocytes of the uveal tract.  It is the most common primary intraocular tumor in the United States and Western Europe.  Similar to melanoma of the skin, it is rare in Africa and Asia.  Diagnostic procedures include ophthalmoscopic exam, fluorescein angiography and ultrasound.  Treatment includes: surgical excision of the eye, iridocyclectomy and tumor resection.  Recent treatments also include radiotherapy or photo coagulation.  Classification of uveal melanomas recognizes four cell types within these tumors: epithelioid, intermediate, mixed cell, and spindle cell types.  The spindle cell type uveal melanomas are further sub-classified as spindle cell type A and spindle cell type B.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A758F49E-9ECF-73F4-E040-BB89AD430DFE","latestVersionIndicator":"Yes","beginDate":"2011-07-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B6DDA-078E-7758-E053-F662850A2630","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Uterine Neoplasm","valueDescription":"Uterine Neoplasm","ValueMeaning":{"publicId":"2593184","version":"1","preferredName":"Uterine Neoplasm","longName":"2593184","preferredDefinition":"Abnormal growth in the tissues of uterus, either cancerous or non-cancerous.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Uterine Neoplasm","conceptCode":"C3435","definition":"A benign or malignant neoplasm that affects the uterine corpus or the cervix. Representative examples of benign neoplasms include leiomyoma, adenomyoma, and endocervical polyp. Representative examples of malignant neoplasms include endometrial carcinoma, carcinosarcoma, and cervical carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28701A35-6684-579B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B6DDA-0799-7758-E053-F662850A2630","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Uterine Corpus Sarcoma","valueDescription":"UT-SARC - 200.0; Uterine Sarcoma","ValueMeaning":{"publicId":"2572702","version":"1","preferredName":"UT-SARC - 200.0; Uterine Sarcoma","longName":"2572702","preferredDefinition":"A malignant mesenchymal tumor arising from the wall of the uterine corpus (uterine body).  The most representative examples are leiomyosarcoma and endometrial stromal sarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Uterine Corpus Sarcoma","conceptCode":"C6339","definition":"A malignant mesenchymal neoplasm arising from the wall of the uterine corpus (uterine body).  The most representative examples are leiomyosarcoma and endometrial stromal sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E90B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B6DDA-07AE-7758-E053-F662850A2630","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Uterine Corpus Cancer","valueDescription":"Uterine Corpus Cancer","ValueMeaning":{"publicId":"3210731","version":"1","preferredName":"Uterine Corpus Cancer","longName":"3210731","preferredDefinition":"A malignant neoplasm arising from the uterine corpus. This category includes endometrial carcinoma and carcinosarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Uterine Corpus Cancer","conceptCode":"C61574","definition":"A malignant neoplasm arising from the uterine corpus. This category includes endometrial carcinoma and carcinosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-95CC-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B6DDA-07B9-7758-E053-F662850A2630","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Urethral Carcinoma","valueDescription":"Urethral Carcinoma","ValueMeaning":{"publicId":"6832786","version":"1","preferredName":"Urethral Carcinoma","longName":"6832786","preferredDefinition":"A carcinoma that arises from the urethra. Morphologically, the tumors are similar to those described in the bladder.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Urethral Carcinoma","conceptCode":"C9106","definition":"A carcinoma that arises from the urethra. Morphologically, the tumors are similar to those described in the bladder.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B6DDA-07C7-7758-E053-F662850A2630","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B6DDA-07E0-7758-E053-F662850A2630","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Leukemia","valueDescription":"Leukemia","ValueMeaning":{"publicId":"3179697","version":"1","preferredName":"Leukemia","longName":"3179697","preferredDefinition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood.  Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present.  Leukemia is usually associated with anemia, fever, hemorrhagic episodes and splenomegaly.  Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia.  Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leukemia","conceptCode":"C3161","definition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"98F258D4-9F60-3E56-E040-BB89AD436715","latestVersionIndicator":"Yes","beginDate":"2011-01-03","endDate":null,"createdBy":"SHIDED","dateCreated":"2011-01-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8BAD903C-9D46-6283-E053-F662850A5DDE","beginDate":"2019-06-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-19","modifiedBy":"ONEDATA","dateModified":"2019-06-19","deletedIndicator":"No"},{"value":"Osteosarcoma","valueDescription":"Osteosarcoma","ValueMeaning":{"publicId":"2573004","version":"1","preferredName":"Osteosarcoma","longName":"2573004","preferredDefinition":"A usually aggressive malignant bone-forming mesenchymal neoplasm, predominantly affecting adolescents and young adults. It usually involves bones and less frequently extraosseous sites. It often involves the long bones (particularly distal femur, proximal tibia, and proximal humerus). Pain with or without a palpable mass is the most frequent clinical symptom. It may spread to other anatomic sites, particularly the lungs.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Osteosarcoma","conceptCode":"C9145","definition":"A usually aggressive malignant bone-forming mesenchymal neoplasm, predominantly affecting adolescents and young adults. It usually involves bones and less frequently extraosseous sites. It often involves the long bones (particularly distal femur, proximal tibia, and proximal humerus). Pain with or without a palpable mass is the most frequent clinical symptom. It may spread to other anatomic sites, particularly the lungs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EA39-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"COOPERM","dateModified":"2019-04-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E97F2C6-61F5-72AB-E053-F662850AEE3A","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Oropharyngeal Carcinoma","valueDescription":"Oropharyngeal Carcinoma","ValueMeaning":{"publicId":"2683233","version":"1","preferredName":"Oropharyngeal Carcinoma","longName":"2683233","preferredDefinition":"Carcinoma, predominantly squamous cell, arising from epithelial cells of the oropharynx. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oropharyngeal Carcinoma","conceptCode":"C9105","definition":"Carcinoma, predominantly squamous cell, arising from the epithelial cells of the oropharynx.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A83FCB0-9D0F-2594-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-19","endDate":null,"createdBy":"JOSHUAT","dateCreated":"2007-09-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E97F2C6-620B-72AB-E053-F662850AEE3A","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Orbital Melanoma","valueDescription":"Orbital Melanoma","ValueMeaning":{"publicId":"6832298","version":"1","preferredName":"Orbital Melanoma","longName":"6832298","preferredDefinition":"A melanoma that arises from the structures of the orbit.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Orbital Melanoma","conceptCode":"C118828","definition":"A melanoma that arises from the structures of the orbit.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E97F2C6-6219-72AB-E053-F662850AEE3A","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E97F2C6-6232-72AB-E053-F662850AEE3A","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Oral Cavity Carcinoma","valueDescription":"Oral Cavity Carcinoma","ValueMeaning":{"publicId":"3813823","version":"1","preferredName":"Oral Cavity Carcinoma","longName":"3813823","preferredDefinition":"Cancer that forms in tissues of the oral cavity (the mouth). The tissues of the oral cavity include the lips, the lining inside the cheeks and lips, the front two thirds of the tongue, the upper and lower gums, the floor of the mouth under the tongue, the bony roof of the mouth, and the small area behind the wisdom teeth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oral Cavity Carcinoma","conceptCode":"C8990","definition":"A carcinoma arising in the oral cavity.  Most oral cavity carcinomas are squamous cell carcinomas of the tongue, buccal mucosa, or gums.  Less frequent morphologic variants include mucoepidermoid carcinoma and adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E2346CC1-C211-646B-E040-BB89AD434597","latestVersionIndicator":"Yes","beginDate":"2013-07-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2013-07-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E97F2C6-6247-72AB-E053-F662850AEE3A","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Ocular Melanoma","valueDescription":"Ocular Melanoma","ValueMeaning":{"publicId":"6832300","version":"1","preferredName":"Ocular Melanoma","longName":"6832300","preferredDefinition":"A melanoma that arises from the structures of the eye or ocular adnexa.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ocular Melanoma","conceptCode":"C8562","definition":"A melanoma that arises from the structures of the eye or ocular adnexa.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E97F2C6-6255-72AB-E053-F662850AEE3A","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"GDEEN","dateModified":"2023-06-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E97F2C6-626E-72AB-E053-F662850AEE3A","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Non-Small Cell Carcinoma","valueDescription":"Non-Small Cell Carcinoma","ValueMeaning":{"publicId":"2837836","version":"1","preferredName":"Non-Small Cell Carcinoma","longName":"2837836","preferredDefinition":"A malignant epithelial neoplasm characterized by the absence of neoplastic small epithelial cells. A representative example is the lung non-small cell carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Non-Small Cell Carcinoma","conceptCode":"C65151","definition":"A malignant epithelial neoplasm characterized by the absence of neoplastic small epithelial cells. A representative example is the lung non-small cell carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6281C75A-488E-A127-E040-BB89AD431A41","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E97F2C6-6282-72AB-E053-F662850AEE3A","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Non-Hodgkin Lymphoma","valueDescription":"Non-Hodgkin Lymphoma","ValueMeaning":{"publicId":"2573076","version":"1","preferredName":"Non-Hodgkin Lymphoma","longName":"2573076","preferredDefinition":"Distinct from Hodgkin lymphoma both morphologically and biologically, non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Non-Hodgkin Lymphoma","conceptCode":"C3211","definition":"Distinct from Hodgkin lymphoma both morphologically and biologically, non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EA81-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-09","endDate":null,"createdBy":"KLINGERK","dateCreated":"2005-02-04","modifiedBy":"PWEST","dateModified":"2014-05-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E97F2C6-628C-72AB-E053-F662850AEE3A","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Non-Cutaneous Melanoma","valueDescription":"Non-Cutaneous Melanoma","ValueMeaning":{"publicId":"6832302","version":"1","preferredName":"Non-Cutaneous Melanoma","longName":"6832302","preferredDefinition":"Melanoma is a malignant tumor of melanocytes, cells that are derived from the neural crest. Although most melanomas arise in the skin, they also may arise from mucosal surfaces or at other sites to which neural crest cells migrate. (PDQ)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Non-Cutaneous Melanoma","conceptCode":"C8711","definition":"A melanoma that arises from a site other than skin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E97F2C6-6299-72AB-E053-F662850AEE3A","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E97F2C6-62B2-72AB-E053-F662850AEE3A","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Solitary Fibrous Tumor","valueDescription":"Malignant Solitary Fibrous Tumor","ValueMeaning":{"publicId":"3123919","version":"1","preferredName":"Malignant Solitary Fibrous Tumor","longName":"3123919","preferredDefinition":"A malignant neoplasm of probable fibroblastic derivation. It is characterized by the presence of atypical round to spindle-shaped cells, increased cellularity, necrotic change and high mitotic activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Solitary Fibrous Tumor","conceptCode":"C6894","definition":"A malignant neoplasm of probable fibroblastic derivation. It is characterized by the presence of atypical round to spindle-shaped cells, increased cellularity, necrotic change and high mitotic activity.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BD13A85-447B-7057-E040-BB89AD4314E1","latestVersionIndicator":"Yes","beginDate":"2010-07-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED57FE4-73BF-297C-E053-F662850AE546","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Spermatic Cord Neoplasm","valueDescription":"Malignant Spermatic Cord Neoplasm","ValueMeaning":{"publicId":"6835281","version":"1","preferredName":"Malignant Spermatic Cord Neoplasm","longName":"6835281","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the spermatic cord.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Spermatic Cord Neoplasm","conceptCode":"C3559","definition":"A primary or metastatic malignant neoplasm that affects the spermatic cord.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED57FE4-73CD-297C-E053-F662850AE546","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED57FE4-73E6-297C-E053-F662850AE546","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Sphenoid Sinus Neoplasm","valueDescription":"Malignant Sphenoid Sinus Neoplasm","ValueMeaning":{"publicId":"6835283","version":"1","preferredName":"Malignant Sphenoid Sinus Neoplasm","longName":"6835283","preferredDefinition":"A primary or metastatic malignant neoplasm involving the sphenoid sinus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Sphenoid Sinus Neoplasm","conceptCode":"C3543","definition":"A primary or metastatic malignant neoplasm involving the sphenoid sinus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED57FE4-73F3-297C-E053-F662850AE546","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED57FE4-740C-297C-E053-F662850AE546","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Spinal Cord Neoplasm","valueDescription":"Malignant Spinal Cord Neoplasm","ValueMeaning":{"publicId":"6835285","version":"1","preferredName":"Malignant Spinal Cord Neoplasm","longName":"6835285","preferredDefinition":"A primary or metastatic malignant neoplasm affecting the spinal cord.  Representative examples include lymphoma, melanoma, and sarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Spinal Cord Neoplasm","conceptCode":"C3572","definition":"A primary or metastatic malignant neoplasm affecting the spinal cord.  Representative examples include lymphoma, melanoma, and sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED57FE4-7419-297C-E053-F662850AE546","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED57FE4-7432-297C-E053-F662850AE546","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Splenic Neoplasm","valueDescription":"Malignant Splenic Neoplasm","ValueMeaning":{"publicId":"3210713","version":"1","preferredName":"Malignant Splenic Neoplasm","longName":"3210713","preferredDefinition":"A malignant neoplasm affecting the spleen. Representative examples include leukemias, lymphomas, and sarcomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Splenic Neoplasm","conceptCode":"C3539","definition":"A malignant neoplasm affecting the spleen. Representative examples include leukemias, lymphomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-92AE-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED57FE4-743C-297C-E053-F662850AE546","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Subglottis Neoplasm","valueDescription":"Malignant Subglottis Neoplasm","ValueMeaning":{"publicId":"6835287","version":"1","preferredName":"Malignant Subglottis Neoplasm","longName":"6835287","preferredDefinition":"A malignant neoplasm that affects the subglottic area of the larynx.  The vast majority of cases are squamous cell carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Subglottis Neoplasm","conceptCode":"C3546","definition":"A malignant neoplasm that affects the subglottic area of the larynx.  The vast majority of cases are squamous cell carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED57FE4-744A-297C-E053-F662850AE546","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED57FE4-7463-297C-E053-F662850AE546","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Sublingual Gland Neoplasm","valueDescription":"Malignant Sublingual Gland Neoplasm","ValueMeaning":{"publicId":"6835289","version":"1","preferredName":"Malignant Sublingual Gland Neoplasm","longName":"6835289","preferredDefinition":"A rare malignant neoplasm that arises from the sublingual gland.  The majority are carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Sublingual Gland Neoplasm","conceptCode":"C3527","definition":"A rare malignant neoplasm that arises from the sublingual gland.  The majority are carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED57FE4-7470-297C-E053-F662850AE546","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED57FE4-7489-297C-E053-F662850AE546","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Submandibular Gland Neoplasm","valueDescription":"Malignant Submandibular Gland Neoplasm","ValueMeaning":{"publicId":"6835291","version":"1","preferredName":"Malignant Submandibular Gland Neoplasm","longName":"6835291","preferredDefinition":"A malignant neoplasm that arises from the submandibular gland.  The majority are carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Submandibular Gland Neoplasm","conceptCode":"C3526","definition":"A malignant neoplasm that arises from the submandibular gland.  The majority are carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED57FE4-7496-297C-E053-F662850AE546","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED57FE4-74AF-297C-E053-F662850AE546","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Nodular Sclerosis Classic Hodgkin Lymphoma","valueDescription":"Nodular Sclerosis Classical Hodgkin Lymphoma","ValueMeaning":{"publicId":"4973639","version":"1","preferredName":"Nodular Sclerosis Classical Hodgkin Lymphoma","longName":"4973639","preferredDefinition":"A subtype of classical Hodgkin lymphoma characterized by collagen bands that surround at least one nodule, and Hodgkin and Reed-Sternberg cells with lacunar type morphology. (WHO, 2008)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nodular Sclerosis Classic Hodgkin Lymphoma","conceptCode":"C3518","definition":"A subtype of classic Hodgkin lymphoma characterized by collagen bands that surround at least one nodule, and Hodgkin and Reed-Sternberg cells with lacunar type morphology. (WHO, 2008)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1D88C8D5-A86A-472E-E050-BB89AD434958","latestVersionIndicator":"Yes","beginDate":"2015-08-17","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E97F2C6-62C6-72AB-E053-F662850AEE3A","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Pharyngeal Carcinoma","valueDescription":"Pharyngeal Carcinoma","ValueMeaning":{"publicId":"6832320","version":"1","preferredName":"Pharyngeal Carcinoma","longName":"6832320","preferredDefinition":"Carcinoma, predominantly squamous cell, arising from the epithelial cells of the pharynx.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pharyngeal Carcinoma","conceptCode":"C9466","definition":"Carcinoma, predominantly squamous cell, arising from the epithelial cells of the pharynx.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E98BD11-EA73-319D-E053-F662850A9BD2","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E98BD11-EA8E-319D-E053-F662850A9BD2","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Laryngeal Carcinoma","valueDescription":"Laryngeal Carcinoma","ValueMeaning":{"publicId":"3813819","version":"1","preferredName":"Laryngeal Carcinoma","longName":"3813819","preferredDefinition":"Carcinoma that arises from the laryngeal epithelium. More than 90% of laryngeal carcinomas are squamous cell carcinomas. The remainder are adenoid cystic carcinomas, mucoepidermoid carcinomas and carcinomas with neuroendocrine differentiation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Laryngeal Carcinoma","conceptCode":"C4855","definition":"Carcinoma that arises from the laryngeal epithelium. More than 90% of laryngeal carcinomas are squamous cell carcinomas. The remainder are adenoid cystic carcinomas, mucoepidermoid carcinomas and carcinomas with neuroendocrine differentiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E2346CC1-C1AB-646B-E040-BB89AD434597","latestVersionIndicator":"Yes","beginDate":"2013-07-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2013-07-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AFFB0-8677-7955-E053-F662850AF56F","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Large Cell Carcinoma","valueDescription":"Large Cell Carcinoma","ValueMeaning":{"publicId":"4264919","version":"1","preferredName":"Large Cell Carcinoma","longName":"4264919","preferredDefinition":"A malignant epithelial neoplasm composed of large, atypical cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Large Cell Carcinoma","conceptCode":"C3780","definition":"A malignant epithelial neoplasm composed of large, atypical cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67FEA17-6068-3E0B-E040-BB89AD4363B5","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AFFB0-868C-7955-E053-F662850AF56F","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Langerhans Cell Sarcoma","valueDescription":"Langerhans Cell Sarcoma","ValueMeaning":{"publicId":"2838587","version":"1","preferredName":"Langerhans Cell Sarcoma","longName":"2838587","preferredDefinition":"A neoplastic proliferation of Langerhans cells with overtly malignant cytologic features.  It can be considered a higher grade variant of Langerhans cell histiocytosis (LCH) and it can present de novo or progress from antecedent LCH. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Langerhans Cell Sarcoma","conceptCode":"C6921","definition":"A neoplastic proliferation of Langerhans cells with overtly malignant cytologic features.  It can be considered a higher grade variant of Langerhans cell histiocytosis (LCH) and it can present de novo or progress from antecedent LCH. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A5F1C9-F6B4-B082-E040-BB89AD436154","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AFFB0-8696-7955-E053-F662850AF56F","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Kidney Carcinoma","valueDescription":"Kidney Carcinoma","ValueMeaning":{"publicId":"5581334","version":"1","preferredName":"Kidney Carcinoma","longName":"5581334","preferredDefinition":"A carcinoma arising from the epithelium of the renal parenchyma or the renal pelvis.  The majority are renal cell carcinomas.  Kidney carcinomas usually affect middle aged and elderly adults.  Hematuria, abdominal pain, and a palpable mass are common symptoms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Kidney Carcinoma","conceptCode":"C9384","definition":"A carcinoma arising from the epithelium of the renal parenchyma or the renal pelvis.  The majority are renal cell carcinomas.  Kidney carcinomas usually affect middle aged and elderly adults.  Hematuria, abdominal pain, and a palpable mass are common symptoms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42019733-B77F-634F-E053-F662850A5A61","latestVersionIndicator":"Yes","beginDate":"2016-11-23","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2016-11-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AFFB0-86AD-7955-E053-F662850AF56F","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Kaposi Sarcoma","valueDescription":"Kaposi Sarcoma","ValueMeaning":{"publicId":"3251916","version":"1","preferredName":"Kaposi Sarcoma","longName":"3251916","preferredDefinition":"A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin however, it may also occur internally.  It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Kaposi Sarcoma","conceptCode":"C9087","definition":"A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin; however it may also occur internally. It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A77CE4DC-24A0-EFB7-E040-BB89AD430FFC","latestVersionIndicator":"Yes","beginDate":"2011-07-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-07","modifiedBy":"TSESU","dateModified":"2023-01-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AFFB0-86B8-7955-E053-F662850AF56F","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Juvenile Myelomonocytic Leukemia","valueDescription":"Juvenile Myelomonocytic Leukemia","ValueMeaning":{"publicId":"2838584","version":"1","preferredName":"Juvenile Myelomonocytic Leukemia","longName":"2838584","preferredDefinition":"A myelodysplastic/myeloproliferative disease of childhood that is characterized by proliferation principally of the granulocytic and monocytic lineages.  Myelomonocytic proliferation is seen in the bone marrow and the blood.  The leukemic cells may infiltrate any tissue, however liver, spleen, lymph nodes, skin, and respiratory tract are the most common sites of involvement.  The prognosis is usually poor.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Juvenile Myelomonocytic Leukemia","conceptCode":"C9233","definition":"A clonal myeloid disorder of childhood previously classified as myelodysplastic/myeloproliferative neoplasm. It is characterized by the presence of monocytic proliferation in peripheral blood, less than 20% blasts in bone marrow and peripheral blood, splenomegaly, and the absence of BCR-ABL1 fusion. Almost all patients carry mutations of the RAS pathway.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A51A25-5942-CA49-E040-BB89AD435D3A","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"KUMMEROA","dateModified":"2023-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AFFB0-86C3-7955-E053-F662850AF56F","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Invasive Malignant Neoplasm","valueDescription":"Invasive Malignant Neoplasm","ValueMeaning":{"publicId":"5627939","version":"1","preferredName":"Invasive Malignant Neoplasm","longName":"5627939","preferredDefinition":"Cancer that has spread beyond the layer of tissue in which it developed and is growing into surrounding, healthy tissues.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Invasive Malignant Neoplasm","conceptCode":"C8505","definition":"Cancer that has spread beyond the layer of tissue in which it developed and is growing into surrounding, healthy tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45FDE7CF-F17A-6146-E053-F662850A5EA6","latestVersionIndicator":"Yes","beginDate":"2017-01-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-01-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AFFB0-86D7-7955-E053-F662850AF56F","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Invasive Carcinoma","valueDescription":"Invasive Carcinoma","ValueMeaning":{"publicId":"2947204","version":"1","preferredName":"Invasive Carcinoma","longName":"2947204","preferredDefinition":"A carcinoma that is not confined to the epithelium, and has spread to the surrounding stroma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Invasive Carcinoma","conceptCode":"C9480","definition":"A carcinoma that is not confined to the epithelium, and has spread to the surrounding stroma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"74B8CCF7-601E-8C1B-E040-BB89AD430406","latestVersionIndicator":"Yes","beginDate":"2009-09-29","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-09-29","modifiedBy":"ONEDATA","dateModified":"2009-09-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AFFB0-86E2-7955-E053-F662850AF56F","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Intrahepatic Cholangiocarcinoma","valueDescription":"Intrahepatic Cholangiocarcinoma","ValueMeaning":{"publicId":"3248570","version":"1","preferredName":"Intrahepatic Cholangiocarcinoma","longName":"3248570","preferredDefinition":"A carcinoma that arises from the intrahepatic bile duct epithelium in any site of the intrahepatic biliary tree.  Grossly, the malignant lesions are solid, nodular, and grayish.  Morphologically, the vast majority of cases are adenocarcinomas.  Signs and symptoms include malaise, weight loss, right upper quadrant abdominal pain, and night sweats.  Early detection is difficult and the prognosis is generally poor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intrahepatic Cholangiocarcinoma","conceptCode":"C35417","definition":"A carcinoma that arises from the intrahepatic bile duct epithelium in any site of the intrahepatic biliary tree.  Grossly, the malignant lesions are solid, nodular, and grayish.  Morphologically, the vast majority of cases are adenocarcinomas.  Signs and symptoms include malaise, weight loss, right upper quadrant abdominal pain, and night sweats.  Early detection is difficult and the prognosis is generally poor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6BBE041-BE25-9503-E040-BB89AD435A00","latestVersionIndicator":"Yes","beginDate":"2011-06-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-27","modifiedBy":"COOPERM","dateModified":"2018-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AFFB0-86ED-7955-E053-F662850AF56F","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Interdigitating Dendritic Cell Sarcoma","valueDescription":"Interdigitating Dendritic Cell Sarcoma/Tumor","ValueMeaning":{"publicId":"2838586","version":"1","preferredName":"Interdigitating Dendritic Cell Sarcoma/Tumor","longName":"2838586","preferredDefinition":"A neoplastic proliferation of spindle to ovoid cells which show phenotypic features similar to those of interdigitating dendritic cells.  The clinical course is variable ranging from benign localized disease to widespread lethal disease. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interdigitating Dendritic Cell Sarcoma","conceptCode":"C9282","definition":"A neoplastic proliferation of spindle to ovoid cells which show phenotypic features similar to those of interdigitating dendritic cells.  The clinical course is generally aggressive. (WHO, 2008)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A51A25-59A7-CA49-E040-BB89AD435D3A","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AFFB0-8702-7955-E053-F662850AF56F","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Infratentorial Neoplasm","valueDescription":"Infratentorial Neoplasm","ValueMeaning":{"publicId":"6832609","version":"1","preferredName":"Infratentorial Neoplasm","longName":"6832609","preferredDefinition":"A benign or malignant neoplasm that occurs in brain parenchymal tissue below the tentorium cerebelli.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Infratentorial Neoplasm","conceptCode":"C3139","definition":"A benign or malignant neoplasm that occurs in brain parenchymal tissue below the tentorium cerebelli.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AFFB0-870F-7955-E053-F662850AF56F","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AFFB0-8728-7955-E053-F662850AF56F","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Immunodeficiency-Related Malignant Neoplasm","valueDescription":"Immunodeficiency-Related Malignant Neoplasm","ValueMeaning":{"publicId":"6832611","version":"1","preferredName":"Immunodeficiency-Related Malignant Neoplasm","longName":"6832611","preferredDefinition":"Malignant neoplasm occurring in immunodeficient patients.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immunodeficiency-Related Malignant Neoplasm","conceptCode":"C27770","definition":"Malignant neoplasm occurring in immunodeficient patients.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AFFB0-8735-7955-E053-F662850AF56F","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AFFB0-874E-7955-E053-F662850AF56F","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Ileal Neuroendocrine Tumor G1","valueDescription":"Ileal Neuroendocrine Tumor G1","ValueMeaning":{"publicId":"6832613","version":"1","preferredName":"Ileal Neuroendocrine Tumor G1","longName":"6832613","preferredDefinition":"A well differentiated, low grade neuroendocrine tumor (carcinoid tumor) that arises from the ileum.  The mitotic count is less than 2 per 10 HPF and/or the Ki67 index is equal to or less than 2 percent.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ileal Neuroendocrine Tumor G1","conceptCode":"C4935","definition":"A well differentiated, low grade neuroendocrine neoplasm that arises from the ileum. The mitotic count is less than 2 per 10 HPF and/or the Ki67 index is equal to or less than 2 percent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AFFB0-875B-7955-E053-F662850AF56F","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AFFB0-8774-7955-E053-F662850AF56F","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Hypopharyngeal Carcinoma","valueDescription":"Hypopharyngeal Carcinoma","ValueMeaning":{"publicId":"6832615","version":"1","preferredName":"Hypopharyngeal Carcinoma","longName":"6832615","preferredDefinition":"Carcinoma, predominantly squamous cell, arising from the epithelial cells of the hypopharynx.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hypopharyngeal Carcinoma","conceptCode":"C9465","definition":"Carcinoma, predominantly squamous cell, arising from the epithelial cells of the hypopharynx.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9AFFB0-8781-7955-E053-F662850AF56F","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AFFB0-879A-7955-E053-F662850AF56F","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Hodgkin Lymphoma","valueDescription":"Hodgkin Lymphoma","ValueMeaning":{"publicId":"4981811","version":"1","preferredName":"Hodgkin Lymphoma","longName":"4981811","preferredDefinition":"A lymphoma, previously known as Hodgkin's disease, characterized by the presence of large tumor cells in an abundant admixture of nonneoplastic cells. There are two distinct subtypes: nodular lymphocyte predominant Hodgkin lymphoma and classical Hodgkin lymphoma. Hodgkin lymphoma involves primarily lymph nodes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hodgkin Lymphoma","conceptCode":"C9357","definition":"A lymphoma characterized by the presence of relatively few malignant cells called Reed-Sternberg cells and mononuclear Hodgkin cells that are admixed with nonneoplastic inflammatory cells. The malignant cells have a distinctive immunophenotype; they are positive for CD30 and CD15 and negative for CD3, CD20, and CD45.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1E139787-9898-E8CC-E050-BB89AD435F1A","latestVersionIndicator":"Yes","beginDate":"2015-08-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-08-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AFFB0-87A5-7955-E053-F662850AF56F","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Histiocytic Sarcoma","valueDescription":"Histiocytic Sarcoma","ValueMeaning":{"publicId":"2864914","version":"1","preferredName":"Histiocytic Sarcoma","longName":"2864914","preferredDefinition":"An aggressive malignant neoplasm with a poor response to therapy, usually presenting as stage III/IV disease.  It is characterized by the presence of neoplastic cells with morphologic and immunophenotypic characteristics similar to those seen in mature histiocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Histiocytic Sarcoma","conceptCode":"C27349","definition":"An aggressive malignant neoplasm with a poor response to therapy, usually presenting as stage III/IV disease. It is characterized by the presence of neoplastic cells with morphologic and immunophenotypic characteristics similar to those seen in mature histiocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"689FD4E4-A1CC-9A6F-E040-BB89AD432DE8","latestVersionIndicator":"Yes","beginDate":"2009-04-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-28","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AFFB0-87AF-7955-E053-F662850AF56F","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Histiocytic and Dendritic Cell Neoplasm","valueDescription":"Histiocytic and Dendritic Cell Neoplasm","ValueMeaning":{"publicId":"3342947","version":"1","preferredName":"Histiocytic and Dendritic Cell Neoplasm","longName":"3342947","preferredDefinition":"Rare tumors that affect the hematopoietic and lymphoid tissues. The cells of origin are the histiocytes and accessory cells. They can occur at any age and show no significant variations in geographical distribution. This category includes the histiocytic sarcoma, Langerhans cell histiocytosis, Langerhans cell sarcoma, interdigitading dendritic cell sarcoma/tumor, follicular dendritic cell sarcoma/tumor, and dendritic cell sarcoma, not otherwise specified. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Histiocytic and Dendritic Cell Neoplasm","conceptCode":"C9294","definition":"A group of rare tumors that affect the hematopoietic and lymphoid tissues. The cells of origin are the histiocytes and accessory cells. This category includes the following: Langerhans cell histiocytosis, Langerhans cell sarcoma, indeterminate dendritic cell histiocytosis, interdigitating dendritic cell sarcoma, histiocytic sarcoma, disseminated juvenile xanthogranuloma, Erdheim-Chester disease, Rosai-Dorfman-Destombes disease, ALK-positive histiocytosis, and follicular dendritic cell sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B5B5F005-1926-E32B-E040-BB89AD4307AD","latestVersionIndicator":"Yes","beginDate":"2012-01-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-01-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9AFFB0-87C4-7955-E053-F662850AF56F","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Ureter Carcinoma","valueDescription":"Ureter Carcinoma","ValueMeaning":{"publicId":"6832730","version":"1","preferredName":"Ureter Carcinoma","longName":"6832730","preferredDefinition":"A carcinoma of the ureter.  The majority of ureter carcinomas are transitional cell and less frequently squamous cell carcinomas or adenocarcinomas.  --2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ureter Carcinoma","conceptCode":"C8993","definition":"A carcinoma of the ureter.  The majority of ureter carcinomas are transitional cell and less frequently squamous cell carcinomas or adenocarcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B4286-FD57-027B-E053-F662850A2528","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B4286-FD70-027B-E053-F662850A2528","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Unresectable Sarcoma","valueDescription":"Unresectable Sarcoma","ValueMeaning":{"publicId":"6832732","version":"1","preferredName":"Unresectable Sarcoma","longName":"6832732","preferredDefinition":"A sarcoma which is not amenable to surgical resection.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unresectable Sarcoma","conceptCode":"C148331","definition":"A sarcoma which is not amenable to surgical resection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B4286-FD7D-027B-E053-F662850A2528","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B4286-FD96-027B-E053-F662850A2528","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Unresectable Melanoma","valueDescription":"Unresectable Melanoma","ValueMeaning":{"publicId":"6832734","version":"1","preferredName":"Unresectable Melanoma","longName":"6832734","preferredDefinition":"Melanoma which is not amenable to surgical resection.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unresectable Melanoma","conceptCode":"C148517","definition":"Melanoma which is not amenable to surgical resection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B4286-FDA3-027B-E053-F662850A2528","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B4286-FDBC-027B-E053-F662850A2528","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Unresectable Malignant Neoplasm","valueDescription":"Unresectable Malignant Neoplasm","ValueMeaning":{"publicId":"6832736","version":"1","preferredName":"Unresectable Malignant Neoplasm","longName":"6832736","preferredDefinition":"A malignant neoplasm which is not amenable to surgical resection.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unresectable Malignant Neoplasm","conceptCode":"C27359","definition":"A malignant neoplasm which is not amenable to surgical resection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B4286-FDC9-027B-E053-F662850A2528","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B4286-FDE2-027B-E053-F662850A2528","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Unresectable Carcinoma","valueDescription":"Unresectable Carcinoma","ValueMeaning":{"publicId":"6832738","version":"1","preferredName":"Unresectable Carcinoma","longName":"6832738","preferredDefinition":"Carcinoma that is not amenable to surgical resection.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unresectable Carcinoma","conceptCode":"C148124","definition":"Carcinoma that is not amenable to surgical resection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B4286-FDEF-027B-E053-F662850A2528","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B4286-FE08-027B-E053-F662850A2528","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Undifferentiated Carcinoma","valueDescription":"Undifferentiated Carcinoma","ValueMeaning":{"publicId":"2838871","version":"1","preferredName":"Undifferentiated Carcinoma","longName":"2838871","preferredDefinition":"A usually aggressive malignant epithelial neoplasm composed of atypical cells which do not display evidence of glandular, squamous, or transitional cell differentiation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Undifferentiated Carcinoma","conceptCode":"C3692","definition":"A usually aggressive malignant epithelial neoplasm composed of atypical cells which do not display evidence of glandular, squamous, or transitional cell differentiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A9E389-5897-FD59-E040-BB89AD432A90","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B4286-FE12-027B-E053-F662850A2528","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Trophoblastic Tumor","valueDescription":"Trophoblastic Tumor","ValueMeaning":{"publicId":"3211502","version":"1","preferredName":"Trophoblastic Tumor","longName":"3211502","preferredDefinition":"A gestational or non-gestational neoplasm composed of neoplastic trophoblastic cells. Representative examples include hydatidiform mole and choriocarcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trophoblastic Tumor","conceptCode":"C3422","definition":"A gestational or non-gestational neoplasm characterized by excessive proliferation of trophoblastic cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0753-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B4286-FE1D-027B-E053-F662850A2528","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Transplant-Related Carcinoma","valueDescription":"Transplant-Related Carcinoma","ValueMeaning":{"publicId":"6832740","version":"1","preferredName":"Transplant-Related Carcinoma","longName":"6832740","preferredDefinition":"A carcinoma that arises in a patient with a history of organ transplantation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Transplant-Related Carcinoma","conceptCode":"C27633","definition":"A carcinoma that arises in a patient with a history of organ transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B4286-FE2B-027B-E053-F662850A2528","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B4286-FE44-027B-E053-F662850A2528","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Transitional Cell Carcinoma","valueDescription":"Transitional Cell Carcinoma","ValueMeaning":{"publicId":"4264983","version":"1","preferredName":"Transitional Cell Carcinoma","longName":"4264983","preferredDefinition":"A malignant neoplasm arising from the transitional epithelium, usually affecting the urinary bladder, ureter, or renal pelvis. It may or may not have a papillary configuration. It is graded 1 to 3 or 4 according to the degree of cellular differentiation and architectural patterns. Grade 1 transitional cell carcinoma is histologically benign but it may recur. Transitional cell carcinomas may also affect the upper respiratory tract and the ovaries.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Transitional Cell Carcinoma","conceptCode":"C2930","definition":"A malignant neoplasm arising from the transitional epithelium, usually affecting the urinary bladder, ureter, or renal pelvis. It may or may not have a papillary configuration. It is graded 1 to 3 or 4 according to the degree of cellular differentiation and architectural patterns. Grade 1 transitional cell carcinoma is histologically benign but it may recur. Transitional cell carcinomas may also affect the upper respiratory tract and the ovaries.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3DD2-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B4286-FE58-027B-E053-F662850A2528","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Tracheal Carcinoma In Situ","valueDescription":"Tracheal Carcinoma In Situ","ValueMeaning":{"publicId":"6832742","version":"1","preferredName":"Tracheal Carcinoma In Situ","longName":"6832742","preferredDefinition":"A carcinoma that arises from the tracheal mucosa and is confined to the epithelial layer without evidence of further tissue invasion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tracheal Carcinoma In Situ","conceptCode":"C3639","definition":"A carcinoma that arises from the tracheal mucosa and is confined to the epithelial layer without evidence of further tissue invasion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B4286-FE65-027B-E053-F662850A2528","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B4286-FE7E-027B-E053-F662850A2528","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Thyroid Gland Neoplasm","valueDescription":"Thyroid Gland Neoplasm","ValueMeaning":{"publicId":"6832744","version":"1","preferredName":"Thyroid Gland Neoplasm","longName":"6832744","preferredDefinition":"A benign or malignant neoplasm affecting the thyroid gland.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thyroid Gland Neoplasm","conceptCode":"C3414","definition":"A benign or malignant neoplasm affecting the thyroid gland.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B4286-FE8B-027B-E053-F662850A2528","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B4286-FEA4-027B-E053-F662850A2528","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Localized Carcinoma","valueDescription":"Localized Carcinoma","ValueMeaning":{"publicId":"6815888","version":"1","preferredName":"Localized Carcinoma","longName":"6815888","preferredDefinition":"A carcinoma which is confined to a specific anatomic site and has not spread to other sites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Localized Carcinoma","conceptCode":"C7625","definition":"A carcinoma that is confined to a specific site without evidence of spread to other anatomic sites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8D597F0F-CE43-5781-E053-F662850A0196","latestVersionIndicator":"Yes","beginDate":"2019-07-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-07-10","modifiedBy":"ONEDATA","dateModified":"2019-07-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B6FB8-F6BD-081C-E053-F662850AA0FF","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Localized Lymphoma","valueDescription":"Localized Lymphoma","ValueMeaning":{"publicId":"6832788","version":"1","preferredName":"Localized Lymphoma","longName":"6832788","preferredDefinition":"A lymphoma that has not spread to other anatomic sites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Localized Lymphoma","conceptCode":"C4938","definition":"A lymphoma that is confined to a specific site without evidence of spread to other anatomic sites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B6FB8-F6CB-081C-E053-F662850AA0FF","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B6FB8-F6E4-081C-E053-F662850AA0FF","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Localized Malignant Neoplasm","valueDescription":"Localized Malignant Neoplasm","ValueMeaning":{"publicId":"6832789","version":"1","preferredName":"Localized Malignant Neoplasm","longName":"6832789","preferredDefinition":"A malignant neoplasm which is confined to a specific anatomic site and has not spread to other sites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Localized Malignant Neoplasm","conceptCode":"C8576","definition":"A malignant neoplasm that is confined to a specific site without evidence of spread to other anatomic sites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B6FB8-F6F0-081C-E053-F662850AA0FF","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B6FB8-F709-081C-E053-F662850AA0FF","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Lung Atypical Carcinoid Tumor","valueDescription":"Lung Atypical Carcinoid Tumor","ValueMeaning":{"publicId":"6832790","version":"1","preferredName":"Lung Atypical Carcinoid Tumor","longName":"6832790","preferredDefinition":"A carcinoid tumor of the lung showing focal necrotic changes or a number of mitotic figures between 2 and 10/10 high power fields.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lung Neuroendocrine Tumor G2","conceptCode":"C45551","definition":"A neuroendocrine tumor of the lung showing focal necrotic changes or a number of mitotic figures between 2 and 10/10 high power fields.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B6FB8-F715-081C-E053-F662850AA0FF","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B6FB8-F72E-081C-E053-F662850AA0FF","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Lung Carcinoid Tumor","valueDescription":"Lung Carcinoid Tumor","ValueMeaning":{"publicId":"6832792","version":"1","preferredName":"Lung Carcinoid Tumor","longName":"6832792","preferredDefinition":"A neuroendocrine neoplasm that arises from the lung.  It is characterized by the presence of uniform polygonal cells with small or moderate amount of cytoplasm and inconspicuous nucleoli.  The cells are usually arranged in organoid and trabecular patterns. It is classified as typical or atypical carcinoid tumor based on the number of mitotic figures and the absence or presence of necrosis.  Atypical carcinoid tumors have a worse prognosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lung Neuroendocrine Tumor","conceptCode":"C4038","definition":"A well-differentiated neuroendocrine neoplasm that arises from the lung. It is characterized by the presence of uniform polygonal cells with small or moderate amount of cytoplasm and inconspicuous nucleoli. The cells are usually arranged in organoid and trabecular patterns. It is classified as grade 1 (G1-typical carcinoid tumor) or grade 2 (G2-atypical carcinoid tumor) based on the number of mitotic figures and the absence or presence of necrosis. Grade 2 neuroendocrine tumors have a worse prognosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B6FB8-F73B-081C-E053-F662850AA0FF","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B6FB8-F754-081C-E053-F662850AA0FF","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Lung Carcinoma","valueDescription":"Lung Carcinoma","ValueMeaning":{"publicId":"5581336","version":"1","preferredName":"Lung Carcinoma","longName":"5581336","preferredDefinition":"A carcinoma originating in the lung. Lung carcinomas usually arise from the epithelium that lines the bronchial tree (bronchogenic carcinomas), and are classified as small cell or non-small cell carcinomas. Non-small cell lung carcinomas are usually adenocarcinomas, squamous cell carcinomas, or large cell carcinomas. Metastatic carcinomas to the lung are also common, and can be difficult to distinguish from primary tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lung Carcinoma","conceptCode":"C4878","definition":"A carcinoma originating in the lung. Lung carcinomas usually arise from the epithelium that lines the bronchial tree (bronchogenic carcinomas), and are classified as small cell or non-small cell carcinomas. Non-small cell lung carcinomas are usually adenocarcinomas, squamous cell carcinomas, or large cell carcinomas. Metastatic carcinomas to the lung are also common, and can be difficult to distinguish from primary tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42019733-B7D0-634F-E053-F662850A5A61","latestVersionIndicator":"Yes","beginDate":"2016-11-23","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2016-11-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B6FB8-F768-081C-E053-F662850AA0FF","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Lung Kaposi Sarcoma","valueDescription":"Lung Kaposi Sarcoma","ValueMeaning":{"publicId":"6832793","version":"1","preferredName":"Lung Kaposi Sarcoma","longName":"6832793","preferredDefinition":"A Kaposi sarcoma arising from the lung.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lung Kaposi Sarcoma","conceptCode":"C3551","definition":"A Kaposi sarcoma arising from the lung.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B6FB8-F773-081C-E053-F662850AA0FF","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B6FB8-F78C-081C-E053-F662850AA0FF","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Astrocytoma","valueDescription":"Astrocytoma","ValueMeaning":{"publicId":"5097352","version":"1","preferredName":"Astrocytoma","longName":"5097352","preferredDefinition":"A tumor of the brain or spinal cord showing astrocytic differentiation. It includes the following clinicopathological entities: pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, pleomorphic xanthoastrocytoma, and subependymal giant cell astrocytoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Astrocytoma","conceptCode":"C60781","definition":"A tumor of the brain or spinal cord showing astrocytic differentiation. It includes the following clinicopathological entities: pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, pleomorphic xanthoastrocytoma, and subependymal giant cell astrocytoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28C2EC05-16DF-7D65-E050-BB89AD433691","latestVersionIndicator":"Yes","beginDate":"2016-01-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C2AA54B-58BF-2521-E053-F662850A2D25","beginDate":"2019-06-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-25","modifiedBy":"ONEDATA","dateModified":"2019-06-25","deletedIndicator":"No"},{"value":"Appendix Neuroendocrine Tumor G1","valueDescription":"Appendix Neuroendocrine Tumor G1","ValueMeaning":{"publicId":"6790736","version":"1","preferredName":"Appendix Neuroendocrine Tumor G1","longName":"6790736","preferredDefinition":"A well differentiated, low grade tumor with neuroendocrine differentiation that arises from the appendix.  The mitotic count is less than 2 per 10 HPF and/or the Ki67 index is equal to or less than 2 percent.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Appendix Neuroendocrine Tumor G1","conceptCode":"C4138","definition":"A well differentiated, low grade neoplasm with neuroendocrine differentiation that arises from the appendix. The mitotic count is less than 2 per 10 HPF and/or the Ki67 index is equal to or less than 2 percent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C2AA54B-58CC-2521-E053-F662850A2D25","latestVersionIndicator":"Yes","beginDate":"2019-06-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-25","modifiedBy":"ONEDATA","dateModified":"2019-06-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C2AA54B-58E5-2521-E053-F662850A2D25","beginDate":"2019-06-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-25","modifiedBy":"ONEDATA","dateModified":"2019-06-25","deletedIndicator":"No"},{"value":"Appendix Carcinoma","valueDescription":"Appendix Carcinoma","ValueMeaning":{"publicId":"3210690","version":"1","preferredName":"Appendix Carcinoma","longName":"3210690","preferredDefinition":"A malignant epithelial neoplasm arising from the appendix.  The vast majority of the cases are adenocarcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Appendix Carcinoma","conceptCode":"C9330","definition":"A malignant epithelial neoplasm arising from the appendix.  The vast majority of the cases are adenocarcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-8E98-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C2AA54B-58EF-2521-E053-F662850A2D25","beginDate":"2019-06-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-25","modifiedBy":"ONEDATA","dateModified":"2019-06-25","deletedIndicator":"No"},{"value":"Angiosarcoma","valueDescription":"Angiosarcoma","ValueMeaning":{"publicId":"2568840","version":"1","preferredName":"Angiosarcoma","longName":"2568840","preferredDefinition":"A malignant tumor arising from the endothelial cells of the blood vessels.  Microscopically, it is characterized by frequently open vascular anastomosing and branching channels.  The malignant cells that line the vascular channels are spindle or epithelioid and often display hyperchromatic nuclei.  Angiosarcomas most frequently occur in the skin and breast.  Patients with long-standing lymphedema are at increased risk of developing angiosarcoma. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Angiosarcoma","conceptCode":"C3088","definition":"A malignant tumor arising from the endothelial cells of the blood vessels.  Microscopically, it is characterized by frequently open vascular anastomosing and branching channels.  The malignant cells that line the vascular channels are spindle or epithelioid and often display hyperchromatic nuclei.  Angiosarcomas most frequently occur in the skin and breast.  Patients with long-standing lymphedema are at increased risk of developing angiosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D9F5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-03-29","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-03-29","modifiedBy":"CAMPBELB","dateModified":"2007-02-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C2AA54B-58FA-2521-E053-F662850A2D25","beginDate":"2019-06-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-25","modifiedBy":"ONEDATA","dateModified":"2019-06-25","deletedIndicator":"No"},{"value":"Anaplastic Oligoastrocytoma","valueDescription":"Anaplastic Oligoastrocytoma","ValueMeaning":{"publicId":"3251525","version":"1","preferredName":"Anaplastic Oligoastrocytoma","longName":"3251525","preferredDefinition":"An oligoastrocytoma characterized by the presence of increased cellularity, nuclear atypia, pleomorphism, and high mitotic activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anaplastic Oligoastrocytoma","conceptCode":"C6959","definition":"An oligoastrocytoma characterized by the presence of increased cellularity, nuclear atypia, pleomorphism, and high mitotic activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A766EF05-096F-69EE-E040-BB89AD437928","latestVersionIndicator":"Yes","beginDate":"2011-07-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C2AA54B-5919-2521-E053-F662850A2D25","beginDate":"2019-06-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-25","modifiedBy":"ONEDATA","dateModified":"2019-06-25","deletedIndicator":"No"},{"value":"Anaplastic Malignant Neoplasm","valueDescription":"Anaplastic Malignant Neoplasm","ValueMeaning":{"publicId":"6790738","version":"1","preferredName":"Anaplastic Malignant Neoplasm","longName":"6790738","preferredDefinition":"A malignant neoplasm characterized by the presence of poorly differentiated, often large neoplastic cells with bizarre morphologic characteristics, associated with high mitotic activity and necrotic changes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anaplastic Malignant Neoplasm","conceptCode":"C36025","definition":"A malignant neoplasm characterized by the presence of poorly differentiated, often large neoplastic cells with bizarre morphologic characteristics, associated with high mitotic activity and necrotic changes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C2AA54B-5927-2521-E053-F662850A2D25","latestVersionIndicator":"Yes","beginDate":"2019-06-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-25","modifiedBy":"ONEDATA","dateModified":"2019-06-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C2AA54B-5940-2521-E053-F662850A2D25","beginDate":"2019-06-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-25","modifiedBy":"ONEDATA","dateModified":"2019-06-25","deletedIndicator":"No"},{"value":"Anaplastic Large Cell Lymphoma, ALK-Positive","valueDescription":"Anaplastic Large Cell Lymphoma, ALK-Positive","ValueMeaning":{"publicId":"3928516","version":"1","preferredName":"Anaplastic Large Cell Lymphoma, ALK-Positive","longName":"3928516","preferredDefinition":"A T-cell peripheral lymphoma composed of usually large, pleomorphic, CD30 positive T-lymphocytes with abundant cytoplasm characterized by the presence of a translocation involving the ALK gene and expression of ALK fusion protein.  Most patients present with peripheral and/or abdominal lymphadenopathy, and often have advanced disease and extranodal involvement.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anaplastic Large Cell Lymphoma, ALK-Positive","conceptCode":"C37193","definition":"A T-cell peripheral lymphoma composed of usually large, pleomorphic, CD30 positive T-lymphocytes with abundant cytoplasm. It is characterized by the presence of a translocation involving the ALK gene and expression of ALK fusion protein. Most patients present with peripheral and/or abdominal lymphadenopathy, and often have advanced disease and extranodal involvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E96DEF43-3BCD-7609-E040-BB89AD4366AC","latestVersionIndicator":"Yes","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C2AA54B-5954-2521-E053-F662850A2D25","beginDate":"2019-06-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-25","modifiedBy":"ONEDATA","dateModified":"2019-06-25","deletedIndicator":"No"},{"value":"Anaplastic Large Cell Lymphoma, ALK-Negative","valueDescription":"Anaplastic Large Cell Lymphoma, ALK-Negative","ValueMeaning":{"publicId":"3928514","version":"1","preferredName":"Anaplastic Large Cell Lymphoma, ALK-Negative","longName":"3928514","preferredDefinition":"A T-cell peripheral lymphoma morphologically indistinguishable from anaplastic large cell lymphoma, ALK-positive.  It is characterized by the absence of the translocation involving the ALK gene and lacks expression of ALK fusion protein.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anaplastic Large Cell Lymphoma, ALK-Negative","conceptCode":"C37194","definition":"A T-cell peripheral lymphoma morphologically indistinguishable from anaplastic large cell lymphoma, ALK-positive.  It is characterized by the absence of the translocation involving the ALK gene and lacks expression of ALK fusion protein.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E96DEF43-3BA7-7609-E040-BB89AD4366AC","latestVersionIndicator":"Yes","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C2AA54B-5969-2521-E053-F662850A2D25","beginDate":"2019-06-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-25","modifiedBy":"ONEDATA","dateModified":"2019-06-25","deletedIndicator":"No"},{"value":"Anaplastic Large Cell Lymphoma","valueDescription":"Anaplastic Large Cell Lymphoma","ValueMeaning":{"publicId":"2558222","version":"1","preferredName":"Anaplastic Large Cell Lymphoma","longName":"2558222","preferredDefinition":"A peripheral (mature) T-cell lymphoma, consisting of usually large anaplastic, CD30 positive cells.  Majority of cases are positive for the anaplastic large cell lymphoma (ALK) protein.  The most frequently seen genetic alteration is a t(2;5) translocation.  Majority of patients present with advanced disease.  The most important prognostic indicator is ALK positivity, which has been associated with a favorable prognosis. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anaplastic Large Cell Lymphoma","conceptCode":"C3720","definition":"A peripheral (mature) T-cell lymphoma, consisting of usually large anaplastic, CD30 positive cells. The majority of cases are positive for the anaplastic large cell lymphoma (ALK) protein. The most frequently seen genetic alteration is a t(2;5) translocation. Majority of patients present with advanced disease. The most important prognostic indicator is ALK positivity, which has been associated with a favorable prognosis. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B07B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C2AA54B-5974-2521-E053-F662850A2D25","beginDate":"2019-06-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-25","modifiedBy":"ONEDATA","dateModified":"2019-06-25","deletedIndicator":"No"},{"value":"Anaplastic Ependymoma","valueDescription":"Anaplastic Ependymoma","ValueMeaning":{"publicId":"3249041","version":"1","preferredName":"Anaplastic Ependymoma","longName":"3249041","preferredDefinition":"Anaplastic Ependymoma (WHO grade III) is a malignant glioma of ependymal origin with accelerated growth and an unfavorable clinical outcome, particularly in children. Anaplastic Ependymomas show high mitotic activity, often accompanied by microvascular proliferation and pseudo-palisading necrosis. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anaplastic Ependymoma","conceptCode":"C4049","definition":"A WHO grade 3 malignant glioma of ependymal origin with accelerated growth and an unfavorable clinical outcome, particularly in children. It is characterized by high mitotic activity, often accompanied by microvascular proliferation and pseudo-palisading necrosis. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6CA5E9E-175E-D7DA-E040-BB89AD432E47","latestVersionIndicator":"Yes","beginDate":"2011-06-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C2AA54B-5988-2521-E053-F662850A2D25","beginDate":"2019-06-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-25","modifiedBy":"ONEDATA","dateModified":"2019-06-25","deletedIndicator":"No"},{"value":"Anaplastic Astrocytoma","valueDescription":"Anaplastic astrocytoma","ValueMeaning":{"publicId":"2572930","version":"1","preferredName":"Anaplastic astrocytoma","longName":"2572930","preferredDefinition":"A diffusely infiltrating, WHO grade III astrocytoma with focal or dispersed anaplasia, and a marked proliferative potential. It may arise from a low-grade astrocytoma, but it can also be diagnosed at first biopsy, without indication of a less malignant precursor lesion. It has an intrinsic tendency for malignant progression to glioblastoma. (WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anaplastic Astrocytoma","conceptCode":"C9477","definition":"A diffusely infiltrating, WHO grade 3 astrocytoma with focal or dispersed anaplasia, and a marked proliferative potential. It may arise from a low-grade astrocytoma, but it can also be diagnosed at first biopsy, without indication of a less malignant precursor lesion. It has an intrinsic tendency for malignant progression to glioblastoma. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E9EF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"COOPERM","dateModified":"2017-03-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C2AA54B-5993-2521-E053-F662850A2D25","beginDate":"2019-06-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-25","modifiedBy":"ONEDATA","dateModified":"2019-06-25","deletedIndicator":"No"},{"value":"Malignant Supraglottis Neoplasm","valueDescription":"Malignant Supraglottis Neoplasm","ValueMeaning":{"publicId":"6835293","version":"1","preferredName":"Malignant Supraglottis Neoplasm","longName":"6835293","preferredDefinition":"A malignant neoplasm that affects the supraglottic area of the larynx.  The vast majority of cases are squamous cell carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Supraglottis Neoplasm","conceptCode":"C3545","definition":"A malignant neoplasm that affects the supraglottic area of the larynx.  The vast majority of cases are squamous cell carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED57FE4-74BC-297C-E053-F662850AE546","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED57FE4-74D5-297C-E053-F662850AE546","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Testicular Neoplasm","valueDescription":"Malignant Testicular Neoplasm","ValueMeaning":{"publicId":"5581347","version":"1","preferredName":"Malignant Testicular Neoplasm","longName":"5581347","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the testis.  Representative examples include seminoma, embryonal carcinoma, sarcoma, leukemia, and lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Testicular Neoplasm","conceptCode":"C7251","definition":"A primary or metastatic malignant neoplasm that affects the testis.  Representative examples include seminoma, embryonal carcinoma, sarcoma, leukemia, and lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42019733-B951-634F-E053-F662850A5A61","latestVersionIndicator":"Yes","beginDate":"2016-11-23","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2016-11-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED57FE4-74EB-297C-E053-F662850AE546","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Uterine Corpus Neoplasm","valueDescription":"Malignant Uterine Corpus Neoplasm","ValueMeaning":{"publicId":"6835317","version":"1","preferredName":"Malignant Uterine Corpus Neoplasm","longName":"6835317","preferredDefinition":"A malignant neoplasm that affects the uterine corpus. Representative examples include endometrial carcinoma, carcinosarcoma, leiomyosarcoma, and adenosarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Uterine Corpus Neoplasm","conceptCode":"C3556","definition":"A malignant neoplasm that affects the uterine corpus. Representative examples include endometrial carcinoma, carcinosarcoma, leiomyosarcoma, and adenosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED4B8E8-6153-3184-E053-F662850A89A7","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED4B8E8-616C-3184-E053-F662850A89A7","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Uterine Ligament Neoplasm","valueDescription":"Malignant Uterine Ligament Neoplasm","ValueMeaning":{"publicId":"6835319","version":"1","preferredName":"Malignant Uterine Ligament Neoplasm","longName":"6835319","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the uterine ligament.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Uterine Ligament Neoplasm","conceptCode":"C126498","definition":"A primary or metastatic malignant neoplasm that affects the broad or other uterine ligaments.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED4B8E8-6179-3184-E053-F662850A89A7","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED4B8E8-6192-3184-E053-F662850A89A7","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Uterine Neoplasm","valueDescription":"Malignant Uterine Neoplasm","ValueMeaning":{"publicId":"5581345","version":"1","preferredName":"Malignant Uterine Neoplasm","longName":"5581345","preferredDefinition":"Primary or metastatic malignant neoplasm involving the uterine corpus and/or the cervix.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Uterine Neoplasm","conceptCode":"C3552","definition":"Primary or metastatic malignant neoplasm involving the uterine corpus and/or the cervix.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42019733-B90B-634F-E053-F662850A5A61","latestVersionIndicator":"Yes","beginDate":"2016-11-23","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2016-11-23","modifiedBy":"COOPERM","dateModified":"2019-02-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED4B8E8-61A7-3184-E053-F662850A89A7","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Uvula Neoplasm","valueDescription":"Malignant Uvula Neoplasm","ValueMeaning":{"publicId":"6835321","version":"1","preferredName":"Malignant Uvula Neoplasm","longName":"6835321","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the uvula.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Uvula Neoplasm","conceptCode":"C35177","definition":"A primary or metastatic malignant neoplasm that affects the uvula.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED4B8E8-61B5-3184-E053-F662850A89A7","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED4B8E8-61CE-3184-E053-F662850A89A7","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Vaginal Neoplasm","valueDescription":"Malignant Vaginal Neoplasm","ValueMeaning":{"publicId":"6835322","version":"1","preferredName":"Malignant Vaginal Neoplasm","longName":"6835322","preferredDefinition":"A primary or metastatic malignant neoplasm involving the vagina. Representative examples include carcinomas and sarcomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Vaginal Neoplasm","conceptCode":"C7410","definition":"A primary or metastatic malignant neoplasm involving the vagina. Representative examples include carcinomas and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED4B8E8-61DA-3184-E053-F662850A89A7","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED4B8E8-61F3-3184-E053-F662850A89A7","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Vulvar Neoplasm","valueDescription":"Malignant Vulvar Neoplasm","ValueMeaning":{"publicId":"6835324","version":"1","preferredName":"Malignant Vulvar Neoplasm","longName":"6835324","preferredDefinition":"A primary or metastatic malignant neoplasm involving the vulva.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Vulvar Neoplasm","conceptCode":"C7502","definition":"A primary or metastatic malignant neoplasm involving the vulva.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED4B8E8-6200-3184-E053-F662850A89A7","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED4B8E8-6219-3184-E053-F662850A89A7","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Mantle Cell Lymphoma","valueDescription":"Mantle Cell Lymphoma","ValueMeaning":{"publicId":"2838603","version":"1","preferredName":"Mantle Cell Lymphoma","longName":"2838603","preferredDefinition":"An aggressive, usually diffuse non-Hodgkin lymphoma composed of small to medium sized B-lymphocytes (centrocytes).  Most patients present with advanced stage disease with lymphadenopathy, hepatosplenomegaly, and bone marrow involvement.  The gastrointestinal tract is the most commonly affected extranodal site by this type of non-Hodgkin lymphoma.  The vast majority of cases express the t(11;14)(q13;q32) resulting in the rearrangement of the BCL-1 gene and the overexpression of cyclin D1 mRNA.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mantle Cell Lymphoma","conceptCode":"C4337","definition":"A non-Hodgkin lymphoma composed of small to medium sized B-lymphocytes (centrocytes). Most patients present with advanced stage disease with lymphadenopathy, hepatosplenomegaly, and bone marrow involvement. The gastrointestinal tract is the most commonly affected extranodal site by this type of non-Hodgkin lymphoma. The vast majority of cases express the t(11;14)(q13;q32) resulting in the rearrangement of the BCL-1 gene and the overexpression of cyclin D1 mRNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6485A-AE62-B656-E040-BB89AD437D5F","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"COOPERM","dateModified":"2017-10-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED4B8E8-6223-3184-E053-F662850A89A7","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Marginal Zone Lymphoma","valueDescription":"Marginal Zone Lymphoma","ValueMeaning":{"publicId":"3251331","version":"1","preferredName":"Marginal Zone Lymphoma","longName":"3251331","preferredDefinition":"A usually indolent mature B-cell lymphoma, arising from the marginal zone of lymphoid tissues.  It is characterized by the presence of small to medium sized atypical lymphocytes.  It comprises three entities, according to the anatomic sites involved: extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue, which affects extranodal sites (most often stomach, lung, skin, and ocular adnexa); nodal marginal zone B-cell lymphoma, which affects lymph nodes without evidence of extranodal disease; and splenic marginal zone B-cell lymphoma, which affects the spleen and splenic hilar lymph nodes, bone marrow, and often the peripheral blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Marginal Zone Lymphoma","conceptCode":"C4341","definition":"A usually indolent mature B-cell lymphoma, arising from the marginal zone of lymphoid tissues.  It is characterized by the presence of small to medium sized atypical lymphocytes.  It comprises three entities, according to the anatomic sites involved: extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue, which affects extranodal sites (most often stomach, lung, skin, and ocular adnexa); nodal marginal zone B-cell lymphoma, which affects lymph nodes without evidence of extranodal disease; and splenic marginal zone B-cell lymphoma, which affects the spleen and splenic hilar lymph nodes, bone marrow, and often the peripheral blood.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A758F49E-9C05-73F4-E040-BB89AD430DFE","latestVersionIndicator":"Yes","beginDate":"2011-07-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-05","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED4B8E8-6237-3184-E053-F662850A89A7","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Mast Cell Leukemia","valueDescription":"Mast Cell Leukemia","ValueMeaning":{"publicId":"2590857","version":"1","preferredName":"Mast Cell Leukemia","longName":"2590857","preferredDefinition":"A variant of systemic mastocytosis with involvement of the bone marrow (20% or more mast cells) and the peripheral blood (mast cells account for 10% or more of peripheral blood white cells). (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mast Cell Leukemia","conceptCode":"C3169","definition":"A variant of systemic mastocytosis with involvement of the bone marrow (20% or more mast cells) and the peripheral blood (mast cells account for 10% or more of peripheral blood white cells). (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28446C9F-B55A-188F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-30","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED4B8E8-6241-3184-E053-F662850A89A7","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","valueDescription":"Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","ValueMeaning":{"publicId":"2593093","version":"1","preferredName":"Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","longName":"2593093","preferredDefinition":"A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC), this group's unique features warrant separate treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","conceptCode":"C3468","definition":"This type of lymphoma is not frequently seen in the western hemisphere. Clinically, with the exception of anaplastic large cell lymphoma, mature T- and NK-cell lymphomas are among the most aggressive of all hematopoietic neoplasms. Representative disease entities include mycosis fungoides, angioimmunoblastic T-cell lymphoma, hepatosplenic T-cell lymphoma, and anaplastic large cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286BA529-8FE0-7325-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED4B8E8-624C-3184-E053-F662850A89A7","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Melanoma","valueDescription":"Melanoma","ValueMeaning":{"publicId":"5581342","version":"1","preferredName":"Melanoma","longName":"5581342","preferredDefinition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melanoma","conceptCode":"C3224","definition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42019733-B8A2-634F-E053-F662850A5A61","latestVersionIndicator":"Yes","beginDate":"2016-11-23","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2016-11-23","modifiedBy":"FINCHAMB","dateModified":"2024-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED4B8E8-6257-3184-E053-F662850A89A7","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Melanomatosis","valueDescription":"Melanomatosis","ValueMeaning":{"publicId":"6835325","version":"1","preferredName":"Melanomatosis","longName":"6835325","preferredDefinition":"A condition characterized by multiple melanomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melanomatosis","conceptCode":"C9499","definition":"A condition characterized by multiple melanomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED4B8E8-6264-3184-E053-F662850A89A7","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED4B8E8-627D-3184-E053-F662850A89A7","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Meningeal Neoplasm","valueDescription":"Meningeal Neoplasm","ValueMeaning":{"publicId":"5098074","version":"1","preferredName":"Meningeal Neoplasm","longName":"5098074","preferredDefinition":"A benign or malignant neoplasm that affects the meninges.  The majority of the neoplasms arise from meningothelial cells and are called meningiomas.  Non-meningothelial cell neoplasms include mesenchymal, non-meningothelial tumors, hemangiopericytomas, and melanocytic lesions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Meningeal Neoplasm","conceptCode":"C3229","definition":"A benign or malignant neoplasm that affects the meninges.  The majority of the neoplasms arise from meningothelial cells and are called meningiomas.  Non-meningothelial cell neoplasms include mesenchymal, non-meningothelial tumors, hemangiopericytomas, and melanocytic lesions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28C8EDF1-00C7-32DF-E050-BB89AD433904","latestVersionIndicator":"Yes","beginDate":"2016-01-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED4B8E8-6291-3184-E053-F662850A89A7","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Meningioma","valueDescription":"Meningioma","ValueMeaning":{"publicId":"4265263","version":"1","preferredName":"Meningioma","longName":"4265263","preferredDefinition":"A generally slow growing tumor attached to the dura mater. It is composed of neoplastic meningothelial (arachnoidal) cells. It typically occurs in adults, often women and it has a wide range of histopathological appearances. Of the various subtypes, meningothelial, fibrous and transitional meningiomas are the most common. Most meningiomas are WHO grade I tumors, and some are WHO grade II or III tumors. Most subtypes share a common clinical behavior, although some subtypes are more likely to recur and follow a more aggressive clinical course. (Adapted from WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Meningioma","conceptCode":"C3230","definition":"A generally slow growing tumor attached to the dura mater. It is composed of neoplastic meningothelial (arachnoidal) cells. It typically occurs in adults, often women and it has a wide range of histopathological appearances. Of the various subtypes, meningothelial, fibrous and transitional meningiomas are the most common. Most meningiomas are WHO grade 1 tumors, and some are WHO grade 2 or 3 tumors. Most subtypes share a common clinical behavior, although some subtypes are more likely to recur and follow a more aggressive clinical course. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F68D1573-4D52-FC76-E040-BB89AD43431A","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED4B8E8-629B-3184-E053-F662850A89A7","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Metastatic Lymphoma in the Heart","valueDescription":"Secondary Heart Lymphoma","ValueMeaning":{"publicId":"6835437","version":"1","preferredName":"Secondary Heart Lymphoma","longName":"6835437","preferredDefinition":"A lymphoma that has spread to the heart from another primary anatomic site.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Secondary Heart Lymphoma","conceptCode":"C5369","definition":"A lymphoma that has spread to the heart from another primary anatomic site.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED671AF-739A-12E4-E053-F662850AD6F1","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED671AF-73B3-12E4-E053-F662850AD6F1","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Merkel Cell Carcinoma","valueDescription":"Merkel Cell Carcinoma","ValueMeaning":{"publicId":"3210716","version":"1","preferredName":"Merkel Cell Carcinoma","longName":"3210716","preferredDefinition":"A rare malignant cutaneous tumor seen in elderly patients.  Its usual location is on the head, neck and extremities.  The tumor is composed of small round cells with scanty cytoplasm arranged in a trabecular pattern, or in ill-defined nodules or in a diffuse pattern.  The tumor cells contain cytoplasmic membrane-bound dense core granules resembling neurosecretory granules.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Merkel Cell Carcinoma","conceptCode":"C9231","definition":"A rare aggressive neuroendocrine carcinoma that usually arises from the skin. Rarely, it arises from extracutaneous sites, including the oral cavity, salivary glands, breast, vulva, and vaginal wall. The tumor is composed of small round cells with scanty cytoplasm. Merkel cell polyomavirus is implicated in the majority of cases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-935E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED671AF-73BD-12E4-E053-F662850AD6F1","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Mesothelioma","valueDescription":"Mesothelioma","ValueMeaning":{"publicId":"3292894","version":"1","preferredName":"Mesothelioma","longName":"3292894","preferredDefinition":"A usually malignant and aggressive neoplasm of the mesothelium which is often associated with exposure to asbestos.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mesothelioma","conceptCode":"C3234","definition":"A usually malignant and aggressive neoplasm of the mesothelium which is often associated with exposure to asbestos.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AEB9CA2C-4514-D4C6-E040-BB89AD432205","latestVersionIndicator":"Yes","beginDate":"2011-10-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-10-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED671AF-73C7-12E4-E053-F662850AD6F1","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Metachronous Malignant Neoplasm","valueDescription":"Metachronous Malignant Neoplasm","ValueMeaning":{"publicId":"3357337","version":"1","preferredName":"Metachronous Malignant Neoplasm","longName":"3357337","preferredDefinition":"A malignant tumor that arises at a site separate from another, primary malignant tumor in the same anatomic system.  It is not clear if metachronous malignant neoplasms represent new primary tumors or metastatic disease.  Examples include metachronous osteosarcoma of the bones that develops in patients with known primary bone osteosarcoma, and metachronous Wilms' tumor that affects the opposite kidney in patients with a history of Wilms' tumor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metachronous Malignant Neoplasm","conceptCode":"C38156","definition":"A malignant tumor that arises at a site separate from another, primary malignant tumor in the same anatomic system.  It is not clear if metachronous malignant neoplasms represent new primary tumors or metastatic disease.  Examples include metachronous osteosarcoma of the bones that develops in patients with known primary bone osteosarcoma, and metachronous Wilms' tumor that affects the opposite kidney in patients with a history of Wilms' tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6D2999F-E9A5-5972-E040-BB89AD430B3F","latestVersionIndicator":"Yes","beginDate":"2012-01-18","endDate":null,"createdBy":"SHIDED","dateCreated":"2012-01-18","modifiedBy":"FINCHAMB","dateModified":"2023-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED671AF-73D1-12E4-E053-F662850AD6F1","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Metaplastic Carcinoma","valueDescription":"Metaplastic Carcinoma","ValueMeaning":{"publicId":"3248487","version":"1","preferredName":"Metaplastic Carcinoma","longName":"3248487","preferredDefinition":"A general term used to describe carcinomas arising from epithelial cells that have been transformed into another cells type (metaplastic epithelial cells). A representative example is the adenocarcinoma arising in Barrett esophagus. This term is also used to describe carcinomas in which the malignant epithelial cells show differentiation towards another cell type. A representative example of the latter is the metaplastic breast carcinoma in which the malignant glandular cells show squamous, spindle cell, or chondroid/osseous differentiation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metaplastic Carcinoma","conceptCode":"C27949","definition":"A general term used to describe carcinomas arising from epithelial cells that have been transformed into another cells type (metaplastic epithelial cells). A representative example is the adenocarcinoma arising in Barrett esophagus. This term is also used to describe carcinomas in which the malignant epithelial cells show differentiation towards another cell type. A representative example of the latter is the metaplastic breast carcinoma in which the malignant glandular cells show squamous, spindle cell, or chondroid/osseous differentiation.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6B8531E-1718-F891-E040-BB89AD4324F8","latestVersionIndicator":"Yes","beginDate":"2011-06-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED671AF-73DC-12E4-E053-F662850AD6F1","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Metastatic Carcinoid Tumor","valueDescription":"Metastatic Carcinoid Tumor","ValueMeaning":{"publicId":"6835439","version":"1","preferredName":"Metastatic Carcinoid Tumor","longName":"6835439","preferredDefinition":"A carcinoid tumor that has extended beyond its original site of growth to other anatomic sites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metastatic Carcinoid Tumor","conceptCode":"C6431","definition":"A carcinoid tumor that has extended beyond its original site of growth to other anatomic sites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED671AF-73E9-12E4-E053-F662850AD6F1","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED671AF-7402-12E4-E053-F662850AD6F1","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Metastatic Malignant Neoplasm","valueDescription":"Metastatic Malignant Neoplasm","ValueMeaning":{"publicId":"3211553","version":"1","preferredName":"Metastatic Malignant Neoplasm","longName":"3211553v1.00","preferredDefinition":"A malignant tumor that has spread from its original (primary) site of growth to another site close to or distant from the primary site.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metastatic Malignant Neoplasm","conceptCode":"C36263","definition":"A malignant tumor that has spread from its original (primary) site of growth to another site close to or distant from the primary site.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F5324E1-CA6D-4BBA-E040-BB89AD4346F8","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"GDEEN","dateModified":"2023-04-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED671AF-740C-12E4-E053-F662850AD6F1","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Metastatic Malignant Neoplasm in Lymph Node","valueDescription":"LN - 196; Lymph Nodes","ValueMeaning":{"publicId":"2572669","version":"1","preferredName":"LN - 196; Lymph Nodes","longName":"2572669","preferredDefinition":"The spread of a malignant neoplasm to the lymph nodes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metastatic Malignant Neoplasm in the Lymph Nodes","conceptCode":"C4904","definition":"The spread of a malignant neoplasm from its original site of growth to lymph nodes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8EA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LISU","dateModified":"2022-08-03","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED671AF-7421-12E4-E053-F662850AD6F1","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Metastatic Malignant Neoplasm in the Abdominal Cavity","valueDescription":"Metastatic Malignant Neoplasm in the Abdominal Cavity","ValueMeaning":{"publicId":"6835441","version":"1","preferredName":"Metastatic Malignant Neoplasm in the Abdominal Cavity","longName":"6835441","preferredDefinition":"The spread of a malignant neoplasm from a primary site to an unspecified organ in the abdominal cavity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metastatic Malignant Neoplasm in the Abdominal Cavity","conceptCode":"C8615","definition":"The spread of a malignant neoplasm from a primary site to an unspecified organ in the abdominal cavity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED671AF-742F-12E4-E053-F662850AD6F1","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED671AF-7448-12E4-E053-F662850AD6F1","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Metastatic Malignant Neoplasm in the Adrenal Gland","valueDescription":"Metastatic Malignant Neoplasm in the Adrenal Gland","ValueMeaning":{"publicId":"6835443","version":"1","preferredName":"Metastatic Malignant Neoplasm in the Adrenal Gland","longName":"6835443","preferredDefinition":"A malignant tumor that has spread to the adrenal gland from an adjacent or distant anatomic site.  The majority of cases are metastatic carcinomas, and less frequently lymphomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metastatic Malignant Neoplasm in the Adrenal Gland","conceptCode":"C8610","definition":"A malignant tumor that has spread to the adrenal gland from an adjacent or distant anatomic site.  The majority of cases are metastatic carcinomas, and less frequently lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED671AF-7455-12E4-E053-F662850AD6F1","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED671AF-746E-12E4-E053-F662850AD6F1","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Metastatic Malignant Neoplasm in the Bladder","valueDescription":"Metastatic Malignant Neoplasm in the Bladder","ValueMeaning":{"publicId":"6835445","version":"1","preferredName":"Metastatic Malignant Neoplasm in the Bladder","longName":"6835445","preferredDefinition":"The spread of a malignant neoplasm to the urinary bladder wall from an adjacent or distant anatomic site.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metastatic Malignant Neoplasm in the Bladder","conceptCode":"C7650","definition":"The spread of a malignant neoplasm to the urinary bladder wall from an adjacent or distant anatomic site.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED671AF-747B-12E4-E053-F662850AD6F1","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED671AF-7494-12E4-E053-F662850AD6F1","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Metastatic Malignant Neoplasm in the Bone","valueDescription":"Metastatic Malignant Neoplasm to the Bone","ValueMeaning":{"publicId":"2857211","version":"1","preferredName":"Metastatic Malignant Neoplasm to the Bone","longName":"2857211","preferredDefinition":"Cancer that has spread from the original (primary) tumor to the bone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metastatic Malignant Neoplasm in the Bone","conceptCode":"C3580","definition":"The spread of a malignant neoplasm from a primary site to the skeletal system.  The majority of metastatic neoplasms to the bone are carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"661EB49B-B2D9-7D2B-E040-BB89AD4340DC","latestVersionIndicator":"Yes","beginDate":"2009-03-27","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-03-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED671AF-74A8-12E4-E053-F662850AD6F1","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Metastatic Malignant Neoplasm in the Brain","valueDescription":"Metastatic Malignant Neoplasm in the Brain","ValueMeaning":{"publicId":"4722600","version":"1","preferredName":"Metastatic Malignant Neoplasm in the Brain","longName":"4722600","preferredDefinition":"A malignant neoplasm that has spread to the brain from another anatomic site or system. The majority are carcinomas (usually lung or breast carcinomas).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metastatic Malignant Neoplasm in the Brain","conceptCode":"C3813","definition":"A malignant neoplasm that has spread to the brain from another anatomic site or system. The majority are carcinomas (usually lung or breast carcinomas).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A2532-F900-F227-E050-BB89AD433E96","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED671AF-74BD-12E4-E053-F662850AD6F1","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Metastatic Malignant Neoplasm in the Breast","valueDescription":"Metastatic Malignant Neoplasm in the Breast","ValueMeaning":{"publicId":"5914338","version":"1","preferredName":"Metastatic Malignant Neoplasm in the Breast","longName":"5914338","preferredDefinition":"The spread of a malignant neoplasm to the breast. This may be from a primary breast malignant neoplasm on the opposite side, or from a malignant neoplasm at a distant site.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metastatic Malignant Neoplasm in the Breast","conceptCode":"C7511","definition":"The spread of a malignant neoplasm to the breast. This may be from a primary breast malignant neoplasm on the opposite side, or from a malignant neoplasm at a distant site.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54B27B9C-655D-56A3-E053-F662850AF8F5","latestVersionIndicator":"Yes","beginDate":"2017-07-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-07-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED671AF-74D2-12E4-E053-F662850AD6F1","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Metastatic Malignant Neoplasm in the Central Nervous System","valueDescription":"Metastatic Malignant Neoplasm in the Central Nervous System","ValueMeaning":{"publicId":"6835447","version":"1","preferredName":"Metastatic Malignant Neoplasm in the Central Nervous System","longName":"6835447","preferredDefinition":"A malignant neoplasm that has spread to the central nervous system from another anatomic site or system. The majority are carcinomas (usually lung or breast carcinomas).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metastatic Malignant Neoplasm in the Central Nervous System","conceptCode":"C4015","definition":"A malignant neoplasm that has spread to the central nervous system from another anatomic site or system. The majority are carcinomas (usually lung or breast carcinomas).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED671AF-74E0-12E4-E053-F662850AD6F1","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED671AF-74F9-12E4-E053-F662850AD6F1","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Metastatic Malignant Neoplasm in the Large Intestine","valueDescription":"Metastatic Malignant Neoplasm in the Large Intestine","ValueMeaning":{"publicId":"6835449","version":"1","preferredName":"Metastatic Malignant Neoplasm in the Large Intestine","longName":"6835449","preferredDefinition":"The spread of a malignant neoplasm to the large intestine.  This may be from a primary large intestine malignant neoplasm, or from a malignant neoplasm at a distant site.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metastatic Malignant Neoplasm in the Large Intestine","conceptCode":"C4581","definition":"The spread of a malignant neoplasm to the large intestine.  This may be from a primary large intestine malignant neoplasm, or from a malignant neoplasm at a distant site.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED671AF-7506-12E4-E053-F662850AD6F1","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED671AF-751F-12E4-E053-F662850AD6F1","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Neoplasm, Uncertain Whether Benign or Malignant","valueDescription":"Neoplasm, Uncertain Whether Benign or Malignant","ValueMeaning":{"publicId":"6660967","version":"1","preferredName":"Neoplasm, Uncertain Whether Benign or Malignant","longName":"6660967v1.00","preferredDefinition":"A neoplasm which, on morphologic grounds, can not be classified with certainty as benign or malignant.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neoplasm, Uncertain Whether Benign or Malignant","conceptCode":"C65157","definition":"A neoplasm which, on morphologic grounds, can not be classified with certainty as benign or malignant.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"830EC13A-C1C0-147E-E053-F662850AE841","latestVersionIndicator":"Yes","beginDate":"2019-03-01","endDate":null,"createdBy":"TSESU","dateCreated":"2019-03-01","modifiedBy":"GDEEN","dateModified":"2023-04-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED4B8E8-62A6-3184-E053-F662850A89A7","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Neoplastic Syndrome","valueDescription":"Neoplastic Syndrome","ValueMeaning":{"publicId":"6835476","version":"1","preferredName":"Neoplastic Syndrome","longName":"6835476","preferredDefinition":"A broad classification for disorders in which the development of neoplasms typically occur in association with a characteristic set of signs or symptoms. These disorders may be inherited or acquired.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neoplastic Syndrome","conceptCode":"C54705","definition":"A broad classification for disorders in which the development of neoplasms typically occur in association with a characteristic set of signs or symptoms. These disorders may be inherited or acquired.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED4B8E8-62B4-3184-E053-F662850A89A7","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED4B8E8-62CD-3184-E053-F662850A89A7","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Nervous System Neoplasm","valueDescription":"Nervous System Neoplasm","ValueMeaning":{"publicId":"6835478","version":"1","preferredName":"Nervous System Neoplasm","longName":"6835478","preferredDefinition":"A benign or malignant, primary or metastatic neoplasm involving the central or peripheral nervous system.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nervous System Neoplasm","conceptCode":"C3268","definition":"A benign or malignant, primary or metastatic neoplasm involving the central or peripheral nervous system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED4B8E8-62DA-3184-E053-F662850A89A7","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED4B8E8-62F3-3184-E053-F662850A89A7","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Neuroblastoma","valueDescription":"Neuroblastoma","ValueMeaning":{"publicId":"4265259","version":"1","preferredName":"Neuroblastoma","longName":"4265259","preferredDefinition":"A neuroblastic tumor characterized by the presence of neuroblastic cells, the absence of ganglion cells, and the absence of a prominent Schwannian stroma formation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neuroblastoma","conceptCode":"C3270","definition":"A malignant neuroblastic tumor characterized by the presence of neuroblastic cells, the absence of ganglion cells, and the absence of a prominent Schwannian stroma formation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F68D1573-4CCE-FC76-E040-BB89AD43431A","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED4B8E8-62FD-3184-E053-F662850A89A7","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Lung Non-Small Cell Carcinoma","valueDescription":"NSCLC","ValueMeaning":{"publicId":"3534668","version":"1","preferredName":"NSCLC","longName":"3534668","preferredDefinition":"A group of at least three distinct histological types of lung cancer, including squamous cell carcinoma, adenocarcinoma, and large cell carcinoma.  Non-small cell lung carcinomas have a poor response to conventional chemotherapy.  --2002","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lung Non-Small Cell Carcinoma","conceptCode":"C2926","definition":"A group of at least three distinct histological types of lung cancer, including non-small cell squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Non-small cell lung carcinomas have a poor response to conventional chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C597D472-1BE4-C3F6-E040-BB89AD434BBD","latestVersionIndicator":"Yes","beginDate":"2012-07-24","endDate":null,"createdBy":"LEL","dateCreated":"2012-07-24","modifiedBy":"FINCHAMB","dateModified":"2024-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B6FB8-F7A0-081C-E053-F662850AA0FF","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Lung Small Cell Carcinoma","valueDescription":"Small Cell Lung Carcinoma","ValueMeaning":{"publicId":"3297699","version":"1","preferredName":"Small Cell Lung Carcinoma","longName":"3297699","preferredDefinition":"A highly aggressive subtype of lung carcinoma characterized by the presence of malignant small cells and necrosis. Metastatic disease is usually present at the time of diagnosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lung Small Cell Carcinoma","conceptCode":"C4917","definition":"A highly aggressive carcinoma with neuroendocrine differentiation arising from the lung. It is characterized by the presence of malignant small cells and necrosis. Metastatic disease is usually present at the time of diagnosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B035F07A-837C-9251-E040-BB89AD4303FC","latestVersionIndicator":"Yes","beginDate":"2011-10-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-26","modifiedBy":"FINCHAMB","dateModified":"2024-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B6FB8-F7B5-081C-E053-F662850AA0FF","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Lymphadenopathic Kaposi Sarcoma","valueDescription":"Lymphadenopathic Kaposi Sarcoma","ValueMeaning":{"publicId":"6832795","version":"1","preferredName":"Lymphadenopathic Kaposi Sarcoma","longName":"6832795","preferredDefinition":"A Kaposi sarcoma affecting the lymph nodes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphadenopathic Kaposi Sarcoma","conceptCode":"C27500","definition":"A Kaposi sarcoma affecting the lymph nodes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B6FB8-F7C2-081C-E053-F662850AA0FF","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B6FB8-F7DB-081C-E053-F662850AA0FF","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Lymphoblastic Lymphoma","valueDescription":"Lymphoblastic Lymphoma","ValueMeaning":{"publicId":"3210725","version":"1","preferredName":"Lymphoblastic Lymphoma","longName":"3210725","preferredDefinition":"A lymphoma composed of immature small to medium-sized precursor lymphoid cells (lymphoblasts). It includes the B- and T-cell lymphoblastic lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphoblastic Lymphoma","conceptCode":"C9360","definition":"A lymphoma composed of immature small to medium-sized precursor lymphoid cells (lymphoblasts). It includes the B- and T-cell lymphoblastic lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-94D8-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B6FB8-F7E5-081C-E053-F662850AA0FF","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Lymphocyte-Depleted Classic Hodgkin Lymphoma","valueDescription":"Lymphocyte Depleted Hodgkin Lymphoma","ValueMeaning":{"publicId":"2593114","version":"1","preferredName":"Lymphocyte Depleted Hodgkin Lymphoma","longName":"2593114","preferredDefinition":"A diffuse form of classical Hodgkin lymphoma which is rich in Hodgkin and Reed-Sternberg cells and/or depleted in non-neoplastic lymphocytes.  Historically, the clinical course of this type of Hodgkin lymphoma was aggressive.  With current therapy, the course is comparable to patients with other subtypes of classical Hodgkin lymphoma.  Most patients present with advanced stage disease (Stage III or IV) and B-symptoms. (WHO, 2001) -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphocyte-Depleted Classic Hodgkin Lymphoma","conceptCode":"C9283","definition":"A diffuse subtype of classic Hodgkin lymphoma which is rich in Hodgkin and Reed-Sternberg cells and/or depleted in non-neoplastic lymphocytes. (WHO, 2008)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286D2655-C796-1ADB-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B6FB8-F7FA-081C-E053-F662850AA0FF","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Lymphocyte-Rich Classic Hodgkin Lymphoma","valueDescription":"Lymphocyte Rich Classical Hodgkin Lymphoma","ValueMeaning":{"publicId":"2593110","version":"1","preferredName":"Lymphocyte Rich Classical Hodgkin Lymphoma","longName":"2593110","preferredDefinition":"A subtype of classical Hodgkin lymphoma.  Most patients present with peripheral lymphadenopathy and limited stage disease (stage I or II).  The survival and progression free survival are slightly better than in other subtypes of classical Hodgkin lymphoma. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphocyte-Rich Classic Hodgkin Lymphoma","conceptCode":"C6913","definition":"A subtype of classic Hodgkin lymphoma with scattered Hodgkin and Reed-Sternberg cells and a nodular or less often diffuse cellular background consisting of small lymphocytes and with an absence of neutrophils and eosinophils. (WHO, 2008)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286D2655-C748-1ADB-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B6FB8-F80F-081C-E053-F662850AA0FF","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Lymphocytic Neoplasm","valueDescription":"Lymphocytic Neoplasm","ValueMeaning":{"publicId":"4265269","version":"1","preferredName":"Lymphocytic Neoplasm","longName":"4265269","preferredDefinition":"A neoplasm composed of a lymphocytic cell population which is usually malignant (clonal) by molecular genetic and/or immunophenotypic analysis.  Lymphocytic neoplasms include Hodgkin and non-Hodgkin lymphomas, acute and chronic lymphocytic leukemias, and plasma cell neoplasms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphocytic Neoplasm","conceptCode":"C7065","definition":"A neoplasm composed of a lymphocytic cell population which is usually malignant (clonal) by molecular genetic and/or immunophenotypic analysis.  Lymphocytic neoplasms include Hodgkin and non-Hodgkin lymphomas, acute and chronic lymphocytic leukemias, and plasma cell neoplasms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F68D1573-4E06-FC76-E040-BB89AD43431A","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B6FB8-F824-081C-E053-F662850AA0FF","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Lymphoid Leukemia","valueDescription":"Lymphoid Leukemia","ValueMeaning":{"publicId":"2959432","version":"1","preferredName":"Lymphoid Leukemia","longName":"2959432","preferredDefinition":"A malignant lymphocytic neoplasm of B-cell or T-cell lineage involving primarily the bone marrow and the peripheral blood.  This category includes precursor or acute lymphoblastic leukemias and chronic leukemias.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphoid Leukemia","conceptCode":"C7539","definition":"A malignant lymphocytic neoplasm of B-cell or T-cell lineage involving primarily the bone marrow and the peripheral blood.  This category includes precursor or acute lymphoblastic leukemias and chronic leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77FB37D5-02F2-92F5-E040-BB89AD433DB6","latestVersionIndicator":"Yes","beginDate":"2009-11-09","endDate":null,"createdBy":"UMLLOADER_COPPAPRD","dateCreated":"2009-11-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B6FB8-F82E-081C-E053-F662850AA0FF","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Muscle Neoplasm","valueDescription":"Malignant Muscle Neoplasm","ValueMeaning":{"publicId":"6832939","version":"1","preferredName":"Malignant Muscle Neoplasm","longName":"6832939","preferredDefinition":"A malignant neoplasm affecting the skeletal or smooth muscles.  Malignant neoplasms arising from the skeletal muscles are called rhabdomyosarcomas.  Malignant neoplasms arising from the smooth muscles are called leiomyosarcomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Muscle Neoplasm","conceptCode":"C4883","definition":"A malignant neoplasm affecting the skeletal or smooth muscles.  Malignant neoplasms arising from the skeletal muscles are called rhabdomyosarcomas.  Malignant neoplasms arising from the smooth muscles are called leiomyosarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9C13A5-90F2-690F-E053-F662850AD8D9","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9C13A5-910B-690F-E053-F662850AD8D9","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Myoepithelioma","valueDescription":"Malignant Myoepithelioma","ValueMeaning":{"publicId":"3248547","version":"1","preferredName":"Malignant Myoepithelioma","longName":"3248547","preferredDefinition":"An infiltrating malignant epithelial neoplasm characterized by the presence of atypical cells with myoepithelial differentiation. Representative examples include malignant breast myoepithelioma and salivary gland myoepithelial carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Myoepithelioma","conceptCode":"C7596","definition":"An infiltrating malignant tumor characterized by the presence of atypical cells with myoepithelial differentiation. Representative examples include malignant breast myoepithelioma and salivary gland myoepithelial carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6BBE041-BB70-9503-E040-BB89AD435A00","latestVersionIndicator":"Yes","beginDate":"2011-06-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9C13A5-911F-690F-E053-F662850AD8D9","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Nasal Cavity Neoplasm","valueDescription":"Malignant Nasal Cavity Neoplasm","ValueMeaning":{"publicId":"6832941","version":"1","preferredName":"Malignant Nasal Cavity Neoplasm","longName":"6832941","preferredDefinition":"A malignant neoplasm affecting the nasal cavity.  Representative examples include carcinoma and lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Nasal Cavity Neoplasm","conceptCode":"C4918","definition":"A malignant neoplasm affecting the nasal cavity.  Representative examples include carcinoma and lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9C13A5-912C-690F-E053-F662850AD8D9","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9C13A5-9145-690F-E053-F662850AD8D9","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Nasopharyngeal Neoplasm","valueDescription":"Malignant Nasopharyngeal Neoplasm","ValueMeaning":{"publicId":"6832943","version":"1","preferredName":"Malignant Nasopharyngeal Neoplasm","longName":"6832943","preferredDefinition":"A primary or metastatic malignant neoplasm involving the nasopharynx.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Nasopharyngeal Neoplasm","conceptCode":"C9321","definition":"A primary or metastatic malignant neoplasm involving the nasopharynx.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9C13A5-9152-690F-E053-F662850AD8D9","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9C13A5-916B-690F-E053-F662850AD8D9","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Neoplasm","valueDescription":"Malignant Neoplasm","ValueMeaning":{"publicId":"2749852","version":"1","preferredName":"Malignant Neoplasm","longName":"2749852","preferredDefinition":"A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues.  Malignant neoplasms usually metastasize to distant anatomic sites and may recur after excision.  The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin's and non-Hodgkin's lymphomas, leukemias, melanomas, and sarcomas. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D47F93B-9A03-2D84-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CZECHS","dateCreated":"2008-05-15","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9C13A5-9175-690F-E053-F662850AD8D9","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Neoplasm of Lower Jaw Bone","valueDescription":"Malignant Neoplasm of Lower Jaw Bone","ValueMeaning":{"publicId":"6832945","version":"1","preferredName":"Malignant Neoplasm of Lower Jaw Bone","longName":"6832945","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the mandible.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Neoplasm of Mandible","conceptCode":"C35178","definition":"A primary or metastatic malignant neoplasm that affects the mandible.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9C13A5-9182-690F-E053-F662850AD8D9","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9C13A5-919B-690F-E053-F662850AD8D9","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Neoplasm of the Abdominal Esophagus","valueDescription":"Malignant Neoplasm of the Abdominal Esophagus","ValueMeaning":{"publicId":"6832947","version":"1","preferredName":"Malignant Neoplasm of the Abdominal Esophagus","longName":"6832947","preferredDefinition":"A primary or metastatic malignant neoplasm involving the abdominal region of the esophagus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Neoplasm of the Abdominal Esophagus","conceptCode":"C4764","definition":"A primary or metastatic malignant neoplasm involving the abdominal region of the esophagus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9C13A5-91A8-690F-E053-F662850AD8D9","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9C13A5-91C1-690F-E053-F662850AD8D9","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Neoplasm of the Cervical Esophagus","valueDescription":"Malignant Neoplasm of the Cervical Esophagus","ValueMeaning":{"publicId":"6832949","version":"1","preferredName":"Malignant Neoplasm of the Cervical Esophagus","longName":"6832949","preferredDefinition":"A primary or metastatic malignant neoplasm involving the cervical region of the esophagus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Neoplasm of the Cervical Esophagus","conceptCode":"C4763","definition":"A primary or metastatic malignant neoplasm involving the cervical region of the esophagus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9C13A5-91CE-690F-E053-F662850AD8D9","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9C13A5-91E7-690F-E053-F662850AD8D9","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Neoplasm of the Lower Third of the Esophagus","valueDescription":"Malignant Neoplasm of the Lower Third of the Esophagus","ValueMeaning":{"publicId":"6832951","version":"1","preferredName":"Malignant Neoplasm of the Lower Third of the Esophagus","longName":"6832951","preferredDefinition":"A primary or metastatic malignant neoplasm involving the lower third segment of the esophagus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Neoplasm of the Lower Third of the Esophagus","conceptCode":"C3535","definition":"A primary or metastatic malignant neoplasm involving the lower third segment of the esophagus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9C13A5-91F4-690F-E053-F662850AD8D9","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9C13A5-920D-690F-E053-F662850AD8D9","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Neoplasm of the Meninges","valueDescription":"Malignant Neoplasm of the Meninges","ValueMeaning":{"publicId":"6832953","version":"1","preferredName":"Malignant Neoplasm of the Meninges","longName":"6832953","preferredDefinition":"A primary or metastatic malignant tumor occurring in the meninges, which surround the brain and spinal cord.  The most common are meningiomas. - 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Meningeal Neoplasm","conceptCode":"C4628","definition":"A primary or metastatic malignant tumor occurring in the meninges, which surround the brain and spinal cord.  The most common are meningiomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9C13A5-921A-690F-E053-F662850AD8D9","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9C13A5-9233-690F-E053-F662850AD8D9","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Neoplasm of the Middle Third of the Esophagus","valueDescription":"Malignant Neoplasm of the Middle Third of the Esophagus","ValueMeaning":{"publicId":"6832955","version":"1","preferredName":"Malignant Neoplasm of the Middle Third of the Esophagus","longName":"6832955","preferredDefinition":"A primary or metastatic malignant neoplasm involving the middle third segment of the esophagus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Neoplasm of the Middle Third of the Esophagus","conceptCode":"C3534","definition":"A primary or metastatic malignant neoplasm involving the middle third segment of the esophagus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9C13A5-9240-690F-E053-F662850AD8D9","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9C13A5-9259-690F-E053-F662850AD8D9","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Neoplasm of the Thoracic Esophagus","valueDescription":"Malignant Neoplasm of the Thoracic Esophagus","ValueMeaning":{"publicId":"6832957","version":"1","preferredName":"Malignant Neoplasm of the Thoracic Esophagus","longName":"6832957","preferredDefinition":"A primary or metastatic malignant neoplasm involving the thoracic region of the esophagus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Neoplasm of the Thoracic Esophagus","conceptCode":"C3532","definition":"A primary or metastatic malignant neoplasm involving the thoracic region of the esophagus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9C13A5-9266-690F-E053-F662850AD8D9","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9C13A5-927F-690F-E053-F662850AD8D9","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Neoplasm of the Upper Third of the Esophagus","valueDescription":"Malignant Neoplasm of the Upper Third of the Esophagus","ValueMeaning":{"publicId":"6832959","version":"1","preferredName":"Malignant Neoplasm of the Upper Third of the Esophagus","longName":"6832959","preferredDefinition":"A primary or metastatic malignant neoplasm involving the upper third segment of the esophagus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Neoplasm of the Upper Third of the Esophagus","conceptCode":"C3533","definition":"A primary or metastatic malignant neoplasm involving the upper third segment of the esophagus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9C13A5-928C-690F-E053-F662850AD8D9","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9C13A5-92A5-690F-E053-F662850AD8D9","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Neoplasm, Uncertain Whether Primary or Metastatic","valueDescription":"Malignant Neoplasm, Uncertain Whether Primary or Metastatic","ValueMeaning":{"publicId":"6832961","version":"1","preferredName":"Malignant Neoplasm, Uncertain Whether Primary or Metastatic","longName":"6832961v1.00","preferredDefinition":"A malignant neoplasm in which the examined tissue can not be determined with certainty if it represents the primary site of tumor growth or tumor spread from another anatomic site.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Neoplasm, Uncertain Whether Primary or Metastatic","conceptCode":"C65153","definition":"A malignant neoplasm in which the examined tissue can not be determined with certainty if it represents the primary site of tumor growth or tumor spread from another anatomic site.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9C13A5-92B2-690F-E053-F662850AD8D9","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"GDEEN","dateModified":"2023-04-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9C13A5-92CB-690F-E053-F662850AD8D9","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Nervous System Neoplasm","valueDescription":"Malignant Nervous System Neoplasm","ValueMeaning":{"publicId":"6832963","version":"1","preferredName":"Malignant Nervous System Neoplasm","longName":"6832963","preferredDefinition":"A primary or metastatic malignant neoplasm involving the nervous system.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Nervous System Neoplasm","conceptCode":"C4788","definition":"A primary or metastatic malignant neoplasm involving the nervous system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9C13A5-92D8-690F-E053-F662850AD8D9","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9C13A5-92F1-690F-E053-F662850AD8D9","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Nipple Neoplasm","valueDescription":"Malignant Nipple Neoplasm","ValueMeaning":{"publicId":"6832965","version":"1","preferredName":"Malignant Nipple Neoplasm","longName":"6832965","preferredDefinition":"A malignant neoplasm that affects the area of the nipple.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Nipple Neoplasm","conceptCode":"C5213","definition":"A malignant neoplasm that affects the area of the nipple.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9C13A5-92FE-690F-E053-F662850AD8D9","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9C13A5-9317-690F-E053-F662850AD8D9","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Oral Cavity Neoplasm","valueDescription":"Malignant Oral Cavity Neoplasm","ValueMeaning":{"publicId":"6832966","version":"1","preferredName":"Malignant Oral Cavity Neoplasm","longName":"6832966","preferredDefinition":"A primary or metastatic malignant neoplasm involving the oral cavity.  The majority are squamous cell carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Oral Cavity Neoplasm","conceptCode":"C9314","definition":"A primary or metastatic malignant neoplasm involving the oral cavity.  The majority are squamous cell carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9C13A5-9323-690F-E053-F662850AD8D9","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9C13A5-933C-690F-E053-F662850AD8D9","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Oral Neoplasm","valueDescription":"Malignant Oral Neoplasm","ValueMeaning":{"publicId":"6832968","version":"1","preferredName":"Malignant Oral Neoplasm","longName":"6832968","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the lip and/or oral cavity.  The majority of cases are carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Oral Neoplasm","conceptCode":"C9316","definition":"A primary or metastatic malignant neoplasm that affects the lip and/or oral cavity.  The majority of cases are carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9C13A5-9349-690F-E053-F662850AD8D9","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9C13A5-9362-690F-E053-F662850AD8D9","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Pyriform Fossa Neoplasm","valueDescription":"Malignant Pyriform Fossa Neoplasm","ValueMeaning":{"publicId":"6835261","version":"1","preferredName":"Malignant Pyriform Fossa Neoplasm","longName":"6835261","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the pyriform sinus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Pyriform Fossa Neoplasm","conceptCode":"C3531","definition":"A primary or metastatic malignant neoplasm that affects the pyriform sinus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED5EB8E-A0D9-21AC-E053-F662850AA6A9","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED5EB8E-A0F2-21AC-E053-F662850AA6A9","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Rectal Neoplasm","valueDescription":"RECT - 154.1; Rectum","ValueMeaning":{"publicId":"2572684","version":"1","preferredName":"RECT - 154.1; Rectum","longName":"2572684","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the rectum.  Representative examples include carcinoma, lymphoma, and sarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Rectal Neoplasm","conceptCode":"C7418","definition":"A primary or metastatic malignant neoplasm that affects the rectum.  Representative examples include carcinoma, lymphoma, and sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8F9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED5EB8E-A106-21AC-E053-F662850AA6A9","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Rectosigmoid Neoplasm","valueDescription":"Malignant Rectosigmoid Neoplasm","ValueMeaning":{"publicId":"6835263","version":"1","preferredName":"Malignant Rectosigmoid Neoplasm","longName":"6835263","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the rectosigmoid area.  Representative examples include carcinoma, lymphoma, and sarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Rectosigmoid Neoplasm","conceptCode":"C7420","definition":"A primary or metastatic malignant neoplasm that affects the rectosigmoid area.  Representative examples include carcinoma, lymphoma, and sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED5EB8E-A114-21AC-E053-F662850AA6A9","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED5EB8E-A12D-21AC-E053-F662850AA6A9","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Renal Pelvis Neoplasm","valueDescription":"Malignant Renal Pelvis Neoplasm","ValueMeaning":{"publicId":"6835265","version":"1","preferredName":"Malignant Renal Pelvis Neoplasm","longName":"6835265","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the renal pelvis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Renal Pelvis Neoplasm","conceptCode":"C7525","definition":"A primary or metastatic malignant neoplasm that affects the renal pelvis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED5EB8E-A13A-21AC-E053-F662850AA6A9","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED5EB8E-A153-21AC-E053-F662850AA6A9","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Respiratory Tract Neoplasm","valueDescription":"Malignant Respiratory Tract Neoplasm","ValueMeaning":{"publicId":"6835267","version":"1","preferredName":"Malignant Respiratory Tract Neoplasm","longName":"6835267","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the lung parenchyma, bronchial tree, or trachea.  Representative examples include lung carcinoma, carcinoid tumor, lung lymphoma, lung sarcoma, and tracheal carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Respiratory System Neoplasm","conceptCode":"C4571","definition":"A primary or metastatic malignant neoplasm that affects the lung parenchyma, bronchial tree, or trachea.  Representative examples include lung carcinoma, carcinoid tumor, lung lymphoma, lung sarcoma, and tracheal carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED5EB8E-A160-21AC-E053-F662850AA6A9","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED5EB8E-A179-21AC-E053-F662850AA6A9","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Retinal Neoplasm","valueDescription":"Malignant Retinal Neoplasm","ValueMeaning":{"publicId":"6835269","version":"1","preferredName":"Malignant Retinal Neoplasm","longName":"6835269","preferredDefinition":"Abnormal growth of cells comprising the retina with malignant characteristics.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Retinal Neoplasm","conceptCode":"C3216","definition":"A primary or metastatic malignant neoplasm that affects the retina.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED5EB8E-A186-21AC-E053-F662850AA6A9","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED5EB8E-A19F-21AC-E053-F662850AA6A9","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Central Nervous System Leukemia","valueDescription":"Central Nervous System Leukemia","ValueMeaning":{"publicId":"6798052","version":"1","preferredName":"Central Nervous System Leukemia","longName":"6798052","preferredDefinition":"Leukemia infiltrating the central nervous system structures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Central Nervous System Leukemia","conceptCode":"C5440","definition":"Leukemia infiltrating the central nervous system structures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C63928F-2949-641E-E053-F662850A3D36","latestVersionIndicator":"Yes","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C63928F-2962-641E-E053-F662850A3D36","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Cervical Carcinoma","valueDescription":"Cervical Carcinoma","ValueMeaning":{"publicId":"4722592","version":"1","preferredName":"Cervical Carcinoma","longName":"4722592","preferredDefinition":"A carcinoma arising from either the exocervical squamous epithelium or the endocervical glandular epithelium. The major histologic types of cervical carcinoma are: squamous carcinoma, adenocarcinoma, adenosquamous carcinoma, adenoid cystic carcinoma and undifferentiated carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cervical Carcinoma","conceptCode":"C9039","definition":"A carcinoma arising from either the exocervical squamous epithelium or the endocervical glandular epithelium. The major histologic types of cervical carcinoma are squamous cell carcinoma and adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F886EE6-BA8A-DB60-E050-BB89AD4356E3","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C63928F-293F-641E-E053-F662850A3D36","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Central Nervous System Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor","valueDescription":"Central Nervous System Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor","ValueMeaning":{"publicId":"6798054","version":"1","preferredName":"Central Nervous System Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor","longName":"6798054","preferredDefinition":"A rare Ewing sarcoma/peripheral primitive neuroectodermal tumor that affects the central nervous system either as a primary dural neoplasm or by direct extension from adjacent soft tissues or bone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Central Nervous System Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor","conceptCode":"C129537","definition":"A rare Ewing sarcoma/peripheral primitive neuroectodermal tumor that affects the central nervous system either as a primary dural neoplasm or by direct extension from adjacent soft tissues or bone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C63928F-296F-641E-E053-F662850A3D36","latestVersionIndicator":"Yes","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C63928F-2988-641E-E053-F662850A3D36","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Central Nervous System Embryonal Neoplasm","valueDescription":"Central Nervous System Embryonal Neoplasm","ValueMeaning":{"publicId":"5097519","version":"1","preferredName":"Central Nervous System Embryonal Neoplasm","longName":"5097519","preferredDefinition":"A malignant neoplasm of embryonal origin, arising from the central nervous system.  It usually affects children.  Representative examples include ependymoblastoma, medulloblastoma, and atypical teratoid/rhabdoid tumor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Central Nervous System Embryonal Tumor","conceptCode":"C6990","definition":"A malignant neoplasm of embryonal origin, arising from the central nervous system.  It usually affects children.  Representative examples include ependymoblastoma, medulloblastoma, and atypical teratoid/rhabdoid tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28C4D9CD-3384-6F21-E050-BB89AD431A5F","latestVersionIndicator":"Yes","beginDate":"2016-01-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C63928F-299C-641E-E053-F662850A3D36","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Central Nervous System Carcinoma","valueDescription":"Central Nervous System Carcinoma","ValueMeaning":{"publicId":"2672911","version":"1","preferredName":"Central Nervous System Carcinoma","longName":"2672911","preferredDefinition":"A malignant tumor arising in the epithelial cells of the brain or spinal cord.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Central Nervous System Carcinoma","conceptCode":"C62332","definition":"A malignant tumor arising in the epithelial cells of the brain or spinal cord.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37D5FE1C-A754-09FD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-16","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-08-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C63928F-29B0-641E-E053-F662850A3D36","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Carcinoma In Situ","valueDescription":"Carcinoma In Situ","ValueMeaning":{"publicId":"2935534","version":"1","preferredName":"Carcinoma In Situ","longName":"2935534v1.00","preferredDefinition":"A malignant epithelial neoplasm which is confined to the epithelial layer without evidence of further tissue invasion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carcinoma In Situ","conceptCode":"C2917","definition":"A malignant epithelial neoplasm which is confined to the epithelial layer without evidence of further tissue invasion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"71F88553-C4DE-17CC-E040-BB89AD43398B","latestVersionIndicator":"Yes","beginDate":"2009-08-25","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-08-25","modifiedBy":"GDEEN","dateModified":"2023-04-11","changeDescription":"Updated definition with current NCIt. 4.10.19 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C63928F-29BB-641E-E053-F662850A3D36","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Carcinoma Arising from Craniopharyngioma","valueDescription":"Carcinoma Arising from Craniopharyngioma","ValueMeaning":{"publicId":"6798056","version":"1","preferredName":"Carcinoma Arising from Craniopharyngioma","longName":"6798056","preferredDefinition":"A rare condition characterized by the development of a carcinoma in a pre-existing craniopharyngioma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carcinoma Arising from Craniopharyngioma","conceptCode":"C79949","definition":"A rare condition characterized by the development of a carcinoma in a pre-existing craniopharyngioma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C63928F-29C9-641E-E053-F662850A3D36","latestVersionIndicator":"Yes","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C63928F-29E2-641E-E053-F662850A3D36","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Carcinoma","valueDescription":"Carcinoma","ValueMeaning":{"publicId":"2935533","version":"1","preferredName":"Carcinoma","longName":"2935533","preferredDefinition":"A malignant tumor arising from epithelial cells.  Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas.  Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis.  Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated.  Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites.  Lung carcinoma, skin carcinoma, breast carcinoma, and prostate carcinoma are the most frequently seen carcinomas. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carcinoma","conceptCode":"C2916","definition":"A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"71F88553-C4BB-17CC-E040-BB89AD43398B","latestVersionIndicator":"Yes","beginDate":"2009-08-25","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-08-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C63928F-29EC-641E-E053-F662850A3D36","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Carcinoid Tumor","valueDescription":"Carcinoid Tumor","ValueMeaning":{"publicId":"2956072","version":"1","preferredName":"Carcinoid Tumor","longName":"2956072","preferredDefinition":"Carcinoid tumor, also known as well differentiated endocrine neoplasm, is a slow growing neuroendocrine tumor, composed of uniform, round, or polygonal cells having monotonous, centrally located nuclei and small nucleoli, infrequent mitoses, and no necrosis.  The tumor may show a variety of patterns, such as solid, trabecular, and acinar.  Electron microscopy shows small secretory granules.  Immunohistochemical studies reveal NSE, as well as chromogranin immunoreactivity.  Malignant histology (cellular pleomorphism, hyperchromatic nuclei, prominent nucleoli, necrosis, and mitoses) can occasionally be seen.  Such cases may have an aggressive clinical course.  Gastrointestinal tract and lung are common sites of involvement.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carcinoid Tumor","conceptCode":"C2915","definition":"A slow growing neuroendocrine tumor, composed of uniform, round, or polygonal cells having monotonous, centrally located nuclei and small nucleoli, infrequent mitoses, and no necrosis.  The tumor may show a variety of patterns, such as solid, trabecular, and acinar.  Electron microscopy shows small secretory granules.  Immunohistochemical studies reveal NSE, as well as chromogranin immunoreactivity.  Malignant histology (cellular pleomorphism, hyperchromatic nuclei, prominent nucleoli, necrosis, and mitoses) can occasionally be seen.  Such cases may have an aggressive clinical course.  Gastrointestinal tract and lung are common sites of involvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"76EBECE2-B719-A0E2-E040-BB89AD435984","latestVersionIndicator":"Yes","beginDate":"2009-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-10-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C63928F-29F6-641E-E053-F662850A3D36","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Burkitt Lymphoma","valueDescription":"Burkitt Lymphoma","ValueMeaning":{"publicId":"4173731","version":"1","preferredName":"Burkitt Lymphoma","longName":"4173731","preferredDefinition":"A highly aggressive lymphoma composed of monomorphic medium-sized B-cells with basophilic cytoplasm and numerous mitotic figures.  It is often associated with the presence of Epstein-Barr virus (EBV) and is commonly seen in AIDS patients.  Three morphologic variants are recognized: classical Burkitt lymphoma, Burkitt lymphoma with plasmacytoid differentiation, and atypical Burkitt/Burkitt-like lymphoma.  All cases express the MYC translocation [t(8;14)]. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Burkitt Lymphoma","conceptCode":"C2912","definition":"A highly aggressive lymphoma composed of monomorphic medium-sized B-cells with basophilic cytoplasm and numerous mitotic figures.  It is often associated with the presence of Epstein-Barr virus (EBV) and is commonly seen in AIDS patients.  Three morphologic variants are recognized: classical Burkitt lymphoma, Burkitt lymphoma with plasmacytoid differentiation, and atypical Burkitt/Burkitt-like lymphoma.  All cases express the MYC translocation [t(8;14)]. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F33D05F6-4928-3FBE-E040-BB89AD433F7A","latestVersionIndicator":"Yes","beginDate":"2014-02-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2014-02-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C63928F-2A0A-641E-E053-F662850A3D36","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Burkitt Leukemia","valueDescription":"Burkitt Leukemia","ValueMeaning":{"publicId":"4722744","version":"1","preferredName":"Burkitt Leukemia","longName":"4722744","preferredDefinition":"The leukemic counterpart of Burkitt's lymphoma. The characteristic Burkitt cells are seen in the bone marrow and the peripheral blood. This is an aggressive leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Burkitt Leukemia","conceptCode":"C7400","definition":"The leukemic counterpart of Burkitt's lymphoma. The characteristic Burkitt cells are seen in the bone marrow and the peripheral blood. This is an aggressive leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8AB028-C458-4E21-E050-BB89AD43094A","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C63928F-2A1E-641E-E053-F662850A3D36","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Bronchogenic Carcinoma","valueDescription":"Bronchogenic Carcinoma","ValueMeaning":{"publicId":"3210692","version":"1","preferredName":"Bronchogenic Carcinoma","longName":"3210692","preferredDefinition":"A lung carcinoma arising from the bronchial epithelium.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bronchogenic Carcinoma","conceptCode":"C35875","definition":"A lung carcinoma arising from the bronchial epithelium.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-8EF8-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C63928F-2A29-641E-E053-F662850A3D36","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Breast Neoplasm","valueDescription":"Breast Neoplasm","ValueMeaning":{"publicId":"4395786","version":"1","preferredName":"Breast Neoplasm","longName":"4395786","preferredDefinition":"A benign or malignant neoplasm of the breast parenchyma. It can originate from the ducts, lobules or the breast adipose tissue. Breast neoplasms are much more common in females than males.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Neoplasm","conceptCode":"C2910","definition":"A benign or malignant neoplasm of the breast parenchyma. It can originate from the ducts, lobules or the breast adipose tissue. Breast neoplasms are much more common in females than males.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FEB8F754-DB64-8D06-E040-BB89AD437F49","latestVersionIndicator":"Yes","beginDate":"2014-07-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C63928F-2A34-641E-E053-F662850A3D36","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Breast Melanoma","valueDescription":"Breast Melanoma","ValueMeaning":{"publicId":"6798058","version":"1","preferredName":"Breast Melanoma","longName":"6798058","preferredDefinition":"A melanoma that arises usually from the breast skin and less often from the breast glandular tissue.  Primary breast melanomas are rare.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Melanoma","conceptCode":"C8410","definition":"A melanoma that arises usually from the breast skin and less often from the breast glandular tissue.  Primary breast melanomas are rare.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C63928F-2A42-641E-E053-F662850A3D36","latestVersionIndicator":"Yes","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C63928F-2A5B-641E-E053-F662850A3D36","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Breast Carcinoma","valueDescription":"Breast Carcinoma","ValueMeaning":{"publicId":"5581329","version":"1","preferredName":"Breast Carcinoma","longName":"5581329","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42019733-B6D0-634F-E053-F662850A5A61","latestVersionIndicator":"Yes","beginDate":"2016-11-23","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2016-11-23","modifiedBy":"FINCHAMB","dateModified":"2024-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C63928F-2A6F-641E-E053-F662850A3D36","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Carcinoma in a Polyp","valueDescription":"Carcinoma in a Polyp","ValueMeaning":{"publicId":"6835482","version":"1","preferredName":"Carcinoma in a Polyp","longName":"6835482","preferredDefinition":"Carcinoma arising in a polyp.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carcinoma in a Polyp","conceptCode":"C7682","definition":"Carcinoma arising in a polyp.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED6DB46-A3D7-0FAD-E053-F662850AAFE1","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED6DB46-A3F0-0FAD-E053-F662850AAFE1","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Neuroendocrine Carcinoma","valueDescription":"Neuroendocrine Carcinoma","ValueMeaning":{"publicId":"5340871","version":"1","preferredName":"Neuroendocrine Carcinoma","longName":"5340871","preferredDefinition":"A malignant neuroendocrine neoplasm composed of cells containing secretory granules that stain positive for NSE and chromogranin.  The neoplastic cells are often round and form clusters or trabecular sheets.  Representative examples are small cell carcinoma, large cell neuroendocrine carcinoma, and Merkel cell carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neuroendocrine Carcinoma","conceptCode":"C3773","definition":"A usually aggressive carcinoma composed of malignant cells exhibiting neuroendocrine differentiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"375CBC91-9462-3C74-E050-BB89AD4344B9","latestVersionIndicator":"Yes","beginDate":"2016-07-11","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-07-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED4B8E8-6311-3184-E053-F662850A89A7","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Cerebral Neoplasm","valueDescription":"Malignant Cerebral Neoplasm","ValueMeaning":{"publicId":"6835483","version":"1","preferredName":"Malignant Cerebral Neoplasm","longName":"6835483","preferredDefinition":"A malignant neoplasm involving the cerebrum.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Cerebral Neoplasm","conceptCode":"C4577","definition":"A malignant neoplasm involving the cerebrum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED6DB46-A3FC-0FAD-E053-F662850AAFE1","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED6DB46-A415-0FAD-E053-F662850AAFE1","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Intracranial Neoplasm","valueDescription":"Malignant Intracranial Neoplasm","ValueMeaning":{"publicId":"6835484","version":"1","preferredName":"Malignant Intracranial Neoplasm","longName":"6835484","preferredDefinition":"A malignant neoplasm involving the intracranial space.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Intracranial Neoplasm","conceptCode":"C5114","definition":"A malignant neoplasm involving the intracranial space.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED6DB46-A421-0FAD-E053-F662850AAFE1","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED6DB46-A43A-0FAD-E053-F662850AAFE1","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Neoplasm by Grade","valueDescription":"Malignant Neoplasm by Grade","ValueMeaning":{"publicId":"6835485","version":"1","preferredName":"Malignant Neoplasm by Grade","longName":"6835485","preferredDefinition":"A term that refers to the categorization of malignant neoplasm by histologic grade.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Neoplasm by Grade","conceptCode":"C36041","definition":"A term that refers to the categorization of malignant neoplasm by histologic grade.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED6DB46-A446-0FAD-E053-F662850AAFE1","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED6DB46-A45F-0FAD-E053-F662850AAFE1","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Neoplasm of Multiple Primary Sites","valueDescription":"Malignant Neoplasm of Multiple Primary Sites","ValueMeaning":{"publicId":"6835486","version":"1","preferredName":"Malignant Neoplasm of Multiple Primary Sites","longName":"6835486","preferredDefinition":"A malignant neoplasm arising in multiple primary sites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Neoplasm of Multiple Primary Sites","conceptCode":"C35427","definition":"A malignant neoplasm arising in multiple primary sites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED6DB46-A46B-0FAD-E053-F662850AAFE1","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED6DB46-A484-0FAD-E053-F662850AAFE1","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Retroperitoneal Neoplasm","valueDescription":"Malignant Retroperitoneal Neoplasm","ValueMeaning":{"publicId":"6835271","version":"1","preferredName":"Malignant Retroperitoneal Neoplasm","longName":"6835271","preferredDefinition":"A primary or metastatic malignant neoplasm involving the retroperitoneum.  The vast majority of cases are carcinomas, lymphomas, or sarcomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Retroperitoneal Neoplasm","conceptCode":"C3537","definition":"A primary or metastatic malignant neoplasm involving the retroperitoneum.  The vast majority of cases are carcinomas, lymphomas, or sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED5EB8E-A1AC-21AC-E053-F662850AA6A9","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED5EB8E-A1C5-21AC-E053-F662850AA6A9","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Salivary Gland Neoplasm","valueDescription":"Malignant Salivary Gland Neoplasm","ValueMeaning":{"publicId":"4722785","version":"1","preferredName":"Malignant Salivary Gland Neoplasm","longName":"4722785","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the major or minor salivary glands.  Representative examples include carcinoma, lymphoma, and sarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Salivary Gland Neoplasm","conceptCode":"C3811","definition":"A primary or metastatic malignant neoplasm that affects the major or minor salivary glands.  Representative examples include carcinoma, lymphoma, and sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-237F-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED5EB8E-A1D9-21AC-E053-F662850AA6A9","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Scrotal Neoplasm","valueDescription":"Malignant Scrotal Neoplasm","ValueMeaning":{"publicId":"6835273","version":"1","preferredName":"Malignant Scrotal Neoplasm","longName":"6835273","preferredDefinition":"A primary or metastatic malignant neoplasm affecting the scrotum.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Scrotal Neoplasm","conceptCode":"C3560","definition":"A primary or metastatic malignant neoplasm affecting the scrotum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED5EB8E-A1E6-21AC-E053-F662850AA6A9","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED5EB8E-A1FF-21AC-E053-F662850AA6A9","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Skin Neoplasm","valueDescription":"Malignant Skin Neoplasm","ValueMeaning":{"publicId":"3210712","version":"1","preferredName":"Malignant Skin Neoplasm","longName":"3210712","preferredDefinition":"A primary or metastatic tumor involving the skin. Primary malignant skin tumors most often are carcinomas (either basal cell or squamous cell carcinomas that arise from cells in the epidermis) or melanomas that arise from pigment-containing skin melanocytes. Metastatic tumors to the skin include carcinomas and lymphomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Skin Neoplasm","conceptCode":"C2920","definition":"A primary or metastatic malignant neoplasm involving the skin. Primary malignant skin neoplasms most often are carcinomas (either basal cell or squamous cell carcinomas) or melanomas. Metastatic malignant neoplasms to the skin include carcinomas and lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-928C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED5EB8E-A209-21AC-E053-F662850AA6A9","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Small Intestinal Neoplasm","valueDescription":"Malignant Small Intestinal Neoplasm","ValueMeaning":{"publicId":"6835275","version":"1","preferredName":"Malignant Small Intestinal Neoplasm","longName":"6835275","preferredDefinition":"A primary or metastatic malignant neoplasm involving the small intestine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Small Intestinal Neoplasm","conceptCode":"C7523","definition":"A primary or metastatic malignant neoplasm involving the small intestine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED5EB8E-A217-21AC-E053-F662850AA6A9","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED5EB8E-A230-21AC-E053-F662850AA6A9","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Soft Palate Neoplasm","valueDescription":"Malignant Soft Palate Neoplasm","ValueMeaning":{"publicId":"6835277","version":"1","preferredName":"Malignant Soft Palate Neoplasm","longName":"6835277","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the soft palate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Soft Palate Neoplasm","conceptCode":"C3529","definition":"A primary or metastatic malignant neoplasm that affects the soft palate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED5EB8E-A23D-21AC-E053-F662850AA6A9","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED5EB8E-A256-21AC-E053-F662850AA6A9","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Soft Tissue Neoplasm","valueDescription":"SFT-NOS - 171.9; Soft Tissue","ValueMeaning":{"publicId":"2572692","version":"1","preferredName":"SFT-NOS - 171.9; Soft Tissue","longName":"2572692","preferredDefinition":"A malignant mesenchymal neoplasm arising exclusively from the soft tissues.  Representative examples include soft tissue sarcoma, extraosseous Ewing sarcoma/peripheral primitive neuroectodermal tumor, and malignant hemangiopericytoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Soft Tissue Neoplasm","conceptCode":"C4867","definition":"A malignant neoplasm arising exclusively from the soft tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E901-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED5EB8E-A26A-21AC-E053-F662850AA6A9","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Solid Neoplasm","valueDescription":"Malignant Solid Neoplasm","ValueMeaning":{"publicId":"6835279","version":"1","preferredName":"Malignant Solid Neoplasm","longName":"6835279","preferredDefinition":"A malignant neoplasm arising from tissues that do not include fluid areas. Representative examples include carcinomas and sarcomas. Hematopoietic and lymphoid tissue malignancies are not considered solid neoplasms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Solid Neoplasm","conceptCode":"C132146","definition":"A malignant neoplasm arising from tissues that do not include fluid areas. Representative examples include carcinomas and sarcomas. Hematopoietic and lymphoid tissue malignancies are not considered solid neoplasms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED5EB8E-A278-21AC-E053-F662850AA6A9","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED5EB8E-A291-21AC-E053-F662850AA6A9","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Well Differentiated Malignant Neoplasm","valueDescription":"Well Differentiated Malignant Neoplasm","ValueMeaning":{"publicId":"6838671","version":"1","preferredName":"Well Differentiated Malignant Neoplasm","longName":"6838671","preferredDefinition":"A neoplasm whose histologic characteristics are similar to the tissue from which it arose.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Well Differentiated Malignant Neoplasm","conceptCode":"C36052","definition":"A malignant neoplasm with morphological features reminiscent of the tissue from which it arose.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED68514-B39D-6087-E053-F662850A81CE","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED68514-B3B6-6087-E053-F662850A81CE","beginDate":"2019-07-29","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Virus-Related Carcinoma","valueDescription":"Virus-Related Carcinoma","ValueMeaning":{"publicId":"6838672","version":"1","preferredName":"Virus-Related Carcinoma","longName":"6838672","preferredDefinition":"Carcinoma that develops in the context of an individual infected with a virus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Virus-Related Carcinoma","conceptCode":"C27698","definition":"Carcinoma that develops in the context of an individual infected with a virus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED68514-B3C2-6087-E053-F662850A81CE","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED68514-B3DB-6087-E053-F662850A81CE","beginDate":"2019-07-29","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Undifferentiated Malignant Neoplasm","valueDescription":"Undifferentiated Malignant Neoplasm","ValueMeaning":{"publicId":"6838673","version":"1","preferredName":"Undifferentiated Malignant Neoplasm","longName":"6838673","preferredDefinition":"A neoplasm that has minimal to no differentiating features.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Undifferentiated Malignant Neoplasm","conceptCode":"C36051","definition":"A neoplasm that has minimal to no differentiating features.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED68514-B3E7-6087-E053-F662850A81CE","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED68514-B400-6087-E053-F662850A81CE","beginDate":"2019-07-29","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Recurrent Melanoma","valueDescription":"Recurrent Melanoma","ValueMeaning":{"publicId":"6838674","version":"1","preferredName":"Recurrent Melanoma","longName":"6838674","preferredDefinition":"The reemergence of a melanoma after a period of remission.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recurrent Melanoma","conceptCode":"C7087","definition":"The reemergence of a melanoma after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED68514-B40C-6087-E053-F662850A81CE","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED68514-B425-6087-E053-F662850A81CE","beginDate":"2019-07-29","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Primary Carcinoma","valueDescription":"Primary Carcinoma","ValueMeaning":{"publicId":"6838675","version":"1","preferredName":"Primary Carcinoma","longName":"6838675","preferredDefinition":"A carcinoma that exits in its original anatomic site of growth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Non-Metastatic Carcinoma","conceptCode":"C9481","definition":"Carcinoma that is confined to the site in which it initially manifested.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED68514-B431-6087-E053-F662850A81CE","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED68514-B44A-6087-E053-F662850A81CE","beginDate":"2019-07-29","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Poorly Differentiated Malignant Neoplasm","valueDescription":"Poorly Differentiated Malignant Neoplasm","ValueMeaning":{"publicId":"6838676","version":"1","preferredName":"Poorly Differentiated Malignant Neoplasm","longName":"6838676","preferredDefinition":"A neoplasm whose histologic characteristics have regressed and are more similar to stem cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Poorly Differentiated Malignant Neoplasm","conceptCode":"C36050","definition":"A neoplasm whose histologic characteristics have regressed and are more similar to stem cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED68514-B456-6087-E053-F662850A81CE","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED68514-B46F-6087-E053-F662850A81CE","beginDate":"2019-07-29","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Acute Leukemia","valueDescription":"Acute Leukemia","ValueMeaning":{"publicId":"2590858","version":"1","preferredName":"Acute Leukemia","longName":"2590858","preferredDefinition":"leukemia in which the involved cell shows little or no differentiation, usually consisting of blast cells; two types are distinguished, acute lymphocytic and acute myelogenous leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Leukemia","conceptCode":"C9300","definition":"A clonal (malignant) hematopoietic disorder with an acute onset, affecting the bone marrow and the peripheral blood.  The malignant cells show minimal differentiation and are called blasts, either myeloid blasts (myeloblasts) or lymphoid blasts (lymphoblasts).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28446C9F-B57E-188F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-30","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED74ACF-F614-337A-E053-F662850AFA7E","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Acute Myeloid Leukemia with Multilineage Dysplasia","valueDescription":"De novo Acute Myeloid Leukemia with Multilineage Dysplasia","ValueMeaning":{"publicId":"3322412","version":"1","preferredName":"De novo Acute Myeloid Leukemia with Multilineage Dysplasia","longName":"3322412","preferredDefinition":"An acute myeloid leukemia, characterized by the presence of myelodysplastic features in at least 50% of the cells of at least two hematopoietic cell lines, arising de novo and not as a result of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with Multilineage Dysplasia","conceptCode":"C9289","definition":"An acute myeloid leukemia arising de novo and not as a result of treatment. It is characterized by the presence of myelodysplastic features in at least 50% of the cells of at least two hematopoietic cell lines. Patients often present with severe cytopenia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B36DFA8A-BE08-6AE7-E040-BB89AD432073","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED74ACF-F628-337A-E053-F662850AFA7E","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Acute Promyelocytic Leukemia with PML-RARA","valueDescription":"Acute Promyelocytic Leukemia with t(15;17)(q22;q12); PML-RARA","ValueMeaning":{"publicId":"4722782","version":"1","preferredName":"Acute Promyelocytic Leukemia with t(15;17)(q22;q12); PML-RARA","longName":"4722782","preferredDefinition":"An acute myeloid leukemia (AML) in which abnormal promyelocytes predominate.  It is characterized by the t(15;17)(q22;q12) translocation.  There are two variants: the typical and microgranular variant.  This AML is particularly sensitive to treatment with all trans-retinoic acid and has a favorable prognosis.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Promyelocytic Leukemia with t(15;17)(q24.1;q21.2); PML-RARA","conceptCode":"C3182","definition":"An acute myeloid leukemia (AML) in which abnormal promyelocytes predominate. It is characterized by the PML-RARA fusion. There are two variants: the typical and microgranular variant.  This AML is particularly sensitive to treatment with all trans-retinoic acid and has a favorable prognosis. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-22C4-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED74ACF-F63C-337A-E053-F662850AFA7E","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Adrenal Cortex Neoplasm","valueDescription":"Malignant Adrenal Cortex Neoplasm","ValueMeaning":{"publicId":"6840368","version":"1","preferredName":"Malignant Adrenal Cortex Neoplasm","longName":"6840368","preferredDefinition":"A primary or metastatic malignant neoplasm affecting the adrenal cortex.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Adrenal Cortical Neoplasm","conceptCode":"C9327","definition":"A primary or metastatic malignant neoplasm affecting the adrenal cortex.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED74ACF-F649-337A-E053-F662850AFA7E","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED74ACF-F662-337A-E053-F662850AFA7E","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Ethmoid Sinus Neoplasm","valueDescription":"Malignant Ethmoid Sinus Neoplasm","ValueMeaning":{"publicId":"6840370","version":"1","preferredName":"Malignant Ethmoid Sinus Neoplasm","longName":"6840370","preferredDefinition":"A primary or metastatic malignant neoplasm involving the ethmoid sinus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Ethmoid Sinus Neoplasm","conceptCode":"C3541","definition":"A primary or metastatic malignant neoplasm involving the ethmoid sinus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED74ACF-F66F-337A-E053-F662850AFA7E","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED74ACF-F688-337A-E053-F662850AFA7E","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Exocervical Neoplasm","valueDescription":"Malignant Exocervical Neoplasm","ValueMeaning":{"publicId":"6840372","version":"1","preferredName":"Malignant Exocervical Neoplasm","longName":"6840372","preferredDefinition":"A malignant neoplasm that affects the exocervix.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Exocervical Neoplasm","conceptCode":"C3554","definition":"A malignant neoplasm that affects the exocervix.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED74ACF-F695-337A-E053-F662850AFA7E","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED74ACF-F6AE-337A-E053-F662850AFA7E","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Eye Neoplasm","valueDescription":"EYE - 190.9; Eye, part unspecified","ValueMeaning":{"publicId":"3826038","version":"1","preferredName":"EYE - 190.9; Eye, part unspecified","longName":"3826038","preferredDefinition":"A primary or metastatic malignant neoplasm involving the structures of the eye (conjunctiva, cornea, uvea, retina), the lacrimal gland, and the eyelid. Representative examples include melanoma, carcinoma, lymphoma, and retinoblastoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Eye Neoplasm","conceptCode":"C4767","definition":"A primary or metastatic malignant neoplasm involving the structures of the eye (conjunctiva, cornea, uvea, retina), the lacrimal system, and the eyelid. Representative examples include melanoma, carcinoma, lymphoma, and retinoblastoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E25C7C1F-51AE-1CCC-E040-BB89AD434814","latestVersionIndicator":"Yes","beginDate":"2013-07-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-07-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED74ACF-F6C2-337A-E053-F662850AFA7E","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Ocular Melanoma with Extraocular Extension","valueDescription":"Ocular Melanoma with Extraocular Extension","ValueMeaning":{"publicId":"6840373","version":"1","preferredName":"Ocular Melanoma with Extraocular Extension","longName":"6840373","preferredDefinition":"A melanoma arising from and extending beyond the structures of the eye.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ocular Melanoma with Extraocular Extension","conceptCode":"C7913","definition":"A melanoma arising from and extending beyond the structures of the eye.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED74ACF-F6CF-337A-E053-F662850AFA7E","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED74ACF-F6E8-337A-E053-F662850AFA7E","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Pancreatic Neuroendocrine Carcinoma","valueDescription":"Pancreatic Neuroendocrine Carcinoma","ValueMeaning":{"publicId":"3211336","version":"1","preferredName":"Pancreatic Neuroendocrine Carcinoma","longName":"3211336","preferredDefinition":"A malignant endocrine neoplasm arising from the islets of Langerhans.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pancreatic Neuroendocrine Carcinoma","conceptCode":"C3770","definition":"An aggressive, high-grade, and poorly differentiated carcinoma with neuroendocrine differentiation that arises from the pancreas. The mitotic count is more than 20 per 10 HPF. It is classified as either small or large cell neuroendocrine carcinoma based on the size of the malignant cells, the prominence of the nucleoli, and the amount of cytoplasm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-EFA7-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED74ACF-F6FC-337A-E053-F662850AFA7E","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Tracheal Carcinoma","valueDescription":"Tracheal Carcinoma","ValueMeaning":{"publicId":"6834700","version":"1","preferredName":"Tracheal Carcinoma","longName":"6834700","preferredDefinition":"Malignant epithelial neoplasm arising from the tracheal mucosa.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tracheal Carcinoma","conceptCode":"C9347","definition":"Malignant epithelial neoplasm arising from the tracheal mucosa.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8EBFA9C9-856A-695C-E053-F662850A6B91","latestVersionIndicator":"Yes","beginDate":"2019-07-28","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-28","modifiedBy":"ONEDATA","dateModified":"2019-07-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED74ACF-F707-337A-E053-F662850AFA7E","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Yolk Sac Tumor","valueDescription":"Yolk Sac Tumor","ValueMeaning":{"publicId":"4264851","version":"1","preferredName":"Yolk Sac Tumor","longName":"4264851","preferredDefinition":"A non-seminomatous malignant germ cell tumor composed of primitive germ cells.  It is the most common malignant germ cell tumor in the pediatric population. It occurs in the infant testis, ovary, sacrococcygeal region, vagina, uterus, prostate, abdomen, liver, retroperitoneum, thorax, and pineal/third ventricle. The tumor mimics the yolk sac of the embryo and produces alpha-fetoprotein (AFP). Treatment includes: surgical resection, radiation, and chemotherapy. This tumor is very responsive to chemotherapy regimens that include cisplatinum.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yolk Sac Tumor","conceptCode":"C3011","definition":"A non-seminomatous malignant germ cell tumor composed of primitive germ cells.  It is the most common malignant germ cell tumor in the pediatric population. It occurs in the infant testis, ovary, sacrococcygeal region, vagina, uterus, prostate, abdomen, liver, retroperitoneum, thorax, and pineal/third ventricle. The tumor mimics the yolk sac of the embryo and produces alpha-fetoprotein (AFP). Treatment includes: surgical resection, radiation, and chemotherapy. This tumor is very responsive to chemotherapy regimens that include cisplatinum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67A42F0-0203-5F77-E040-BB89AD433177","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED74ACF-F71B-337A-E053-F662850AFA7E","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Adenocarcinoma","valueDescription":"Adenocarcinoma","ValueMeaning":{"publicId":"2831117","version":"1","preferredName":"Adenocarcinoma","longName":"2831117","preferredDefinition":"carcinoma derived from glandular tissue or in which tumor cells form recognizable glandular structures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adenocarcinoma","conceptCode":"C2852","definition":"A common cancer characterized by the presence of malignant glandular cells.  Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous).  Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"61F598EF-7D06-BDE9-E040-BB89AD43552F","latestVersionIndicator":"Yes","beginDate":"2009-02-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-02-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9A5256-BA69-5250-E053-F662850AEFA8","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Hodgkins Paragranuloma","valueDescription":"HD - 201.0; Hodgkins Disease","ValueMeaning":{"publicId":"2572657","version":"1","preferredName":"HD - 201.0; Hodgkins Disease","longName":"2572657v1.00","preferredDefinition":"An obsolete term that includes cases currently classified as nodular lymphocyte predominant Hodgkin lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hodgkin's Paragranuloma","conceptCode":"C26956","definition":"An obsolete term that includes cases currently classified as nodular lymphocyte predominant Hodgkin lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8DE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"KUMMEROA","dateModified":"2023-09-05","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/26/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8EEC240D-8AD2-7DCB-E053-F662850AA3D9","beginDate":"2019-07-30","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-07-30","modifiedBy":"ONEDATA","dateModified":"2019-07-30","deletedIndicator":"No"},{"value":"Mixed Germ Cell Tumor","valueDescription":"Mixed Germ Cell Tumor","ValueMeaning":{"publicId":"3249742","version":"1","preferredName":"Mixed Germ Cell Tumor","longName":"3249742","preferredDefinition":"A malignant germ cell tumor characterized by the presence of at least two different germ cell components. The different germ cell components include choriocarcinoma, embryonal carcinoma, yolk sac tumor, teratoma, and seminoma. It occurs in the ovary, testis, and extragonadal sites including central nervous system and mediastinum.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mixed Germ Cell Tumor","conceptCode":"C4290","definition":"A malignant germ cell tumor characterized by the presence of at least two different germ cell tumor components. The different germ cell tumor components include choriocarcinoma, embryonal carcinoma, yolk sac tumor, teratoma, and seminoma. It occurs in the ovary, testis, and extragonadal sites including central nervous system and mediastinum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6D9FB96-39AC-EB3C-E040-BB89AD435DB4","latestVersionIndicator":"Yes","beginDate":"2011-06-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED6BCAF-DBC5-7037-E053-F662850AD8D2","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Moderately Differentiated Malignant Neoplasm","valueDescription":"Moderately Differentiated Malignant Neoplasm","ValueMeaning":{"publicId":"6835470","version":"1","preferredName":"Moderately Differentiated Malignant Neoplasm","longName":"6835470","preferredDefinition":"A neoplasm whose histologic characteristics are intermediate between poorly differentiated and well differentiated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Moderately Differentiated Malignant Neoplasm","conceptCode":"C36049","definition":"A neoplasm whose histologic characteristics are intermediate between poorly differentiated and well differentiated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED6BCAF-DBD2-7037-E053-F662850AD8D2","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED6BCAF-DBEB-7037-E053-F662850AD8D2","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Monoclonal Immunoglobulin Deposition Disease","valueDescription":"Monoclonal Immunoglobulin Deposition Disease","ValueMeaning":{"publicId":"6690778","version":"1","preferredName":"Monoclonal Immunoglobulin Deposition Disease","longName":"6690778","preferredDefinition":"A plasma cell neoplasm characterized by the deposition of immunoglobulin in tissues, resulting in impaired organ function. It includes the following entities: primary amyloidosis, heavy chain deposition disease, and light chain deposition disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Monoclonal Immunoglobulin Deposition Disease","conceptCode":"C7151","definition":"A mature B-cell neoplasm characterized by the deposition of immunoglobulin in tissues, resulting in impaired organ function. It includes the following entities: primary amyloidosis, heavy chain deposition disease, and light chain deposition disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"865593A6-39E0-70DE-E053-F662850AC416","latestVersionIndicator":"Yes","beginDate":"2019-04-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-04-12","modifiedBy":"ONEDATA","dateModified":"2019-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED6BCAF-DBFF-7037-E053-F662850AD8D2","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Mucin-Producing Carcinoma","valueDescription":"Mucin-Producing Carcinoma","ValueMeaning":{"publicId":"6835472","version":"1","preferredName":"Mucin-Producing Carcinoma","longName":"6835472","preferredDefinition":"A carcinoma that produces mucin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mucin-Producing Carcinoma","conceptCode":"C27825","definition":"A carcinoma that produces mucin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED6BCAF-DC0D-7037-E053-F662850AD8D2","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED6BCAF-DC26-7037-E053-F662850AD8D2","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Mycosis Fungoides","valueDescription":"Mycosis Fungoides","ValueMeaning":{"publicId":"4264966","version":"1","preferredName":"Mycosis Fungoides","longName":"4264966","preferredDefinition":"A peripheral (mature) T-cell lymphoma presenting in the skin with patches/plaques. It is characterized by epidermal and dermal infiltration of small to medium-sized T-cells with cerebriform nuclei.  Patients with limited disease generally have an excellent prognosis.  In the more advanced stages, the prognosis is poor. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycosis Fungoides","conceptCode":"C3246","definition":"A peripheral (mature) T-cell lymphoma presenting in the skin with patches/plaques. It is characterized by epidermal and dermal infiltration of small to medium-sized T-cells with cerebriform nuclei.  Patients with limited disease generally have an excellent prognosis.  In the more advanced stages, the prognosis is poor. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3BBF-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED6BCAF-DC30-7037-E053-F662850AD8D2","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Myelodysplastic Syndrome","valueDescription":"Myelodysplastic Syndrome","ValueMeaning":{"publicId":"3946618","version":"1","preferredName":"Myelodysplastic Syndrome","longName":"3946618","preferredDefinition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome","conceptCode":"C3247","definition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA87B0E5-6712-6876-E040-BB89AD437204","latestVersionIndicator":"Yes","beginDate":"2013-11-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-11-06","modifiedBy":"GDEEN","dateModified":"2022-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED6BCAF-DC3A-7037-E053-F662850AD8D2","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Myelodysplastic Syndrome with Excess Blasts","valueDescription":"Refractory Anemia with Excess Blasts","ValueMeaning":{"publicId":"2838712","version":"1","preferredName":"Myelodysplastic Syndrome with Excess Blasts","longName":"2838712v1.00","preferredDefinition":"Myelodysplastic syndrome characterized by the presence of 5-9% blasts in bone marrow and 2-9% blasts in peripheral blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome with Excess Blasts","conceptCode":"C7506","definition":"Myelodysplastic syndrome characterized by the presence of 5-9% blasts in bone marrow and 2-9% blasts in peripheral blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A740CA-9753-2FE1-E040-BB89AD4311CA","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED6BCAF-DC4E-7037-E053-F662850AD8D2","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Myelodysplastic Syndrome with Excess Blasts-2","valueDescription":"RAEB-2","ValueMeaning":{"publicId":"2582030","version":"1","preferredName":"RAEB-2","longName":"2582030","preferredDefinition":"A myelodysplastic syndrome defined by 10-19% blasts in the bone marrow or 5-19% blasts in the blood. Approximately 33% of cases progress to acute leukemia.  The prognosis is usually poor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome/Acute Myeloid Leukemia","conceptCode":"C7168","definition":"A myelodysplastic syndrome characterized by the presence of dysplasia in one or more hematopoietic cell lineages and 10-19% blasts in bone marrow or peripheral blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0D7B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-21","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-11-21","modifiedBy":"KUMMEROA","dateModified":"2022-07-21","changeDescription":"Refreshed concept association to pick up correct symbol instead of  <. 12.15.17 Updated definition to match current NCIt as requested by NMDP. mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED6BCAF-DC62-7037-E053-F662850AD8D2","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Myelodysplastic Syndrome with Isolated del(5q)","valueDescription":"Myelodysplastic Syndrome Associated with Isolated del (5q) Chromosome Abnormality","ValueMeaning":{"publicId":"2738446","version":"1","preferredName":"Myelodysplastic Syndrome Associated with Isolated del (5q) Chromosome Abnormality","longName":"2738446","preferredDefinition":"A myelodysplastic syndrome characterized by a deletion between bands q31 and 33 on chromosome 5.  The number of blasts in the bone marrow and blood is <5%.  The bone marrow is usually hypercellular or normocellular with normal to increased, often hypolobated megakaryocytes.  The peripheral blood shows macrocytic anemia.  This syndrome occurs predominantly but not exclusively in middle age to older women.  The prognosis is good and transformation to acute leukemia is rare.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome with del(5q)","conceptCode":"C6867","definition":"A myelodysplastic syndrome characterized by a deletion between bands q31 and 33 on chromosome 5.  The number of blasts in the bone marrow and blood is <5%.  The bone marrow is usually hypercellular or normocellular with increased number of often hypolobated megakaryocytes.  The peripheral blood shows macrocytic anemia.  This syndrome occurs predominantly but not exclusively in middle age to older women.  The prognosis is good and transformation to acute leukemia is rare.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"49BDA45E-ED8B-65D3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-03-31","modifiedBy":"KUMMEROA","dateModified":"2022-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED6BCAF-DC77-7037-E053-F662850AD8D2","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Myelodysplastic/Myeloproliferative Neoplasm","valueDescription":"Myelodysplastic/Myeloproliferative Neoplasm","ValueMeaning":{"publicId":"5098072","version":"1","preferredName":"Myelodysplastic/Myeloproliferative Neoplasm","longName":"5098072","preferredDefinition":"A category of clonal hematopoietic disorders that have both myelodysplastic and myeloproliferative features at the time of initial presentation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic/Myeloproliferative Neoplasm","conceptCode":"C27262","definition":"A category of clonal hematopoietic disorders that have both myelodysplastic and myeloproliferative features at the time of initial presentation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28C8EDF1-003B-32DF-E050-BB89AD433904","latestVersionIndicator":"Yes","beginDate":"2016-01-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-01-07","modifiedBy":"GDEEN","dateModified":"2022-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED6BCAF-DC8C-7037-E053-F662850AD8D2","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Myeloid Leukemia","valueDescription":"Myeloid Leukemia","ValueMeaning":{"publicId":"4903679","version":"1","preferredName":"Myeloid Leukemia","longName":"4903679","preferredDefinition":"A clonal proliferation of myeloid cells and their precursors in the bone marrow, peripheral blood, and spleen. When the proliferating cells are immature myeloid cells and myeloblasts, it is called acute myeloid leukemia. When the proliferating myeloid cells are neutrophils, it is called chronic myelogenous leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myeloid Leukemia","conceptCode":"C3172","definition":"A clonal proliferation of myeloid cells and their precursors in the bone marrow, peripheral blood, and spleen. When the proliferating cells are immature myeloid cells and myeloblasts, it is called acute myeloid leukemia. When the proliferating myeloid cells are neutrophils, it is called chronic myelogenous leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B153AB5-0D14-4322-E050-BB89AD433CC8","latestVersionIndicator":"Yes","beginDate":"2015-07-17","endDate":null,"createdBy":"WONGW","dateCreated":"2015-07-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED6BCAF-DC96-7037-E053-F662850AD8D2","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Myeloid Neoplasm","valueDescription":"Myeloid Neoplasm","ValueMeaning":{"publicId":"6835473","version":"1","preferredName":"Myeloid Neoplasm","longName":"6835473","preferredDefinition":"Diseases in which too many blood cells are made in the bone marrow.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myeloid Neoplasm","conceptCode":"C9290","definition":"Proliferation of myeloid cells originating from a primitive stem cell.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED6BCAF-DCA3-7037-E053-F662850AD8D2","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED6BCAF-DCBC-7037-E053-F662850AD8D2","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Myeloid Sarcoma","valueDescription":"Myeloid Sarcoma","ValueMeaning":{"publicId":"2836806","version":"1","preferredName":"Myeloid Sarcoma","longName":"2836806","preferredDefinition":"A tumor mass composed of myeloblasts or immature myeloid cells.  It occurs in extramedullary sites or the bone.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myeloid Sarcoma","conceptCode":"C3520","definition":"A tumor mass composed of myeloblasts or immature myeloid cells.  It occurs in extramedullary sites or the bone.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6246291A-4BBC-4EA6-E040-BB89AD432443","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED6BCAF-DCD0-7037-E053-F662850AD8D2","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Myeloproliferative Neoplasm","valueDescription":"Myeloproliferative Neoplasm","ValueMeaning":{"publicId":"4264963","version":"1","preferredName":"Myeloproliferative Neoplasm","longName":"4264963","preferredDefinition":"A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. (WHO 2008)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myeloproliferative Neoplasm","conceptCode":"C4345","definition":"A group of myeloid neoplasms that includes the following: chronic myeloid leukemia, BCR-ABL1 positive; polycythemia vera; essential thrombocythemia;  primary myelofibrosis; chronic neutrophilic leukemia; chronic eosinophilic leukemia, not otherwise specified; and myeloproliferative neoplasm, unclassifiable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3B48-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED6BCAF-DCE5-7037-E053-F662850AD8D2","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Nasal Cavity and Paranasal Sinus Carcinoma","valueDescription":"Nasal Cavity and Paranasal Sinus Carcinoma","ValueMeaning":{"publicId":"6835474","version":"1","preferredName":"Nasal Cavity and Paranasal Sinus Carcinoma","longName":"6835474","preferredDefinition":"A carcinoma arising from the nasal cavity or paranasal sinuses.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sinonasal Carcinoma","conceptCode":"C54293","definition":"A carcinoma arising from the nasal cavity or paranasal sinuses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED6BCAF-DCEF-7037-E053-F662850AD8D2","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED6BCAF-DD08-7037-E053-F662850AD8D2","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Nasopharyngeal Carcinoma","valueDescription":"Nasopharyngeal Carcinoma","ValueMeaning":{"publicId":"4264956","version":"1","preferredName":"Nasopharyngeal Carcinoma","longName":"4264956","preferredDefinition":"A carcinoma arising from the nasopharyngeal epithelium.  It includes the following types: keratinizing squamous cell carcinoma, nonkeratinizing carcinoma (differentiated and undifferentiated), basaloid squamous cell carcinoma, and papillary adenocarcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nasopharyngeal Carcinoma","conceptCode":"C3871","definition":"A carcinoma arising from the nasopharyngeal epithelium.  It includes the following types: keratinizing squamous cell carcinoma, nonkeratinizing carcinoma (differentiated and undifferentiated), basaloid squamous cell carcinoma, and papillary adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3A91-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED6BCAF-DD13-7037-E053-F662850AD8D2","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Autoimmune Lymphoproliferative Syndrome-Associated Lymphoma","valueDescription":"Autoimmune Lymphoproliferative Syndrome-Associated Lymphoma","ValueMeaning":{"publicId":"6796709","version":"1","preferredName":"Autoimmune Lymphoproliferative Syndrome-Associated Lymphoma","longName":"6796709","preferredDefinition":"A lymphoma that arises in the context of autoimmune lymphoproliferative syndrome.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Autoimmune Lymphoproliferative Syndrome-Related Lymphoma","conceptCode":"C39578","definition":"A lymphoma that arises in the context of autoimmune lymphoproliferative syndrome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C5201B3-7023-5291-E053-F662850A82DE","latestVersionIndicator":"Yes","beginDate":"2019-06-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-27","modifiedBy":"TAYLORT","dateModified":"2019-08-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"90287F31-0185-1EDD-E053-F662850A7F0C","beginDate":"2019-08-15","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-08-15","modifiedBy":"ONEDATA","dateModified":"2019-08-15","deletedIndicator":"No"},{"value":"Benign Eyelid Neoplasm","valueDescription":"Benign Eyelid Neoplasm","ValueMeaning":{"publicId":"6797938","version":"1","preferredName":"Benign Eyelid Neoplasm","longName":"6797938","preferredDefinition":"A non-metastasizing neoplasm that arises from the upper or lower eyelid.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benign Eyelid Neoplasm","conceptCode":"C4354","definition":"A neoplasm that arises from the upper or lower eyelid and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C62F83B-6A7E-170D-E053-F662850AD8EA","latestVersionIndicator":"Yes","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C62F83B-6A97-170D-E053-F662850AD8EA","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Benign Exocrine Pancreas Neoplasm","valueDescription":"Benign Exocrine Pancreas Neoplasm","ValueMeaning":{"publicId":"6797940","version":"1","preferredName":"Benign Exocrine Pancreas Neoplasm","longName":"6797940","preferredDefinition":"A benign, non-metastasizing neoplasm arising from the exocrine pancreas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benign Exocrine Pancreas Neoplasm","conceptCode":"C4613","definition":"A neoplasm that arises from the exocrine pancreas and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C62F83B-6AA4-170D-E053-F662850AD8EA","latestVersionIndicator":"Yes","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C62F83B-6ABD-170D-E053-F662850AD8EA","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Benign Digestive System Neoplasm","valueDescription":"Benign Digestive System Neoplasm","ValueMeaning":{"publicId":"6797942","version":"1","preferredName":"Benign Digestive System Neoplasm","longName":"6797942","preferredDefinition":"A non-metastasizing neoplasm arising from any part of the digestive system.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benign Digestive System Neoplasm","conceptCode":"C4787","definition":"A neoplasm that arises from the digestive system and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C62F83B-6ACA-170D-E053-F662850AD8EA","latestVersionIndicator":"Yes","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C62F83B-6AE3-170D-E053-F662850AD8EA","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Peritoneal Mesothelioma","valueDescription":"Peritoneal Mesothelioma","ValueMeaning":{"publicId":"6832314","version":"1","preferredName":"Peritoneal Mesothelioma","longName":"6832314","preferredDefinition":"A benign or malignant mesothelial neoplasm that arises from the peritoneum.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Peritoneal Mesothelial Neoplasm","conceptCode":"C7633","definition":"A mesothelial neoplasm that arises from the peritoneum. It includes adenomatoid tumor, well differentiated papillary mesothelial tumor, multicystic mesothelioma, and malignant mesothelioma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E98B1C2-3A9E-1F35-E053-F662850ACC5E","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E98B1C2-3AB7-1F35-E053-F662850ACC5E","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Peripheral T-Cell Lymphoma, Not Otherwise Specified","valueDescription":"Peripheral T-Cell Lymphoma, Not Otherwise Specified","ValueMeaning":{"publicId":"4173735","version":"1","preferredName":"Peripheral T-Cell Lymphoma, Not Otherwise Specified","longName":"4173735","preferredDefinition":"Aggressive nodal or extranodal mature (peripheral) T-cell lymphomas that do not belong to the better defined entities of the remainder of mature T-cell lymphomas.  This category includes the following variants: lymphoepithelioid cell variant (Lennert's lymphoma), follicular variant, and T-zone variant.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Peripheral T-Cell Lymphoma, Not Otherwise Specified","conceptCode":"C4340","definition":"A group of peripheral T-cell lymphomas that do not meet the criteria for any other category of specifically defined entities of peripheral T-cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F33D84E5-7AD8-4906-E040-BB89AD434E8B","latestVersionIndicator":"Yes","beginDate":"2014-02-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2014-02-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E98B1C2-3ACB-1F35-E053-F662850ACC5E","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Penile Carcinoma","valueDescription":"Penile Carcinoma","ValueMeaning":{"publicId":"4722582","version":"1","preferredName":"Penile Carcinoma","longName":"4722582","preferredDefinition":"A carcinoma that arises from the penis. Risk factors include phimosis and human papillomavirus infection. The majority of penile carcinomas are squamous cell carcinomas. The most frequent clinical presentation is an irregular mass in the glans of the penis. Treatment includes surgical management and radiation therapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Penile Carcinoma","conceptCode":"C9061","definition":"A carcinoma that arises from the penis. Risk factors include phimosis and human papillomavirus infection. The majority of penile carcinomas are squamous cell carcinomas. The most frequent clinical presentation is an irregular mass in the glans of the penis. Treatment includes surgical management and radiation therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F886EE6-B916-DB60-E050-BB89AD4356E3","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E98B1C2-3ADF-1F35-E053-F662850ACC5E","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Parathyroid Gland Carcinoma","valueDescription":"Parathyroid Gland Carcinoma","ValueMeaning":{"publicId":"3210719","version":"1","preferredName":"Parathyroid Gland Carcinoma","longName":"3210719","preferredDefinition":"A malignant tumor arising from the parenchymal cells of the parathyroid gland. It is associated with the symptoms of primary hyperparathyroidism, resulting from the excessive production of parathyroid hormone. Morphologically, the differential diagnosis from parathyroid gland adenoma may be difficult. A definitive diagnosis of carcinoma is made only in the presence of capsular invasion, vascular invasion, and/or perineural invasion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Parathyroid Gland Carcinoma","conceptCode":"C4906","definition":"A malignant tumor arising from the parenchymal cells of the parathyroid gland. It is associated with the symptoms of primary hyperparathyroidism, resulting from the excessive production of parathyroid hormone. Morphologically, the differential diagnosis from parathyroid gland adenoma may be difficult. A definitive diagnosis of carcinoma is made only in the presence of capsular invasion, vascular invasion, and/or perineural invasion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-93FA-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E98B1C2-3AE9-1F35-E053-F662850ACC5E","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Parasite-Related Carcinoma","valueDescription":"Parasite-Related Carcinoma","ValueMeaning":{"publicId":"6832316","version":"1","preferredName":"Parasite-Related Carcinoma","longName":"6832316","preferredDefinition":"A term that refers to a group of carcinomas that are caused by parasites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Parasite-Related Carcinoma","conceptCode":"C27767","definition":"A term that refers to a group of carcinomas that are caused by parasites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E98B1C2-3AF6-1F35-E053-F662850ACC5E","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E98B1C2-3B0F-1F35-E053-F662850ACC5E","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Papillary Carcinoma","valueDescription":"Papillary Carcinoma","ValueMeaning":{"publicId":"4264950","version":"1","preferredName":"Papillary Carcinoma","longName":"4264950","preferredDefinition":"A malignant epithelial neoplasm characterized by a papillary growth pattern. A papillary carcinoma may be composed of glandular cells (papillary adenocarcinoma), squamous cells (papillary squamous cell carcinoma), or transitional cells (papillary transitional cell carcinoma). Bladder carcinoma is a representative example of papillary transitional cell carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Papillary Carcinoma","conceptCode":"C2927","definition":"A malignant epithelial neoplasm characterized by a papillary growth pattern. A papillary carcinoma may be composed of glandular cells (papillary adenocarcinoma), squamous cells (papillary squamous cell carcinoma), or transitional cells (papillary transitional cell carcinoma). Bladder carcinoma is a representative example of papillary transitional cell carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3955-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E98B1C2-3B23-1F35-E053-F662850ACC5E","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Pancreatic Neuroendocrine Tumor","valueDescription":"Pancreatic Neuroendocrine Tumor","ValueMeaning":{"publicId":"3250495","version":"1","preferredName":"Pancreatic Neuroendocrine Tumor","longName":"3250495","preferredDefinition":"A low or intermediate grade well differentiated tumor with neuroendocrine differentiation that arises from the pancreas.  According to the presence or absence of clinical syndromes that result from hormone hypersecretion, pancreatic neuroendocrine tumors are classified either as functional or nonfunctional.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pancreatic Neuroendocrine Tumor","conceptCode":"C27720","definition":"A well differentiated, low, intermediate, or high grade neoplasm with neuroendocrine differentiation that arises from the pancreas.  According to the presence or absence of clinical syndromes that result from hormone hypersecretion, pancreatic neuroendocrine tumors are classified either as functional or nonfunctional.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6F215E6-C657-B293-E040-BB89AD432EF3","latestVersionIndicator":"Yes","beginDate":"2011-06-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E98B1C2-3B37-1F35-E053-F662850ACC5E","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Pancreatic Carcinoma","valueDescription":"Pancreatic Carcinoma","ValueMeaning":{"publicId":"2672905","version":"1","preferredName":"Pancreatic Carcinoma","longName":"2672905","preferredDefinition":"A carcinoma arising from the exocrine pancreas. The overwhelming majority of pancreatic carcinomas are adenocarcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pancreatic Carcinoma","conceptCode":"C3850","definition":"A carcinoma arising from the exocrine pancreas. The overwhelming majority of pancreatic carcinomas are adenocarcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37D5FE1C-A62B-09FD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-16","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-08-16","modifiedBy":"COOPERM","dateModified":"2019-04-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E98B1C2-3B43-1F35-E053-F662850ACC5E","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Palate Kaposi Sarcoma","valueDescription":"Palate Kaposi Sarcoma","ValueMeaning":{"publicId":"6832318","version":"1","preferredName":"Palate Kaposi Sarcoma","longName":"6832318","preferredDefinition":"A Kaposi sarcoma arising from the palate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Palate Kaposi Sarcoma","conceptCode":"C6749","definition":"Kaposi sarcoma arising from the palate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E98B1C2-3B51-1F35-E053-F662850ACC5E","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E98B1C2-3B6A-1F35-E053-F662850ACC5E","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Paget Disease","valueDescription":"Paget's Disease","ValueMeaning":{"publicId":"3251708","version":"1","preferredName":"Paget's Disease","longName":"3251708","preferredDefinition":"A malignant neoplasm composed of large cells with large nuclei, prominent nucleoli, and abundant pale cytoplasm (Paget cells).  Paget's cell neoplasms include Paget's disease of the nipple and extramammary Paget's disease which may affect the vulva, penis, anus, skin and scrotum. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Paget Disease","conceptCode":"C7073","definition":"A malignant neoplasm composed of large cells with large nuclei, prominent nucleoli, and abundant pale cytoplasm (Paget cells).  Paget cell neoplasms include Paget disease of the nipple and extramammary Paget disease which may affect the vulva, penis, anus, skin and scrotum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A7696A98-D61A-85AE-E040-BB89AD433885","latestVersionIndicator":"Yes","beginDate":"2011-07-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E98B1C2-3B7E-1F35-E053-F662850ACC5E","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Ovarian Neoplasm","valueDescription":"Ovarian Neoplasm","ValueMeaning":{"publicId":"2673721","version":"1","preferredName":"Ovarian Neoplasm","longName":"2673721","preferredDefinition":"A benign or malignant, primary or metastatic neoplasm involving the ovary.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ovarian Neoplasm","conceptCode":"C4984","definition":"A benign, borderline, or malignant neoplasm involving the ovary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"38221278-3716-119A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-20","endDate":null,"createdBy":"UMLLOADER_BCR","dateCreated":"2007-08-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E98B1C2-3B93-1F35-E053-F662850ACC5E","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Ovarian Carcinoma","valueDescription":"Ovarian Carcinoma","ValueMeaning":{"publicId":"2593147","version":"1","preferredName":"Ovarian Carcinoma","longName":"2593147","preferredDefinition":"A malignant neoplasm originating from the surface ovarian epithelium.  It accounts for the greatest number of deaths from malignancies of the female genital tract and is the fifth leading cause of cancer fatalities in women.  It is predominantly a disease of older white women of northern European extraction, but it is seen in all ages and ethnic groups.  Adenocarcinomas constitute the vast majority of ovarian carcinomas.  The pattern of metastatic spread in ovarian carcinoma is similar regardless of the microscopic type.  The most common sites of involvement are the contralateral ovary, peritoneal cavity, para-aortic and pelvic lymph nodes, and liver.  Lung and pleura are the most common sites of extra-abdominal spread.  The primary form of therapy is surgical.  The overall prognosis of ovarian carcinoma remains poor, a direct result of its rapid growth rate and the lack of early symptoms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ovarian Carcinoma","conceptCode":"C4908","definition":"A malignant neoplasm originating from the surface ovarian epithelium.  It accounts for the greatest number of deaths from malignancies of the female genital tract and is the fifth leading cause of cancer fatalities in women.  It is predominantly a disease of older white women of northern European extraction, but it is seen in all ages and ethnic groups.  Adenocarcinomas constitute the vast majority of ovarian carcinomas.  The pattern of metastatic spread in ovarian carcinoma is similar regardless of the microscopic type.  The most common sites of involvement are the contralateral ovary, peritoneal cavity, para-aortic and pelvic lymph nodes, and liver.  Lung and pleura are the most common sites of extra-abdominal spread.  The primary form of therapy is surgical.  The overall prognosis of ovarian carcinoma remains poor, a direct result of its rapid growth rate and the lack of early symptoms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286E976F-6E43-3730-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"COOPERM","dateModified":"2019-02-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E98B1C2-3B9E-1F35-E053-F662850ACC5E","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Chondrosarcoma","valueDescription":"Chondrosarcoma","ValueMeaning":{"publicId":"3179236","version":"1","preferredName":"Chondrosarcoma","longName":"3179236","preferredDefinition":"A malignant mesenchymal tumor arising from cartilage-forming tissues involving the bones.  It affects middle-aged to elderly adults, and the pelvic bones, ribs, shoulder girdle, and long bones are the most common sites of involvement.  Most chondrosarcomas arise de novo, but some may develop in a preexisting benign cartilaginous lesion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chondrosarcoma","conceptCode":"C2946","definition":"A malignant cartilaginous matrix-producing mesenchymal neoplasm arising from the bone and soft tissue.  It usually affects middle-aged to elderly adults.  The pelvic bones, ribs, shoulder girdle, and long bones are the most common sites of involvement.  Most chondrosarcomas arise de novo, but some may develop in a preexisting benign cartilaginous lesion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9881C41C-CDA1-C63B-E040-BB89AD437873","latestVersionIndicator":"Yes","beginDate":"2010-12-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-28","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E98B1C2-3BAB-1F35-E053-F662850ACC5E","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Central Nervous System Neoplasm","valueDescription":"Central Nervous System Neoplasm","ValueMeaning":{"publicId":"2593161","version":"1","preferredName":"Central Nervous System Neoplasm","longName":"2593161","preferredDefinition":"Abnormal growth of cells that comprise the tissues of the central nervous system (brain and spinal cord), without designation of benign or malignant nature.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Central Nervous System Neoplasm","conceptCode":"C9293","definition":"A benign or malignant, primary or metastatic neoplasm that affects the brain, meninges, or spinal cord.  Representative examples of primary neoplasms include astrocytoma, oligodendroglioma, ependymoma, and meningioma.  Representative examples of metastatic neoplasms include carcinoma and leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286E976F-6FA9-3730-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"KUMMEROA","dateModified":"2022-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E98B1C2-3BB5-1F35-E053-F662850ACC5E","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Central Nervous System Lymphoma","valueDescription":"Central Nervous System Lymphoma","ValueMeaning":{"publicId":"2573501","version":"1","preferredName":"Central Nervous System Lymphoma","longName":"2573501","preferredDefinition":"Cancer that arises in the lymphoid tissue found in the central nervous system (CNS). The CNS includes the brain and spinal cord.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Central Nervous System Lymphoma","conceptCode":"C9301","definition":"A non-Hodgkin or Hodgkin lymphoma that arises in the brain or spinal cord as a primary lesion. There is no evidence of lymphoma outside the central nervous system at the time of diagnosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EC2A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-15","modifiedBy":"CAMPBELB","dateModified":"2007-02-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E98B1C2-3BC0-1F35-E053-F662850ACC5E","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Brain Neoplasm","valueDescription":"Brain Neoplasm","ValueMeaning":{"publicId":"2961460","version":"1","preferredName":"Brain Neoplasm","longName":"2961460","preferredDefinition":"Benign and malignant neoplasms that arise from or metastasize to structures within the cranium.  This includes meningeal and other tumors that occur in the spaces that surround the brain, and neoplasms of the brain.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Brain Neoplasm","conceptCode":"C2907","definition":"A benign or malignant neoplasm that arises from or metastasizes to the brain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"78AB07DC-B5A1-F05E-E040-BB89AD43180B","latestVersionIndicator":"Yes","beginDate":"2009-11-18","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-11-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E98B1C2-3BD5-1F35-E053-F662850ACC5E","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Bone Sarcoma","valueDescription":"Bone Sarcoma","ValueMeaning":{"publicId":"2593148","version":"1","preferredName":"Bone Sarcoma","longName":"2593148","preferredDefinition":"A malignant mesenchymal tumor of the bone.  Bone sarcomas can either arise from the bones (primary bone sarcomas) or spread to the bones from other anatomic sites. --2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bone Sarcoma","conceptCode":"C9312","definition":"A sarcoma that arises from the bone.  Representative examples are osteosarcoma and chondrosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286E976F-6E67-3730-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E98B1C2-3BDF-1F35-E053-F662850ACC5E","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Bladder Neoplasm","valueDescription":"Bladder Neoplasm","ValueMeaning":{"publicId":"3210914","version":"1","preferredName":"Bladder Neoplasm","longName":"3210914","preferredDefinition":"A benign or malignant, primary or metastatic neoplasm of the bladder. - 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bladder Neoplasm","conceptCode":"C2901","definition":"A benign or malignant, primary or metastatic neoplasm of the bladder.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B38C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E98B1C2-3BE9-1F35-E053-F662850ACC5E","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Atypical Teratoid/Rhabdoid Tumor","valueDescription":"Atypical Teratoid/Rhabdoid Tumor","ValueMeaning":{"publicId":"4722554","version":"1","preferredName":"Atypical Teratoid/Rhabdoid Tumor","longName":"4722554","preferredDefinition":"An aggressive malignant embryonal neoplasm arising from the central nervous system.  It is composed of cells with a large eccentric nucleus, prominent nucleolus, and abundant cytoplasm.  It may be associated with loss of chromosome 22.  The vast majority of cases occur in childhood.  Symptoms include lethargy, vomiting, cranial nerve palsy, headache, and hemiplegia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atypical Teratoid/Rhabdoid Tumor","conceptCode":"C6906","definition":"An aggressive malignant embryonal neoplasm arising from the central nervous system. It is composed of cells with a large eccentric nucleus, prominent nucleolus, and abundant cytoplasm. Mutations of the SMARCB1 gene or very rarely SMARCA4 (BRG1) gene are present. The vast majority of cases occur in childhood. Symptoms include lethargy, vomiting, cranial nerve palsy, headache, and hemiplegia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F886EE6-B6B7-DB60-E050-BB89AD4356E3","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SOKKERL","dateModified":"2024-02-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E98B1C2-3BF4-1F35-E053-F662850ACC5E","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Angioimmunoblastic T-Cell Lymphoma","valueDescription":"Angioimmunoblastic T-Cell Lymphoma","ValueMeaning":{"publicId":"3088583","version":"1","preferredName":"Angioimmunoblastic T-Cell Lymphoma","longName":"3088583","preferredDefinition":"A mature T-cell non-Hodgkin lymphoma, characterized by systemic disease and a polymorphous infiltrate involving lymph nodes and extranodal sites.  The clinical course is typically aggressive.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type","conceptCode":"C7528","definition":"An aggressive follicular helper T-cell lymphoma affecting lymph nodes and other sites. It is characterized by a polymorphous infiltrate and prominent proliferation of high endothelial venules and follicular dendritic cells. It is associated with EBV infection and affects mainly older adults.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86E3DD57-D15A-A26A-E040-BB89AD437117","latestVersionIndicator":"Yes","beginDate":"2010-05-18","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-05-18","modifiedBy":"COOPERM","dateModified":"2017-10-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E98B1C2-3BFE-1F35-E053-F662850ACC5E","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Anal Carcinoma","valueDescription":"Anal Carcinoma","ValueMeaning":{"publicId":"4722735","version":"1","preferredName":"Anal Carcinoma","longName":"4722735","preferredDefinition":"A carcinoma that arises from the anus.  Anal carcinomas include the anal canal and anal margin (perianal skin) carcinomas.  The anal margin carcinoma is staged separately as a skin carcinoma.  Anal cancer stage terms are used as synonyms for anal canal cancer stage terms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anal Carcinoma","conceptCode":"C9291","definition":"A carcinoma that arises from the anus. Anal carcinomas include the anal canal and perianal area (anal margin) carcinomas. Perianal carcinomas are staged separately as skin carcinomas in AJCC v6 and v7 editions. The AJCC v8 edition staging system applies to all carcinomas arising in the anal canal, including carcinomas that arise within anorectal fistulas and those arising in the perianal area (anal margin).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-1ED1-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E98B1C2-3C12-1F35-E053-F662850ACC5E","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Choriocarcinoma","valueDescription":"Choriocarcinoma","ValueMeaning":{"publicId":"2837860","version":"1","preferredName":"Choriocarcinoma","longName":"2837860","preferredDefinition":"An aggressive malignant tumor arising from trophoblastic cells.  The vast majority of cases arise in the uterus and represent gestational choriocarcinomas that derive from placental trophoblastic cells.  Approximately half of the cases develop from a complete hydatidiform mole.  A minority of cases arise in the testis or the ovaries.  There is often marked elevation of human chorionic gonadotropin (hCG) in the blood.  Choriocarcinomas disseminate rapidly through the hematogenous route; the lungs are most frequently affected. --2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Choriocarcinoma","conceptCode":"C2948","definition":"An aggressive malignant tumor arising from trophoblastic cells. The vast majority of cases arise in the uterus and represent gestational choriocarcinomas that derive from placental trophoblastic cells. Approximately half of the cases develop from a complete hydatidiform mole. A minority of cases arise in the testis or the ovaries. There is often marked elevation of human chorionic gonadotropin (hCG) in the blood. Choriocarcinomas disseminate rapidly through the hematogenous route; the lungs are most frequently affected.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6281C75A-491B-A127-E040-BB89AD431A41","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C6203A0-A6EA-1725-E053-F662850AC42D","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Chordoma","valueDescription":"Chordoma","ValueMeaning":{"publicId":"3179237","version":"1","preferredName":"Chordoma","longName":"3179237","preferredDefinition":"A malignant bone tumor arising from the remnants of the fetal notochord. Although it can occur at all ages, it is more frequently seen in middle-aged adults. Most frequent sites of involvement are: sacrococcygeal area, spheno-occipital area, and the cervico-thoraco-lumbar spine. Microscopically, chordomas are composed of cells that form cords and lobules, separated by mucoid intercellular tissue. Some of the cells are large (physaliphorous) and have vacuolated cytoplasm and prominent vesicular nuclei. Other tumor cells are small with small nuclei without visible nucleoli. Chordomas tend to recur and may metastasize. The most common sites of metastasis are skin and bone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chordoma","conceptCode":"C2947","definition":"A malignant bone tumor arising from the remnants of the fetal notochord. Although it can occur at all ages, it is more frequently seen in middle-aged adults. The most frequent sites of involvement are the sacrococcygeal area, spheno-occipital area, and cervico-thoraco-lumbar spine. Chordomas tend to recur and may metastasize. The most common sites of metastasis are lung, bone, lymph nodes, and subcutaneous tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9881C41C-CDC6-C63B-E040-BB89AD437873","latestVersionIndicator":"Yes","beginDate":"2010-12-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-28","modifiedBy":"SOKKERL","dateModified":"2024-02-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C6203A0-A6F4-1725-E053-F662850AC42D","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Cholangiocarcinoma","valueDescription":"Cholangiocarcinoma","ValueMeaning":{"publicId":"4722725","version":"1","preferredName":"Cholangiocarcinoma","longName":"4722725","preferredDefinition":"A carcinoma that arises from the intrahepatic biliary tree (intrahepatic cholangiocarcinoma) or from the junction, or adjacent to the junction, of the right and left hepatic ducts (hilar cholangiocarcinoma). Grossly, the malignant lesions are solid, nodular, and grayish. Morphologically, the vast majority of cases are adenocarcinomas. Signs and symptoms include malaise, weight loss, right upper quadrant abdominal pain, and night sweats. Early detection is difficult and the prognosis is generally poor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cholangiocarcinoma","conceptCode":"C4436","definition":"A carcinoma that arises from the intrahepatic bile ducts, the hepatic ducts, or the common bile duct distal to the insertion of the cystic duct. The vast majority of tumors are adenocarcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-1D7B-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C6203A0-A6FF-1725-E053-F662850AC42D","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Childhood Melanoma","valueDescription":"Childhood Melanoma","ValueMeaning":{"publicId":"6798861","version":"1","preferredName":"Childhood Melanoma","longName":"6798861","preferredDefinition":"A melanoma that occurs during childhood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Childhood Melanoma","conceptCode":"C131506","definition":"A melanoma that occurs during childhood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C6203A0-A70D-1725-E053-F662850AC42D","latestVersionIndicator":"Yes","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C6203A0-A726-1725-E053-F662850AC42D","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Childhood Malignant Neoplasm","valueDescription":"Childhood Malignant Neoplasm","ValueMeaning":{"publicId":"6798862","version":"1","preferredName":"Childhood Malignant Neoplasm","longName":"6798862","preferredDefinition":"A malignant tumor that occurs in children.  Representative examples include soft tissue and bone sarcomas (e.g. osteosarcoma) and embryonal neoplasms (e.g. hepatoblastoma and rhabdoid tumor).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Childhood Malignant Neoplasm","conceptCode":"C4005","definition":"A malignant neoplasm that occurs during childhood. Representative examples include acute leukemias, malignant brain neoplasms, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C6203A0-A732-1725-E053-F662850AC42D","latestVersionIndicator":"Yes","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C6203A0-A74B-1725-E053-F662850AC42D","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Childhood Lymphoma","valueDescription":"Childhood Lymphoma","ValueMeaning":{"publicId":"6798864","version":"1","preferredName":"Childhood Lymphoma","longName":"6798864","preferredDefinition":"A Hodgkin or non-Hodgkin lymphoma that occurs during childhood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Childhood Lymphoma","conceptCode":"C5165","definition":"A Hodgkin or non-Hodgkin lymphoma that occurs during childhood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C6203A0-A758-1725-E053-F662850AC42D","latestVersionIndicator":"Yes","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C6203A0-A771-1725-E053-F662850AC42D","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Childhood Leukemia","valueDescription":"Childhood Leukemia","ValueMeaning":{"publicId":"6798866","version":"1","preferredName":"Childhood Leukemia","longName":"6798866","preferredDefinition":"An acute or chronic leukemia that occurs during childhood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Childhood Leukemia","conceptCode":"C4989","definition":"An acute or chronic leukemia that occurs during childhood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C6203A0-A77E-1725-E053-F662850AC42D","latestVersionIndicator":"Yes","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C6203A0-A797-1725-E053-F662850AC42D","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Chest Wall Sarcoma","valueDescription":"Chest Wall Sarcoma","ValueMeaning":{"publicId":"6798868","version":"1","preferredName":"Chest Wall Sarcoma","longName":"6798868","preferredDefinition":"A sarcoma that arises from the anatomic structures that surround the lungs and the pleura.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chest Wall Sarcoma","conceptCode":"C155873","definition":"A sarcoma that arises from the anatomic structures that surround the lungs and the pleura.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C6203A0-A7A4-1725-E053-F662850AC42D","latestVersionIndicator":"Yes","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C6203A0-A7BD-1725-E053-F662850AC42D","beginDate":"2019-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"Plasma Cell Myeloma","valueDescription":"Plasma Cell Myeloma","ValueMeaning":{"publicId":"5581351","version":"1","preferredName":"Plasma Cell Myeloma","longName":"5581351","preferredDefinition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multiple Myeloma","conceptCode":"C3242","definition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42019733-B9DD-634F-E053-F662850A5A61","latestVersionIndicator":"Yes","beginDate":"2016-11-23","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2016-11-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E986C3C-1E0F-1F39-E053-F662850A91B3","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Plasma Cell Leukemia","valueDescription":"Plasma Cell Leukemia","ValueMeaning":{"publicId":"2579742","version":"1","preferredName":"Plasma Cell Leukemia","longName":"2579742","preferredDefinition":"An aggressive plasma cell neoplasm characterized by the presence of neoplastic plasma cells in the peripheral blood. It is characterized by the presence of a circulating clonal plasma cell count that exceeds 2x10^9/L or is 20% of the leukocyte differential count.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plasma Cell Leukemia","conceptCode":"C3180","definition":"An aggressive plasma cell neoplasm characterized by the presence of neoplastic plasma cells in the peripheral blood. It is characterized by the presence of a circulating clonal plasma cell count that exceeds 2x10^9/L or is 20% of the leukocyte differential count.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-048B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-15","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-15","modifiedBy":"COOPERM","dateModified":"2016-06-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E986C3C-1E24-1F39-E053-F662850A91B3","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Pituitary Gland Neoplasm","valueDescription":"Pituitary Gland Neoplasm","ValueMeaning":{"publicId":"3210722","version":"1","preferredName":"Pituitary Gland Neoplasm","longName":"3210722","preferredDefinition":"A benign or malignant neoplasm affecting the pituitary gland. The vast majority are adenomas arising from the anterior lobe of the pituitary gland.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pituitary Gland Neoplasm","conceptCode":"C3330","definition":"A benign or malignant neoplasm affecting the pituitary gland. The vast majority are pituitary neuroendocrine tumors (formerly pituitary adenomas).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9460-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E986C3C-1E2F-1F39-E053-F662850A91B3","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Pituitary Gland Carcinoma","valueDescription":"Pituitary Gland Carcinoma","ValueMeaning":{"publicId":"4722742","version":"1","preferredName":"Pituitary Gland Carcinoma","longName":"4722742","preferredDefinition":"A rare adenocarcinoma with poor prognosis, arising from the adenohypophysial cells of the anterior lobe of the pituitary gland or pre-existing adenomas.  The majority are hormonally functioning neoplasms, usually producing prolactin or ACTH.  The diagnosis is based on the presence of metastases.  Syndromes associated with pituitary gland carcinomas include hyperprolactinemia, Cushing disease, and acromegaly.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metastatic Pituitary Neuroendocrine Tumor","conceptCode":"C4536","definition":"Pituitary neuroendocrine tumor that has spread from its original site of growth to another anatomic site.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-2098-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E986C3C-1E44-1F39-E053-F662850A91B3","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Pineoblastoma","valueDescription":"Pineoblastoma","ValueMeaning":{"publicId":"3251836","version":"1","preferredName":"Pineoblastoma","longName":"3251836","preferredDefinition":"Pineoblastoma (WHO grade IV) is a highly malignant, primitive embryonal neoplasm, which occurs more commonly in children. It is composed of patternless sheets of densely packed small cells with round-to-irregular nuclei and scant cytoplasm, similar to medulloblastoma and related primitive neuroectodermal tumors. A frequent complication is metastasis via cerebrospinal fluid pathways, which is often associated with a fatal outcome. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pineoblastoma","conceptCode":"C9344","definition":"A poorly differentiated malignant embryonal neoplasm arising from the pineal region.  It usually occurs in children and it is characterized by the presence of small immature neuroepithelial cells.  It may follow an aggressive clinical course.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A76E3677-AE5C-F84A-E040-BB89AD435C45","latestVersionIndicator":"Yes","beginDate":"2011-07-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-06","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E986C3C-1E4F-1F39-E053-F662850A91B3","beginDate":"2019-07-26","endDate":null,"createdBy":"LUY","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Orbit Neoplasm","valueDescription":"Malignant Orbit Neoplasm","ValueMeaning":{"publicId":"6832992","version":"1","preferredName":"Malignant Orbit Neoplasm","longName":"6832992","preferredDefinition":"A primary or metastatic malignant neoplasm involving the orbit.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Orbit Neoplasm","conceptCode":"C3562","definition":"A primary or metastatic malignant neoplasm involving the orbit.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B10CC-DBB4-2301-E053-F662850AB843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B10CC-DBCD-2301-E053-F662850AB843","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Oropharyngeal Neoplasm","valueDescription":"Malignant Oropharyngeal Neoplasm","ValueMeaning":{"publicId":"6832994","version":"1","preferredName":"Malignant Oropharyngeal Neoplasm","longName":"6832994","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the oropharynx.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Oropharyngeal Neoplasm","conceptCode":"C7398","definition":"A primary or metastatic malignant neoplasm that affects the oropharynx.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B10CC-DBDA-2301-E053-F662850AB843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B10CC-DBF3-2301-E053-F662850AB843","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Ovarian Neoplasm","valueDescription":"Malignant Ovarian Neoplasm","ValueMeaning":{"publicId":"3210710","version":"1","preferredName":"Malignant Ovarian Neoplasm","longName":"3210710","preferredDefinition":"A primary or metastatic malignant tumor involving the ovary. Most primary malignant ovarian neoplasms are either carcinomas (serous, mucinous, or endometrioid adenocarcinomas) or malignant germ cell tumors. Metastatic malignant neoplasms to the ovary include carcinomas, lymphomas, and melanomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Ovarian Neoplasm","conceptCode":"C7431","definition":"A primary or metastatic malignant neoplasm involving the ovary. Most primary malignant ovarian neoplasms are either carcinomas (serous, mucinous, or endometrioid adenocarcinomas) or malignant germ cell tumors. Metastatic malignant neoplasms to the ovary include carcinomas, lymphomas, and melanomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9248-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B10CC-DBFE-2301-E053-F662850AB843","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Palate Neoplasm","valueDescription":"Malignant Palate Neoplasm","ValueMeaning":{"publicId":"6833017","version":"1","preferredName":"Malignant Palate Neoplasm","longName":"6833017","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the hard palate, soft palate, or uvula.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Palate Neoplasm","conceptCode":"C3530","definition":"A primary or metastatic malignant neoplasm that affects the hard palate, soft palate, or uvula.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B10CC-DC0C-2301-E053-F662850AB843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B10CC-DC25-2301-E053-F662850AB843","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Pancreatic Neoplasm","valueDescription":"PANC - 157.9; Pancreas","ValueMeaning":{"publicId":"2572680","version":"1","preferredName":"PANC - 157.9; Pancreas","longName":"2572680","preferredDefinition":"A primary or metastatic malignant tumor involving the pancreas.  Representative examples include carcinoma and lymphoma. -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Pancreatic Neoplasm","conceptCode":"C9005","definition":"A primary or metastatic malignant tumor involving the pancreas.  Representative examples include carcinoma and lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8F5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B10CC-DC39-2301-E053-F662850AB843","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Paraganglioma","valueDescription":"Malignant Paraganglioma","ValueMeaning":{"publicId":"6833019","version":"1","preferredName":"Malignant Paraganglioma","longName":"6833019","preferredDefinition":"A paraganglioma that metastasizes to regional or distant anatomic sites.  Extraadrenal paragangliomas have a higher tendency to metastasize, as compared to pheochromocytomas.  Common sites of metastasis include the lymph nodes, lungs, bones, and liver.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metastatic Paraganglioma","conceptCode":"C8559","definition":"A paraganglioma that metastasizes to regional or distant anatomic sites.  Extraadrenal paragangliomas have a higher tendency to metastasize, as compared to pheochromocytomas.  Common sites of metastasis include the lymph nodes, lungs, bones, and liver.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B10CC-DC47-2301-E053-F662850AB843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B10CC-DC60-2301-E053-F662850AB843","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Paranasal Sinus Neoplasm","valueDescription":"Malignant Paranasal Sinus Neoplasm","ValueMeaning":{"publicId":"6833021","version":"1","preferredName":"Malignant Paranasal Sinus Neoplasm","longName":"6833021","preferredDefinition":"A primary or metastatic malignant neoplasm involving the paranasal sinuses.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Paranasal Sinus Neoplasm","conceptCode":"C7487","definition":"A primary or metastatic malignant neoplasm involving the paranasal sinuses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B10CC-DC6D-2301-E053-F662850AB843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B10CC-DC86-2301-E053-F662850AB843","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Parathyroid Gland Neoplasm","valueDescription":"PTH - 194.1; Parathyroid","ValueMeaning":{"publicId":"2572681","version":"1","preferredName":"PTH - 194.1; Parathyroid","longName":"2572681","preferredDefinition":"A primary or metastatic malignant neoplasm affecting the parathyroid glands.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Parathyroid Gland Neoplasm","conceptCode":"C9322","definition":"A primary or metastatic malignant neoplasm affecting the parathyroid glands.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8F6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B10CC-DC9A-2301-E053-F662850AB843","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Parotid Gland Neoplasm","valueDescription":"Malignant Parotid Gland Neoplasm","ValueMeaning":{"publicId":"6833023","version":"1","preferredName":"Malignant Parotid Gland Neoplasm","longName":"6833023","preferredDefinition":"A primary or metastatic malignant neoplasm involving the parotid gland.  Representative examples include carcinoma, malignant mixed tumor, and non-Hodgkin lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Parotid Gland Neoplasm","conceptCode":"C3525","definition":"A primary or metastatic malignant neoplasm involving the parotid gland.  Representative examples include carcinoma, malignant mixed tumor, and non-Hodgkin lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B10CC-DCA8-2301-E053-F662850AB843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B10CC-DCC1-2301-E053-F662850AB843","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Pelvic Neoplasm","valueDescription":"Malignant Pelvic Neoplasm","ValueMeaning":{"publicId":"6833025","version":"1","preferredName":"Malignant Pelvic Neoplasm","longName":"6833025","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the organs and structures of the pelvis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Pelvic Neoplasm","conceptCode":"C156715","definition":"A primary or metastatic malignant neoplasm that affects the organs and structures of the pelvis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B10CC-DCCE-2301-E053-F662850AB843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B10CC-DCE7-2301-E053-F662850AB843","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Penile Neoplasm","valueDescription":"Malignant Penile Neoplasm","ValueMeaning":{"publicId":"6833027","version":"1","preferredName":"Malignant Penile Neoplasm","longName":"6833027","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the penis.  Representative examples include penile carcinoma and penile sarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Penile Neoplasm","conceptCode":"C7547","definition":"A primary or metastatic malignant neoplasm that affects the penis.  Representative examples include penile carcinoma and penile sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B10CC-DCF4-2301-E053-F662850AB843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B10CC-DD0D-2301-E053-F662850AB843","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Peripheral Nerve Sheath Tumor","valueDescription":"Malignant Peripheral Nerve Sheath Tumor","ValueMeaning":{"publicId":"2838605","version":"1","preferredName":"Malignant Peripheral Nerve Sheath Tumor","longName":"2838605","preferredDefinition":"An uncommon, highly aggressive malignant tumor, arising from the peripheral nerves and affecting mostly adults in their third to sixth decades of life.  It usually occurs in medium-sized and large nerves of the buttock, thigh, upper arm, or the paraspinal region.  It may be associated with neurofibromatosis 1 (NF1).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Peripheral Nerve Sheath Tumor","conceptCode":"C3798","definition":"An uncommon, highly aggressive malignant tumor, arising from the peripheral nerves and affecting mostly adults in their third to sixth decades of life.  It usually occurs in medium-sized and large nerves of the buttock, thigh, upper arm, or the paraspinal region.  It may be associated with neurofibromatosis 1 (NF1).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6485A-AE88-B656-E040-BB89AD437D5F","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B10CC-DD17-2301-E053-F662850AB843","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Peripheral Nervous System Neoplasm","valueDescription":"CA - 199.1; NOS","ValueMeaning":{"publicId":"2572675","version":"1","preferredName":"CA - 199.1; NOS","longName":"2572675","preferredDefinition":"Malignant growth of cells in the peripheral nervous system (PNS)or Autonomic Nervous System (ANS), without specification as to location","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Peripheral Nervous System Neoplasm","conceptCode":"C4961","definition":"Malignant growth of cells in the peripheral nervous system (PNS)or Autonomic Nervous System (ANS), without specification as to location","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8F0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B10CC-DD2B-2301-E053-F662850AB843","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Peritoneal and Retroperitoneal Neoplasm","valueDescription":"Malignant Peritoneal and Retroperitoneal Neoplasm","ValueMeaning":{"publicId":"6833029","version":"1","preferredName":"Malignant Peritoneal and Retroperitoneal Neoplasm","longName":"6833029","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the peritoneum and/or retroperitoneum.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Peritoneal and Retroperitoneal Neoplasm","conceptCode":"C156711","definition":"A primary or metastatic malignant neoplasm that affects the peritoneum and/or retroperitoneum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B10CC-DD39-2301-E053-F662850AB843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B10CC-DD52-2301-E053-F662850AB843","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Peritoneal Neoplasm","valueDescription":"Malignant Peritoneal Neoplasm","ValueMeaning":{"publicId":"6833030","version":"1","preferredName":"Malignant Peritoneal Neoplasm","longName":"6833030","preferredDefinition":"A primary or metastatic malignant neoplasm involving the peritoneum. Representative examples include carcinoma and malignant mesothelioma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Peritoneal Neoplasm","conceptCode":"C3538","definition":"A primary or metastatic malignant neoplasm involving the peritoneum. Representative examples include carcinoma and malignant mesothelioma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B10CC-DD5C-2301-E053-F662850AB843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B10CC-DD75-2301-E053-F662850AB843","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Pharyngeal Neoplasm","valueDescription":"Malignant Pharyngeal Neoplasm","ValueMeaning":{"publicId":"6833032","version":"1","preferredName":"Malignant Pharyngeal Neoplasm","longName":"6833032","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the pharynx.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Pharyngeal Neoplasm","conceptCode":"C7545","definition":"A primary or metastatic malignant neoplasm that affects the pharynx.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B10CC-DD82-2301-E053-F662850AB843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B10CC-DD9B-2301-E053-F662850AB843","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Pineal Region Neoplasm","valueDescription":"Malignant Pineal Region Neoplasm","ValueMeaning":{"publicId":"3210711","version":"1","preferredName":"Malignant Pineal Region Neoplasm","longName":"3210711","preferredDefinition":"Abnormal malignant growth of the cells that comprise the pineal parenchyma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Pineal Region Neoplasm","conceptCode":"C3573","definition":"A malignant neoplasm that affects the pineal region.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-926A-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B10CC-DDA5-2301-E053-F662850AB843","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Pituitary Gland Neoplasm","valueDescription":"Malignant Pituitary Gland Neoplasm","ValueMeaning":{"publicId":"6833034","version":"1","preferredName":"Malignant Pituitary Gland Neoplasm","longName":"6833034","preferredDefinition":"A primary or metastatic malignant neoplasm affecting the pituitary gland.  Representative examples include functioning or non-functioning carcinomas arising from the anterior lobe of the pituitary gland, chordomas, chondrosarcomas, and metastatic carcinomas from the breast, lung, and gastrointestinal tract.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Pituitary Gland Neoplasm","conceptCode":"C4769","definition":"A primary or metastatic malignant neoplasm affecting the pituitary gland.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B10CC-DDB3-2301-E053-F662850AB843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B10CC-DDCC-2301-E053-F662850AB843","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Placental Neoplasm","valueDescription":"Malignant Placental Neoplasm","ValueMeaning":{"publicId":"6833036","version":"1","preferredName":"Malignant Placental Neoplasm","longName":"6833036","preferredDefinition":"A primary or metastatic neoplasm that affects the placenta.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Placental Neoplasm","conceptCode":"C3555","definition":"A primary or metastatic neoplasm that affects the placenta.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9B10CC-DDD9-2301-E053-F662850AB843","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B10CC-DDF2-2301-E053-F662850AB843","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Pleural Neoplasm","valueDescription":"PLEURA NOS - 163.9; Pleura, unspecified","ValueMeaning":{"publicId":"3826039","version":"1","preferredName":"PLEURA NOS - 163.9; Pleura, unspecified","longName":"3826039","preferredDefinition":"A primary or metastatic malignant neoplasm affecting the pleura.  A representative example of primary malignant pleural neoplasm is the malignant pleural mesothelioma.  A representative example of metastatic malignant neoplasm to the pleura is metastatic carcinoma that has spread to the pleura from another anatomic site.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Pleural Neoplasm","conceptCode":"C3547","definition":"A primary or metastatic malignant neoplasm affecting the pleura.  A representative example of primary malignant pleural neoplasm is the malignant pleural mesothelioma.  A representative example of metastatic malignant neoplasm to the pleura is metastatic carcinoma that has spread to the pleura from another anatomic site.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E25C7C1F-51D1-1CCC-E040-BB89AD434814","latestVersionIndicator":"Yes","beginDate":"2013-07-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-07-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9B10CC-DE06-2301-E053-F662850AB843","beginDate":"2019-07-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Malignant Postcricoid Neoplasm","valueDescription":"Malignant Postcricoid Neoplasm","ValueMeaning":{"publicId":"6835256","version":"1","preferredName":"Malignant Postcricoid Neoplasm","longName":"6835256","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the postcricoid region.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Postcricoid Neoplasm","conceptCode":"C9323","definition":"A primary or metastatic malignant neoplasm that affects the postcricoid region.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED5EB8E-A068-21AC-E053-F662850AA6A9","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED5EB8E-A081-21AC-E053-F662850AA6A9","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Posterior Tongue Neoplasm","valueDescription":"Malignant Posterior Tongue Neoplasm","ValueMeaning":{"publicId":"6835258","version":"1","preferredName":"Malignant Posterior Tongue Neoplasm","longName":"6835258","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the base of the tongue.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Posterior Tongue Neoplasm","conceptCode":"C3524","definition":"A primary or metastatic malignant neoplasm that affects the base of the tongue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED5EB8E-A08E-21AC-E053-F662850AA6A9","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED5EB8E-A0A7-21AC-E053-F662850AA6A9","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Malignant Prostate Neoplasm","valueDescription":"Malignant Prostate Neoplasm","ValueMeaning":{"publicId":"6835259","version":"1","preferredName":"Malignant Prostate Neoplasm","longName":"6835259","preferredDefinition":"A primary or metastatic malignant tumor involving the prostate gland.  The vast majority are carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Prostate Neoplasm","conceptCode":"C7378","definition":"A primary or metastatic malignant tumor involving the prostate gland.  The vast majority are carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED5EB8E-A0B3-21AC-E053-F662850AA6A9","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED5EB8E-A0CC-21AC-E053-F662850AA6A9","beginDate":"2019-07-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6785215","version":"1","preferredName":"CPTAC Neoplasms Codelist Name","preferredDefinition":"Terminology used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) with the focus on neoplasms.:The words or language units by which a thing is known.","longName":"C156966:C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CPTAC Neoplasms Codelist","conceptCode":"C156966","definition":"Terminology used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) with the focus on neoplasms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BAD903C-9D1E-6283-E053-F662850A5DDE","latestVersionIndicator":"Yes","beginDate":"2019-06-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-19","modifiedBy":"ONEDATA","dateModified":"2019-06-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BAD903C-9D2F-6283-E053-F662850A5DDE","latestVersionIndicator":"Yes","beginDate":"2019-06-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-19","modifiedBy":"KNABLEJ","dateModified":"2019-11-10","changeDescription":"11/10/19 jk Released per CPTAC SME (Linda) for Medical History CRF.  6-19-19 tt created for CPTAC Medical History CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"6601273","version":"1","longName":"CPTAC (Clinical Proteomic Tumor Analysis Consortium)","context":"OCCPR","ClassificationSchemeItems":[{"publicId":"6776734","version":"1","longName":"All Generic CRFs","context":"OCCPR"},{"publicId":"10000400","version":"1","longName":"Medical History","context":"OCCPR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Malignant Neoplasm","type":"Preferred Question Text","description":"Malignant Neoplasm","url":null,"context":"OCCPR"}],"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BAD2E01-6F6F-3765-E053-F662850AFAD5","latestVersionIndicator":"Yes","beginDate":"2019-06-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-19","modifiedBy":"KNABLEJ","dateModified":"2019-11-10","changeDescription":"11/10/19 jk Released per CPTAC SME (Linda) for Medical History CRF.  6-19-19 tt created for CPTAC Medical History CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}